0001171843-25-001611.txt : 20250321 0001171843-25-001611.hdr.sgml : 20250321 20250321090032 ACCESSION NUMBER: 0001171843-25-001611 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 68 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250321 DATE AS OF CHANGE: 20250321 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNITED GUARDIAN INC CENTRAL INDEX KEY: 0000101295 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 111719724 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10526 FILM NUMBER: 25758665 BUSINESS ADDRESS: STREET 1: 230 MARCUS BLVD CITY: HAUPPAUGE STATE: NY ZIP: 11788 BUSINESS PHONE: 631-273-0900 MAIL ADDRESS: STREET 1: 230 MARCUS BLVD. CITY: HAUPPAUGE STATE: NY ZIP: 11788 FORMER COMPANY: FORMER CONFORMED NAME: UNITED INTERNATIONAL RESEARCH INC DATE OF NAME CHANGE: 19820422 10-K 1 ug20241231_10k.htm FORM 10-K ug20241231_10k.htm
FY 2024 --12-31 false 0000101295 1 6 2 0 0 0 0 0 0 0 0 0 3 3 4 4 0 0 0 0.10 0.10 false false false false true true false true true true 00001012952024-01-012024-12-31 thunderdome:item iso4217:USDxbrli:shares 0000101295us-gaap:SubsequentEventMember2025-01-272025-01-27 iso4217:USD 0000101295ug:AccountingAndTaxServicesMembersrt:DirectorMember2023-01-012023-12-31 0000101295ug:AccountingAndTaxServicesMembersrt:DirectorMember2024-01-012024-12-31 0000101295ug:ConsultingServicesMemberug:PreviousPresidentAndCeoMember2023-01-012023-12-31 0000101295ug:ConsultingServicesMemberug:PreviousPresidentAndCeoMember2024-01-012024-12-31 xbrli:shares 00001012952024-12-31 00001012952023-12-31 00001012952023-01-012023-12-31 0000101295ug:AllOtherCustomersMember2023-01-012023-12-31 0000101295ug:AllOtherCustomersMember2024-01-012024-12-31 0000101295ug:CustomerDMember2023-01-012023-12-31 0000101295ug:CustomerDMember2024-01-012024-12-31 0000101295ug:CustomerCMember2023-01-012023-12-31 0000101295ug:CustomerCMember2024-01-012024-12-31 0000101295ug:CustomerBMember2023-01-012023-12-31 0000101295ug:CustomerBMember2024-01-012024-12-31 0000101295ug:CustomerAMember2023-01-012023-12-31 0000101295ug:CustomerAMember2024-01-012024-12-31 0000101295us-gaap:NonUsMember2023-01-012023-12-31 0000101295us-gaap:NonUsMember2024-01-012024-12-31 0000101295country:US2023-01-012023-12-31 0000101295country:US2024-01-012024-12-31 0000101295ug:IndustrialAndOtherMember2023-01-012023-12-31 0000101295ug:MedicalLubricantsMember2023-01-012023-12-31 0000101295ug:MedicalLubricantsMember2024-01-012024-12-31 0000101295ug:PharmaceuticalsMember2023-01-012023-12-31 0000101295ug:PharmaceuticalsMember2024-01-012024-12-31 0000101295ug:CosmeticIngredientsMember2023-01-012023-12-31 0000101295ug:CosmeticIngredientsMember2024-01-012024-12-31 xbrli:pure utr:Y 0000101295ug:DCPlanMemberug:DiscretionaryContributionsVestingEachAdditionalYearMember2024-01-012024-12-31 0000101295ug:DCPlanMemberug:DiscretionaryContributionsVestingAtTwoYearsMember2024-01-012024-12-31 0000101295ug:DCPlanMember2024-01-012024-12-31 0000101295us-gaap:CertificatesOfDepositMember2023-12-31 0000101295ug:EquityAndOtherMutualFundsMember2023-12-31 0000101295us-gaap:USTreasuryBillSecuritiesMember2024-12-31 0000101295us-gaap:CertificatesOfDepositMember2024-12-31 0000101295ug:EquityAndOtherMutualFundsMember2024-12-31 0000101295us-gaap:DemandDepositsMember2023-12-31 0000101295us-gaap:DemandDepositsMember2024-12-31 0000101295us-gaap:CostOfGoodsProductLineMemberus-gaap:SupplierConcentrationRiskMemberug:ThreeRawMaterialVendorsMember2023-01-012023-12-31 0000101295us-gaap:CostOfGoodsProductLineMemberus-gaap:SupplierConcentrationRiskMemberug:ThreeRawMaterialVendorsMember2024-01-012024-12-31 0000101295us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberug:DistributorsAndMarketingPartnersMember2023-01-012023-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberug:DistributorsAndMarketingPartnersMember2023-01-012023-12-31 0000101295ug:DistributorsAndMarketingPartnersMember2023-01-012023-12-31 0000101295us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberug:DistributorsAndMarketingPartnersMember2024-01-012024-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberug:DistributorsAndMarketingPartnersMember2024-01-012024-12-31 0000101295ug:DistributorsAndMarketingPartnersMember2024-01-012024-12-31 0000101295us-gaap:BuildingImprovementsMember2024-12-31 0000101295us-gaap:BuildingMember2024-12-31 0000101295ug:FactoryEquipmentAndFixturesMembersrt:MaximumMember2024-12-31 0000101295ug:FactoryEquipmentAndFixturesMembersrt:MinimumMember2024-12-31 0000101295ug:O2023Q3DividendsMember2023-09-30 0000101295ug:O2023Q3DividendsMember2023-07-012023-09-30 0000101295ug:O2023Q3DividendsMember2024-07-012024-09-30 0000101295ug:O2025Q1DividendsMembersrt:ScenarioForecastMember2025-01-012025-03-31 0000101295ug:O2024Q1DividendsMember2024-03-31 0000101295ug:O2024Q1DividendsMember2024-01-012024-03-31 0000101295ug:O2024Q3DividendsMember2024-09-30 0000101295ug:O2024Q3DividendsMember2024-07-012024-09-30 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:ASIMembercountry:CN2023-01-012023-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:ASIMembercountry:CN2024-01-012024-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:ASIMemberus-gaap:NonUsMember2023-01-012023-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:ASIMemberus-gaap:NonUsMember2024-01-012024-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:PersonalCareMemberus-gaap:NonUsMember2023-01-012023-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:PersonalCareMemberus-gaap:NonUsMember2024-01-012024-12-31 0000101295ug:AccruedExpensesMember2023-12-31 0000101295ug:AccruedExpensesMember2024-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberug:RenacidinMember2023-01-012023-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberug:RenacidinMember2024-01-012024-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberug:LubrajelMember2023-01-012023-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberug:LubrajelMember2024-01-012024-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberug:LUBRAJELAndRENACIDINIRRIGATIONMember2023-01-012023-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberug:LUBRAJELAndRENACIDINIRRIGATIONMember2024-01-012024-12-31 00001012952022-12-31 0000101295us-gaap:RetainedEarningsMember2024-12-31 0000101295us-gaap:CommonStockMember2024-12-31 0000101295us-gaap:RetainedEarningsMember2024-01-012024-12-31 0000101295us-gaap:RetainedEarningsMember2023-12-31 0000101295us-gaap:CommonStockMember2023-12-31 0000101295us-gaap:RetainedEarningsMember2023-01-012023-12-31 0000101295us-gaap:RetainedEarningsMember2022-12-31 0000101295us-gaap:CommonStockMember2022-12-31 00001012952025-03-01 00001012952024-06-30
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

 

☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2024

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______________________ to ___________________________________________

 

Commission file number 1-10526

 

UNITED-GUARDIAN, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   11-1719724
State or other jurisdiction of incorporation or organization   (I.R.S. Employer Identification No.)

 

230 Marcus Blvd., Hauppauge, NY 11788

(Address of principal executive offices, including zip code)

 

(631) 273-0900
Registrant's telephone number, including area code

 

Securities registered pursuant to Section l2(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.10 par value

UG

The NASDAQ Global Market

 

Securities registered pursuant to Section 12(g) of the Act:

None

 

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☑

 

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☑

 

 
 

 

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

 

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

                  

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

 

Large accelerated filer 

☐

  

Smaller reporting company  

☑

  
 

Accelerated filer  

☐

  

Emerging growth company

 ☐  
 

Non-accelerated filer  

☑

        

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐       

                  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☑

 

As of June 30, 2024, the last business day of the Registrant’s most recently completed second fiscal quarter, the aggregate market value of the voting and non-voting common equity held by non-affiliates, computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, was approximately $41,073,211 (based on a closing price of $8.94 per share). (For the purpose of this report it has been assumed that all officers and directors of the Registrant, as well as all stockholders holding 10% or more of Registrant's stock, are affiliates of the Registrant).

 

As of March 1, 2025, the Registrant had issued and outstanding 4,594,319 shares of Common Stock, $0.10 par value per share.                  

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Selected portions of the Registrant’s Proxy Statement for its 2025 Annual Meeting of Stockholders are incorporated by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the Registrant’s fiscal year ended December 31, 2024

 

2
 

  

 

SPECIAL NOTE ABOUT FORWARD LOOKING STATEMENTS

 

This Annual Report on Form 10-K for the year ended December 31, 2024 (“Annual Report”) contains both historical and forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which provides a safe harbor for forward-looking statements by the Registrant about its expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters. The Registrant desires to take advantage of such “safe harbor” provisions and is including this statement for that express purpose. Words such as “anticipates”, “believes”, “expects”, “intends”, “future”, and similar expressions identify forward-looking statements. Any such forward-looking statements in this report reflect the Registrant's views as of the date of filing of this report with the United States Securities and Exchange Commission (the “SEC”) with respect to future events and financial performance, and are subject to a variety of factors that could cause the Registrant's actual results or performance to differ materially from historical results or from the anticipated results or performance expressed or implied by such forward-looking statements. Because of such factors, there can be no assurance that the actual results or developments anticipated by the Registrant will be realized or, even if substantially realized, that they will have the anticipated results. The risks and uncertainties that may affect the Registrant's business include, but are not limited to: economic conditions, governmental regulations, technological advances, pricing and competition, acceptance by the marketplace of new products, retention of key personnel, the sufficiency of financial resources to sustain and expand the Registrant's operations, and other factors described in this report and in prior filings with the SEC. Readers should not place undue reliance on such forward-looking statements, which speak only as of the date hereof, and should be aware that except as may be otherwise legally required of the Registrant, the Registrant undertakes no obligation to publicly revise any such forward-looking statements to reflect events or circumstances that may arise after the date hereof. Past results are no guaranty of future performance.

 

 

 

 

 

 

 

 

 

3
 

 

 

INDEX TO ANNUAL REPORT ON FORM 10-K

 

 

Part I   5
     
Item 1. Business 5
Item 1A. Risk Factors 16
Item 1B. Unresolved Staff Comments 16
Item 1C. Cybersecurity 16
Item 2. Properties 17
Item 3. Legal Proceedings 17
Item 4. Mine Safety Disclosures 17
     
Part II   18
     
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 18
Item 6. [Reserved] 18
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 18
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 25
Item 8. Financial Statements and Supplementary Data 25
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 25
Item 9A. Controls and Procedures 25
Item 9B. Other Information 26
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 26
     
Part III   26
     
Item 10. Directors, Executive Officers and Corporate Governance 26
Item 11. Executive Compensation 26
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 26
Item 13. Certain Relationships and Related Transactions and Director Independence 26
Item 14. Principal Accountant Fees and Services 26
     
Part IV   27
     
Item 15. Exhibits and Financial Statement Schedules 27
     
Signatures 27

 

4
 

  

 

PART I

 

Item 1.

Business

 

Overview

 

United-Guardian, Inc. (“Company”) is a Delaware corporation that, through its Guardian Laboratories division, manufactures, markets and develops specialty cosmetic ingredients, pharmaceutical products, medical lubricants and sexual wellness ingredients. Prior to July 1, 2023, we manufactured and reported sales of a line of specialty industrial products; however, this product line was discontinued after the second quarter of 2023 due to low sales volume with no growth prospects. In October 2023, we entered into a distribution agreement with Brenntag Specialties, a global market leader in chemicals and ingredients distribution, for the distribution of our new Natrajel® line of sexual wellness ingredients in the United States, Canada, Mexico, Central America and South America. Although there were no sales of these products during 2024, we anticipate that we will begin manufacturing and reporting sales of this new line of products in 2025.

 

We conduct various research and development activities. Our research and development department primarily develops new and unique specialty cosmetic and sexual wellness ingredients. We develop new products using natural and environmentally friendly raw materials, which is a priority for many of our cosmetic customers. Our research and development department also modifies, refines, and expands the uses for existing products, with the goal of further developing the markets that our products are used in. All the products that we market, except for Renacidin®, are produced at our facility in Hauppauge, New York. Renacidin, a urological product, is manufactured for us by an outside contract manufacturer.

 

Our predecessor entity, United International Research, Inc. (“UIR”), was founded and incorporated in New York in 1942 by Dr. Alfred R. Globus, our Chairman and Director of Research until his death on April 9, 2009. On February 10, 1982, a merger took place between UIR and Guardian Chemical Corporation (“Guardian”), an affiliate of UIR, whereby Guardian was merged into UIR and the name was changed to United-Guardian, Inc., a New York corporation. On September 14, 1987, United-Guardian, Inc., a New York corporation, was merged with and into a newly formed Delaware corporation by the same name, United-Guardian, Inc., for the purpose of changing the domicile to the State of Delaware.

 

The cornerstone of our business is our product innovation. We use our product development and formulation expertise to maintain our market position and to propel future growth. We also focus on the development of new products that fill unmet market needs and have unique properties.

 

Our products are sold into stable and growing markets such as personal care, medical devices and healthcare. Our current product offerings include cosmetic ingredients, medical lubricants, pharmaceuticals and sexual wellness ingredients.

 

Our website, www.u-g.com, contains our annual reports on Form 10-K, quarterly reports on Form 10-Q, and any amendments to those reports. All such reports are available as soon as reasonably practicable after they are electronically filed with, or electronically furnished to, the U.S. Securities and Exchange Commission (“SEC”). These documents are also available in print to any stockholder who requests them. The information contained on our website is not part of this Annual Report on Form 10-K and is not incorporated by reference in this document. The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC.

 

Business Description

 

We manufacture, market and develop specialty cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness ingredients. Prior to July 1, 2023, we manufactured and reported sales of a line of specialty industrial products; however, this product line was discontinued after the second quarter of 2023 due to low sales volume and no growth prospects. In October 2023, we entered into a distribution agreement with Brenntag Specialties, a global market leader in chemicals and ingredients distribution, for distribution of our new Natrajel line of sexual wellness ingredients in the United States, Canada, Mexico, Central America and South America. Although there were no sales of these products during 2024, we anticipate that we will begin manufacturing and reporting sales of this new line of products in 2025.

 

5
 

 

We also conduct research and development, primarily related to the development of new and unique cosmetic ingredients, sexual wellness ingredients and medical lubricants. We focus on the development of products that fill unmet market needs, have unique properties, and use proprietary technology that we typically protect as trade secrets rather than with patents. Many of our products are marketed through collaborative distribution agreements with larger companies.

 

The cosmetic ingredients we manufacture are marketed to end users through our worldwide network of distributors and are currently used by many of the major manufacturers of cosmetic products. One of our most important product lines is our Lubrajel® line of multifunctional hydrogel formulations, which are designed to provide sensory enhancement, lubrication, hydration, and texture to both personal care and medical products. In the last few years, to meet the growing demand for “green” and sustainable products, we have focused on developing and launching new products which only contain ingredients that are considered “natural.” Our Lubrajel products in the natural line have been certified to meet the Cosmetic Organic and Natural Standard (“COSMOS”). This standard is recognized globally by the cosmetic industry. We ship our cosmetic ingredients to our distributors Ex Works (“EXW”) from our facility in Hauppauge, New York. Those distributors in turn resell those products to their customers, who are typically the manufacturers and marketers of cosmetic and personal care products. The cosmetic ingredients are not sold on a consignment basis, so unless a product is determined to be defective, it is not returnable, except at our discretion.

 

Our pharmaceutical products are sold primarily to several full-line drug wholesalers which in turn supply those products to pharmacies, physicians, and hospitals. We arrange for, and cover the cost of, shipping our pharmaceutical products, and sales of those products are final when shipped. They are returnable only under specific circumstances in accordance with pharmaceutical industry standards, such as if the products are (a) damaged when received; (b) defective; (c) too close to their expiration dates to sell; or (d) within a year after their expiration dates.

 

We operate as a single business segment. Our current products are separated into four distinct product categories: cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. Each product category is marketed differently. Effective July 1, 2023, we discontinued our industrial product line of products and beginning in 2024, we added sexual wellness ingredients to our portfolio of product categories.

 

Our cosmetic ingredients are currently marketed globally by five distributors, of which Ashland Specialty Ingredients (“ASI”), a business segment of Ashland, Inc., is the largest. ASI manufactures and markets globally an extensive line of personal care and pharmaceutical additives and various other specialty products. We sell our cosmetic ingredients directly to those distributors, which in turn resell our products to their customers for use in the formulation of one or more of the customers’ personal care and cosmetic products. Our non-pharmaceutical medical lubricants are sold directly to marketers of finished medical products or to the contract manufacturers utilized by those marketers. We market our pharmaceutical products primarily through our dedicated Renacidin website. The pharmaceutical products are sold through full-line drug wholesalers, which purchase our products outright for resale to primarily, hospitals and pharmacies. We also sell a small quantity of pharmaceutical products directly to hospitals and pharmacies. Our products are sold under trademarks or trade names that we own, some of which are registered with the United States Patent and Trademark Office as well as with comparable regulatory agencies in some foreign countries. We maintain a corporate website at www.u-g.com, and a specific website for Renacidin at www.renacidin.com. The information contained on either website is not part of this Annual Report on Form 10-K and is not incorporated by reference in this document.

 

All references in this Annual Report to “sales” or “Sales” shall mean “net sales” unless specifically identified as “gross sales.”

 

6
 

 

Products

 

Our current product offerings are segregated into the following categories:

 

 

●

Cosmetic Ingredients: Cosmetic ingredients include an extensive line of multifunctional hydrogel formulations designed to offer sensory enhancement, lubrication, texture and moisturization to personal care products.

 

 

●

Medical Lubricants: Medical lubricants include a line of hydrogel formulations designed to offer sensory enhancement and lubrication to medical products.

 

 

●

Pharmaceutical Products: Pharmaceutical products include an FDA approved prescription drug that is used primarily to prevent and to dissolve calcifications in urethral catheters, as well as a chlorine-based topical antimicrobial.

 

 

●

Sexual Wellness Ingredients: Sexual wellness ingredients include a line of hydrogel formulations designed to offer sensory enhancement, lubrication and moisturization to sexual wellness applications.

 

Cosmetic Ingredients – Products

 

 

●

LUBRAJEL is an extensive line of multifunctional hydrogel formulations designed to mainly provide sensory enhancement, lubrication, and texture to personal care products. Most if not all of the Lubrajel products also offer skin hydration benefits. The Lubrajel products are primarily used in skin care products such as moisturizers, anti-aging creams, body lotions, face serums and masks, spa products and sunscreens. The Lubrajel products are also used in makeup products such as primers and foundations. Each Lubrajel product offers unique benefits for the formulation of skin care and color cosmetic products. The basic product line includes Lubrajel CG, Lubrajel DV, Lubrajel IIXD, Lubrajel MS, Lubrajel NP and Lubrajel Oil.

 

 

 

To address customer demand for preservative-free products, we developed and launched Lubrajel DV PF, Lubrajel IIXD PF, Lubrajel MS PF, Lubrajel Oil PF and Lubrajel PF. To address customer demand for paraben-free products, we developed and launched Lubrajel DV free, Lubrajel IIXD free, Lubrajel MS free, Lubrajel NP Free and Lubrajel Oil free.

 

 

 

In the last few years, to meet the growing consumer demand for “green” and sustainable products, we have focused on developing and launching new products which only contain ingredients that are considered “natural.” The Lubrajel products in the natural line have been certified to meet the Cosmetic Organic and Natural Standard (“COSMOS”). This standard is recognized globally by the cosmetic industry.

 

 

 

The COSMOS line of products includes Lubrajel Natural, Lubrajel Marine, Lubrajel Oil Natural and Lubrajel Terra. All of the natural products are designed using green technology and contain natural raw materials. These products are multifunctional, Roundtable on Sustainable Palm Oil (“RSPO”) certified, Vegan, biodegradable and COSMOS approved. Each one offers a unique skin feel and improves the sensory characteristics of personal care formulations.

 

 

 

In addition to the Lubrajel line of products, we also manufacture the following additional cosmetic ingredients, which accounted for less than 10% of total sales in 2024 and 2023:

 

 

●

B-122™ is a powdered lubricant used in the manufacture of certain cosmetics, such as pressed powders, eyeliners, and rouges, as well as some industrial products. The product acts as a binder, increases water-repellency and drop strength, and lowers the coefficient of friction in the products in which it is used.

 

 

●

ORCHID COMPLEX™ is an oil-based extract of fresh orchids. It is characterized by its excellent lubricity, spreadability, light feel, and emolliency. Because of its alcohol solubility it may also be used in fragrance products, such as perfumes and toiletries. Its emolliency makes it an excellent additive to shampoos, bath products and facial cleansers.

 

 

●

LUBRASIL™ II SB is a special formulation of Lubrajel in which silicone oil is incorporated into a Lubrajel base using proprietary technology that enables the product to maintain much of the clarity of regular Lubrajel. The product has a silky feel and is water resistant while at the same time providing moisturization.

 

7
 

 

Sales of our cosmetic ingredients represented approximately 45% and 38% of our total sales for the years ended December 31, 2024 and 2023, respectively.

 

The cosmetic ingredients we manufacture are marketed and sold to end users through our worldwide network of distributors and marketing partners. Our cosmetic ingredients are currently sold globally by five distributors, of which Ashland Specialty Ingredients (“ASI”), a business segment of Ashland, Inc., is the largest. ASI is the exclusive distributor of these products in the United States, Canada, Asia, South & Central America, Mexico, Europe (all regions other than France, the United Kingdom, Italy & Switzerland), Scandinavia, Africa, Australia, and the Middle East. ASI had been our distributor in South Korea until February 5, 2025, at which time we formally entered into a new marketing and distribution agreement with Azelis Group NV (“Azelis”) to market our products in South Korea. Azelis also markets our cosmetic ingredients in the United Kingdom and Ireland. Our other cosmetic ingredient distributors are Sederma SAS (a subsidiary of Croda International Plc.) in France, Safic-Alcan S.p.A. in Italy, and Azelis Cosmetics GmbH in Switzerland. We are currently in the process of renegotiating some of our marketing and distribution agreements.

 

We ship our cosmetic ingredients to our distributors Ex Works (“EXW”) from our facility in Hauppauge, New York. The distributors resell the products to their customers, which are typically major manufacturers and marketers of cosmetic and personal care products who utilize our products in their finished products. The cosmetic ingredients are not sold on a consignment basis, so unless a product is determined to be defective, it is not returnable, except at our discretion.

 

Since our Lubrajel hydrogels are well-known and established specialties, we believe that in the event ASI or any of our other cosmetic product distributors were to cease marketing and selling our products, alternative distribution agreements could be signed with other distributors of cosmetic ingredients in the affected territory or territories. These new distributors would continue supplying products to customers currently using our products, without any significant interruption of sales. If necessary, we would also be able to sell directly to the end users of our products until a new distribution arrangement was put in place.

 

We believe that there is potential to continue growing the sales of our cosmetic ingredients through the development of new products, product applications, additional claim substantiations, and geographic expansion. Although we have experienced significant pricing pressure from low-cost competitors, we believe that we can compete effectively with these low-cost competitors because our customers value our innovation capabilities, the quality of our products, the reliability of supply and our technical expertise.

 

Medical Lubricants– Products

 

Our medical lubricants are sold directly to manufacturers and marketers of finished medical products or to the contract manufacturers utilized by those companies. Sales of our medical lubricants are shipped EXW from our facility in Hauppauge, New York. Sales are deemed final upon shipment, and we have no obligation to repurchase or allow the return of these goods unless they are defective.

 

Our medical lubricants are also sold under the Lubrajel brand since they are hydrogel formulations designed to provide sensory enhancement and lubrication to medical products. The Lubrajel medical lubricant products are primarily used in catheters, condoms, personal lubricants and in oral care applications such as mouthwashes.

 

Currently, we offer medical lubricant products for catheter lubrication, medical devices, condom lubrication and oral care. In addition, we develop and sell customized exclusive products for all these applications.

 

Our medical lubricants include Lubrajel MG, Lubrajel MGL, Lubrajel RRCG, Lubrajel RR, Lubrajel RC, Lubrajel RA, Lubrajel Fluid, Lubrajel LC, Lubrajel BA, and Lubrajel FACO.

 

8
 

 

Lubrajel MG and Lubrajel MGL are our standard medical lubricants and can be applied to catheters, thermometers and other instruments to ensure ease of use and patient comfort. Our R-line of products, Lubrajel RRCG, Lubrajel RR, Lubrajel RC and Lubrajel RA can withstand sterilization by gamma radiation, which is one of the methods of terminally sterilizing medical and hospital products. Lubrajel Fluid is designed as an alternative to traditional silicone-based lubricants. The water-based formula offers easy clean up and is non-staining. It is compatible with traditional condom release powders which are used during the manufacture of latex condoms.

 

Lubrajel LC, Lubrajel BA and Lubrajel FACO are hydrogel formulations developed for use in oral care applications.

 

Sales of medical lubricants represented approximately 17% and 16% of our total sales for the years ended December 31, 2024 and 2023, respectively.

 

We believe that there is potential to continue growing the sales of our medical lubricants through new product development, development of new product applications and markets, and geographic expansion. Pursuant to this cause, the agreement we signed on February 5, 2025 with Azelis gave Azelis the rights to distribute our medical lubricants in the UK and Ireland. We believe this will create opportunities to expand the medical lubricant business.

 

Pharmaceuticals – Products

 

 

●

RENACIDIN is a prescription drug approved by the FDA that is used primarily to prevent and to dissolve calcifications in urethral catheters. We maintain a specific website dedicated to this product at www.renacidin.com.

 

 

●

CLORPACTIN® WCS-90 (“Clorpactin”) is a chlorine-based drug that is marketed as a topical antimicrobial and is also used in urology. It is also a powerful disinfectant, fungicide, and deodorizer.

 

Our pharmaceutical products represented 39% and 45% of our total sales for the years ended December 31, 2024 and 2023, respectively.

 

We sell our pharmaceutical products primarily to full-line drug wholesalers, which in turn supply those products to pharmacies, physicians, hospitals, long-term care facilities, the U.S. Department of Veterans Affairs, and other government agencies. We also sell a small quantity of pharmaceutical products directly to hospitals and pharmacies. We arrange for, and cover the cost of, shipping our pharmaceutical products, and sales of those products are final when shipped. The pharmaceutical products are returnable only under specific circumstances in accordance with pharmaceutical industry standards, such as if the products are (a) damaged when received; (b) defective; (c) too close to their expiration dates to sell; or (d) within a year after their expiration dates. These return policies are in conformance with standard pharmaceutical industry practice.

 

We believe that there is potential to grow the sales of our pharmaceutical products through additional marketing strategies and geographic expansion.

 

Sexual Wellness Ingredients – Products

 

Sexual wellness ingredients include a line of hydrogel formulations designed to offer sensory enhancement, lubrication, and moisturization to sexual wellness applications. Although we did not manufacture or have any sales of these products during 2024, we anticipate that we will begin manufacturing and reporting sales of this new line of products in 2025.

 

The new Natrajel line of products comprises Natrajel NT, Natrajel MA, Natrajel ON and Natrajel TE. This line was designed using green technology and contains natural raw materials. All the products are RSPO certified, vegan, biodegradable and COSMOS approved.

 

9
 

 

Domestic Sales

 

For the years ended December 31, 2024 and 2023, approximately 84% and 79%, respectively, of our sales were from domestic sources, which represents sales within the United States only.

 

Cosmetic Ingredients – Domestic Sales

 

In the United States, our cosmetic ingredient products have been marketed and distributed exclusively by ASI in accordance with a marketing agreement entered into in 1996 with its predecessor company, International Specialty Products (“ISP”) and last automatically renewed on January 1, 2022. That agreement was for the marketing of the Company’s cosmetic ingredients in North America, Central America, South America, Asia Pacific, and EMEA. ASI also had the exclusive right to market four of our products globally: Lubrajel Marine, Lubrajel BA, Lubrajel Oil PF and Lubrajel II XD PF. The current agreement with ASI terminated on December 31, 2023, pursuant to a letter provided by us to ASI on October 10, 2023. The purpose of the termination was to renegotiate the terms and conditions of the distribution agreement between the two companies. At this time we have not finalized a new agreement, but we are hopeful that a new agreement will be executed by the end of the second quarter of 2025, although there can be no assurance that a new agreement will be executed. We continued to work with ASI as we negotiate a new agreement by fulfilling orders, discussing marketing strategies, and continuing to engage with them on other marketing matters in a manner consistent with past practice.

 

Domestic sales of cosmetic ingredients accounted for approximately 41% of total sales in 2024, compared with 31% in 2023. Sales to our largest distributor, ASI, accounted for approximately 41% of total sales in 2024 and 30% of sales in 2023.

 

Medical Lubricants – Domestic Sales

 

We sell our medical lubricants directly to end users or to contract manufacturers utilized by the end users. Domestic sales of medical lubricants accounted for approximately 4% of our total sales in 2024 and 3% of total sales in 2023. Although all shipments of medical lubricants to U.S. locations are considered domestic sales, a percentage of those shipments are subsequently shipped by some customers to foreign manufacturing facilities, which then produce finished products that could be marketed globally.

 

Pharmaceuticals – Domestic Sales

 

Our pharmaceutical products are marketed only in the United States and are sold primarily through full-line drug wholesalers. Sales of those products accounted for approximately 39% of sales in 2024, compared with approximately 45% in 2023.

 

During 2024 and 2023, we participated in various government drug rebate programs related to the sale of Renacidin, our most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (“FSS”), and the Medicare Part D Coverage Gap Discount Program (“CGDP”). These programs require us to sell our product at a discounted price, typically given in the form of a rebate. Our sales, as reported, are net of these rebates, some of which are estimated and are recorded in the same period that the revenue is recognized.

 

10
 

 

Sexual Wellness – Domestic Sales

 

         Sexual wellness ingredients include a line of hydrogel formulations designed to offer sensory enhancement, lubrication, and moisturization to sexual wellness applications. Although we did not manufacture or have any sales of these products during 2024, we anticipate that we will begin manufacturing and reporting sales of this new line of products in 2025.

 

Foreign Sales

 

For the years ended December 31, 2024 and 2023, approximately 16% and 21%, respectively, of our sales revenue was from foreign sources, and was derived from (a) sales of our cosmetic ingredients to foreign distributors, which accounted for approximately 7% of sales for each of the years ended December 31, 2024 and 2023, respectively, and (b) sales of medical lubricants directly to certain customers in foreign countries, which accounted for approximately 9% and 14% of our sales revenue for the years ended December 31, 2024 and 2023, respectively.

 

Because all shipments to our largest distributor, ASI, are delivered to ASI’s warehouses in the U.S., all sales to ASI are considered domestic sales, even though a significant percentage of ASI’s sales of our products are to customers in foreign countries. Based on sales information provided by ASI, 79% of ASI’s sales of our products in 2024 were to customers in foreign countries, compared with 69% in 2023. ASI’s largest foreign market in both 2024 and 2023 was China, which accounted for approximately 43% of ASI’s sales of our products in 2024 and 29% in 2023.

 

Since sales of our products are in U.S. Dollars, our selling prices are generally not affected by fluctuations in foreign currency exchange rates, except to the extent that a stronger dollar compared with foreign currencies can make our products less competitive in foreign markets, sometimes requiring adjustments to our prices in order to be more competitive. We continue to work closely with our network of distributors to price our products as competitively as possible and, when appropriate, to offer additional volume discounts and more aggressive pricing to maintain and increase sales and expand our customer base.

 

ISO 9001:2015 Certification

 

On July 23, 2018, we were certified by DQS Inc. to be in compliance with the latest ISO standard, ISO 9001:2015, indicating that our documented procedures and overall operations had attained the high level of quality needed to comply with this current ISO certification level.

 

Our current ISO 9001:2015 certification is valid through July 22, 2027. We have been in continuous compliance with ISO standards since November 1998. Between November 1998 and December 2003, we were registered under the ISO 9002 standard. From December 2003 to December 2009, we were registered under the ISO 9001:2000 standard. From December 2009 to July 2018, we were registered under the ISO 9001:2008 standard.

 

Competition

 

We primarily compete in the specialty ingredients space. The participants in this space offer a broad range of product lines designed to meet specific customer needs. Competition is largely based on product performance, price, quality, service, product availability, security of supply, and responsiveness of product development in cooperation with customers. Many key competitors are significantly larger than us and have greater financial resources, leading to greater operating and financial flexibility.

 

To improve our competitive position, we are strengthening our core capabilities and investing in product development, especially in naturally derived products. We will continue to provide high-quality products, technical expertise and be a reliable supplier to our distributors and customers.

 

11
 

 

Intellectual Property

 

In recent years, we have elected to rely on trade secret protection to protect our intellectual property for proprietary product formulations and manufacturing methods. We will file for patent protection in situations where we believe that relying on trade secret protection alone would not provide sufficient protection.

 

We own the Lubrajel®, Renacidin®, Clorpactin®, Excellence Through Innovation®, and Natrajel® trademarks.

 

Raw Materials

 

We purchase a predominant amount of our raw materials from multiple sources in the United States and believe that raw material supplies will be available in quantities sufficient to meet demand in 2025. Although some of those raw materials may be manufactured overseas, all but one of our suppliers are located within the United States.

 

The Trump administration has communicated its intention to impose tariffs on many products imported from China, Canada and Mexico. Some of those tariffs went into effect on March 4, 2025. Since that time the Trump administration has increased some of those tariffs and postponed others. It has threatened to levy tariffs on additional countries, including those of the European Union. Many of the countries on which those tariffs have been levied have imposed their own retaliatory tariffs or threated to impose tariffs on goods they import from the U.S. The tariff situation remains fluid and is subject to modification at any time. At this time, it is difficult to determine the impact of these tariffs on our business. We will continue to monitor this situation closely.

 

While we obtain most of our raw materials and lab supplies from domestic sources, we have three suppliers that obtain their raw materials from China. These materials are not purchased by us in large quantities, and we have adequate stock on hand to cover the next six months. In addition, we have one direct raw material supplier in China; however, the raw materials we purchase from this supplier are not in large quantities and the effect of this tariff would not materially impact the pricing of our products.

 

The principal raw materials we use consist of common industrial organic and inorganic chemicals. We have three major raw material vendors that together accounted for approximately 83% of our raw material purchases in 2024 and 76% in 2023.

 

Inventories, Returns, and Allowances

 

We believe it is important to maintain moderate inventory levels of some of our finished goods in order to fulfill purchase orders in a timely manner. Historically, sufficient inventory levels, returns, and allowances have not been a significant factor in our business.

 

Backlog

 

We do not currently have any significant backlog of orders.

 

Seasonality

 

Due to the nature of our business and the types of products that we market, we are not subject to any significant seasonal fluctuations in sales.

 

Customers

 

Our cosmetic ingredients are currently marketed and sold globally by five distributors. Those distributors, in turn, market and distribute those products to their customers. Although we depend on these distributors for the marketing and distribution of our cosmetic ingredients, we believe that if any of our distributors were to decide not to sell our products, or if we chose to replace one or more of those distributors, we would be able to put new marketing agreements in place to service our customers in all the geographic areas affected. If necessary, we would also be able to sell directly to the end users of our products until such time as a new distributor is put in place.

 

12
 

 

Our pharmaceutical products are sold to, and distributed by, full-line drug wholesalers throughout the United States. Our medical products are sold directly by us to the end users of those products or, in some cases, to contract manufacturers used by some of those end users.

 

Research and Development

 

Our research and development (“R&D”) team’s main focus is to develop new products and product-line extensions. The product development activities are focused on developing products for identified customers and unmet market needs. We frequently collaborate with customers to develop the desired product to meet their specific needs. The R&D team also provides technical support services to assist our customers with application development and co-development. In addition, the R&D team provides ongoing technical assistance and know-how to quality assurance and manufacturing personnel to ensure consistent standards for our products and to deliver environmentally responsible products that exceed customer expectations.

 

Our research and development expenses in 2024 were $456,779 compared with $463,992 in 2023. We expect our research and development expenses in 2025 to be higher than those in 2024 in order to support innovation and growth initiatives. Any additional increase in R&D expenses will also depend on whether capital investments are required in order to continue development work on, or to manufacture, any of the new products under development.

 

We require all employees and consultants who may receive confidential and proprietary information to agree in writing to keep such information confidential.

 

Government Regulation

 

Regulation by governmental authorities in the United States and other countries is a significant factor in the manufacturing and marketing of many of our products. Some of the products we develop and sell in the United States may require approval from federal regulatory agencies, such as the U.S. Food & Drug Administration (“FDA”), as well as state regulatory agencies. Some products sold outside the United States may require approval from foreign regulatory agencies.

 

Our operations and many of our products are subject to chemical control laws. These laws include regulation of chemical substances and inventories under and the Registration, Evaluation and Authorization of Chemicals (“REACH”) regulation in Europe, Right to Know laws under the Global Harmonized System (“GHS”) for hazard communication, and the regulation of chemicals used in the manufacture of pharmaceuticals and personal care products and contact food under the Food, Drug and Cosmetics Act in the United States. We are an FDA Drug Establishment registered site.

 

We are required to comply with all pertinent current Good Manufacturing Practices of the FDA for medical devices and drugs our products may be subject to. Accordingly, the regulations to which we and certain of our products may be subject, and any changes with respect thereto, may materially affect our ability to produce and market new products.

 

Our present and future activities are, and will likely continue to be, subject to varying degrees of additional regulation under the Occupational Safety and Health Act, Environmental Protection Act, import, export and customs regulations, and other present and possible future foreign, federal, state and local regulations.

 

Portions of our operating expenses are directly attributable to complying with federal, state, and local environmental statutes and regulations. In 2024 and 2023, we incurred approximately $24,000 and $41,000, respectively, in federal, state, and local environmental law compliance expenses. There was no material financial or other impact on our results of operations as a result of compliance with environmental laws.

 

13
 

 

Health and Safety

 

We value all of our employees, suppliers, customers and distributors as well as the broader environment in which we all live and work. We are committed to protecting the safety, health and security of our employees and that of the environment in which we operate. We are further committed and have implemented strict policies against anti-discrimination, anti-harassment and anti-bulling, and will not compromise employee health and safety or the environment for profit.

 

Environmental and Corporate Social Responsibility

 

Sustainability

 

We have a proactive mindset for sustainability. We are committed to sustainable growth and minimizing our impact on the local community and the environment. We are committed to measuring and monitoring our impact on the environment and, where appropriate, making improvements. We comply in all material respects with all federal, state and local environmental regulations.

 

We have created a sustainability committee that reviews our Scope 1 and Scope 2 emissions to determine ways in which we can reduce our impact on the environment. We recently installed an energy efficient roof to lower our energy consumption. We have established goals to lower our energy emissions and recycle water used in our manufacturing process. We have also joined initiatives for core raw materials, such as the Roundtable on Sustainable Palm Oil (“RSPO”), to ensure that we support suppliers in protecting the environment and the people in it. We are committed to using green chemistry principles to produce biodegradable, natural, and safe products with renewable feedstocks.

 

Solid Waste

 

We do not produce hazardous waste. We comply with U.S. Environmental Protection Agency (“EPA”) and Department of Transportation’s (“DOT”) regulations for the disposal of the solid waste.

 

Water Discharge

 

We comply in all material respects with all laws and regulations on water discharge.

 

ECOVADIS

 

We joined EcoVadis as part of our commitment to Corporate Social Responsibility (“CSR”). EcoVadis is a global leader in guiding, measuring, and improving corporate environmental and social responsibility and sustainability performance. The EcoVadis assessment measured 21 key issues centered on the environment, labor & human rights, ethics, and sustainable procurement. In its latest evaluation we scored in the top 15% of companies evaluated.

 

As part of the assessment, it was determined that we were strong in the following four areas:

 

 

1.

Environmental:

 

 

●

Company-specific emergency preparedness and response procedure regarding customer health and safety
 

●

Measures to detect and/or eliminate accidental water contamination
 

●

Formalized procedure related to materials/chemicals management
 

●

Provision of Safety Data Sheets
 

●

Employee awareness/training program on transportation of hazardous materials
 

●

Measures to avoid emissions of dust or particles

 

14
 

 

 

2.

Labor & Human Rights:

 

 

●

Labor and human rights policy
 

●

Formalized procedure related to employee health and safety
 

●

Compensation for extra or atypical working hours
 

●

Additional leave beyond standard vacation days
 

●

Bonus scheme related to Company performance
 

●

Heath care coverage of employees in place
 

●

Whistleblower procedure on discrimination and harassment
 

●

Awareness training regarding diversity, discrimination and/or harassment
 

●

Regular assessment (yearly) of individual performance
 

●

Active preventative measures for stress and noise
 

●

Training of relevant employees on health and safety risks and best working practices

 

 

3.

Ethics:

 

 

●

Disciplinary sanctions to deal with policy violations
 

●

Policy on information security
 

●

Polices on corruption
 

●

Whistleblower procedure to report ethics issues

 

 

4.

Sustainable Procurement:

 

 

●

RSPO Supply Chain Certification
 

●

Formal assessment of supplier’s progress with regards to REACH requirements
 

●

No use of tin, tantalum, tungsten, gold, and/or their derivatives

         

Areas that required continual improvements were reviewed, and programs and policies were implemented as follows:

 

 

1)

Environmental impact from product end of life: we joined a prescription take-back program for our pharmaceutical products in the state of California.

 

 

2)

Measures on energy consumption and GHG’s: we created a sustainability committee that meets monthly to review our Scope 1 and Scope 2 emissions as well as determine ways to reduce our energy consumption.

 

 

3)

Established formal CSR Policy: we created a CSR policy to establish a framework for our commitment to sustainable performance.

 

Employees

 

Human Capital Management

 

We currently have 25 employees, 3 of whom serve in an executive capacity, 18 in research, quality control and manufacturing, 1 in maintenance and construction, and 3 in office and administrative support services. Of the total number of employees, 24 are employed full-time.

 

Compensation and Benefits

 

We are committed to paying our employees in a fair and equitable manner, regardless of race, gender or country of origin. We believe employees should be compensated equitably based on performance, skills, and experience. We offer a competitive benefits program to support employees through all life stages.

 

15
 

 

Employee Engagement

 

We focus significant resources on developing and retaining diverse talent and are committed to actively creating a collaborative environment of innovation that leverages the talents of our workforce to drive sustainable growth and create value for our stockholders, customers, employees, and the community in which we operate.

 

Talent Management

 

The talent management process includes a well-established performance assessment process that seeks to provide employees with ongoing feedback to enhance their performance in support of business objectives.

 

Item 1A.

Risk Factors.

 

The information to be reported under this item is not required of smaller reporting companies.

 

Item 1B.

Unresolved Staff Comments.

 

None.

 

 

Item 1C.

Cybersecurity.

 

We continue to augment the capabilities of our people, processes, and technologies to address our cybersecurity risks. Our cybersecurity risks, and the controls designed to mitigate those risks, are integrated into our overall risk management governance and are reviewed yearly by our Board of Directors.

 

We take steps to protect our data and third-party data we receive through the implementation of technological and organizational measures designed to reduce the risk from cybersecurity threats, including data theft or destruction.

 

We have undertaken a program of annual enterprise-wide cybersecurity risk assessments and have implemented policies, procedures, and programs designed to help manage the risks to which we are exposed in our business. As part of our risk management process, we have implemented a risk-based approach to identify and assess the cybersecurity threats that could affect our business and information systems, as well as the systems of third parties on whom we rely, such as any cloud hosting partners. Our cybersecurity program is designed to assess, identify, and manage material risks and vulnerabilities to our security posture, including prioritizing and remediating cybersecurity risks.

 

Our program includes, among other things:

 

• Incorporation of cybersecurity in our overall enterprise risk management processes, including periodic risk assessments and tools used to track and monitor risks.

 

• Regular reviews of cybersecurity risks and mitigation efforts.

 

• Use of software and hardware tools and services to help safeguard our systems, information, and data.

 

• Assessments designed to help identify cybersecurity risks to our critical systems, information, products, services, and our broader enterprise IT environment.

 

• An employee information security training program to educate employees on various cybersecurity risks and mitigation strategies.

 

• Policies and processes governing our third-party security risks.

 

16
 

 

Risk Management and Strategy

 

We have implemented a set of comprehensive cybersecurity and data protection policies and procedures. Risks from cybersecurity threats are regularly evaluated as a part of our broader risk management activities and as a fundamental component of our internal control system. Our employees receive ongoing cybersecurity awareness training, including specific topics related to social engineering and email fraud. We utilize an outsourced information technology firm and consultants with significant expertise in cybersecurity. We invest in advanced technologies for continuous cybersecurity monitoring across our information technology environment which are designed to prevent, detect, and minimize cybersecurity attacks, as well as alert management of such attacks.

 

Our Information Technology General Controls are firmly established based on the National Institute of Standards and Technology (“NIST”) cybersecurity framework and cover areas such as risk management, data backup, and disaster recovery. We have utilized an outsourced information technology consultant to reduce and monitor security threats and vulnerabilities.  As part of our gap analysis, identified vulnerabilities have been, and will continue to be, promptly addressed with our senior business leadership and our Board of Directors. 

 

 

Governance

 

Our Board of Directors is responsible for overseeing our cybersecurity risk management and strategy. Our President regularly meets with and provides periodic briefings to our Board of Directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.

 

 

Item 2.

Properties

 

We own our principal office, manufacturing, and research and development facility consisting of a 50,000 square foot facility on a 2.7-acre parcel located at 230 Marcus Boulevard, Hauppauge, New York 11788. Approximately 30,000 square feet of the facility is manufacturing space, 15,000 square feet is warehouse space, and 5,000 square feet is office and laboratory space. We believe that the property is adequate for our immediately foreseeable needs. The property is presently unencumbered and we believe the property is adequately insured.

 

Item 3.

Legal Proceedings

 

From time to time, we are subject to ordinary routine litigation and claims incidental to our business. We are not currently involved in any legal proceedings that we believe are material.

 

Item 4.

Mine Safety Disclosures

 

Not applicable.

 

 

 

17
 

 

PART II

 

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

 

Market Information

 

Our Common Stock is currently traded on the NASDAQ Global Market, under the symbol “UG”

 

Holders of Record

 

As of March 3, 2025, there were 342 holders of record of Common Stock.

 

Dividend Policy

 

On July 10, 2024, our Board of Directors declared a cash dividend of $0.35 per share, which was paid on July 31, 2024, to all holders of record as of July 23, 2024. On January 30, 2024, our Board of Directors declared a cash dividend of $0.25 per share, which was paid on February 20, 2024, to all holders of record as of February 12, 2024. On January 27, 2025, our Board of Directors declared a cash dividend of $0.35 per share, which was paid on February 18, 2025, to all holders of record as of February 10, 2025.

 

On July 12, 2023, our Board of Directors declared a cash dividend of $0.10 per share, which was paid on August 2, 2023, to all stockholders of record as of July 26, 2023. We did not declare any other dividends in 2023. In June of 2023, our Board of Directors changed the dividend declaration practice to a semi-annual dividend declaration in January and July of each year.

 

Item 6.

[RESERVED]

 

Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

 

You should read the following discussion and analysis in conjunction with our financial statements and related notes contained elsewhere in this Annual Report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors discussed in this report and those discussed in other documents we file with the SEC. In light of these risks, uncertainties and assumptions, readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements represent beliefs and assumptions as of the date of this report. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Past performance does not guarantee future results.

 

Executive Level Overview

 

We specialize in manufacturing cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients through our Guardian Laboratories division. With a long-standing reputation for delivering high-quality specialty products, we are committed to serving diverse markets with innovative solutions.

 

As part of our strategic focus, we discontinued our specialty industrial products line in mid-2023 due to low sales and limited growth potential. This shift allows us to concentrate on higher-value product categories with greater market opportunities.

 

In October 2023, we took a significant step toward expanding our presence in the sexual wellness market by partnering with Brenntag Specialties, a global leader in chemicals and ingredients distribution. Under this agreement, Brenntag will distribute our new Natrajel line of sexual wellness ingredients across North and South America. While we reported no sales of this product in 2024, we anticipate beginning manufacturing and revenue generation in 2025.

 

18
 

 

With a refined product portfolio and strategic partnerships, we are well-positioned for future growth, leveraging our expertise in specialty ingredients to capitalize on emerging market opportunities.

 

Impact of Global Supply Chain Instability, Inflation and Tariffs

 

The continued supply chain instability, primarily caused by military tensions in the Middle East, continues to impact vessels’ access to the Red Sea and Suez Canal. Shipping experts say this crisis may last into the first half of 2025. We continue to work with our suppliers regarding lead times and continue to closely monitor this situation. Although we have not yet experienced any delays in receiving raw materials or an increase in shipping costs, we are aware that the situation is fluid and could impact us at any time. If that occurs, we may experience longer lead times and increased shipping costs for some of our raw materials, which may impact our future gross margins. As a result of this global supply chain instability, there continues to be uncertainty regarding the potential impact on our operations or financial results and we are unable to provide an accurate estimate or projection as to what the future impact will be.

 

The Trump administration has communicated its intention to impose tariffs on many products imported from China, Canada and Mexico. Some of those tariffs went into effect on March 4, 2025. Since that time the Trump administration has increased some of those tariffs and postponed others. It has threatened to levy tariffs on additional countries, including those of the European Union. Many of the countries on which those tariffs have been levied have imposed their own retaliatory tariffs or threated to impose tariffs on goods they import from the U.S. The tariff situation remains fluid and is subject to modification at any time. At this time, it is difficult to determine the impact of these tariffs on our business. We will continue to monitor this situation closely.

 

While we obtain most of our raw materials and lab supplies from domestic sources, we have three suppliers that obtain their raw materials from China. These materials are not purchased by us in large quantities, and we have adequate stock on hand to cover the next six months. In addition, we have one direct raw material supplier in China; however, the raw materials we purchase from this supplier are not in large quantities and the effect of this tariff would not materially impact the pricing of our products.

 

Many of our products are used in the formulation of finished products that are manufactured in China and then imported back into the United States (“U.S.”) for sale. There is the possibility that the tariffs levied on these finished products could result in an increase in their price, which could potentially impact demand for these products in the U.S.

 

Due to the continued uncertainty of this, any other tariffs that may be imposed, there continues to be uncertainty regarding the future impact of any additional tariffs on our operations or financial results.

 

Critical Accounting Policies

 

Our financial statements have been prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“US GAAP”). Preparation of financial statements requires us to make estimates and assumptions affecting the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities. We use our historical experience and other relevant factors when developing our estimates and assumptions, which are continually evaluated. Note A, Nature of Business and Summary of Significant Accounting Policies, of the Notes to Financial Statements, included in Item 8, Financial Statements and Supplementary Data, of this Annual Report, includes a discussion of our significant accounting policies. The following accounting policies are those that we consider critical to an understanding of the financial statements because their application places the most significant demands on management’s judgment. Our financial results might have been different if other assumptions had been used or other conditions had prevailed.

 

Marketable Securities

 

Our marketable securities include investments in equity mutual funds, Certificates of Deposit and U.S. Treasury Bills with original maturities of greater than three months. Our marketable equity securities are reported at fair value with the related unrealized and realized gains and losses included in net income. Certificates of Deposit and U.S. Treasury Bills with original maturities of more than 3 months are recorded at amortized cost. Realized gains or losses on mutual funds are determined on a specific identification basis. We evaluate our investments periodically for possible other-than-temporary impairment by reviewing factors such as the length of time and extent to which fair value had been below cost basis, the financial condition of the issuer, and our ability and intent to hold the investment for a period of time which may be sufficient for anticipated recovery of market value. We record an impairment charge to the extent that the cost of the available-for-sale securities exceeds the estimated fair value of the securities and the decline in value is determined to be other-than-temporary. During 2024 and 2023, we did not record an impairment charge regarding our investment in marketable securities because management believes, based on an evaluation of the circumstances, that any decline in fair value below the cost of certain of our marketable securities is temporary.

 

19
 

 

Revenue Recognition

 

We record revenue in accordance with ASC Topic 606 “Revenue from Contracts with Customers.” Under this guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. Our principal source of revenue is product sales.

 

Our sales, as reported, are subject to a variety of deductions, some of which are estimated. These deductions are recorded in the same period in which the revenue is recognized. Such deductions, primarily related to the sale of our pharmaceutical products, include chargebacks from the United States Department of Veterans Affairs (“VA”), rebates in connection with our current participation in Medicare programs, distribution fees, discounts, and outdated product returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on sales for a reporting period.

 

During 2024 and 2023, we participated in various government drug rebate programs related to the sale of Renacidin, our most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (“FSS”), and the Medicare Part D Coverage Gap Discount Program (“CGDP”). These programs require us to sell our products at a discounted price, typically in the form of a rebate. Our sales, as reported, are net of these rebates, some of which are estimated and are recorded in the same period that the revenue is recognized.

 

On January 1, 2025, the Centers for Medicare & Medicaid Services (“CMS”) implemented a new Medicare Part D Manufacturer Discount Program (“Discount Program”), which replaced the prior CGDP. The new Discount Program eliminates the coverage gap benefit phase, introduces pharmaceutical manufacturer discounts in the initial and catastrophic coverage phases, and lowers the cap on enrollee out-of-pocket costs. Under the new Discount Program, additional rebates are expected to be owed by pharmaceutical manufacturers due to the restructuring of the benefit periods and removal of the cap that was in place that limited the drug manufacturer’s liability. The overall financial impact of this new program will vary depending on the products being reimbursed but it is expected to increase Medicare Part D rebates for drug manufacturers.

 

On January 31, 2024, we were notified by CMS that we qualified as a “specified small manufacturer” and would be entitled to a multi-year phase-in period during which we would pay a lower percentage discount on drugs dispensed to beneficiaries. Based on our “specified small manufacturer” designation, it appears, based on our current level of sales through the Medicare Part D Program, we would have reduced rebate liabilities in years 2025 and 2026, with rebates gradually increasing each year after, until they reach their full phase-in by 2031. By the end of the phase in period in 2031, these rebate liabilities are expected to significantly exceed the liabilities we have recorded under the CGDP in previous years.

 

As long as a valid purchase order has been received and future collection of the sale amount is reasonably assured, we recognize revenue from sales of our products when those products are shipped, which is when our performance obligation is satisfied. Our cosmetic products are shipped EXW from our facility in Hauppauge, NY, and the risk of loss and responsibility for the shipment passes to the customer upon shipment. Sales of our medical lubricant products are deemed final upon shipment, and we have no obligation to repurchase or allow the return of these goods unless they are defective. Sales of our pharmaceutical products are final upon shipment unless (a) they are found to be defective; (b) the product is damaged in shipping; (c) the product is too close to its expiration date for the customer to sell; or (d) the product is expired but is not more than one year after its expiration date. These return policies are in conformance with standard pharmaceutical industry practice. We estimate an allowance for outdated material returns based on previous years’ historical returns of our pharmaceutical products.

 

20
 

 

We do not make sales on consignment, and the collection of the proceeds of the sale of any of our products is not contingent upon the customer being able to sell the goods to a third party.

 

Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience under ASC Topic 606-10-32-8. We have not experienced significant fluctuations between estimated allowances and actual activity.

 

We have distribution agreements with certain distributors of our pharmaceutical products that entitle those distributors to distribution and services-related fees. We record distribution fees, and estimates of distribution fees, as offsets to revenue.

 

Accounting for Financial Instruments - Credit Losses

 

We recognize an allowance for our trade receivables to present the net amount expected to be collected as of the balance sheet date. This allowance is based on the credit losses expected to arise over the life of the asset and are based on Current Expected Credit Losses (CECL).

 

We perform ongoing credit evaluations of our customers and adjust credit limits, as determined by a review of current credit information. We continuously monitor collection and payments from customers and maintain an allowance for credit losses based upon historical experience, anticipation of uncollectible accounts receivable and any specific customer collection issues that have been identified. While our credit losses have historically been low and within expectations, we may not experience the same credit loss rates that have historically been attained in the future. The receivables are highly concentrated in a relatively small number of customers. Therefore, a significant change in the liquidity, financial position, or willingness to pay timely, or at all, of any one of our significant customers would have a significant impact on our results of operations and cash flows. When determining the reserve for credit losses, we take into consideration current and future economic conditions and the impact that these changing dynamics may have on potential future losses.

 

The timing between recognition of revenue for product sales and the receipt of payment is not significant. Our standard credit terms, which vary depending on the customer, range between 30 and 60 days. We provide an allowance for credit losses related to our accounts receivable for which collection is doubtful in accordance with ASU 2016-13. In accordance with FASB ASC Topic 326, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, (“ASC 326”), we present financial assets at the net amount expected to be collected, requiring immediate recognition of estimated credit losses expected to occur over the asset’s remaining life.

 

As of December 31, 2024 and December 31, 2023, the allowance for credit losses on accounts receivable was $14,342 and $16,672, respectively. Prompt-pay discounts are offered to some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded when they are taken.

 

Inventory Valuation Allowance

 

In conjunction with our ongoing analysis of inventory valuation, management constantly monitors projected demand on a product-by-product basis. Based on these projections, management evaluates the levels of write-downs required for inventory on hand and inventory on order from contract manufacturers. Although we believe that we have been reasonably successful in identifying write-downs in a timely manner, sudden changes in buying patterns from customers, either due to a shift in product interest and/or a complete pullback from their expected order levels, may result in the recognition of larger-than-anticipated write-downs. We have performed an evaluation of our inventory on hand as of December 31, 2024 and December 31, 2023, and believe the reserves are adequate to cover any slow-moving or obsolete inventory.

 

21
 

 

Results of Operations

 

Sales

 

Sales increased by approximately 12%, from $10,885,154 in 2023 to $12,181,971 in 2024. The increase in sales was primarily due to an increase in sales of our cosmetic ingredient products, specifically an increase of 51% in sales to our largest distributor, ASI, in 2024 compared with 2023. In addition, sales of our medical lubricants increased by 16%, primarily due to increased orders placed by our largest customer in China.

 

Cosmetic Ingredients

 

Sales of our cosmetic ingredients increased by approximately 32%, from $4,132,334 in 2023 to $5,438,262 in 2024. The increase was primarily due to an increase in sales to ASI. Based on information provided to the Company by ASI, the reasons for the increase during 2024 was due to increased demand for our products in China due to regaining market share at certain key accounts. This increase was offset by sales to our other four distributors, whose sales decreased by a net of approximately 49%, while sales from two of our small direct cosmetic ingredient customers increased by approximately 19%. This decrease was primarily due to reformulations.

 

We continue to experience global competition from Asian and European companies that manufacture and sell products that are competitive with our products. These competitive products are usually sold at a lower price than our products; however, they may not compare favorably to the level of performance and quality of our products. We work closely with our network of distributors to price our products as competitively as possible and, when appropriate, to offer additional volume discounts and more aggressive pricing to maintain and increase sales and expand our customer base. We expect that this competitive environment will continue in 2025 and we plan to enhance our competitive position by strengthening our core capabilities and investing in new products, especially in the area of naturally derived products. We will continue to provid high-quality products, technical expertise, and the reliability our customers have come to expect from us.

 

Pharmaceuticals

 

Because there are fees, rebates, and allowances associated with sales of our two pharmaceutical products, Renacidin and Clorpactin, discussion of our pharmaceutical sales includes references to both gross sales (before fees, rebates and allowances) and net sales (after fees, rebates and allowances). Gross sales of our two pharmaceutical products, Renacidin and Clorpactin, together decreased by approximately 5%, from $5,894,220 in 2023 to $5,602,259 in 2024. Gross sales of Renacidin decreased by approximately 4%, from $5,127,069 in 2023 to $4,897,331 in 2024, and gross sales of Clorpactin decreased by 8% from $767,151 in 2023 to $704,928 in 2024.

 

The primary reason for the decrease in Renacidin sales was due to our contract manufacturer temporarily ceasing manufacturing during the latter part of 2023 and the beginning of 2024. During this time, we were unable to fill complete orders of Renacidin and were allocating product to all of our pharmaceutical distributors. We resumed filling orders in full towards the end of March 2024.

 

Net sales of our pharmaceutical products decreased by approximately 5% in 2024 compared with the same period in 2023. The decrease in net sales was due to a decrease in gross sales combined with a commensurate decrease in certain pharmaceutical-related rebates and allowances. The decrease in pharmaceutical-related rebates and allowances in 2024 was primarily due to a decrease in VA Chargebacks and Medicare rebates.

 

22
 

 

Medical Lubricants

 

Sales of our medical lubricants increased by approximately 16% in 2024, from $1,750,632 in 2023 to $2,028,564 in 2024. The increase in sales was driven by increased demand from one of our larger contract manufacturer customers located in China.

 

Sexual Wellness Ingredients         

 

There were no sales of our sexual wellness ingredients in 2024, since we only began our marketing efforts for those products in mid-2023. Customers need to qualify new ingredients and perform product development testing prior to launching a new product. It is not unusual for this process to take a year or more and inherently it will require additional time for new ingredients to generate sales. Our distributor for these products has informed us of the possibility of orders being placed in mid-2025.

 

Industrial Products

 

There were no sales of our industrial products during 2024 due to this product line being discontinued after the second quarter of 2023.

 

Gross Profit on Sales

 

Gross profit on sales was 53% in 2024 compared with 50% in 2023. The increase in gross profit was primarily due to two factors. The first was an increase in sales of our cosmetic ingredients of 32% in 2024 compared to 2023, which carry a higher profit margin than our pharmaceutical products, combined with the fact that in 2024, the percentage of cosmetic product sales as a percentage of total sales increased to approximately 45%, compared with 38% in 2023. The second factor was lower per unit overhead costs due to increased production, which was caused by higher demand for some of our products.

 

Operating Expenses

 

Operating expenses increased by approximately 13%, from $2,078,564 in 2023 to $2,356,819 in 2024. The increase was mainly attributable to the following: 1) increases in sales and marketing expenses incurred in connection with the hiring of our new Marketing Director; 2) an increase in payroll and payroll-related expenses; and 3) an increase in fees paid to our Board of Directors. In connection with our growth initiatives, we anticipate that operating expenses will increase modestly in 2025.

 

Research and Development Expenses

 

Research and development expenses decreased by approximately 2%, from $463,992 in 2023 to $456,779 in 2024. In connection with the Company’s growth initiatives, we expect our research and development expenses to increase modestly during 2025.

 

Investment Income

 

Investment income increased by approximately 42%, from $306,651 in 2023 to $434,679 in 2024. The increase was primarily due to an increase in interest income from investments in longer term U.S. Treasury Bills and Certificates of Deposit in 2024 compared to 2023. In addition, during 2024 we held more funds in money market accounts which yielded higher interest income compared to 2023. During the second half of 2023, we repositioned our marketable securities portfolio, liquidating most of our equity and fixed income mutual funds. The proceeds from these sales were used to purchase U.S. Treasury Bills and Certificates of Deposit to take advantage of the increase in interest rates.

 

23
 

 

Net Gain on Marketable Securities

 

For the year ended December 31, 2024, we recorded net gains on our marketable securities portfolio of $26,989 compared with net gains of $81,095 in 2023. We repositioned our marketable securities portfolio in the second half of 2023 to take advantage of the increase in interest rates. Management, as well as the Investment Committee of the Board of Directors, continue to closely monitor our investment portfolio and will make any adjustments they believe may be necessary or appropriate in order to minimize the future impact on our financial performance due to volatility of the global financial markets.

 

Provision for Income Taxes

 

The provision for income taxes increased from $669,408 in 2023 to $857,582 in 2024. This increase was due to an increase in income before taxes. Our effective income tax rate was 20.9% in 2024 and 20.6% in 2023.

 

Liquidity and Capital Resources

 

Working capital increased from $10,718,457 at December 31, 2023 to $10,751,082 at December 31, 2024. The increase in working capital was mainly due to an increase in cash and cash equivalents, marketable securities and inventories. The current ratio decreased from 8.0 to 1 at December 31, 2023 to 6.6 to 1 at December 31, 2024. The decrease in the current ratio was due mainly due to an increase in accounts payable.

 

Accounts receivable (net of allowance for credit losses) as of December 31, 2024 decreased from $1,566,839 in 2023 to $1,428,455 in 2024. The decrease in accounts receivable was due to a decrease in sales during the fourth quarter of 2024. The receivables turnover, or “Days Sales Outstanding,” for 2024, was 45 days, compared with 50 days in 2023. The allowance for credit losses on accounts receivable decreased from $16,672 in 2023 to $14,342 in 2024, and we believe that the net balance of our accounts receivable as of December 31, 2024 was, and continues to be, fully collectible.

 

We generated cash from operations of $3,466,251 in 2024 compared with $3,144,480 in 2023. The increase in 2024 was primarily due to an increase in net income, offset by increases in inventories and deferred income taxes.

 

Net cash used in investing activities was $7,077,395 for the year ended December 31, 2024, compared with net cash provided by investing activities of $4,277,577 for the year ended December 31, 2023. The shift was primarily due an increase in the purchase of longer-term investments in 2024 that are classified as marketable securities. During 2023, most of the of our marketable securities consisted of U.S. Treasury Bills and Certificates of Deposit that had maturities of less than three months and were included in cash and cash equivalents. During 2024, we changed our investment strategy to longer term fixed income investments due to the anticipated decrease in interest rates.

 

Net cash used in financing activities was $2,756,323 and $459,387 for the years ended December 31, 2024 and 2023, respectively. The increase was due to the payment of higher dividends in 2024 compared with 2023. During 2024, we paid dividends of $0.60 per share compared with $0.10 per share in 2023.

 

We believe that our working capital is sufficient to support our operating requirements for the next fiscal year. Our long-term liquidity position will be dependent upon our ability to generate sufficient cash flow from profitable operations, and we expect to continue to use our cash to make dividend payments, purchase marketable securities, and to take advantage of growth opportunities that may arise that are in the best interest of the business and our stockholders.

 

In connection with an upgrade to our building sprinkler system, costs of approximately $181,000 have been incurred as of December 31, 2024. The project is substantially complete and is expected to be fully complete by the end of the first quarter of 2025, with additional planned expenditures of $14,000.

 

During the fourth quarter of 2024, the Company replaced the roof on a portion of its facility in Hauppauge, New York at a cost of approximately $237,000.

 

We have no off-balance-sheet transactions that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

24
 

 

New Accounting Pronouncements

 

See Note “A” to the financial statements regarding new accounting pronouncements, which note is incorporated herein by reference.

 

Item 7A.

Quantitative and Qualitative Disclosures about Market Risk.

 

The information to be reported under this item is not required of smaller reporting companies.

 

Item 8.

Financial Statements and Supplementary Data.

 

Annexed hereto starting on page F-1.

 

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

 

None.

 

Item 9A.

Controls and Procedures.

 

(a)   Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, has evaluated the design, operation, and effectiveness of the Company’s disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act as of December 31, 2024. On the basis of that evaluation, management concluded that our disclosure controls and procedures are designed to be, and are, effective at providing reasonable assurance that the information required to be disclosed in reports filed or submitted pursuant to the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to management, including our Principal Executive Officer and Principal Financial Officer as appropriate, to allow timely decisions regarding required disclosure.

 

(b)   Management’s Report on Internal Control over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Our internal control system is designed to provide reasonable assurance to management and to our Board of Directors regarding the preparation and fair presentation of published financial statements. Under the supervision and with the participation of management, including our Principal Executive Officer and Principal Financial Officer, management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO 2013”). Based on management’s evaluation under the framework in Internal Control—Integrated Framework, management concluded that our internal control over financial reporting was effective as of December 31, 2024.

 

This Annual Report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Since we are a non-accelerated filer, management’s report is not subject to attestation by our registered public accounting firm pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002. As a result, this Annual Report contains only management’s report on internal controls.

 

25
 

 

(c)   Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting in the fourth quarter of 2024 that materially affected, or would be reasonably likely to materially affect, our internal control over financial reporting.

 

(d)   Limitations of the Effectiveness of Internal Controls

 

The effectiveness of our system of disclosure controls and procedures and internal control over financial reporting is subject to certain limitations, including the exercise of judgment in designing, implementing and evaluating the control system, the assumptions used in identifying the likelihood of future events, and the inability to eliminate fraud and misconduct completely. As a result, there can be no assurance that our disclosure controls and procedures and internal control over financial reporting will detect all errors or fraud. However, our control systems have been designed to provide reasonable assurance of achieving their objectives, and our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures and internal control over financial reporting are effective at the reasonable assurance level.

 

 

Item 9B.

Other Information.

 

None.
 

 

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 

Not applicable.

 

PART III

 

 

Item 10.

Directors, Executive Officers and Corporate Governance.

 

The information required by this item is incorporated by reference to our Proxy Statement for the 2025 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2024.

 

Item 11.

Executive Compensation.

 

The information required by this item is incorporated by reference to our Proxy Statement for the 2025 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2024.

 

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 

The information required by this item is incorporated by reference to our Proxy Statement for the 2025 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2024.

 

Item 13.

Certain Relationships and Related Transactions, and Director Independence.

 

The information required by this item is incorporated by reference to our Proxy Statement for the 2025 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2024.

 

Item 14.

Principal Accounting Fees and Services.

 

The information required by this item is incorporated by reference to our Proxy Statement for the 2025 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2024.

 

26
 

 

PART IV

 

Item 15.

Exhibits and Financial Statement Schedules.

 

(a)

   Documents filed as part of this report.

 

 

 

 

(i)

Financial Statements - see Item 8. Financial Statements and Supplementary Data.

 

 

 

 

(ii)

Financial Statement Schedules – None. (Financial statement schedules have been omitted either because they are not applicable, not required, or the information required to be set forth therein is included in the financial statements or notes thereto.)

 

 

 

(iii)

Report of Independent Registered Public Accounting Firm.
   

 

(iv)

Notes to Financial Statements.
   

(b)

   Exhibits
   

 

   The exhibits listed on the accompanying Exhibit Index are filed as part of this Annual Report.

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  UNITED-GUARDIAN, INC.
   
  By: /s/ Donna Vigilante
        Donna Vigilante 
Date: March 19, 2025       President

 

27
 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

Signature

  

 

Title

  

Date
         

By: /s/ Donna Vigilante

        Donna Vigilante

  

President (Principal Executive Officer)

  

March 19, 2025

       

  

     

  

 

By: /s/ Andrea Young

        Andrea Young

  

Chief Financial Officer (Controller, Principal Financial Officer, and Principal Accounting Officer); Treasurer; Secretary

  

March 19, 2025
         

By: /s/ Lawrence F. Maietta

  

Director

  

March 19, 2025

       Lawrence F. Maietta

        
         

By: /s/ Arthur M. Dresner

  

Director

  

March 19, 2025

       Arthur M. Dresner  

  

   

  

 
         

By: /s/ Andrew A. Boccone

  

Director

  

March 19, 2025

        Andrew A. Boccone  

  

 

  

 
         

By: /s/ Catherine Kolinski

  

Director

  

March 19, 2025

        Catherine Kolinski

  

 

  

 
         

By: /s/ S. Ari Papoulias

  

Director

  

March 19, 2025

        S. Ari Papoulias

        
         

By: /s/ Ken Globus

       Ken Globus

  

Chairman of the Board of Directors

  

March 19, 2025

 

 

 

28
 

 

EXHIBIT INDEX

 

Exhibit # Description

2.1

Certificate of Merger of United-Guardian, Inc. (New York) with and into United-Guardian, Inc. (Delaware) as filed with the Secretary of State of the State of Delaware on September 10, 1987. (Incorporated by reference to Exhibit 3(b) of the Registrant's Annual Report on Form 10-K for the fiscal year ended February 29, 1988)

3.1

Certificate of Incorporation of the Company as filed April 22, 1987 (Incorporated by reference to Exhibit 4.1 of the Registrant's Current Report on Form 8-K, dated September 21, 1987)

3.2

By-laws of the Company, as amended and adopted by the Board of Directors on March 18, 2020 (Incorporated by reference to Exhibit 3.2 of the Registrant's Current Report on Form 8-K, dated April 10, 2020)

10.1**

Memorandum of Understanding (separation agreement) between Ken Globus and the Company effective November 1, 2022 (Incorporated by reference to Exhibit 10.2 of the Registrant’s Current Report on Form 10-Q for the fiscal quarter ended September 30, 2022)

10.2

Manufacturing and supply agreement between the Company and Amsino Healthcare USA, Inc. signed March 30, 2023 and effective as of January 1, 2023 (Incorporated by reference to Exhibit 10.2 of the Registrant’s Current Report on Form 8-K dated and filed March 1, 2024)

14.1

Code of Ethics and amendments thereto (Incorporated by reference to Exhibit 14 of the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2019)
19.1* Insider Trading Policy

21.1

Subsidiaries of the Company: None

31.1*

Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002

31.2*

Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002

32*

Joint certification pursuant to Section 906 of Sarbanes-Oxley Act of 2002

97.1

Policy Relating to Recovery of Erroneously Awarded Compensation (Incorporated by reference to Exhibit 97.1 of the Registrant’s Current Report on Form 10-K for fiscal year ended December 31, 2023)

101.INS***

Inline XBRL Instance Document

101.SCH***

Inline XBRL Taxonomy Extension Schema Document

101.CAL***

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF***

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB***

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE***

Inline XBRL Taxonomy Extension Label Presentation Document

104***

Cover Page Interactive Data File (Embedded within the inline XBRL document and included in Exhibit 101)

 

* Filed herewith.

 

** Management contract or compensatory arrangement.

 

*** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended and otherwise is not subject to liability under these sections.

 

29
 
 
 

INDEX TO FINANCIAL STATEMENTS

(For the years ended

December 31, 2024 and 2023)

 

Report of Grassi & Co. CPAs P.C, Independent Registered Public Accounting Firm (PCAOB ID 606)

F-2
   

Financial Statements  

 
   

        Statements of Income

F-3
   

        Balance Sheets

F-4 & F-5

                         

 

         Statements of Stockholders' Equity

F-6
   

        Statements of Cash Flows

F-7
   

        Notes to Financial Statements

F-8 - F-22

 

 

 

 

 

 

 

 

 

 

F-1
 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Audit Committee and Stockholders of
United-Guardian, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying balance sheet of United-Guardian, Inc. (the “Company”) as of December 31, 2024 and 2023, and the related statements of income, stockholders’ equity, and cash flows for the year ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 

Critical Audit Matters

 

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there were no critical audit matters.

 

 

signature.jpg

GRASSI & CO., CPAs, P.C.
 

We have served as the Company’s auditors since 2023.

Jericho, New York

March 19, 2025

 

F-2
 

  

 

STATEMENTS OF INCOME

 

   

Years ended December 31,

  
   

2024

    

2023

  
                 

Net sales

   $ 12,181,971     $ 10,885,154  
                 

Costs and expenses:

                

Cost of sales

     5,721,584       5,479,566  

Operating expenses

     2,356,819       2,078,564  

Research and development

     456,779       463,992  

Total costs and expenses

     8,535,182       8,022,122  

Income from operations

     3,646,789       2,863,032  

Other income:

                

Investment income

     434,679       306,651  

Net gain on marketable securities

     26,989       81,095  

Total other income

    461,668       387,746  
                 

Income before provision for income taxes

     4,108,457       3,250,778  
                 

Provision for income taxes

     857,582       669,408  

Net income

   $ 3,250,875     $ 2,581,370  
                 

Earnings per common share (basic and diluted)

   $ 0.71     $ 0.56  
                 

Weighted average shares (basic and diluted)

     4,594,319       4,594,319  

 

See Notes to Financial Statements

 

 

 

 

 

F-3
 
 

 

BALANCE SHEETS

 

ASSETS

 

   

December 31,

  
   

2024

    

2023

  

Current assets:

                

Cash and cash equivalents

   $ 1,875,655     $ 8,243,122  

Marketable securities

     7,522,625       851,318  

Accounts receivable, net of allowance for credit losses of $14,342 in 2024 and $16,672 in 2023

     1,428,455       1,566,839  

Inventories, net

     1,451,995       1,223,506  

Prepaid expenses and other current assets

     207,804       191,708  

Prepaid income taxes

     179,017       176,220  
                 

Total current assets

     12,665,551       12,252,713  
                 

Deferred income taxes, net

     175,397       50,930  
                 

Property, plant, and equipment:

                

Land

     69,000       69,000  

Factory equipment and fixtures

     4,743,238       4,669,936  

Building and improvements

     3,336,352       2,976,577  

Total property, plant and equipment

     8,148,590       7,715,513  
                 

Less accumulated depreciation

     7,192,203       7,096,318  

Total property, plant, and equipment, net

     956,387       619,195  
                 

TOTAL ASSETS

   $ 13,797,335     $ 12,922,838  

 

See Notes to Financial Statements

 

 

 

 

 

 

 

 

F-4
 

 

BALANCE SHEETS

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

   

December 31,

  
   

2024

    

2023

  

Current liabilities:

                

Accounts payable

   $ 425,003     $ 134,449  

Accrued expenses

     1,467,933       1,363,044  

Deferred revenue

     ---       15,498  

Dividends payable

     21,533       21,265  

Total current liabilities

    1,914,469       1,534,256  

Total liabilities

     1,914,469       1,534,256  
                 
Commitments and contingencies            
                 
Stockholders’ equity:                

Common stock, $.10 par value; 10,000,000 shares authorized; 4,594,319 shares issued and outstanding at December 31, 2024 and 2023

     459,432       459,432  

Retained earnings

     11,423,434       10,929,150  

Total stockholders’ equity

     11,882,866       11,388,582  

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

   $ 13,797,335     $ 12,922,838  

 

See Notes to Financial Statements

 

 

 

 

 

 

 

F-5
 
 

 

STATEMENTS OF STOCKHOLDERS' EQUITY

 

Years ended December 31, 2024 and 2023

 

    Common stock     Retained        
   

Shares

     Amount    

earnings

    

Total

  
                                 

Balance, January 1, 2023

     4,594,319     $ 459,432     $ 8,807,212     $ 9,266,644  
                                 
                                 

Net income

     ---       ---       2,581,370       2,581,370  
                                 

Dividends declared, not paid ($0.10 per share)

     ---       ---       (45

)

     (45

)
                                 

Dividends declared and paid ($0.10 per share)

     ---       ---       (459,387

)

     (459,387

)
                                 

Balance, December 31, 2023

     4,594,319     $ 459,432     $ 10,929,150     $ 11,388,582  
                                 
                                 

Net income

     ---       ---       3,250,875       3,250,875  
                                 

Dividends declared, not paid ($0.60 per share)

     ---       ---       (268

)

     (268

)
                                 

Dividends declared and paid ($0.60 per share)

     ---       ---       (2,756,323

)

     (2,756,323

)
                                 

Balance, December 31, 2024

     4,594,319     $ 459,432     $ 11,423,434     $ 11,882,866  

 

See Notes to Financial Statements

 

 

 

 

 

 

 

 

F-6
 
 

 

STATEMENTS OF CASH FLOWS

 

   

Years ended December 31,

  
   

2024

    

2023

  

Cash flows from operating activities:

                

Net income

   $ 3,250,875     $ 2,581,370  

Adjustments to reconcile net income to net cash provided by operating activities:

                

Depreciation and amortization

     95,885       105,682  

Gain on sale of asset

     ---       (10,000 )

Net gain on marketable securities

     (26,989 )     (81,095 )

Allowance for credit losses

     (2,330

)

     (3,391 )

Allowance for obsolete inventory

     (14,208 )     (17,000 )

Deferred income taxes

     (124,467 )     59,614  

Decrease (increase) in operating assets:

                

Accounts receivable

     140,714       (135,872 )

Inventories

     (214,281 )     465,506  

Prepaid expenses and other current assets

     (16,096 )     10,138  

Prepaid income taxes

     (2,797 )     9,008  

Increase (decrease) in operating liabilities:

                

Accounts payable

     290,554       104,034  

Accrued expenses

     104,889       40,988  

Deferred revenue

     (15,498 )     15,498  

Net cash provided by operating activities

     3,466,251       3,144,480  
                 

Cash flows from investing activities:

                

Acquisitions of property, plant and equipment

     (433,077

)

     (165,716

)

Proceeds from sale of asset

     ---       10,000  

Purchases of marketable securities

     (8,459,318

)

     (621,852

)

Proceeds from sales of marketable securities

     1,815,000       5,505,145  

Net cash (used in) provided by investing activities

     (7,077,395 )     4,727,577  
                 

Cash flows from financing activities:

                

Dividends paid

     (2,756,323

)

     (459,387

)

Net cash used in financing activities

     (2,756,323

)

     (459,387

)
                 

Net (decrease) increase in cash and cash equivalents

     (6,367,467 )     7,412,670  

Cash and cash equivalents, beginning of year

     8,243,122       830,452  

Cash and cash equivalents, end of year

   $ 1,875,655     $ 8,243,122  
                 

Supplemental disclosure of cash flow information

                

Taxes paid

   $ 1,050,795     $ 600,000  
                 

Supplemental disclosure of non-cash items:

                

Dividends payable

   $ 268     $ 45  

 

See Notes to Financial Statements

 

F-7
 

 

NOTES TO FINANCIAL STATEMENTS

 

 

 

 

NOTE A - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Nature of Business

 

United-Guardian, Inc. (“Registrant” or “Company”) is a Delaware corporation that, through its Guardian Laboratories division, manufactures, markets and develops specialty cosmetic ingredients, pharmaceutical products, medical lubricants and sexual wellness ingredients. Prior to July 1, 2023, the Company manufactured and reported sales of a line of specialty industrial products; however, this product line was discontinued after the second quarter of 2023 due to low sales volume with no growth prospects. The Company also conducts research and product development, primarily related to the development of new and unique cosmetic ingredients. The Company’s research and development department also modifies, refines, and expands the uses for existing products, with the goal of further developing the market for the Company's products. Two major product lines, Lubrajel and Renacidin Irrigation Solution (“Renacidin”) together accounted for approximately 93% and 92% of the Company’s sales for the years ended December 31, 2024 and December 31, 2023, respectively. Lubrajel accounted for approximately 60% and 54% of the Company’s sales for the years ended December 31, 2024 and December 31, 2023, respectively, and Renacidin accounted for approximately 33% and 38% of the Company’s sales for the years ended December 31, 2024 and December 31, 2023, respectively.

 

Segment Information

 

The Company operates its business under one operating segment, which is also its reportable segment. The Company's chief operating decision maker (“CODM”), who is the President, reviews financial information presented at the consolidated level and decides how to allocate resources based on financial metrics, including net income. The measure of segment assets is reported on the balance sheet as total consolidated assets. The CODM, along with the Board Of Directors, use such financial metrics, including net income, to evaluate income generated from segment assets (return on assets) in deciding whether to reinvest profits or allocate to other parts of the organization, such as working capital needs, mandatory and discretionary capital expenditures or other growth opportunities that may arise that are in the Company’s best interest and the best interest of the stockholders.

 

Net income, other financial metrics and sales forecasts are used to monitor budget versus actual results. The reported segment revenue, segment profit or loss and significant segment expenses are the same as the consolidated results disclosed on the consolidated statements of income.

 

Impact of Global Supply Chain Instability, Inflation and Tariffs

 

The continued supply chain instability, primarily caused by military tensions in the Middle East, continues to impact vessels’ access to the Red Sea and Suez Canal. Shipping experts say this crisis may last into the first half of 2025. The Company continues to work with its suppliers regarding lead times and is closely monitoring this situation. Although the Company has not yet experienced any delays in receiving raw materials or an increase in shipping costs, the Company is aware that the situation is fluid and could impact it at any time. If that occurs, the Company may experience longer lead times and increased shipping costs for some of its raw materials, which may impact future gross margins. As a result of this global supply chain instability, there continues to be uncertainty regarding the potential impact on the Company’s operations or financial results and its unable to provide an accurate estimate or projection as to what the future impact will be.

 

The Trump administration has communicated its intention to impose tariffs on many products imported from China, Canada and Mexico. Some of those tariffs went into effect on March 4, 2025. Since that time the Trump administration has increased some of those tariffs and postponed others. It has threatened to levy tariffs on additional countries, including those of the European Union. Many of the countries on which those tariffs have been levied have imposed their own retaliatory tariffs or threated to impose tariffs on goods they import from the U.S. The tariff situation remains fluid and is subject to modification at any time. At this time, it is difficult for the Company to determine the impact of these tariffs on its business. The Company will continue to monitor this situation closely.

 

F-8
 

  

While the Company obtains most of its raw materials and lab supplies from domestic sources, it has three suppliers that obtain their raw materials from China. These materials are not purchased by the Company in large quantities, and it has adequate stock on hand to cover the next six months. In addition, the Company has one direct raw material supplier in China; however, the raw materials purchased from this supplier are not in large quantities and the effect of this tariff would not materially impact the pricing of its products.

 

Many of the Company’s products are used in the formulation of finished products that are manufactured in China and then imported back into the United States (“U.S.”) for sale. There is the possibility that the tariffs levied on these finished products could result in an increase in their price, which could potentially impact demand for these products in the U.S.

 

Due to the continued uncertainty of this, any other tariffs that may be imposed, there continues to be uncertainty regarding the future impact of any additional tariffs on the Company’s operations or financial results.

 

Use of Estimates

 

In preparing financial statements in conformity with a Generally Accepted Accounting Principles in the United States of America (“US GAAP”), management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the allowance for credit losses, reserve for inventory obsolescence, accrued distribution fees, outdated material returns, possible impairment of marketable securities and the allocation of overhead.

 

Accounts Receivable and Reserves

 

In accordance with FASB ASC Topic 326, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”, (“ASC 326”), the Company presents financial assets at the net amount expected to be collected, requiring immediate recognition of estimated credit losses expected to occur over the asset’s remaining life. This is in contrast to previous U.S. GAAP, under which credit losses were not recognized until it was probable that a loss had been incurred. The Company performed its expected credit loss calculation based on historical accounts receivable write-offs, including consideration of then-existing economic conditions and expected future conditions. The adoption of this ASU did not have a significant impact on the financial statements. Prior to the implementation of ASU No. 2016-13, the Company calculated its reserve for accounts receivable by considering many factors including historical data, experience, customer types, credit worthiness and economic trends.

 

The carrying amount of accounts receivable is reduced by an allowance for credit losses that reflects the Company’s best estimate of the amounts that will not be collected as of the balance sheet date. This allowance is based on the credit losses expected to arise over the life of the asset and is based on the Current Expected Credit Losses (“CECL”). At December 31, 2024 and 2023, the allowance for credit losses related to accounts receivable amounted to $14,342 and $16,672, respectively.

 

F-9
 

  

Revenue Recognition

 

The Company records revenue in accordance with ASC Topic 606 “Revenue from Contracts with Customers.” Under this guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company’s principal source of revenue is product sales.

 

The Company’s sales, as reported, are subject to a variety of deductions, some of which are estimated. These deductions are recorded in the same period in which the revenue is recognized. Such deductions, primarily related to the sale of the Company’s pharmaceutical products, include chargebacks from the United States Department of Veterans Affairs (“VA”), rebates in connection with the Company’s current participation in Medicare programs, distribution fees, discounts, and outdated product returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on sales for a reporting period.

 

During 2024 and 2023, the Company participated in various government drug rebate programs related to the sale of Renacidin, its most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (“FSS”), and the Medicare Part D Coverage Gap Discount Program (“CGDP”). These programs require the Company to sell its product at a discounted price. The Company’s sales, as reported, are net of these rebates, some of which are estimated and are recorded in the same period that the revenue is recognized.

 

On January 1, 2025, the Centers for Medicare & Medicaid Services (“CMS”) implemented a new Medicare Part D Manufacturer Discount Program (“Discount Program”), which replaced the prior CGDP. The new Discount Program eliminates the coverage gap benefit phase, introduces pharmaceutical manufacturer discounts in the initial and catastrophic coverage phases, and lowers the cap on enrollee out-of-pocket costs. Under the new Discount Program, additional rebates are expected to be owed by pharmaceutical manufacturers due to the restructuring of the benefit periods and removal of the cap that was in place that limited the drug manufacturer’s liability. The overall financial impact of this new program will vary depending on the products being reimbursed but is expected to increase Medicare Part D rebates for drug manufacturers. On January 31, 2024, the Company was notified by CMS that it qualified as a “specified small manufacturer” and would be entitled to a multi-year phase-in period during which it would pay a lower percentage discount on drugs dispensed to beneficiaries. Based on the “specified small manufacturer” designation, it appears, that based on our current level of sales through the Medicare Part D Program, the Company would have reduced rebate liabilities in years 2025 and 2026, with rebates gradually increasing each year until they reach their full value in 2031. By the end of the phase in period in 2031, these rebate liabilities are expected to significantly exceed the liabilities we have recorded under the CGDP in previous years.

 

As long as a valid purchase order has been received and future collection of the sale amount is reasonably assured, the Company recognizes revenue from sales of its products when those products are shipped, which is when the Company’s performance obligation is satisfied. The Company’s cosmetic products are shipped EXW from the Company’s facility in Hauppauge, NY, and the risk of loss and responsibility for the shipment passes to the customer upon shipment. Sales of the Company’s non-pharmaceutical medical products are deemed final upon shipment, and there is no obligation on the part of the Company to repurchase or allow the return of these goods unless they are defective. Sales of the Company’s pharmaceutical products are final upon shipment unless (a) they are found to be defective; (b) the product is damaged in shipping; (c) the product cannot be sold because it is too close to its expiration date; or (d) the product has expired (but it is not more than one year after the expiration date). This return policy conforms to standard pharmaceutical industry practice. The Company estimates an allowance for outdated material returns based on previous years’ historical returns of its pharmaceutical products.

 

The Company does not make sales on consignment, and the collection of the proceeds of the sale of any of the Company’s products is not contingent upon the customer being able to sell the goods to a third party.

 

F-10
 

  

Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience under ASC Topic 606-10-32-8. At December 31, 2024 and 2023, the Company had an allowance of $276,732 and $247,847, respectively, for possible outdated material returns, which is included in accrued expenses. There is no asset value associated with these outdated material returns, as these products are destroyed.

 

The timing between recognition of revenue for product sales and the receipt of payment is not significant. The Company’s standard credit terms, which vary depending on the customer, range between 30 and 60 days. The Company recognizes an allowance for credit losses on its accounts receivable in accordance with ASU 2016-13, which is based on the credit losses expected to arise over the life of the asset and is based on Current Expected Credit Loss (“CECL”). Prompt-pay discounts are offered to some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded when they are taken.

 

At December 31, 2023, the Company recorded advance payments from two of its customers in the amount of $15,498, which was recorded as deferred revenue on the balance sheet. The related performance obligations associated with these payments were satisfied in the first quarter of 2024. No such advanced payments existed at December 31, 2024.

 

The Company has distribution agreements with certain distributors of its pharmaceutical products that entitle those distributors to distribution and services-related fees. The Company records distribution fees, and estimates of distribution fees, as offsets to revenue.

 

Disaggregated net sales by product class are as follows:

 

   

Years ended December 31,

  
    2024     2023  

Cosmetic ingredients

   $ 5,438,262     $ 4,132,334  

Pharmaceuticals

     4,715,145       4,950,594  

Medical lubricants

     2,028,564       1,750,632  

Industrial and other

     ---       51,594  

Total Net Sales

   $ 12,181,971     $ 10,885,154  

 

The Company’s cosmetic ingredients are currently marketed worldwide by five distributors, of which the United States (“U.S.”)-based ASI purchases the largest volume. For the years ended December 31, 2024 and 2023, approximately 16% and 21%, respectively, of the Company’s sales were to (a) its foreign-based distributors (which does not include ASI), which marketed and distributed the Company’s cosmetic ingredients to customers outside the U.S, and (b) a few foreign customers for the Company’s medical lubricants, which were sold directly to those customers by the Company.

 

Disaggregated sales by geographic region are as follows:

 

Years ended December 31,

  
   

2024

    

2023

  

United States*

   $ 10,175,926     $ 8,601,205  

Other countries

     2,006,045       2,283,949  

Net Sales

   $ 12,181,971     $ 10,885,154  

 

* Although a significant percentage of ASI’s purchases from the Company are sold to foreign customers, all sales to ASI are considered U.S. sales for financial reporting purposes, since all shipments to ASI are shipped to ASI’s warehouses in the U.S. A certain percentage of those products are subsequently shipped by ASI to its foreign customers. Based on sales information provided to the Company by ASI, 79% of ASI’s sales in 2024 were to customers in foreign countries, compared with 69% in 2023. ASI’s largest foreign market in both 2024 and 2023 was China, which accounted for approximately 43% of ASI’s sales in 2024 and 29% of sales in 2023.

 

F-11
 

  

Cash and Cash Equivalents

 

For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of three months or less at the time of purchase. The Company deposits cash and cash equivalents with financially strong, FDIC-insured financial institutions, and it believes that any amounts above FDIC insurance limitations are at minimal risk. The amounts held in excess of FDIC limits at any point in time are considered temporary and are primarily due to the timing of maturities of United States Treasury Bills and Certificates of Deposit. Cash and cash equivalents held in these accounts are currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to a maximum of $250,000. At December 31, 2024 and 2023, approximately $234,000 and $311,000 respectively, exceeded the FDIC limit. The Company also invests in certain money market mutual funds that are protected as securities by the Securities Investor Protection Corporation (“SIPC”). At December 31, 2024, cash held in these money market mutual funds of approximately $563,000 exceeded the SIPC limit. At December 31, 2023, cash held in these money market mutual funds was below the SIPC limit.

 

Dividends

 

On July 10, 2024, the Company’s Board of Directors declared a cash dividend of $0.35 per share, which was paid on July 31, 2024, to all holders of record as of July 23, 2024. Dividends totaling $1,607,855 were paid and the balance of $156 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment. On January 30, 2024, the Company’s Board of Directors declared a cash dividend of $0.25 per share, which was paid on February 20, 2024, to all holders of record as of February 12, 2024. Dividends totaling $1,148,468 were paid. The balance of $112 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment. On January 27, 2025, the Company’s Board of Directors declared a cash dividend of $.0.35 per share, which was paid on February 18, 2025, to all stockholders of record as of February 10, 2025.

 

On July 12, 2023, the Company’s Board of Directors declared a cash dividend of $0.10 per share, which was paid on August 2, 2023, to all stockholders of record as of July 26, 2023. The Company did not declare any other dividends in 2023. During 2023, the Company declared total dividends of $459,432, of which $459,387 was paid. The balance of $45 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment. In June of 2023, the Company’s Board of Directors changed the Company’s dividend declaration practice and expects to consider a semi-annual dividend declaration in January and July of each year.

 

Marketable Securities

 

The Company’s marketable securities include investments in equity mutual funds, United States Treasury Bills (“U.S. Treasury Bills”) and Certificates of Deposit with maturities longer than 3 months. The Company’s marketable equity securities are reported at fair value with the related unrealized and realized gains and losses included in net income. U.S Treasury Bills and Certificates of Deposit are recorded at amortized cost. Realized gains or losses on mutual funds are determined on a specific identification basis. The Company evaluates its investments periodically for possible other-than-temporary impairment by reviewing factors such as the length of time and extent to which fair value had been below cost basis, the financial condition of the issuer and the Company’s ability and intent to hold the investment for a period of time which may be sufficient for anticipated recovery of market value. The Company would record an impairment charge to the extent that the cost of the available-for-sale securities exceeds the estimated fair value of the securities and the decline in value is determined to be other-than-temporary. During 2024 and 2023, the Company did not record an impairment charge regarding its investment in marketable securities because management believes, based on its evaluation of the circumstances, that the decline in fair value below the cost of certain of the Company’s marketable securities is temporary.

 

F-12
 

  

Inventories

 

Inventories are valued at the lower of cost and net realizable value. Net realizable value is equal to the selling price less the estimated costs of selling and/or disposing of the product. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out (“FIFO”) method. Inventory costs include material, labor and factory overhead.

 

Property, Plant and Equipment

 

Property, plant and equipment are carried at cost, less accumulated depreciation. Major replacements and betterments are capitalized, while routine maintenance and repairs are expensed as incurred. Assets are depreciated under both accelerated and straight-line methods. Depreciation charged as a result of using accelerated methods was not materially different than that which would result from using the straight-line method for all periods presented. Certain factory equipment and fixtures are constructed by the Company using purchased materials and in-house labor. Such assets are capitalized and depreciated on a basis consistent with the Company's purchased fixed assets.

 

Estimated useful lives are as follows: 

 

Factory equipment and fixtures  

5 - 7 years  

Building  

40 years  

Building improvements  

Lesser of useful life or 20 years  

 

Impairment of Long-Lived Assets

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No impairments were necessary at December 31, 2024 and 2023.

 

Fair Value of Financial Instruments

 

Management of the Company believes that the fair value of financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses, approximates their carrying value due to their short payment terms and liquid nature.

 

Concentration of Credit Risk

 

Accounts receivable potentially expose the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history to determine how much credit to allow or whether credit should be given at all. It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable. As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its accounts receivable credit risk has been reduced.

 

F-13
 

  

For the year ended December 31, 2024, four of the Company’s pharmaceutical wholesalers and cosmetic ingredient distributors accounted for approximately 80% of the Company’s gross sales during the year and approximately 87% of its outstanding accounts receivable on December 31, 2024. For the year ended December 31, 2023, the same four pharmaceutical wholesalers and cosmetic ingredient distributors accounted for a total of approximately 77% of the Company’s gross sales during the year and 89% of its outstanding accounts receivable on December 31, 2023.

 

Supplier Concentration

 

Most of the principal raw materials used by the Company consist of common industrial organic and inorganic chemicals and are available in ample supply from numerous sources. However, there are some raw materials used by the Company that are not readily available or require longer lead times. The Company has three major raw material vendors that collectively accounted for approximately 83% and 76% of the raw material purchases by the Company in 2024 and 2023, respectively. In addition to the Company’s raw materials concentration, the Company utilizes one contract manufacturer for the production of its pharmaceutical product, Renacidin. Any disruption in this manufacturer’s operations could have a material impact on the Company’s revenue stream.

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to the temporary differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized.

 

Uncertain tax positions are accounted for utilizing a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As of December 31, 2024 and 2023, the Company did not have any unrecognized income tax benefits. It is the Company’s policy to recognize interest and penalties related to taxes as interest expense as incurred. During the years ended December 31, 2024 and 2023, the Company did not record any tax-related interest or penalties. The Company’s tax returns for 2021 and all subsequent years are subject to examination by the United States Internal Revenue Service (“IRS) and by the State of New York.

 

Research and Development

 

Research and development expenses are expenditures incurred in connection with in-house research on new and existing products. It includes payroll and payroll related expenses, outside laboratory expenditures, lab supplies, equipment repairs and maintenance and equipment depreciation.

 

F-14
 

  

Advertising Expenses

 

Advertising costs are expensed as incurred. The Company did not incur any advertising costs for the years ended December 31, 2024 or 2023.

 

Earnings Per Share Information

 

Basic earnings per share are computed by dividing net income by the weighted average number of common shares outstanding during the year. Diluted earnings per share would include the dilutive effect of outstanding stock options, if any.

 

New Accounting Standards

 

On November 4, 2024, the FASB issued ASU 2024-03 “Disaggregation of Income Statement Expenses” (“DISE”). This guidance requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. Subsequently issued ASU 2025-01, clarified the effective date of this standard. This guidance is effective for annual reporting periods beginning after December 15, 2026, and for interim periods, within annual reporting periods beginning after December 15, 2027.

 

In December 2023, the FASB issued ASU 2023-09 “Income Taxes- Improvements to Income Tax Disclosures”. This guidance enhances the transparency and decision usefulness of income tax disclosures. More specifically, the amendments relate to the income tax rate reconciliation and income taxes paid disclosures and require 1) consistent categories and greater disaggregation of information in the rate reconciliation and 2) income taxes paid disaggregated by jurisdiction. This guidance is effective for fiscal years beginning after December 31, 2024.

 

In November 2023, the FASB issued ASU 2023-07, "Improvements to Reportable Segment Disclosures". This amendment requires additional disclosures by public entities, including those with a single reportable segment, to disclose significant segment expenses and other segment items for each reportable segment. The guidance applies to fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. On January 1, 2024, we adopted the new standard and applied the guidance under the new standard to include additional disclosures for our single reportable segment. See notes A and G for additional information.

 

 

NOTE B – CASH AND CASH EQUIVALENTS

 

Cash and cash equivalents include currency on hand, demand deposits with banks or financial institutions, and short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. The following table summarizes the Company’s cash and cash equivalents:

 

F-15
 

  

 

 

    December 31,  
    2024     2023  

Demand Deposits

   $ 404,801     $ 340,034  

Certificates of Deposit (original 3-month maturity)

     ---       125,000  

Money market funds

     1,470,854       1,031,361  

U.S. Treasury Bills (original 3-month maturity)

     ---       6,746,727  

Total cash and cash equivalents

   $ 1,875,655     $ 8,243,122  

  
 

NOTE C - MARKETABLE SECURITIES

 

Marketable securities include investments in equity mutual funds, which are reported at their fair values, and U.S. Treasury Bills and Certificates of Deposit with original maturities greater than 3 months, which are recorded at amortized cost.

 

The disaggregated net gains and losses on the marketable securities recognized in the income statement for the years ended December 31, 2024 and 2023 are as follows:

 

    Years ended December 31,  
    2024     2023  

Net gains recognized during the year on marketable securities

   $ 26,989    

$

 81,095  

Less: Net losses realized during the year on marketable securities sold during the period

     ---       433,769  

Net unrealized gains recognized during the reporting year on marketable securities still held at the reporting date

   $ 26,989    

$

 514,864  

 

The fair values of the Company’s marketable securities are determined in accordance with US GAAP, with fair value being defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes the three-tier value hierarchy, as prescribed by US GAAP, which prioritizes the inputs used in measuring fair value as follows:

 

•    Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

•    Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

•    Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

F-16
 

 

The Company’s marketable equity securities, which are considered available-for-sale securities, are re-measured to fair value on a recurring basis and are valued using Level 1 inputs using quoted prices (unadjusted) for identical assets in active markets. The following tables summarize the Company’s investments:

 

December 31, 2024

 

    Cost     Fair Value       Unrealized Gain  

Equity Securities:

                        

Equity and other mutual funds

   $ 634,705     $ 663,682     $ 28,977  
                         

Other short-term investments:

                        

Fixed income Certificates of Deposit (original maturities > 3 months)

     570,000       570,000       ---  

U.S. Treasury Bills (original maturities > 3 months)

     6,288,943       6,288,943       ---  
                         

Total other short-term investments

   $ 6,858,943     $ 6,858,943     $ ---  

Total marketable securities

   $ 7,493,648     $ 7,522,625     $ 28,977  

 

December 31, 2023

 

    Cost     Fair Value     Unrealized Gain  

Equity Securities:

                        

Equity and other mutual funds

   $ 574,330     $ 576,318     $ 1,988  
                         

Other short-term investments:

                        

Fixed income Certificates of Deposit (original maturities > 3 months)

     275,000       275,000       ---  

Total marketable securities

   $ 849,330     $ 851,318     $ 1,988  

 

Investment income is recognized when earned and consists principally of dividend income from equity mutual funds and interest income on United States Treasury Bills, Certificates of Deposit and money market funds. Realized gains and losses on sales of investments are determined on a specific identification basis.

 

Proceeds from the sale and redemption of marketable securities amounted to $1,815,000 for the year ended December 31, 2024 and there were no realized gains or losses. Proceeds from the sale and redemption of marketable securities for the year ended December 31, 2023, amounted to $5,505,145, which included realized losses of $433,769.

 

F-17
 

  
 

NOTE D – INVENTORIES 

 

Inventories consist of the following:

 

   

December 31,

  
   

2024

    

2023

  

Raw materials

   $ 448,113     $ 476,501  

Work in process

     58,699       92,089  

Finished products

     945,183       654,916  

Total Inventories

   $ 1,451,995     $ 1,223,506  

 

Inventories are valued at the lower of cost and net realizable value. Net realizable value is equal to the selling price less the estimated costs of selling and/or disposing of the product. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out method. Finished product inventories on December 31, 2024 and December 31, 2023 are net of a reserve of $32,792 and $47,000, respectively.

 

 

NOTE E – INCOME TAXES

 

The provision for income taxes consists of the following:

 

   

Years ended December 31,

  

Current

  

2024

    

2023

  

Federal

   $ 981,244     $ 609,006  

State

     805       788  

Total current provision for income taxes

     982,049       609,794  
                 

Deferred

                

Federal

     (124,467 )     59,614  

Total deferred (benefit) expense from income taxes

     (124,467 )     59,614  
                 

Total provision for income taxes

   $ 857,582     $ 669,408  

 

The following is a reconciliation of the Company’s effective income tax rate to the Federal statutory rate:

 

   

Years ended December 31, .

  
    2024     2023  
    ($)    

Tax rate

     ($)    

Tax rate

  

Income taxes at statutory federal income tax rate

   $ 862,776       21.0

%

   $ 682,664       21.0

%

State taxes, net of federal benefit

     636       ---       623       ---  

Research & development credits

     (9,000

)

     (0.1 )     (14,000

)

     (0.4

)

Other, net

     3,170       ---       121       ---  

Provision for income taxes

   $ 857,582       20.9

%

   $ 669,408       20.6

%

 

F-18
 

  

The tax effects of temporary differences which comprise the deferred tax assets and liabilities are as follows:

 

   

December 31,

  
   

2024

    

2023

  

Deferred tax assets

                

Allowance for credit losses

   $ 3,012     $ 3,501  

Inventories

     6,886       9,870  

Accounts payable

     89,251       28,235  

R&D expenses

     206,069       159,838  

Accrued expenses

     306,381       285,200  

Total deferred tax assets

   $ 611,599     $ 486,644  

Deferred tax liabilities

                

Accounts receivable

     (302,987

)

     (332,537

)

Prepaid expenses

     (58,171

)

     (46,484

)

Depreciation on property, plant and equipment

     (68,959

)

     (56,275

)

Unrealized gain on marketable securities

     (6,085 )     (418 )

Total deferred tax liabilities

     (436,202

)

     (435,714

)

Net deferred tax asset

  $ 175,397     $ 50,930  

  
 

NOTE F - BENEFIT PLANS

 

Defined Contribution Plan

 

The Company sponsors a 401(k) defined contribution plan (“DC Plan”) that provides for a dollar-for-dollar employer matching contribution of the first 4% of each employee's pay. Employees become fully vested in employer matching contributions immediately. Company 401(k) matching contributions were approximately $84,000 and $83,000 for the years ended December 31, 2024 and 2023, respectively.

 

The Company also makes discretionary contributions to each employee's account based on a “pay-to-pay” safe-harbor formula that qualifies the 401(k) Plan under current IRS regulations. For the years ended December 31, 2024 and 2023, the Company’s Board of Directors authorized discretionary contributions in the amount of $115,000 and $109,000, respectively, to be allocated among all eligible employees. Employees become vested in the discretionary contributions as follows: 20% after two years of employment, and 20% for each year of employment thereafter until the employee becomes fully vested after six years of employment. The discretionary contribution for 2024 was paid in February 2025 and is included in accrued expenses.

 

 

NOTE G - GEOGRAPHIC AND OTHER INFORMATION

 

Through its Guardian Laboratories division, the Company conducts research, product development, manufacturing, and marketing of cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness ingredients. Prior to July 1, 2023, the Company manufactured and reported sales of a line of specialty industrial products, however this produce line was discontinued after the second quarter of 2023 due to low sales volume with no growth. All the products that the Company markets, with the exception of Renacidin, are produced at its facility in Hauppauge, New York. Renacidin, a urological product, is manufactured for the Company by an outside contract manufacturer. The Company’s R&D department not only develops new products but also modifies and refines existing products, with the goal of expanding the potential markets for the Company’s products. Many of the cosmetic ingredients manufactured by the Company, particularly its Lubrajel line of water-based moisturizing and lubricating gels, are currently used by many of the major multinational personal care products companies.

 

The Company operates in one business segment. The Company’s products are separated into five distinct product categories: cosmetic ingredients, pharmaceuticals, medical lubricants, sexual wellness ingredients and industrial products. The Company discontinued its industrial line of products after the second quarter of 2023 due to a low volume of sales and no growth. Each product category is marketed differently.

 

F-19
 

  

The cosmetic ingredients are marketed through a global network of distributors. These distributors purchase products outright from the Company and provide the main marketing and sales functions for these products on behalf of the Company. They in turn receive their compensation for those efforts by re-selling those products at a markup to their customers. This enables the Company to aggressively have its products marketed without the high cost of maintaining its own in-house marketing and sales staff. In 2024 we hired a marketing director to work alongside our distributors and provide marketing materials, training and aid in customer visits. We believe this strategy will allow us to better serve our mutual customers and build stronger relationships with our distributors. The Company currently has one written distribution agreements with the companies that market its cosmetic ingredients. The marketing contract with ASI terminated on December 31, 2023, and the Company is currently in negotiations with ASI to establish a new marketing agreement. The Company is hopeful that it will have a new marketing agreement in place with ASI by mid-2025. The Company’s relationship with ASI continues to be strong, and during this period of renegotiation the Company continues to fill ASI’s orders on a timely basis. All sales of the Company’s cosmetic ingredients are final other than product later determined to be defective, and the Company does not make any sales on consignment.

 

No prior regulatory approval is needed by the Company to sell any products other than its pharmaceutical products. The end users of its products may or may not need regulatory approvals, depending on the intended claims and uses of those products.

 

The pharmaceutical products include a urological product and a topical biocide that are sold to end users primarily through distribution agreements with major drug wholesalers. For these products, the Company does the marketing, and the drug wholesalers supply the product to the end users, such as hospitals and pharmacies. The Company’s marketing effort for Renacidin, its most important drug product, currently includes a Renacidin website which provides product information to patients and healthcare providers as well as a focus group study that was conducted in 2024. There is currently no active marketing effort for Clorpactin. Both of these products were originally developed in the 1950s. Clorpactin pre-dated the need for a formal New Drug Application (“NDA”), and the current sterile liquid form of Renacidin is marketed under an NDA that was approved by the FDA in 1990.

 

The medical lubricants are not pharmaceutical products. They consist primarily of water-based lubricating gels, which are marketed by the Company directly to manufacturers that incorporate them into urologic catheters and other medical devices and products that they sell. These products are distinguished from pharmaceutical products in that, unlike the pharmaceutical products, the Company is not required to obtain regulatory approval prior to marketing them. Regulatory approvals are the responsibility of the companies that market the finished products in which the Company’s products are used, which are typically classified as medical devices. However, the Company is responsible for manufacturing these products in accordance with current Good Manufacturing Practices, and its manufacturing facility is subject to regular FDA oversight.

 

The industrial products were marketed by the Company directly to manufacturers, and generally did not require that the Company obtain regulatory approval. However, the manufacturers of the finished products may have to obtain such regulatory approvals before marketing these products. The Company discontinued this product line on July 1, 2023.         

 

The sexual wellness ingredients are marketed by Brenntag Specialties, a global market leader in chemicals and ingredient distribution. The Company entered into a marketing and distribution agreement with Brenntag in October of 2023 in the United States, Canada, Mexico, Central America and South America.

 

The following tables present the significant concentrations of the Company’s sales. Although a significant percentage of Customer A’s purchases from the Company are sold to foreign customers, in table “(b)” below all sales to Customer A are included in the “United States” sales numbers because all shipments to Customer A are delivered to Customer A's warehouses in the U.S.

 

F-20
 

  

In addition, there are four customers for the Company’s medical lubricants that take delivery of their shipments in the U.S. but potentially ship some of that product to manufacturing facilities outside the U.S. Since the Company makes those shipments to U.S. locations, sales to those customers are also included in the “United States” sales number in the table below.

 

 

(a)

Net Sales                                                                      

 

    Years ended December 31,  
    2024     2023  

Cosmetic Ingredients

   $ 5,817,172     $ 4,283,071  

Pharmaceuticals

     5,602,259       5,894,220  

Medical Lubricants

     2,028,564       1,750,632  

Industrial and other

     ---       51,594  

Gross Sales

     13,447,995       11,979,517  

Less: Discounts and allowances

     (1,266,024

)

     (1,094,363

)

Net Sales

   $ 12,181,971     $ 10,885,154  

 

 

(b)

Geographic Information

 

   

Years ended December 31, .

  
   

2024

    

2023

  

United States

   $ 10,175,926     $ 8,601,205  

Other countries

     2,006,045       2,283,949  

Net Sales

   $ 12,181,971     $ 10,885,154  

 

 

(c)

Gross Sales to Major Customers

 

    Years ended December 31,  
   

2024

    

2023

  

Customer A

   $ 5,387,048     $ 3,464,861  

Customer B

     2,239,705       2,502,846  

Customer C

     1,831,551       1,726,753  

Customer D

     1,331,544       1,490,158  

All other customers

     2,658,147       2,794,899  

Total Gross Sales

   $ 13,447,995     $ 11,979,517  

  
 

NOTE H - ACCRUED EXPENSES

 

Accrued expenses on December 31, 2024 and 2023 consist of:

 

   

2024

    

2023

  

Bonuses

   $ 290,000     $ 187,002  

Distribution fees

     441,397       407,133  

Payroll and related expenses

     73,915       96,157  

Company 401(k) contribution

     115,000       109,000  

Annual report expenses

     83,238       81,725  

Audit fee

     73,364       71,000  

Reserve for outdated material returns

     276,732       247,847  

Sales rebates

     90,904       132,250  

Other

     23,383       30,930  

Total accrued expenses

   $ 1,467,933     $ 1,363,044  

 

F-21
 

  
 

NOTE I - SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES

 

As of December 31, 2024, the Company had a number of unconverted Guardian Chemical shares that would convert to approximately 447 shares of United-Guardian, Inc. common stock if all of the remaining holders of those Guardian shares converted their Guardian stock to United-Guardian stock. The Company’s transfer agent continues to try to locate the holders of those shares in anticipation of escheating them to the appropriate state jurisdictions. The Company is currently accruing dividends on the 447 shares that have not yet been exchanged or designated for escheatment as of December 31, 2024, and the Company will continue to do so as dividends are declared.

 

 

NOTE J - RELATED PARTY TRANSACTIONS

 

During the years ended December 31, 2024 and 2023, the Company made payments of $20,000 and $100,000 respectively, to Ken Globus, the Company’s former President, for consulting services subsequent to his departure from the Company. The Company’s consulting agreement with Ken Globus expired on May 31, 2024. Ken Globus is a director of the Company and currently serves as Chairman of the Board of Directors.

 

During the years ended December 31, 2024 and 2023, the Company paid PKF O’Connor Davies $23,250 and $20,000, respectively, for accounting and tax services. Lawrence Maietta, a partner at PKF O’Connor Davies, is a director of the Company.

 

 

NOTE K – SUBSEQUENT EVENTS

 

On January 27, 2025, the Company’s Board of Directors declared a cash dividend of $0.35 per share, which was paid on February 18, 2025 to all stockholders of record as of February 10, 2025.

 

 

 

 
F-22
 EX-19.1 2 ex_790490.htm EXHIBIT 19.1 ex_790490.htm

EXHIBIT 19.1

 

UNITED-GUARDIAN, INC.

 

INSIDER TRADING COMPLIANCE POLICY

 

A.

Introduction

 

United-Guardian, Inc. (the “Company”) has adopted this Insider Trading Compliance Policy (this “Policy”) to assist its directors, officers, employees, agents or advisors in complying with insider trading laws, avoiding even the appearance of improper insider trading, and ensuring compliance with the Company’s obligation under Item 408 of Regulation S-K and Rule 10b-5 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These obligations include the public disclosure of information regarding the Company’s insider trading compliance policy, practices, and the use of certain trading arrangements by Company insiders.

 

Federal and state securities laws strictly prohibit trading in a company’s securities while in possession of “material nonpublic information” about the company. This practice, known as “insider trading,” can result in severe civil and criminal penalties. These laws are based on the principle that individuals trading in a company’s securities should not benefit from having unfair access to material nonpublic information. Furthermore, these laws prohibit the disclosure of material nonpublic information to others who might use it for trading purposes. All directors, officers, and employees are required to fully understand and comply with these laws. Violating insider trading laws not only undermines public trust but also subjects individuals and the Company to significant legal penalties and reputational harm. 

 

These rules apply to all transactions involving the Company’s securities, including non-derivative and derivative securities, unless subject to an applicable exemption under Section G.

 

B.

Application

 

This Policy applies to all directors, officers, employees of the Company, and the Company itself (collectively, “Insiders”), their Related Parties, and any individuals designated as Insiders by the Compliance Officer.

 

“Related Parties” include:

 

 

●

Individuals living in the same household as an Insider.

 

 

●

Family members outside the household whose transactions in Company securities are influenced or directed by the Insider, also referred to as “tipping” (see Section E).

 

 

●

Entities controlled or influenced by an Insider, such as corporations, partnerships, or trusts.

 

“Family members” include a child, stepchild, grandchild, parent, stepparent, grandparent, spouse (or equivalent cohabitation relationship), sibling, in-laws, and adoptive relatives.

 

An individual is considered an Insider if they enter into a confidential relationship with the Company related to its affairs and, as a result, gain access to or learn confidential information through their work or representation of the Company. Insiders may include, but are not limited to, the Company’s auditors, attorneys, consultants, independent contractors, and employees of such organizations.

 

To avoid any appearance of impropriety, additional restrictions apply to “Section 16 Individuals” and “Key Employees.”

 

“Section 16 Individuals” are the Company’s directors and officers who are subject to the reporting and trading restrictions of Section 16 of the Exchange Act. This includes all members of the Board of Directors and officers designated by the Board as “Section 16 Officers.”

 

“Key Employees” are individuals who, due to their role within the Company, have access to material nonpublic information, as well as any other individuals designated by the Compliance Officer as Key Employees.

 

 

1
 

 

Both Section 16 Individuals and Key Employees, who regularly have access to confidential information, are prohibited from buying, selling, donating, or otherwise transacting in Company securities outside the Company’s designated trading windows (see Section H). In addition, these individuals must obtain prior approval from the Compliance Officer for all trades in Company securities, in accordance with the procedures outlined in Section I.

 

C.

Materiality

 

Information is considered “material” if it could influence a person’s decision whether to buy, sell or hold the Company’s securities. Materiality is dependent on the specific facts and circumstances of each situation. Generally, any information (positive or negative) that could reasonably be expected to affect the Company’s stock price should be considered material.

 

Material information can relate to any aspect of the Company’s business or its securities, including debt or equity. Enforcement authorities often assess materiality with the benefit of hindsight. If the Company’s stock price changes after the information is made public, it will likely be deemed material.

 

Although not exhaustive, the following types of information are typically considered material:

 

 

●

Quarterly and year-end financial results, and significant changes in financial performance.

 

 

●

Projections of future earnings or losses, guidance, strategic plans, or changes thereto.

 

 

●

Proposals, plans or agreements, involving mergers, acquisitions, tender offers, divestitures, recapitalizations, joint ventures, strategic alliances, licensing arrangements, or transactions involving substantial assets.

 

 

●

Execution, modification, or termination of significant contracts.

 

 

●

The acquisition or loss of a significant customer.

 

 

●

Determinations to declare a dividend.

 

 

●

Major developments involving products or business strategies.

 

 

●

New equity or debt offerings, whether public or private.

 

 

●

The contents of upcoming reports or publications that may impact the Company’s stock price.

 

 

●

Changes in control or senior management.

 

 

●

Cybersecurity risks and incidents, including significant breaches.

 

 

●

Actual or threatened major litigation, resolution of such litigation, or other similar disputes.

 

 

●

Decreases in capital resources or liquidity, or impending bankruptcy or receivership.

 

If an Insider is uncertain whether particular information is material, the Insider should assume it is and consult with the Compliance Officer before disclosing it or trading while in possession of such information.

 

D.

Nonpublic Information

 

Information is considered “nonpublic” if it has not been made available to the general public. To be deemed “public”, it must have been disclosed in the Company’s filings with the Securities and Exchange Commission (the “SEC”) or disseminated in a manner designed to broadly reach investors, where they have time to absorb and evaluate the information. Additionally, a reasonable period of time must pass after the Company publicly announces material information for the market to fully react.

 

For purposes of this Policy, information will be considered public only after the close of trading on the second business day following its public release. Insiders with material nonpublic information must wait until after the close of trading on the second full trading day before engaging in any transactions in Company securities.

As with materiality, if an Insider is unsure whether information is public, the Insider should assume it is nonpublic, treat it as confidential, and consult with the Compliance Officer.

 

2
 

 

E.

General Policy

 

The following guidelines on trading or causing trading while in possession of material nonpublic information must be followed to ensure compliance with applicable federal and state securities laws and with this Policy:

 

1.

Non-Disclosure of Material Nonpublic Information. Insiders are prohibited from disclosing material nonpublic information to anyone until it has been publicly released by the Company, except those within the Company or third-party agents of the Company whose roles require access to know such information (e.g., auditors, legal counsel, and investment banking advisors).

 

2.

Prohibition Against Tipping. “Tipping” refers to providing material nonpublic information to others who may trade or advise others to trade on such information. This practice is illegal and Insider’s must not “tip” or otherwise disclose material nonpublic information about the Company to outsiders, unless required as part of their regular duties and authorized by the Compliance Officer. All inquiries from outsiders regarding material nonpublic information about the Company must be forwarded to the Compliance Officer. Outsiders include, but are not limited to, family members, analysts, actual or potential investors, members of the press, and others seeking information.

 

3.

Prohibition Against Providing Trading Advice. Insiders are prohibited from providing trading advice about the Company to anyone, whether or not they possess material nonpublic information. Insiders should, however, advise other Insiders against trading if it could violate this Policy or applicable law.

 

4.

Prohibition from Trading in the Company’s Securities. Insiders are prohibited from buying, selling, donating, recommending, or otherwise transacting in the Company’s securities while aware of material nonpublic information about the Company. Insiders are also prohibited from transacting in the Company’s securities during any special blackout period applicable to such Insider as designated by the Compliance Officer.

 

5.

Prohibition from Trading in Other Securities. No Insider is permitted to trade or “tip” information about another company’s securities while in possession of material nonpublic information about that company obtained through their employment or affiliation with the Company.

 

F.

Other Prohibited Transactions

 

Investing in the Company’s common stock offers an opportunity to share in the Company’s growth. In contrast, short-term speculation on market fluctuations may distract directors, officers, and employees from the Company’s long-term goals and may conflict with the best interests of the Company and its stockholders. Additionally, such activities can create the appearance of improper conduct. Therefore, Insiders are subject to the following additional restrictions: 

 

1.

Prohibition Against Short Selling. Insiders are prohibited from engaging in short sales of the Company securities. A short sale involves selling a security that the seller does not own at the time of the transaction. In addition to this Policy, Section 16(c) of the Exchange Act prohibits Section 16 Officers and Directors from engaging in short sales.

 

2.

Prohibition Against Derivative Transactions. Insiders are prohibited from engaging in transactions involving puts, calls, or other derivative instruments related to Company securities. Such transactions are speculative and may create the appearance of trading based on nonpublic information.

 

3.

Prohibition Against Hedging. No Insider may engage in hedging transactions involving Company securities, including forward sale or purchase contracts, equity swaps, collars, or exchange funds. Such transactions are speculative and may create the appearance of trading based on nonpublic information.

 

4.

Prohibition Against Trading on Margin or Pledging. Insiders are prohibited from holding Company securities in margin accounts or pledging them as collateral for loans. If a margin call occurs or a loan is in default, securities could be sold without the Insider’s consent, potentially during a time when the Insider is aware of material nonpublic information.

 

3
 

 

5.

Limited Use of Standing and Limit Orders. Standing and limit orders pose a risk for insider trading violations because the timing of the transaction is beyond the Insider’s control, potentially resulting in a trade while in possession of material nonpublic information. The Company strongly discourages placing such orders. If an Insider deems it necessary, the order should be limited to no more than five business days and comply with all applicable restrictions and pre-clearance requirements. A standing order as part of a Rule 10b5-1 trading plan approved by the Compliance Officer is permitted.

 

G.

Exceptions for Certain Transactions

 

The trading restrictions in this Policy do not apply to (a) stock option exercises (but they do apply to the sale of any securities acquired through such exercises); and (b) bona fide gifts of Company stock (however the recipient of the gift is subject to this Policy’s trade restrictions for any subsequent sale of the gifted securities).

 

H.

Trading Windows and Blackout Periods

 

In addition to the other limitations in this Policy, Insiders are prohibited from trading Company securities during the following blackout periods:

 

1.

Blackout Periods. Trading in the Company’s securities is prohibited beginning on the 15th calendar day before the end of each fiscal quarter and fiscal year (or the preceding Friday if the 15th falls on a weekend). The blackout period ends after the close of trading on the second full business day following the public release of the Company’s quarterly or annual earnings. During these blackout periods, Insiders are generally presumed to possess material nonpublic information regarding the Company’s financial performance.

 

2.

Special Blackout Periods. From time to time, material nonpublic information about the Company, such as negotiations related to mergers or acquisitions, may require additional blackout periods. The Compliance Officer will notify those affected by the special blackout period. During these times, Insiders with knowledge of the information are prohibited from trading in Company securities and must keep the existence of the special blackout period confidential.

 

3.

Exceptions for Hardship Cases. The Compliance Officer may authorize trading outside the designated windows (but not during special blackout periods) due to financial or other hardships, following the procedures outlined in Section I.

 

Be advised that trading windows are not “safe harbors” guaranteeing compliance with securities laws. Insiders must exercise good judgment and remain responsible for their trades at all times.

 

I.

Procedures for Approving Trades by Section 16 Individuals, Key Employees and Hardship Cases

 

1.

Section 16 Individual/Key Employee Trades. No Section 16 Individual or Key Employee may trade in Company securities until:

 

 

a.

the person trading notifies the Compliance Officer in writing of the amount and nature of the proposed trade(s);

 

 

b.

the person trading certifies to the Compliance Officer in writing, no earlier than two business days prior to the proposed trade, that (i) they are not in possession of material nonpublic information concerning the Company and (ii) the proposed trade(s) do not violate the trading restrictions of Section 16 of the Exchange Act or Rule 144 of the Securities Act; and

 

 

c.

the Compliance Officer approves the trade(s) and has certified the approval in writing.

 

2.

Hardship Cases. The Compliance Officer may, on a case-by-case basis, authorize trading in Company securities outside of the applicable trading windows due to financial or other hardships, only after:

 

 

a.

the person trading has notified the Compliance Officer in writing of the circumstances of the hardship and the amount and nature of the proposed trade(s);

 

 

b.

the person trading has certified to the Compliance Officer in writing, no earlier than two business days prior to the proposed trade(s), that they are not in possession of material nonpublic information; and

 

 

c.

the Compliance Officer has approved the trade(s) and certifies the approval in writing.

 

4
 

 

3.

No Obligation to Approve Trades. The approval procedures outlined above do not obligate the Compliance Officer to approve any requested trades. The Compliance Officer may reject any trade requests at their sole discretion.

 

J.

Compliance Officer

 

The Compliance Officer is responsible for reviewing and either approving or prohibiting proposed trades by Section 16 Individuals and Key Employees in accordance with the procedures outlined in Section I. 

 

In addition to the trading approval duties described in Section I, the Compliance Officer’s responsibilities include the following:

 

 

●

Administering this Policy and monitoring and enforcing compliance with all provisions and procedures.

 

 

●

Responding to inquiries related to this Policy and its procedures.

 

 

●

Designating and announcing quarterly and special trading blackout periods during which certain Insiders may not trade in Company securities.

 

 

●

Providing copies of this Policy and other relevant materials to new Insiders and tracking signed acknowledgments.

 

 

●

Administering, monitoring, and enforcing compliance with all federal and state insider trading laws and regulations.

 

 

●

Revising the Policy as necessary to reflect changes in federal or state insider trading laws and regulations or as otherwise deemed necessary or appropriate.

 

The Compliance Officer may designate one or more individuals to perform these duties if they are unable or unavailable to do so.

 

K.

Post-Termination Transactions

 

The restrictions outlined in this Policy remain in effect for transactions involving the Company’s securities even after an individual’s employment or engagement with the Company has terminated. If an individual possesses material nonpublic information at the time of such termination, or if the Company’s trading window is closed, they must refrain from trading in the Company’s securities until the material nonpublic information has been publicly disclosed or is no longer material, and/or the Company’s trading window has reopened.

 

L.

Penalties and Disciplinary Actions

 

The consequences of engaging in prohibited insider trading or tipping can be severe. Violators may be required to:

 

 

●

Disgorge profits made or losses avoided through improper trading.

 

 

●

Compensate individuals harmed by purchasing securities from, or selling securities to, the insider or tippee.

 

 

●

Pay substantial civil and/or criminal penalties.

 

 

●

Face disqualification from serving as an officer or director of a public company.

 

 

●

Serve prison sentences.

 

The Company may also face significant civil and criminal penalties if violations occur.

 

Any violation of this Policy or applicable federal or state insider trading or tipping laws by an Insider may result in disciplinary action. For directors, this could include dismissal proceedings. For officers or employees, this could include disciplinary measures up to and including termination for cause.

 

Insiders who violate this Policy or any insider trading or tipping laws or who are aware of any such violations by others, must report the violation immediately to the Compliance Officer. Upon receiving such reports, the Compliance Officer, in consultation with legal counsel, will determine whether the Company should disclose the material nonpublic information or report the violation to the SEC or other appropriate governmental authorities.

 

5
 

 

M.

Miscellaneous

 

This Policy will be distributed to all directors, officers, employees, and designated Insiders upon its adoption or subsequent revision by the Company. It will also be provided to all new directors, officers, employees, and designated Insiders at the commencement of their employment or relationship with the Company.

 

Upon receiving a copy of this Policy or any subsequent revisions, each Section 16 Individual and Key Employee must sign an acknowledgment that they have received a copy of this Policy and agree to comply with its terms.

 

The Company shall file this Policy as Exhibit 19 to its Annual Report on Form 10-K.

 

Last Updated: March 19, 2025

 

 

 

 

6
 

 

UNITED-GUARDIAN, INC.

 

INSIDER TRADING COMPLIANCE POLICY

 

ACKNOWLEDGEMENT

 

The undersigned hereby acknowledges receipt of the attached Insider Trading Compliance Policy of United-Guardian, Inc. (the “Company”) and hereby agrees to strictly comply with such policy. The undersigned also agrees that if they are contemplating a sale or purchase transaction involving any Company stock (as described in the Insider Trading Compliance Policy) and are unsure of the applicability of this policy, they will contact the Compliance Officer of the Company prior to executing the transaction to determine if they may proceed.

 

Please acknowledge your receipt of the attached Insider Trading Compliance Policy by dating and signing this acknowledgment and returning it to the Compliance Officer.

 

   
  Name:
   
  Title:
   
  Date:

 

 

 

 

 

7
 EX-31.1 3 ex_790491.htm EXHIBIT 31.1 HTML Editor

EXHIBIT 31.1

 

SECTION 302 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

 

I, Donna Vigilante, certify that:

 

 

1.

I have reviewed this Annual Report of United-Guardian, Inc. on Form 10-K for the year ended December 31, 2024;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a.

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b.

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d.

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

a.

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 19, 2025  By: /s/ Donna Vigilante 
    Donna Vigilante
    President and Principal Executive Officer

 

 
 EX-31.2 4 ex_790492.htm EXHIBIT 31.2 HTML Editor

EXHIBIT 31.2

 

SECTION 302 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

 

I, Andrea Young, certify that:

 

 

1.

I have reviewed this Annual Report of United-Guardian, Inc. on Form 10-K for the year ended December 31, 2024;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a.

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b.

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d.

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

a.

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 19, 2025 

By:

 /s/ Andrea Young
   

Andrea Young
   

Principal Financial Officer

 

 
 EX-32 5 ex_790493.htm EXHIBIT 32 HTML Editor

EXHIBIT 32

 

CERTIFICATIONS PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the annual report of United-Guardian, Inc. (the "Company") on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the "Report"), I, Donna Vigilante, President and Principal Executive Officer of the Company, and I, Andrea Young, Principal Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C.  Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(i) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(ii) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 19, 2025 

By:

/s/ Donna Vigilante 
   

Donna Vigilante
   

President and Principal Executive Officer

 

 

By:

/s/ Andrea Young
   

Andrea Young
    Principal Financial Officer

 

 
 EX-101.SCH 6 ug-20241231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Statements of Income link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Balance Sheets link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Statements of Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Statements of Stockholders' Equity (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 995550 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 995551 - Disclosure - Note B - Cash and Cash Equivalents link:calculationLink link:definitionLink link:presentationLink 995552 - Disclosure - Note C - Marketable Securities link:calculationLink link:definitionLink link:presentationLink 995553 - Disclosure - Note D - Inventories link:calculationLink link:definitionLink link:presentationLink 995554 - Disclosure - Note E - Income Taxes link:calculationLink link:definitionLink link:presentationLink 995555 - Disclosure - Note F - Benefit Plans link:calculationLink link:definitionLink link:presentationLink 995556 - Disclosure - Note G - Geographic and Other Information link:calculationLink link:definitionLink link:presentationLink 995557 - Disclosure - Note H - Accrued Expenses link:calculationLink link:definitionLink link:presentationLink 995558 - Disclosure - Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities link:calculationLink link:definitionLink link:presentationLink 995559 - Disclosure - Note J - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 995560 - Disclosure - Note K - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 995561 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995562 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 995563 - Disclosure - Note B - Cash and Cash Equivalents (Tables) link:calculationLink link:definitionLink link:presentationLink 995564 - Disclosure - Note C - Marketable Securities (Tables) link:calculationLink link:definitionLink link:presentationLink 995565 - Disclosure - Note D - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 995566 - Disclosure - Note E - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 995567 - Disclosure - Note G - Geographic and Other Information (Tables) link:calculationLink link:definitionLink link:presentationLink 995568 - Disclosure - Note H - Accrued Expenses (Tables) link:calculationLink link:definitionLink link:presentationLink 995569 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995570 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies - Disaggregated Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 995571 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies - Revenue by Geographic Region (Details) link:calculationLink link:definitionLink link:presentationLink 995572 - Disclosure - Note B - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) link:calculationLink link:definitionLink link:presentationLink 995573 - Disclosure - Note C - Marketable Securities (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995574 - Disclosure - Note C - Marketable Securities - Net Gains and Losses on Marketable Securities (Details) link:calculationLink link:definitionLink link:presentationLink 995575 - Disclosure - Note C - Marketable Securities - Summary of Investments (Details) link:calculationLink link:definitionLink link:presentationLink 995576 - Disclosure - Note D - Inventories (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995577 - Disclosure - Note D - Inventories - Summary of Inventories (Details) link:calculationLink link:definitionLink link:presentationLink 995578 - Disclosure - Note E - Income Taxes - Provision for Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 995579 - Disclosure - Note E - Income Taxes - Reconciliation of the Effective Income Tax Rate (Details) link:calculationLink link:definitionLink link:presentationLink 995580 - Disclosure - Note E - Income Taxes - Deferred Tax Assets and Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995581 - Disclosure - Note F - Benefit Plans (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995582 - Disclosure - Note G - Geographic and Other Information (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995583 - Disclosure - Note G - Geographic and Other Information - Net Sales (Details) link:calculationLink link:definitionLink link:presentationLink 995584 - Disclosure - Note G - Geographic and Other Information - Geographic Information (Details) link:calculationLink link:definitionLink link:presentationLink 995585 - Disclosure - Note G - Geographic and Other Information - Sales to Major Customers (Details) link:calculationLink link:definitionLink link:presentationLink 995586 - Disclosure - Note H - Accrued Expenses - Summary of Accrued Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 995587 - Disclosure - Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995588 - Disclosure - Note J - Related Party Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995589 - Disclosure - Note K - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 7 ug-20241231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 ug-20241231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Fair Value of Financial Instruments, Policy [Policy Text Block] Note To Financial Statement Details Textual ug_AccruedDistributionFeesCurrent Distribution fees Accrued distribution fees Significant Accounting Policies us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Income taxes at statutory federal income tax rate Note A - Nature of Business and Summary of Significant Accounting Policies Note B - Cash and Cash Equivalents Note C - Marketable Securities Segment Reporting, Policy [Policy Text Block] Note D - Inventories Note E - Income Taxes Note G - Geographic and Other Information Note H - Accrued Expenses Note A - Nature of Business and Summary of Significant Accounting Policies - Disaggregated Revenue (Details) Income Tax Disclosure [Text Block] Note A - Nature of Business and Summary of Significant Accounting Policies - Revenue by Geographic Region (Details) Discretionary Contributions Vesting Each Additional Year [Member] Represents discretionary contributions vesting each additional year of employment. ug_SalesReturnsAndAllowances Less: Discounts and allowances Total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions) and price reductions (allowance, price protection agreements) given by the entity. Returns and allowances are a deduction from gross revenue in arriving at net revenue. Note B - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) Discretionary Contributions Vesting at Two Years [Member] Represents discretionary contributions vesting after two years of employment. Gross Sales Gross Amount before sales allowance and return, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Note C - Marketable Securities - Net Gains and Losses on Marketable Securities (Details) Note C - Marketable Securities - Summary of Investments (Details) us-gaap_LiabilitiesCurrent Total current liabilities Note D - Inventories - Summary of Inventories (Details) Note E - Income Taxes - Provision for Income Taxes (Details) Note E - Income Taxes - Reconciliation of the Effective Income Tax Rate (Details) Note E - Income Taxes - Deferred Tax Assets and Liabilities (Details) Earnings Per Share, Policy [Policy Text Block] Note G - Geographic and Other Information - Net Sales (Details) Note G - Geographic and Other Information - Geographic Information (Details) Note G - Geographic and Other Information - Sales to Major Customers (Details) Note H - Accrued Expenses - Summary of Accrued Expenses (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Income Tax, Policy [Policy Text Block] ug_EquitySecuritiesFvniAccumulatedUnrealizedGainLoss Equity securities, unrealized gain Accumulated amount of unrealized gain (loss) on equity securities. Proceeds from sales of marketable securities Proceeds from Sale and Maturity of Marketable Securities Equity securities, cost Research, Development, and Computer Software, Policy [Policy Text Block] Depreciation and amortization us-gaap_AssetsCurrent Total current assets us-gaap_RealizedInvestmentGainsLosses Net gain on marketable securities Net unrealized gains recognized during the reporting year on marketable securities still held at the reporting date ug_AllowanceForMaterialReturns Allowance for Material Returns The amount of allowance for material returns. Accrued Expenses [Member] Related to accrued expenses. Advertising Cost [Policy Text Block] Common stock, $.10 par value; 10,000,000 shares authorized; 4,594,319 shares issued and outstanding at December 31, 2024 and 2023 us-gaap_PaymentsToAcquireMarketableSecurities Purchases of marketable securities Financial Instruments [Domain] Retirement Plan Name [Axis] Adjustments to reconcile net income to net cash provided by operating activities: Retirement Plan Name [Domain] Common Stock, Shares Authorized (in shares) Deferred revenue Contract with Customer, Liability, Current Common Stock, Shares, Issued (in shares) Financial Instrument [Axis] Certificates of Deposit [Member] Common Stock, Par or Stated Value Per Share (in dollars per share) Stockholders' Equity, Policy [Policy Text Block] Accrued expenses Total accrued expenses Statistical Measurement [Domain] Maximum [Member] Dividends payable Minimum [Member] Accounts payable Proceeds from sale of asset Product and Service [Axis] Product and Service [Domain] us-gaap_DeferredTaxAssetsNet Total deferred tax assets Statistical Measurement [Axis] us-gaap_AccruedBonusesCurrent Bonuses us-gaap_DeferredTaxAssetsLiabilitiesNet Net deferred tax asset us-gaap_OtherAccruedLiabilitiesCurrent Other Prepaid income taxes us-gaap_AccruedSalariesCurrent Payroll and related expenses us-gaap_PolicyTextBlockAbstract Accounting Policies Cash Flow, Supplemental Disclosures [Text Block] Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Geographical [Axis] Geographical [Domain] us-gaap_DeferredIncomeTaxLiabilities Total deferred tax liabilities Inventories, net Total Inventories Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] us-gaap_AccruedProfessionalFeesCurrent Audit fee us-gaap_AccruedMarketingCostsCurrent Sales rebates Net Sales Net sales us-gaap_InventoryValuationReserves Inventory Valuation Reserves us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Acquisitions of property, plant and equipment ug_PaymentsForAccruedDividendsOnUnconvertedShares Payments for Accrued Dividends on Unconverted Shares The amount of cash outflow for payments for accrued dividends on unconverted shares. Supplemental disclosure of non-cash items: Segment, Reconciliation of Other Items from Segments to Consolidated [Table Text Block] Lubrajel [Member] Customer [Axis] us-gaap_DeferredTaxAssetsInventory Inventories Renacidin [Member] Represents the product line, Renacidin. Customer [Domain] Factory Equipment And Fixtures [Member] Taxes paid Net gains recognized during the year on marketable securities Current liabilities: Equity And Other Mutual Funds [Member] Equity And Other Mutual Funds Member us-gaap_Assets TOTAL ASSETS Supplemental disclosure of cash flow information us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Accrued expenses us-gaap_PropertyPlantAndEquipmentUsefulLife Property, Plant and Equipment, Useful Life (Year) Personal Care [Member] The products for personal care. Property, plant, and equipment: Pharmaceuticals [Member] Cash flows from operating activities: Industrial And Other [Member] us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts Allowance for credit losses Schedule of Segment Reporting Information, by Segment [Table Text Block] Revenue [Policy Text Block] Statement [Line Items] us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Accounts Receivable, Allowance for Credit Loss, Current Customer A [Member] Represents customer A. Accounts receivable, net of allowance for credit losses of $14,342 in 2024 and $16,672 in 2023 us-gaap_NumberOfOperatingSegments Number of Operating Segments Customer B [Member] Represents a second customer. All Other Customers [Member] Deferred income taxes, net Building [Member] Building Improvements [Member] us-gaap_MarketableSecuritiesCurrent Marketable securities Stockholders’ equity: Property, Plant and Equipment, Policy [Policy Text Block] us-gaap_NonoperatingIncomeExpense Total other income Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Segment Reporting Disclosure [Text Block] Investment income Current assets: Net income Net income us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Inventory, Policy [Policy Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net (decrease) increase in cash and cash equivalents us-gaap_Liabilities Total liabilities us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities Commitments and Contingencies Director [Member] us-gaap_OperatingIncomeLoss Income from operations Other income: us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by operating activities Prepaid expenses and other current assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash (used in) provided by investing activities Cost of sales ug_DefinedContributionDiscretionaryContributionPlanVestingPeriod Defined Contribution, Discretionary Contribution Plan, Vesting Period (Year) Represents the vesting period of discretionary contributions made under the defined contribution plan. us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities Company 401(k) contribution us-gaap_InventoryWriteDown Allowance for obsolete inventory Less accumulated depreciation us-gaap_PropertyPlantAndEquipmentNet Total property, plant, and equipment, net us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued us-gaap_PropertyPlantAndEquipmentGross Total property, plant and equipment Marketable Securities, Policy [Policy Text Block] Other Short-term Investments, cost Represents the amount of other short-term investments at cost. Land Concentration Risk, Credit Risk, Policy [Policy Text Block] ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIUnrealizedGainLoss Total marketable securities, unrealized gain Amount of accumulated unrealized gain (loss) in debt securities classified as held to maturity and equity securities. us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities Unrealized gain on marketable securities us-gaap_Dividends Dividends declared Dividends ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIFairValue Total marketable securities, fair value Fair value of investment in debt securities classified as held to maturity and equity securities. Building and improvements Other Short-term Investments, fair value Represents the fair value of other short-term investments. ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNICost Total marketable securities, cost Cost of investment in debt securities classified as held to maturity and equity securities. us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment Depreciation on property, plant and equipment Factory equipment and fixtures us-gaap_DeferredTaxLiabilitiesPrepaidExpenses Prepaid expenses Other Liabilities Disclosure [Text Block] us-gaap_PaymentsOfDividends Dividends paid Deferred tax liabilities us-gaap_PaymentsOfDividendsCommonStock Payments of Ordinary Dividends, Common Stock us-gaap_CostsAndExpenses Total costs and expenses Cash flows from investing activities: Scenario [Domain] Forecast [Member] Retained Earnings [Member] Equity securities, fair value us-gaap_CurrentStateAndLocalTaxExpenseBenefit State Scenario [Axis] Accounting and Tax Services [Member] Represents accounting and tax services. us-gaap_RelatedPartyTransactionAmountsOfTransaction Related Party Transaction, Amounts of Transaction Common Stock [Member] us-gaap_CurrentFederalTaxExpenseBenefit Federal us-gaap_DeferredFederalIncomeTaxExpenseBenefit Federal Related Party Transactions Disclosure [Text Block] us-gaap_IncomeTaxExpenseBenefit Provision for income taxes Total provision for income taxes us-gaap_IncreaseDecreaseInAccruedLiabilities Accrued expenses ug_ConvertibleCommonStockSharesIssuableUponConversion Convertible Common Stock, Shares Issuable upon Conversion Number of shares issuable upon the conversion of convertible common stock. Equity Components [Axis] Equity Component [Domain] CHINA us-gaap_CurrentIncomeTaxExpenseBenefit Total current provision for income taxes Accounts payable us-gaap_IncreaseDecreaseInAccountsPayable Gain (Loss) on Securities [Table Text Block] Net gain on marketable securities us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income before provision for income taxes us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount dei_IcfrAuditorAttestationFlag ICFR Auditor Attestation Flag us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Demand Deposits Cash and cash equivalents Total cash and cash equivalents Disaggregation of Revenue [Table Text Block] U.S. Treasury Bills (original 3-month maturity) Certificates of Deposit (original 3-month maturity) Money market funds dei_DocumentAnnualReport Document Annual Report Statement of Financial Position Location, Balance [Axis] Cash and Cash Equivalents, Policy [Policy Text Block] ug_DefinedContributionPlanEmployerDiscretionaryContributionAmountPerYearAuthorized Defined Contribution Plan, Employer Discretionary Contribution Amount Per Year Authorized Defined Contribution Plan, Employer Discretionary Contribution Amount Per Year, Authorized. Statement of Financial Position Location, Balance [Domain] Entity Incorporation, State or Country Code Amendment Flag us-gaap_UnrecognizedTaxBenefits Unrecognized Tax Benefits Accounting Policies [Abstract] Distributors and Marketing Partners [Member] Represents distributors and marketing partners of the company. dei_DocumentTransitionReport Document Transition Report dei_CityAreaCode City Area Code dei_DocumentFinStmtErrorCorrectionFlag Document Financial Statement Error Correction [Flag] Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] dei_EntityInteractiveDataCurrent Entity Interactive Data Current us-gaap_CommonStockDividendsPerShareDeclared Common Stock, Dividends, Per Share, Declared Dividends declared per share (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) us-gaap_IncreaseDecreaseInContractWithCustomerLiability Deferred revenue O 2024 Q1 Dividends [Member] Represents the ordinary dividends for Q1 of 2024. Security Exchange Name Common Stock, Shares, Outstanding (in shares) O 2023 Q3 Dividends [Member] Represents the ordinary dividends for Q3 of 2023. Title of 12(b) Security O 2024 Q3 Dividends [Member] Represents the ordinary dividends for Q3 of 2024. Current Fiscal Year End Date Increase (decrease) in operating liabilities: Less: Net losses realized during the year on marketable securities sold during the period us-gaap_DebtAndEquitySecuritiesRealizedGainLoss Debt and Equity Securities, Realized Gain (Loss) Customer C [Member] Represents a third customer. Customer D [Member] Represents a fourth customer. us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets Document Fiscal Period Focus Document Fiscal Year Focus Medical Lubricants [Member] Represents medical lubricants. dei_DocumentPeriodEndDate Document Period End Date dei_EntityFileNumber Entity File Number us-gaap_IncreaseDecreaseInPrepaidTaxes Prepaid income taxes Entity Emerging Growth Company dei_DocumentType Document Type Cosmetic Ingredients [Member] Represents information related to cosmetic ingredients. R&D expenses Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development. Entity Small Business dei_EntityShellCompany Entity Shell Company dei_AuditorName Auditor Name Document Information [Line Items] Document Information [Table] dei_EntityPublicFloat Entity Public Float Entity Filer Category dei_AuditorFirmId Auditor Firm ID dei_EntityCurrentReportingStatus Entity Current Reporting Status dei_EntityVoluntaryFilers Entity Voluntary Filers dei_AuditorLocation Auditor Location dei_EntityWellKnownSeasonedIssuer Entity Well-known Seasoned Issuer Three Raw Material Vendors [Member] Represents the three raw material vendors. us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Impairment, Long-Lived Asset, Held-for-Use Previous President and CEO [Member] Represents previous President and CEO. Consulting Services [Member] Represents consulting services. us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage Entity Tax Identification Number Non-US [Member] Entity Central Index Key dei_EntityRegistrantName Entity Registrant Name Product Concentration Risk [Member] Entity [Domain] Customer Concentration Risk [Member] Legal Entity [Axis] Statement [Table] dei_EntityAddressAddressLine1 Entity Address, Address Line One Statement of Financial Position [Abstract] Supplier Concentration Risk [Member] Weighted average shares (basic and diluted) (in shares) ecd_NonRule10b51ArrTrmntdFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments Other, net, tax rate dei_EntityAddressCityOrTown Entity Address, City or Town ecd_Rule10b51ArrTrmntdFlag Rule 10b5-1 Arrangement Terminated [Flag] Geographic Concentration Risk [Member] ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] us-gaap_EffectiveIncomeTaxRateContinuingOperations Provision for income taxes, tax rate dei_EntityAddressPostalZipCode Entity Address, Postal Zip Code Earnings per common share (basic and diluted) (in dollars per share) dei_EntityAddressStateOrProvince Entity Address, State or Province ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] Concentration Risk Type [Axis] Credit Loss, Financial Instrument [Policy Text Block] Material Terms of Trading Arrangement [Text Block] Concentration Risk Type [Domain] us-gaap_AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss ug_DividendsDeclared Dividends declared The value of dividends declared. Statement of Cash Flows [Abstract] Cost of Goods and Service, Product and Service Benchmark [Member] dei_EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding (in shares) Trading Arrangements, by Individual [Table] Statement of Stockholders' Equity [Abstract] Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] ug_AccruedReserveForOutdatedMaterial Reserve for outdated material returns Carrying value on reserves for outdated material. Income Statement [Abstract] ug_AccruedAnnualReportExpensesCurrent Annual report expenses The carrying value of accrued annual report expenses classified as current liabilities. Marketable Securities [Table Text Block] us-gaap_AdvertisingExpense Advertising Expense Revenue Benchmark [Member] Revenue from External Customers by Geographic Areas [Table Text Block] Accounts Receivable [Member] Schedule of Accrued Liabilities [Table Text Block] US Treasury Bill Securities [Member] us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] dei_LocalPhoneNumber Local Phone Number Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] us-gaap_TableTextBlock Notes Tables us-gaap_GainLossOnDispositionOfAssets1 Gain on sale of asset Related and Nonrelated Parties [Axis] Related and Nonrelated Parties [Domain] us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent us-gaap_ProvisionForDoubtfulAccounts Allowance for credit losses us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Research & development credits, tax rate us-gaap_DividendPayableDateToBePaidDayMonthAndYear Dividends Payable, Date to be Paid us-gaap_IncomeTaxReconciliationOtherAdjustments Other, net Cash flows from financing activities: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Income taxes at statutory federal income tax rate, tax rate us-gaap_DividendsPayableDateOfRecordDayMonthAndYear Dividends Payable, Date of Record Operating expenses us-gaap_DividendsPayableCurrentAndNoncurrent Dividends payable ug_DeferredTaxAssetsAccountsPayable Accounts payable Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accounts payable. Raw materials ug_DeferredTaxLiabilitiesAccountsReceivable Accounts receivable Amount of deferred tax consequences attributable to taxable temporary differences derived from accounts receivable. us-gaap_LiabilitiesAndStockholdersEquity TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY us-gaap_CashUninsuredAmount Cash, Uninsured Amount Finished products Work in process UNITED STATES Related Party Transaction [Axis] Dividends [Axis] DC Plan [Member] Represents DC plan. Related Party Transaction [Domain] Dividends [Domain] (Increase) decrease in operating assets: Research and development Retained earnings Costs and expenses: Demand Deposits [Member] LUBRAJEL and RENACIDIN IRRIGATION [Member] Refers to the products LUBREJEL and RENACIDIN IRRIGATION. ug_CashSIPCUninsuredAmount Cash, SIPC Uninsured Amount The amount of cash as of the balance sheet date that is not insured by the Securities Investor Protection Corporation. Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] us-gaap_StockholdersEquity Total stockholders’ equity Balance Balance ASI [Member] Refers to information regarding the entity ASI, which is located in Canada. us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Inventory Disclosure [Text Block] Subsequent Event [Member] Schedule of Cash and Cash Equivalents [Table Text Block] Schedule of Inventory, Current [Table Text Block] Class of Stock [Axis] ug_NumberOfCustomers Number of Customers The number of customers affecting an entity's concentration risk. Subsequent Event Type [Axis] Cash and Cash Equivalents Disclosure [Text Block] Subsequent Event Type [Domain] O2025Q1 Dividends [Member] Represents 2025 Q1 dividends. ug_NumberOfVendors Number of Vendors The number of vendors affecting an entity's concentration risk. Retirement Benefits [Text Block] Subsequent Events [Text Block] us-gaap_DeferredIncomeTaxExpenseBenefit Deferred income taxes Total deferred (benefit) expense from income taxes us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes State taxes, net of federal benefit us-gaap_IncomeTaxReconciliationTaxCreditsResearch Research & development credits EX-101.PRE 9 ug-20241231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.CAL 10 ug-20241231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE GRAPHIC 11 signature.jpg begin 644 signature.jpg M_]C_X 02D9)1@ ! 0$ E@"6 #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" \ 2P# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]4Z*** "D MW MC(SUQ7G7[0GQHTS]G[X0>(_'6JH9X=+MRT5L#@SS,=L<8_P!YB!],U\'_ M +"J?$CQ'^VMXA\3^/M;N+O6+SPC'J>HZ<'*PV(NI%:VM@F<#;&%. .,GW- M'Z;45\J_M\?'_P 0_"KP1X<\+^ [[[)\0/&>KP:3I8W]U=Q&3["KU "T4ASV_.EH M **0'-+0 4444 %%%% !17ENA?M/?##Q+\6+SX::9XPL;WQK:!_-TR/?G<@R MZ!]NQF4IH ^(_P#@JKX@_L'X8?#R35$E?PC_ M ,)?:2ZVD0),D$8:15/L2N/KBN6_9?\ B_X.^"GP[\8_&SXL^)=.TOQ+\1K[ M^V(M)BD$MXMDH*VEO'$OS9VG. .A7/2NG_:=>3]L#]H?1/V>-*N6'@OP^(]> M\=7ELPS@$&WLPW\+,2"</#UY3SF8(>>HP: /BGX0>(?%G[2G_!2?P=XL\:Z+V*_4^OCGXS6H\ _P#!1OX'>*_,,=KXLT34O#4_/!>) M3-&/Q9T_*O1M0_;0\%:'^U!+\$]6CGT[5VAMOLNJNP:UGN9D+I;$C[CE<;<_ M>/''< ^@**X/XR_'+P5\ O"@\0^-]:CTBP>46\"!&EFN93TCBB0%G;V X[UR M7PJ_;#^%/QK\4:=X=\'>)/[6UF]T^74A:"VD1X(HY!&XF#*/+<,?NM@D<]* M/::*^?OVR/VEKG]F_P '^%Y](AT^]\1^(M>M=(LK/42PC9'<>:YVD$!5P,]B MPKUOXC_$'2?A;X USQ?KDZV^E:1:/=SN3U"C(4>Y. /G5[BWVV-VLV?EADS\S+C!'U]*\G_ &"?CKXE_:-^!#^- M/%30M>W.LWL4"00K&L-NC@1QX'4J.,GD\5Z%\,OVB?!OQ>\?^.?"/AB[FO[_ M ,'2PP:E<+'_ *.9)-_RQOGYBIC8-Z$=Z /3JHZYK-KX=T6_U6^D\JSLH'N9 MG_NHBEF/Y UD_$GQK:_#?X>^)?%=Z"UIHFG7&H2JHY98HV<@>YQC\:_.CXR: M=\>/B'^Q9X@^,'BGXMSZ?INJZ1_:<7@O1-,AC@6TG*A(I+@_.?D?)_+- '"^ M--=TK]J"PUKQ3K]E<>-/BEX_FETSX<^"HYV,>@Z91]FDC'$C%6P0&?%> MDP:WH5Z%%Q97(.R3:P9>A!&" <@T /\ /B"7Q=X)T#7;BT-C@^+]"D>72-9LX[VV:1=K['&0&'8CH1[ M4 =$[K$C.[!$499F. !ZFOA34/BO\1/VY/BGK7@_X8ZY<^!?@SX?G-KK/C2P MRMYJDH^]#:R?P#GJ.W)/(%>N?\%"OB?J7PL_9:\47>BB3^W-7>'1+%HVPR2W M#[-P]2%WX]\5UOP/^"C? G]F?2? ?AM+>+6;+1W'G,,)+J#QEGD<\Y!E;KSP M!V&* /*?^">-Q?0Z9\7M$'B/5?$WAO0?&=SI>CWFL737,XBCBCWC>W4;R3Z< MFO3OVQ_C1-\"/V?_ !+XCL0'UN1%T_2X\X+74S".,_@3G\*J?L5? [5?V?OV M?]'\.>(727Q1$?$ATN?2=-D\1WRW$0GL[:6-R8)7B/#MD;<'LPH I^/_@=;?LY^%_V5=-T MY(KCXE'QO#RW"$WKG^^H^4>@ %._P""GO[4_B_1M0/PN^'.I3Z/ M>V&FG7_$6IVDA26"!2/*B##E-S%<\\[E'0\^N:1^SU??!76=7_: ^-GQ$G^( MOB7PMI=Q/:^79+:66GQ"-M_DPKP78?+GCK7PKH'Q@^'/B7]GGX[^)?&'BVQE M^+?Q(\^6WTZ1FD:SMXVS!;[L8!.#@9Z!,\B@#]A/A-JUQKWPL\':G=2&:ZO- M'L[B60]6=H48D_4FNI5]V>",>O>O'/V3O%]KKG[*/PUUYY ML/#=LTK@EMOE MQ!7]S@H?RKQ/PE^UI\4_VB+/Q!XE^$^A>'-)\"Z5',UO=^(YGFU'41&&)=+6 M(Y13MP W.3W[ 'V@.E+7&?![Q9K?CSX5>%?$6OZ2= UO4["*ZN].=3^X=ER5 MP>1V.#R,\UV7?VH \ _;J^*LWPG_ &;/$]UI\A77M75-$TM$;#-6N/H" MQ_"OF_\ :,^ .D?LW_L=?#M]/$:>.O"NLZ4=,U.-<7!O)+A3,JX)W;R7R.A MZ5Y;_P %-OB)XI\;_M3^"_A5<:/=ZSX/T9[37C8>&H9+C4KI&_UY*J>&54<+ M@# .<\U]"^"?#/Q"_;#^+7A+Q3XX\&W_ ,-_A)X%N8]1T/PYK"YOM7O O[J> M<'E5C&#@]^.
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�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end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Document And Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2024
Mar. 01, 2025
Jun. 30, 2024
Document Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Document Transition Report false    
Entity File Number 1-10526    
Entity Registrant Name UNITED-GUARDIAN, INC    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 11-1719724    
Entity Address, Address Line One 230 Marcus Blvd.    
Entity Address, City or Town Hauppauge    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 11788    
City Area Code 631    
Local Phone Number 273-0900    
Title of 12(b) Security Common Stock, $0.10 par value    
Trading Symbol UG    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Filer Category Non-accelerated Filer    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 41,073,211
Entity Common Stock, Shares Outstanding (in shares)   4,594,319  
Auditor Firm ID 606    
Auditor Name GRASSI & CO., CPAs, P.C.    
Auditor Location Jericho, New York    
Entity Central Index Key 0000101295    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Amendment Flag false    
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Statements of Income - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Net sales $ 12,181,971 $ 10,885,154
Costs and expenses:    
Cost of sales 5,721,584 5,479,566
Operating expenses 2,356,819 2,078,564
Research and development 456,779 463,992
Total costs and expenses 8,535,182 8,022,122
Income from operations 3,646,789 2,863,032
Other income:    
Investment income 434,679 306,651
Net gain on marketable securities 26,989 81,095
Total other income 461,668 387,746
Income before provision for income taxes 4,108,457 3,250,778
Provision for income taxes 857,582 669,408
Net income $ 3,250,875 $ 2,581,370
Earnings per common share (basic and diluted) (in dollars per share) $ 0.71 $ 0.56
Weighted average shares (basic and diluted) (in shares) 4,594,319 4,594,319
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.25.1
Balance Sheets - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 1,875,655 $ 8,243,122
Marketable securities 7,522,625 851,318
Accounts receivable, net of allowance for credit losses of $14,342 in 2024 and $16,672 in 2023 1,428,455 1,566,839
Inventories, net 1,451,995 1,223,506
Prepaid expenses and other current assets 207,804 191,708
Prepaid income taxes 179,017 176,220
Total current assets 12,665,551 12,252,713
Deferred income taxes, net 175,397 50,930
Property, plant, and equipment:    
Land 69,000 69,000
Factory equipment and fixtures 4,743,238 4,669,936
Building and improvements 3,336,352 2,976,577
Total property, plant and equipment 8,148,590 7,715,513
Less accumulated depreciation 7,192,203 7,096,318
Total property, plant, and equipment, net 956,387 619,195
TOTAL ASSETS 13,797,335 12,922,838
Current liabilities:    
Accounts payable 425,003 134,449
Accrued expenses 1,467,933 1,363,044
Deferred revenue 0 15,498
Dividends payable 21,533 21,265
Total current liabilities 1,914,469 1,534,256
Total liabilities 1,914,469 1,534,256
Commitments and Contingencies  
Stockholders’ equity:    
Common stock, $.10 par value; 10,000,000 shares authorized; 4,594,319 shares issued and outstanding at December 31, 2024 and 2023 459,432 459,432
Retained earnings 11,423,434 10,929,150
Total stockholders’ equity 11,882,866 11,388,582
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 13,797,335 $ 12,922,838
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Balance Sheets (Parentheticals) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Accounts Receivable, Allowance for Credit Loss, Current $ 14,342 $ 16,672
Common Stock, Par or Stated Value Per Share (in dollars per share) $ 0.1 $ 0.1
Common Stock, Shares Authorized (in shares) 10,000,000 10,000,000
Common Stock, Shares, Outstanding (in shares) 4,594,319 4,594,319
Common Stock, Shares, Issued (in shares) 4,594,319 4,594,319
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Statements of Stockholders' Equity - USD ($)
Common Stock [Member]
Retained Earnings [Member]
Total
Balance (in shares) at Dec. 31, 2022 4,594,319    
Balance at Dec. 31, 2022 $ 459,432 $ 8,807,212 $ 9,266,644
Net income   2,581,370 2,581,370
Dividends declared   (45) (45)
Dividends declared   (459,387) (459,387)
Balance (in shares) at Dec. 31, 2023 4,594,319    
Balance at Dec. 31, 2023 $ 459,432 10,929,150 11,388,582
Net income   3,250,875 3,250,875
Dividends declared   (268) (268)
Dividends declared   (2,756,323) (2,756,323)
Balance (in shares) at Dec. 31, 2024 4,594,319    
Balance at Dec. 31, 2024 $ 459,432 $ 11,423,434 $ 11,882,866
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.25.1
Statements of Stockholders' Equity (Parentheticals) - $ / shares
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dividends declared per share (in dollars per share) $ 0.6 $ 0.1
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.25.1
Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities:    
Net income $ 3,250,875 $ 2,581,370
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 95,885 105,682
Gain on sale of asset   (10,000)
Net gain on marketable securities (26,989) (81,095)
Allowance for credit losses (2,330) (3,391)
Allowance for obsolete inventory (14,208) (17,000)
Deferred income taxes (124,467) 59,614
(Increase) decrease in operating assets:    
Accounts receivable 140,714 (135,872)
Inventories (214,281) 465,506
Prepaid expenses and other current assets (16,096) 10,138
Prepaid income taxes (2,797) 9,008
Increase (decrease) in operating liabilities:    
Accounts payable 290,554 104,034
Accrued expenses 104,889 40,988
Deferred revenue (15,498) 15,498
Net cash provided by operating activities 3,466,251 3,144,480
Cash flows from investing activities:    
Acquisitions of property, plant and equipment (433,077) (165,716)
Proceeds from sale of asset   10,000
Purchases of marketable securities (8,459,318) (621,852)
Proceeds from sales of marketable securities 1,815,000 5,505,145
Net cash (used in) provided by investing activities (7,077,395) 4,727,577
Cash flows from financing activities:    
Dividends paid (2,756,323) (459,387)
Net cash used in financing activities (2,756,323) (459,387)
Net (decrease) increase in cash and cash equivalents (6,367,467) 7,412,670
Cash and cash equivalents, beginning of year 8,243,122 830,452
Cash and cash equivalents, end of year 1,875,655 8,243,122
Supplemental disclosure of cash flow information    
Taxes paid 1,050,795 600,000
Supplemental disclosure of non-cash items:    
Dividends payable $ 268 $ 45
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.25.1
Insider Trading Arrangements
 12 Months Ended
Dec. 31, 2024
Trading Arrangements, by Individual [Table]  
Material Terms of Trading Arrangement [Text Block]

Item 9B.

Other Information.

 

None.
Rule 10b5-1 Arrangement Adopted [Flag] false
Non-Rule 10b5-1 Arrangement Adopted [Flag] false
Rule 10b5-1 Arrangement Terminated [Flag] false
Non-Rule 10b5-1 Arrangement Terminated [Flag] false
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.25.1
Cybersecurity Risk Management and Strategy Disclosure
 12 Months Ended
Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]  
Cybersecurity Risk Management Processes Integrated [Flag] true
Cybersecurity Risk Management Processes Integrated [Text Block] We continue to augment the capabilities of our people, processes, and technologies to address our cybersecurity risks. Our cybersecurity risks, and the controls designed to mitigate those risks, are integrated into our overall risk management governance and are reviewed yearly by our Board of Directors.
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] false
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block] We have undertaken a program of annual enterprise-wide cybersecurity risk assessments and have implemented policies, procedures, and programs designed to help manage the risks to which we are exposed in our business. As part of our risk management process, we have implemented a risk-based approach to identify and assess the cybersecurity threats that could affect our business and information systems, as well as the systems of third parties on whom we rely, such as any cloud hosting partners. Our cybersecurity program is designed to assess, identify, and manage material risks and vulnerabilities to our security posture, including prioritizing and remediating cybersecurity risks.
Cybersecurity Risk Board of Directors Oversight [Text Block]

Item 1C.

Cybersecurity.

 

We continue to augment the capabilities of our people, processes, and technologies to address our cybersecurity risks. Our cybersecurity risks, and the controls designed to mitigate those risks, are integrated into our overall risk management governance and are reviewed yearly by our Board of Directors.

 

We take steps to protect our data and third-party data we receive through the implementation of technological and organizational measures designed to reduce the risk from cybersecurity threats, including data theft or destruction.

 

We have undertaken a program of annual enterprise-wide cybersecurity risk assessments and have implemented policies, procedures, and programs designed to help manage the risks to which we are exposed in our business. As part of our risk management process, we have implemented a risk-based approach to identify and assess the cybersecurity threats that could affect our business and information systems, as well as the systems of third parties on whom we rely, such as any cloud hosting partners. Our cybersecurity program is designed to assess, identify, and manage material risks and vulnerabilities to our security posture, including prioritizing and remediating cybersecurity risks.

 

Our program includes, among other things:

 

• Incorporation of cybersecurity in our overall enterprise risk management processes, including periodic risk assessments and tools used to track and monitor risks.

 

• Regular reviews of cybersecurity risks and mitigation efforts.

 

• Use of software and hardware tools and services to help safeguard our systems, information, and data.

 

• Assessments designed to help identify cybersecurity risks to our critical systems, information, products, services, and our broader enterprise IT environment.

 

• An employee information security training program to educate employees on various cybersecurity risks and mitigation strategies.

 

• Policies and processes governing our third-party security risks.

 

 

Risk Management and Strategy

 

We have implemented a set of comprehensive cybersecurity and data protection policies and procedures. Risks from cybersecurity threats are regularly evaluated as a part of our broader risk management activities and as a fundamental component of our internal control system. Our employees receive ongoing cybersecurity awareness training, including specific topics related to social engineering and email fraud. We utilize an outsourced information technology firm and consultants with significant expertise in cybersecurity. We invest in advanced technologies for continuous cybersecurity monitoring across our information technology environment which are designed to prevent, detect, and minimize cybersecurity attacks, as well as alert management of such attacks.

 

Our Information Technology General Controls are firmly established based on the National Institute of Standards and Technology (“NIST”) cybersecurity framework and cover areas such as risk management, data backup, and disaster recovery. We have utilized an outsourced information technology consultant to reduce and monitor security threats and vulnerabilities.  As part of our gap analysis, identified vulnerabilities have been, and will continue to be, promptly addressed with our senior business leadership and our Board of Directors. 
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Our Board of Directors is responsible for overseeing our cybersecurity risk management and strategy. Our President regularly meets with and provides periodic briefings to our Board of Directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] Our Board of Directors is responsible for overseeing our cybersecurity risk management and strategy. Our President regularly meets with and provides periodic briefings to our Board of Directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.
Cybersecurity Risk Role of Management [Text Block] Our Board of Directors is responsible for overseeing our cybersecurity risk management and strategy. Our President regularly meets with and provides periodic briefings to our Board of Directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.
Cybersecurity Risk Management Positions or Committees Responsible [Flag] true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Our Board of Directors is responsible for overseeing our cybersecurity risk management and strategy. Our President regularly meets with and provides periodic briefings to our Board of Directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block] Our Board of Directors is responsible for overseeing our cybersecurity risk management and strategy. Our President regularly meets with and provides periodic briefings to our Board of Directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] Our Board of Directors is responsible for overseeing our cybersecurity risk management and strategy. Our President regularly meets with and provides periodic briefings to our Board of Directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] true
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.25.1
Note A - Nature of Business and Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2024
Notes to Financial Statements  
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

NOTE A - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Nature of Business

 

United-Guardian, Inc. (“Registrant” or “Company”) is a Delaware corporation that, through its Guardian Laboratories division, manufactures, markets and develops specialty cosmetic ingredients, pharmaceutical products, medical lubricants and sexual wellness ingredients. Prior to July 1, 2023, the Company manufactured and reported sales of a line of specialty industrial products; however, this product line was discontinued after the second quarter of 2023 due to low sales volume with no growth prospects. The Company also conducts research and product development, primarily related to the development of new and unique cosmetic ingredients. The Company’s research and development department also modifies, refines, and expands the uses for existing products, with the goal of further developing the market for the Company's products. Two major product lines, Lubrajel and Renacidin Irrigation Solution (“Renacidin”) together accounted for approximately 93% and 92% of the Company’s sales for the years ended December 31, 2024 and December 31, 2023, respectively. Lubrajel accounted for approximately 60% and 54% of the Company’s sales for the years ended December 31, 2024 and December 31, 2023, respectively, and Renacidin accounted for approximately 33% and 38% of the Company’s sales for the years ended December 31, 2024 and December 31, 2023, respectively.

 

Segment Information

 

The Company operates its business under one operating segment, which is also its reportable segment. The Company's chief operating decision maker (“CODM”), who is the President, reviews financial information presented at the consolidated level and decides how to allocate resources based on financial metrics, including net income. The measure of segment assets is reported on the balance sheet as total consolidated assets. The CODM, along with the Board Of Directors, use such financial metrics, including net income, to evaluate income generated from segment assets (return on assets) in deciding whether to reinvest profits or allocate to other parts of the organization, such as working capital needs, mandatory and discretionary capital expenditures or other growth opportunities that may arise that are in the Company’s best interest and the best interest of the stockholders.

 

Net income, other financial metrics and sales forecasts are used to monitor budget versus actual results. The reported segment revenue, segment profit or loss and significant segment expenses are the same as the consolidated results disclosed on the consolidated statements of income.

 

Impact of Global Supply Chain Instability, Inflation and Tariffs

 

The continued supply chain instability, primarily caused by military tensions in the Middle East, continues to impact vessels’ access to the Red Sea and Suez Canal. Shipping experts say this crisis may last into the first half of 2025. The Company continues to work with its suppliers regarding lead times and is closely monitoring this situation. Although the Company has not yet experienced any delays in receiving raw materials or an increase in shipping costs, the Company is aware that the situation is fluid and could impact it at any time. If that occurs, the Company may experience longer lead times and increased shipping costs for some of its raw materials, which may impact future gross margins. As a result of this global supply chain instability, there continues to be uncertainty regarding the potential impact on the Company’s operations or financial results and its unable to provide an accurate estimate or projection as to what the future impact will be.

 

The Trump administration has communicated its intention to impose tariffs on many products imported from China, Canada and Mexico. Some of those tariffs went into effect on March 4, 2025. Since that time the Trump administration has increased some of those tariffs and postponed others. It has threatened to levy tariffs on additional countries, including those of the European Union. Many of the countries on which those tariffs have been levied have imposed their own retaliatory tariffs or threated to impose tariffs on goods they import from the U.S. The tariff situation remains fluid and is subject to modification at any time. At this time, it is difficult for the Company to determine the impact of these tariffs on its business. The Company will continue to monitor this situation closely.

 

While the Company obtains most of its raw materials and lab supplies from domestic sources, it has three suppliers that obtain their raw materials from China. These materials are not purchased by the Company in large quantities, and it has adequate stock on hand to cover the next six months. In addition, the Company has one direct raw material supplier in China; however, the raw materials purchased from this supplier are not in large quantities and the effect of this tariff would not materially impact the pricing of its products.

 

Many of the Company’s products are used in the formulation of finished products that are manufactured in China and then imported back into the United States (“U.S.”) for sale. There is the possibility that the tariffs levied on these finished products could result in an increase in their price, which could potentially impact demand for these products in the U.S.

 

Due to the continued uncertainty of this, any other tariffs that may be imposed, there continues to be uncertainty regarding the future impact of any additional tariffs on the Company’s operations or financial results.

 

Use of Estimates

 

In preparing financial statements in conformity with a Generally Accepted Accounting Principles in the United States of America (“US GAAP”), management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the allowance for credit losses, reserve for inventory obsolescence, accrued distribution fees, outdated material returns, possible impairment of marketable securities and the allocation of overhead.

 

Accounts Receivable and Reserves

 

In accordance with FASB ASC Topic 326, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”, (“ASC 326”), the Company presents financial assets at the net amount expected to be collected, requiring immediate recognition of estimated credit losses expected to occur over the asset’s remaining life. This is in contrast to previous U.S. GAAP, under which credit losses were not recognized until it was probable that a loss had been incurred. The Company performed its expected credit loss calculation based on historical accounts receivable write-offs, including consideration of then-existing economic conditions and expected future conditions. The adoption of this ASU did not have a significant impact on the financial statements. Prior to the implementation of ASU No. 2016-13, the Company calculated its reserve for accounts receivable by considering many factors including historical data, experience, customer types, credit worthiness and economic trends.

 

The carrying amount of accounts receivable is reduced by an allowance for credit losses that reflects the Company’s best estimate of the amounts that will not be collected as of the balance sheet date. This allowance is based on the credit losses expected to arise over the life of the asset and is based on the Current Expected Credit Losses (“CECL”). At December 31, 2024 and 2023, the allowance for credit losses related to accounts receivable amounted to $14,342 and $16,672, respectively.

 

Revenue Recognition

 

The Company records revenue in accordance with ASC Topic 606 “Revenue from Contracts with Customers.” Under this guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company’s principal source of revenue is product sales.

 

The Company’s sales, as reported, are subject to a variety of deductions, some of which are estimated. These deductions are recorded in the same period in which the revenue is recognized. Such deductions, primarily related to the sale of the Company’s pharmaceutical products, include chargebacks from the United States Department of Veterans Affairs (“VA”), rebates in connection with the Company’s current participation in Medicare programs, distribution fees, discounts, and outdated product returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on sales for a reporting period.

 

During 2024 and 2023, the Company participated in various government drug rebate programs related to the sale of Renacidin, its most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (“FSS”), and the Medicare Part D Coverage Gap Discount Program (“CGDP”). These programs require the Company to sell its product at a discounted price. The Company’s sales, as reported, are net of these rebates, some of which are estimated and are recorded in the same period that the revenue is recognized.

 

On January 1, 2025, the Centers for Medicare & Medicaid Services (“CMS”) implemented a new Medicare Part D Manufacturer Discount Program (“Discount Program”), which replaced the prior CGDP. The new Discount Program eliminates the coverage gap benefit phase, introduces pharmaceutical manufacturer discounts in the initial and catastrophic coverage phases, and lowers the cap on enrollee out-of-pocket costs. Under the new Discount Program, additional rebates are expected to be owed by pharmaceutical manufacturers due to the restructuring of the benefit periods and removal of the cap that was in place that limited the drug manufacturer’s liability. The overall financial impact of this new program will vary depending on the products being reimbursed but is expected to increase Medicare Part D rebates for drug manufacturers. On January 31, 2024, the Company was notified by CMS that it qualified as a “specified small manufacturer” and would be entitled to a multi-year phase-in period during which it would pay a lower percentage discount on drugs dispensed to beneficiaries. Based on the “specified small manufacturer” designation, it appears, that based on our current level of sales through the Medicare Part D Program, the Company would have reduced rebate liabilities in years 2025 and 2026, with rebates gradually increasing each year until they reach their full value in 2031. By the end of the phase in period in 2031, these rebate liabilities are expected to significantly exceed the liabilities we have recorded under the CGDP in previous years.

 

As long as a valid purchase order has been received and future collection of the sale amount is reasonably assured, the Company recognizes revenue from sales of its products when those products are shipped, which is when the Company’s performance obligation is satisfied. The Company’s cosmetic products are shipped EXW from the Company’s facility in Hauppauge, NY, and the risk of loss and responsibility for the shipment passes to the customer upon shipment. Sales of the Company’s non-pharmaceutical medical products are deemed final upon shipment, and there is no obligation on the part of the Company to repurchase or allow the return of these goods unless they are defective. Sales of the Company’s pharmaceutical products are final upon shipment unless (a) they are found to be defective; (b) the product is damaged in shipping; (c) the product cannot be sold because it is too close to its expiration date; or (d) the product has expired (but it is not more than one year after the expiration date). This return policy conforms to standard pharmaceutical industry practice. The Company estimates an allowance for outdated material returns based on previous years’ historical returns of its pharmaceutical products.

 

The Company does not make sales on consignment, and the collection of the proceeds of the sale of any of the Company’s products is not contingent upon the customer being able to sell the goods to a third party.

 

Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience under ASC Topic 606-10-32-8. At December 31, 2024 and 2023, the Company had an allowance of $276,732 and $247,847, respectively, for possible outdated material returns, which is included in accrued expenses. There is no asset value associated with these outdated material returns, as these products are destroyed.

 

The timing between recognition of revenue for product sales and the receipt of payment is not significant. The Company’s standard credit terms, which vary depending on the customer, range between 30 and 60 days. The Company recognizes an allowance for credit losses on its accounts receivable in accordance with ASU 2016-13, which is based on the credit losses expected to arise over the life of the asset and is based on Current Expected Credit Loss (“CECL”). Prompt-pay discounts are offered to some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded when they are taken.

 

At December 31, 2023, the Company recorded advance payments from two of its customers in the amount of $15,498, which was recorded as deferred revenue on the balance sheet. The related performance obligations associated with these payments were satisfied in the first quarter of 2024. No such advanced payments existed at December 31, 2024.

 

The Company has distribution agreements with certain distributors of its pharmaceutical products that entitle those distributors to distribution and services-related fees. The Company records distribution fees, and estimates of distribution fees, as offsets to revenue.

 

Disaggregated net sales by product class are as follows:

 

   

Years ended December 31,

  
    2024     2023  

Cosmetic ingredients

   $ 5,438,262     $ 4,132,334  

Pharmaceuticals

     4,715,145       4,950,594  

Medical lubricants

     2,028,564       1,750,632  

Industrial and other

     ---       51,594  

Total Net Sales

   $ 12,181,971     $ 10,885,154  

 

The Company’s cosmetic ingredients are currently marketed worldwide by five distributors, of which the United States (“U.S.”)-based ASI purchases the largest volume. For the years ended December 31, 2024 and 2023, approximately 16% and 21%, respectively, of the Company’s sales were to (a) its foreign-based distributors (which does not include ASI), which marketed and distributed the Company’s cosmetic ingredients to customers outside the U.S, and (b) a few foreign customers for the Company’s medical lubricants, which were sold directly to those customers by the Company.

 

Disaggregated sales by geographic region are as follows:

 

Years ended December 31,

  
   

2024

    

2023

  

United States*

   $ 10,175,926     $ 8,601,205  

Other countries

     2,006,045       2,283,949  

Net Sales

   $ 12,181,971     $ 10,885,154  

 

* Although a significant percentage of ASI’s purchases from the Company are sold to foreign customers, all sales to ASI are considered U.S. sales for financial reporting purposes, since all shipments to ASI are shipped to ASI’s warehouses in the U.S. A certain percentage of those products are subsequently shipped by ASI to its foreign customers. Based on sales information provided to the Company by ASI, 79% of ASI’s sales in 2024 were to customers in foreign countries, compared with 69% in 2023. ASI’s largest foreign market in both 2024 and 2023 was China, which accounted for approximately 43% of ASI’s sales in 2024 and 29% of sales in 2023.

 

Cash and Cash Equivalents

 

For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of three months or less at the time of purchase. The Company deposits cash and cash equivalents with financially strong, FDIC-insured financial institutions, and it believes that any amounts above FDIC insurance limitations are at minimal risk. The amounts held in excess of FDIC limits at any point in time are considered temporary and are primarily due to the timing of maturities of United States Treasury Bills and Certificates of Deposit. Cash and cash equivalents held in these accounts are currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to a maximum of $250,000. At December 31, 2024 and 2023, approximately $234,000 and $311,000 respectively, exceeded the FDIC limit. The Company also invests in certain money market mutual funds that are protected as securities by the Securities Investor Protection Corporation (“SIPC”). At December 31, 2024, cash held in these money market mutual funds of approximately $563,000 exceeded the SIPC limit. At December 31, 2023, cash held in these money market mutual funds was below the SIPC limit.

 

Dividends

 

On July 10, 2024, the Company’s Board of Directors declared a cash dividend of $0.35 per share, which was paid on July 31, 2024, to all holders of record as of July 23, 2024. Dividends totaling $1,607,855 were paid and the balance of $156 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment. On January 30, 2024, the Company’s Board of Directors declared a cash dividend of $0.25 per share, which was paid on February 20, 2024, to all holders of record as of February 12, 2024. Dividends totaling $1,148,468 were paid. The balance of $112 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment. On January 27, 2025, the Company’s Board of Directors declared a cash dividend of $.0.35 per share, which was paid on February 18, 2025, to all stockholders of record as of February 10, 2025.

 

On July 12, 2023, the Company’s Board of Directors declared a cash dividend of $0.10 per share, which was paid on August 2, 2023, to all stockholders of record as of July 26, 2023. The Company did not declare any other dividends in 2023. During 2023, the Company declared total dividends of $459,432, of which $459,387 was paid. The balance of $45 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment. In June of 2023, the Company’s Board of Directors changed the Company’s dividend declaration practice and expects to consider a semi-annual dividend declaration in January and July of each year.

 

Marketable Securities

 

The Company’s marketable securities include investments in equity mutual funds, United States Treasury Bills (“U.S. Treasury Bills”) and Certificates of Deposit with maturities longer than 3 months. The Company’s marketable equity securities are reported at fair value with the related unrealized and realized gains and losses included in net income. U.S Treasury Bills and Certificates of Deposit are recorded at amortized cost. Realized gains or losses on mutual funds are determined on a specific identification basis. The Company evaluates its investments periodically for possible other-than-temporary impairment by reviewing factors such as the length of time and extent to which fair value had been below cost basis, the financial condition of the issuer and the Company’s ability and intent to hold the investment for a period of time which may be sufficient for anticipated recovery of market value. The Company would record an impairment charge to the extent that the cost of the available-for-sale securities exceeds the estimated fair value of the securities and the decline in value is determined to be other-than-temporary. During 2024 and 2023, the Company did not record an impairment charge regarding its investment in marketable securities because management believes, based on its evaluation of the circumstances, that the decline in fair value below the cost of certain of the Company’s marketable securities is temporary.

 

Inventories

 

Inventories are valued at the lower of cost and net realizable value. Net realizable value is equal to the selling price less the estimated costs of selling and/or disposing of the product. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out (“FIFO”) method. Inventory costs include material, labor and factory overhead.

 

Property, Plant and Equipment

 

Property, plant and equipment are carried at cost, less accumulated depreciation. Major replacements and betterments are capitalized, while routine maintenance and repairs are expensed as incurred. Assets are depreciated under both accelerated and straight-line methods. Depreciation charged as a result of using accelerated methods was not materially different than that which would result from using the straight-line method for all periods presented. Certain factory equipment and fixtures are constructed by the Company using purchased materials and in-house labor. Such assets are capitalized and depreciated on a basis consistent with the Company's purchased fixed assets.

 

Estimated useful lives are as follows: 

 

Factory equipment and fixtures  

5 - 7 years  

Building  

40 years  

Building improvements  

Lesser of useful life or 20 years  

 

Impairment of Long-Lived Assets

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No impairments were necessary at December 31, 2024 and 2023.

 

Fair Value of Financial Instruments

 

Management of the Company believes that the fair value of financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses, approximates their carrying value due to their short payment terms and liquid nature.

 

Concentration of Credit Risk

 

Accounts receivable potentially expose the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history to determine how much credit to allow or whether credit should be given at all. It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable. As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its accounts receivable credit risk has been reduced.

 

For the year ended December 31, 2024, four of the Company’s pharmaceutical wholesalers and cosmetic ingredient distributors accounted for approximately 80% of the Company’s gross sales during the year and approximately 87% of its outstanding accounts receivable on December 31, 2024. For the year ended December 31, 2023, the same four pharmaceutical wholesalers and cosmetic ingredient distributors accounted for a total of approximately 77% of the Company’s gross sales during the year and 89% of its outstanding accounts receivable on December 31, 2023.

 

Supplier Concentration

 

Most of the principal raw materials used by the Company consist of common industrial organic and inorganic chemicals and are available in ample supply from numerous sources. However, there are some raw materials used by the Company that are not readily available or require longer lead times. The Company has three major raw material vendors that collectively accounted for approximately 83% and 76% of the raw material purchases by the Company in 2024 and 2023, respectively. In addition to the Company’s raw materials concentration, the Company utilizes one contract manufacturer for the production of its pharmaceutical product, Renacidin. Any disruption in this manufacturer’s operations could have a material impact on the Company’s revenue stream.

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to the temporary differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized.

 

Uncertain tax positions are accounted for utilizing a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As of December 31, 2024 and 2023, the Company did not have any unrecognized income tax benefits. It is the Company’s policy to recognize interest and penalties related to taxes as interest expense as incurred. During the years ended December 31, 2024 and 2023, the Company did not record any tax-related interest or penalties. The Company’s tax returns for 2021 and all subsequent years are subject to examination by the United States Internal Revenue Service (“IRS) and by the State of New York.

 

Research and Development

 

Research and development expenses are expenditures incurred in connection with in-house research on new and existing products. It includes payroll and payroll related expenses, outside laboratory expenditures, lab supplies, equipment repairs and maintenance and equipment depreciation.

 

Advertising Expenses

 

Advertising costs are expensed as incurred. The Company did not incur any advertising costs for the years ended December 31, 2024 or 2023.

 

Earnings Per Share Information

 

Basic earnings per share are computed by dividing net income by the weighted average number of common shares outstanding during the year. Diluted earnings per share would include the dilutive effect of outstanding stock options, if any.

 

New Accounting Standards

 

On November 4, 2024, the FASB issued ASU 2024-03 “Disaggregation of Income Statement Expenses” (“DISE”). This guidance requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. Subsequently issued ASU 2025-01, clarified the effective date of this standard. This guidance is effective for annual reporting periods beginning after December 15, 2026, and for interim periods, within annual reporting periods beginning after December 15, 2027.

 

In December 2023, the FASB issued ASU 2023-09 “Income Taxes- Improvements to Income Tax Disclosures”. This guidance enhances the transparency and decision usefulness of income tax disclosures. More specifically, the amendments relate to the income tax rate reconciliation and income taxes paid disclosures and require 1) consistent categories and greater disaggregation of information in the rate reconciliation and 2) income taxes paid disaggregated by jurisdiction. This guidance is effective for fiscal years beginning after December 31, 2024.

 

In November 2023, the FASB issued ASU 2023-07, "Improvements to Reportable Segment Disclosures". This amendment requires additional disclosures by public entities, including those with a single reportable segment, to disclose significant segment expenses and other segment items for each reportable segment. The guidance applies to fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. On January 1, 2024, we adopted the new standard and applied the guidance under the new standard to include additional disclosures for our single reportable segment. See notes A and G for additional information.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.25.1
Note B - Cash and Cash Equivalents
 12 Months Ended
Dec. 31, 2024
Notes to Financial Statements  
Cash and Cash Equivalents Disclosure [Text Block]

NOTE B – CASH AND CASH EQUIVALENTS

 

Cash and cash equivalents include currency on hand, demand deposits with banks or financial institutions, and short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. The following table summarizes the Company’s cash and cash equivalents:

 

 

 

    December 31,  
    2024     2023  

Demand Deposits

   $ 404,801     $ 340,034  

Certificates of Deposit (original 3-month maturity)

     ---       125,000  

Money market funds

     1,470,854       1,031,361  

U.S. Treasury Bills (original 3-month maturity)

     ---       6,746,727  

Total cash and cash equivalents

   $ 1,875,655     $ 8,243,122  

  
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.25.1
Note C - Marketable Securities
 12 Months Ended
Dec. 31, 2024
Notes to Financial Statements  
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

NOTE C - MARKETABLE SECURITIES

 

Marketable securities include investments in equity mutual funds, which are reported at their fair values, and U.S. Treasury Bills and Certificates of Deposit with original maturities greater than 3 months, which are recorded at amortized cost.

 

The disaggregated net gains and losses on the marketable securities recognized in the income statement for the years ended December 31, 2024 and 2023 are as follows:

 

    Years ended December 31,  
    2024     2023  

Net gains recognized during the year on marketable securities

   $ 26,989    

$

 81,095  

Less: Net losses realized during the year on marketable securities sold during the period

     ---       433,769  

Net unrealized gains recognized during the reporting year on marketable securities still held at the reporting date

   $ 26,989    

$

 514,864  

 

The fair values of the Company’s marketable securities are determined in accordance with US GAAP, with fair value being defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes the three-tier value hierarchy, as prescribed by US GAAP, which prioritizes the inputs used in measuring fair value as follows:

 

•    Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

•    Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

•    Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

The Company’s marketable equity securities, which are considered available-for-sale securities, are re-measured to fair value on a recurring basis and are valued using Level 1 inputs using quoted prices (unadjusted) for identical assets in active markets. The following tables summarize the Company’s investments:

 

December 31, 2024

 

    Cost     Fair Value       Unrealized Gain  

Equity Securities:

                        

Equity and other mutual funds

   $ 634,705     $ 663,682     $ 28,977  
                         

Other short-term investments:

                        

Fixed income Certificates of Deposit (original maturities > 3 months)

     570,000       570,000       ---  

U.S. Treasury Bills (original maturities > 3 months)

     6,288,943       6,288,943       ---  
                         

Total other short-term investments

   $ 6,858,943     $ 6,858,943     $ ---  

Total marketable securities

   $ 7,493,648     $ 7,522,625     $ 28,977  

 

December 31, 2023

 

    Cost     Fair Value     Unrealized Gain  

Equity Securities:

                        

Equity and other mutual funds

   $ 574,330     $ 576,318     $ 1,988  
                         

Other short-term investments:

                        

Fixed income Certificates of Deposit (original maturities > 3 months)

     275,000       275,000       ---  

Total marketable securities

   $ 849,330     $ 851,318     $ 1,988  

 

Investment income is recognized when earned and consists principally of dividend income from equity mutual funds and interest income on United States Treasury Bills, Certificates of Deposit and money market funds. Realized gains and losses on sales of investments are determined on a specific identification basis.

 

Proceeds from the sale and redemption of marketable securities amounted to $1,815,000 for the year ended December 31, 2024 and there were no realized gains or losses. Proceeds from the sale and redemption of marketable securities for the year ended December 31, 2023, amounted to $5,505,145, which included realized losses of $433,769.

 
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.25.1
Note D - Inventories
 12 Months Ended
Dec. 31, 2024
Notes to Financial Statements  
Inventory Disclosure [Text Block]

NOTE D – INVENTORIES 

 

Inventories consist of the following:

 

   

December 31,

  
   

2024

    

2023

  

Raw materials

   $ 448,113     $ 476,501  

Work in process

     58,699       92,089  

Finished products

     945,183       654,916  

Total Inventories

   $ 1,451,995     $ 1,223,506  

 

Inventories are valued at the lower of cost and net realizable value. Net realizable value is equal to the selling price less the estimated costs of selling and/or disposing of the product. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out method. Finished product inventories on December 31, 2024 and December 31, 2023 are net of a reserve of $32,792 and $47,000, respectively.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.25.1
Note E - Income Taxes
 12 Months Ended
Dec. 31, 2024
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

NOTE E – INCOME TAXES

 

The provision for income taxes consists of the following:

 

   

Years ended December 31,

  

Current

  

2024

    

2023

  

Federal

   $ 981,244     $ 609,006  

State

     805       788  

Total current provision for income taxes

     982,049       609,794  
                 

Deferred

                

Federal

     (124,467 )     59,614  

Total deferred (benefit) expense from income taxes

     (124,467 )     59,614  
                 

Total provision for income taxes

   $ 857,582     $ 669,408  

 

The following is a reconciliation of the Company’s effective income tax rate to the Federal statutory rate:

 

   

Years ended December 31, .

  
    2024     2023  
    ($)    

Tax rate

     ($)    

Tax rate

  

Income taxes at statutory federal income tax rate

   $ 862,776       21.0

%

   $ 682,664       21.0

%

State taxes, net of federal benefit

     636       ---       623       ---  

Research & development credits

     (9,000

)

     (0.1 )     (14,000

)

     (0.4

)

Other, net

     3,170       ---       121       ---  

Provision for income taxes

   $ 857,582       20.9

%

   $ 669,408       20.6

%

 

The tax effects of temporary differences which comprise the deferred tax assets and liabilities are as follows:

 

   

December 31,

  
   

2024

    

2023

  

Deferred tax assets

                

Allowance for credit losses

   $ 3,012     $ 3,501  

Inventories

     6,886       9,870  

Accounts payable

     89,251       28,235  

R&D expenses

     206,069       159,838  

Accrued expenses

     306,381       285,200  

Total deferred tax assets

   $ 611,599     $ 486,644  

Deferred tax liabilities

                

Accounts receivable

     (302,987

)

     (332,537

)

Prepaid expenses

     (58,171

)

     (46,484

)

Depreciation on property, plant and equipment

     (68,959

)

     (56,275

)

Unrealized gain on marketable securities

     (6,085 )     (418 )

Total deferred tax liabilities

     (436,202

)

     (435,714

)

Net deferred tax asset

  $ 175,397     $ 50,930  

  
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.25.1
Note F - Benefit Plans
 12 Months Ended
Dec. 31, 2024
Notes to Financial Statements  
Retirement Benefits [Text Block]

NOTE F - BENEFIT PLANS

 

Defined Contribution Plan

 

The Company sponsors a 401(k) defined contribution plan (“DC Plan”) that provides for a dollar-for-dollar employer matching contribution of the first 4% of each employee's pay. Employees become fully vested in employer matching contributions immediately. Company 401(k) matching contributions were approximately $84,000 and $83,000 for the years ended December 31, 2024 and 2023, respectively.

 

The Company also makes discretionary contributions to each employee's account based on a “pay-to-pay” safe-harbor formula that qualifies the 401(k) Plan under current IRS regulations. For the years ended December 31, 2024 and 2023, the Company’s Board of Directors authorized discretionary contributions in the amount of $115,000 and $109,000, respectively, to be allocated among all eligible employees. Employees become vested in the discretionary contributions as follows: 20% after two years of employment, and 20% for each year of employment thereafter until the employee becomes fully vested after six years of employment. The discretionary contribution for 2024 was paid in February 2025 and is included in accrued expenses.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.25.1
Note G - Geographic and Other Information
 12 Months Ended
Dec. 31, 2024
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

NOTE G - GEOGRAPHIC AND OTHER INFORMATION

 

Through its Guardian Laboratories division, the Company conducts research, product development, manufacturing, and marketing of cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness ingredients. Prior to July 1, 2023, the Company manufactured and reported sales of a line of specialty industrial products, however this produce line was discontinued after the second quarter of 2023 due to low sales volume with no growth. All the products that the Company markets, with the exception of Renacidin, are produced at its facility in Hauppauge, New York. Renacidin, a urological product, is manufactured for the Company by an outside contract manufacturer. The Company’s R&D department not only develops new products but also modifies and refines existing products, with the goal of expanding the potential markets for the Company’s products. Many of the cosmetic ingredients manufactured by the Company, particularly its Lubrajel line of water-based moisturizing and lubricating gels, are currently used by many of the major multinational personal care products companies.

 

The Company operates in one business segment. The Company’s products are separated into five distinct product categories: cosmetic ingredients, pharmaceuticals, medical lubricants, sexual wellness ingredients and industrial products. The Company discontinued its industrial line of products after the second quarter of 2023 due to a low volume of sales and no growth. Each product category is marketed differently.

 

The cosmetic ingredients are marketed through a global network of distributors. These distributors purchase products outright from the Company and provide the main marketing and sales functions for these products on behalf of the Company. They in turn receive their compensation for those efforts by re-selling those products at a markup to their customers. This enables the Company to aggressively have its products marketed without the high cost of maintaining its own in-house marketing and sales staff. In 2024 we hired a marketing director to work alongside our distributors and provide marketing materials, training and aid in customer visits. We believe this strategy will allow us to better serve our mutual customers and build stronger relationships with our distributors. The Company currently has one written distribution agreements with the companies that market its cosmetic ingredients. The marketing contract with ASI terminated on December 31, 2023, and the Company is currently in negotiations with ASI to establish a new marketing agreement. The Company is hopeful that it will have a new marketing agreement in place with ASI by mid-2025. The Company’s relationship with ASI continues to be strong, and during this period of renegotiation the Company continues to fill ASI’s orders on a timely basis. All sales of the Company’s cosmetic ingredients are final other than product later determined to be defective, and the Company does not make any sales on consignment.

 

No prior regulatory approval is needed by the Company to sell any products other than its pharmaceutical products. The end users of its products may or may not need regulatory approvals, depending on the intended claims and uses of those products.

 

The pharmaceutical products include a urological product and a topical biocide that are sold to end users primarily through distribution agreements with major drug wholesalers. For these products, the Company does the marketing, and the drug wholesalers supply the product to the end users, such as hospitals and pharmacies. The Company’s marketing effort for Renacidin, its most important drug product, currently includes a Renacidin website which provides product information to patients and healthcare providers as well as a focus group study that was conducted in 2024. There is currently no active marketing effort for Clorpactin. Both of these products were originally developed in the 1950s. Clorpactin pre-dated the need for a formal New Drug Application (“NDA”), and the current sterile liquid form of Renacidin is marketed under an NDA that was approved by the FDA in 1990.

 

The medical lubricants are not pharmaceutical products. They consist primarily of water-based lubricating gels, which are marketed by the Company directly to manufacturers that incorporate them into urologic catheters and other medical devices and products that they sell. These products are distinguished from pharmaceutical products in that, unlike the pharmaceutical products, the Company is not required to obtain regulatory approval prior to marketing them. Regulatory approvals are the responsibility of the companies that market the finished products in which the Company’s products are used, which are typically classified as medical devices. However, the Company is responsible for manufacturing these products in accordance with current Good Manufacturing Practices, and its manufacturing facility is subject to regular FDA oversight.

 

The industrial products were marketed by the Company directly to manufacturers, and generally did not require that the Company obtain regulatory approval. However, the manufacturers of the finished products may have to obtain such regulatory approvals before marketing these products. The Company discontinued this product line on July 1, 2023.         

 

The sexual wellness ingredients are marketed by Brenntag Specialties, a global market leader in chemicals and ingredient distribution. The Company entered into a marketing and distribution agreement with Brenntag in October of 2023 in the United States, Canada, Mexico, Central America and South America.

 

The following tables present the significant concentrations of the Company’s sales. Although a significant percentage of Customer A’s purchases from the Company are sold to foreign customers, in table “(b)” below all sales to Customer A are included in the “United States” sales numbers because all shipments to Customer A are delivered to Customer A's warehouses in the U.S.

 

In addition, there are four customers for the Company’s medical lubricants that take delivery of their shipments in the U.S. but potentially ship some of that product to manufacturing facilities outside the U.S. Since the Company makes those shipments to U.S. locations, sales to those customers are also included in the “United States” sales number in the table below.

 

 

(a)

Net Sales                                                                      

 

    Years ended December 31,  
    2024     2023  

Cosmetic Ingredients

   $ 5,817,172     $ 4,283,071  

Pharmaceuticals

     5,602,259       5,894,220  

Medical Lubricants

     2,028,564       1,750,632  

Industrial and other

     ---       51,594  

Gross Sales

     13,447,995       11,979,517  

Less: Discounts and allowances

     (1,266,024

)

     (1,094,363

)

Net Sales

   $ 12,181,971     $ 10,885,154  

 

 

(b)

Geographic Information

 

   

Years ended December 31, .

  
   

2024

    

2023

  

United States

   $ 10,175,926     $ 8,601,205  

Other countries

     2,006,045       2,283,949  

Net Sales

   $ 12,181,971     $ 10,885,154  

 

 

(c)

Gross Sales to Major Customers

 

    Years ended December 31,  
   

2024

    

2023

  

Customer A

   $ 5,387,048     $ 3,464,861  

Customer B

     2,239,705       2,502,846  

Customer C

     1,831,551       1,726,753  

Customer D

     1,331,544       1,490,158  

All other customers

     2,658,147       2,794,899  

Total Gross Sales

   $ 13,447,995     $ 11,979,517  

  
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.25.1
Note H - Accrued Expenses
 12 Months Ended
Dec. 31, 2024
Notes to Financial Statements  
Other Liabilities Disclosure [Text Block]

NOTE H - ACCRUED EXPENSES

 

Accrued expenses on December 31, 2024 and 2023 consist of:

 

   

2024

    

2023

  

Bonuses

   $ 290,000     $ 187,002  

Distribution fees

     441,397       407,133  

Payroll and related expenses

     73,915       96,157  

Company 401(k) contribution

     115,000       109,000  

Annual report expenses

     83,238       81,725  

Audit fee

     73,364       71,000  

Reserve for outdated material returns

     276,732       247,847  

Sales rebates

     90,904       132,250  

Other

     23,383       30,930  

Total accrued expenses

   $ 1,467,933     $ 1,363,044  

 
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.25.1
Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities
 12 Months Ended
Dec. 31, 2024
Notes to Financial Statements  
Cash Flow, Supplemental Disclosures [Text Block]

NOTE I - SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES

 

As of December 31, 2024, the Company had a number of unconverted Guardian Chemical shares that would convert to approximately 447 shares of United-Guardian, Inc. common stock if all of the remaining holders of those Guardian shares converted their Guardian stock to United-Guardian stock. The Company’s transfer agent continues to try to locate the holders of those shares in anticipation of escheating them to the appropriate state jurisdictions. The Company is currently accruing dividends on the 447 shares that have not yet been exchanged or designated for escheatment as of December 31, 2024, and the Company will continue to do so as dividends are declared.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.25.1
Note J - Related Party Transactions
 12 Months Ended
Dec. 31, 2024
Notes to Financial Statements  
Related Party Transactions Disclosure [Text Block]

NOTE J - RELATED PARTY TRANSACTIONS

 

During the years ended December 31, 2024 and 2023, the Company made payments of $20,000 and $100,000 respectively, to Ken Globus, the Company’s former President, for consulting services subsequent to his departure from the Company. The Company’s consulting agreement with Ken Globus expired on May 31, 2024. Ken Globus is a director of the Company and currently serves as Chairman of the Board of Directors.

 

During the years ended December 31, 2024 and 2023, the Company paid PKF O’Connor Davies $23,250 and $20,000, respectively, for accounting and tax services. Lawrence Maietta, a partner at PKF O’Connor Davies, is a director of the Company.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.25.1
Note K - Subsequent Events
 12 Months Ended
Dec. 31, 2024
Notes to Financial Statements  
Subsequent Events [Text Block]

NOTE K – SUBSEQUENT EVENTS

 

On January 27, 2025, the Company’s Board of Directors declared a cash dividend of $0.35 per share, which was paid on February 18, 2025 to all stockholders of record as of February 10, 2025.

 

 

 

 
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.25.1
Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Segment Reporting, Policy [Policy Text Block]

Segment Information

 

The Company operates its business under one operating segment, which is also its reportable segment. The Company's chief operating decision maker (“CODM”), who is the President, reviews financial information presented at the consolidated level and decides how to allocate resources based on financial metrics, including net income. The measure of segment assets is reported on the balance sheet as total consolidated assets. The CODM, along with the Board Of Directors, use such financial metrics, including net income, to evaluate income generated from segment assets (return on assets) in deciding whether to reinvest profits or allocate to other parts of the organization, such as working capital needs, mandatory and discretionary capital expenditures or other growth opportunities that may arise that are in the Company’s best interest and the best interest of the stockholders.

 

Net income, other financial metrics and sales forecasts are used to monitor budget versus actual results. The reported segment revenue, segment profit or loss and significant segment expenses are the same as the consolidated results disclosed on the consolidated statements of income.
Use of Estimates, Policy [Policy Text Block]

Use of Estimates

 

In preparing financial statements in conformity with a Generally Accepted Accounting Principles in the United States of America (“US GAAP”), management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the allowance for credit losses, reserve for inventory obsolescence, accrued distribution fees, outdated material returns, possible impairment of marketable securities and the allocation of overhead.
Credit Loss, Financial Instrument [Policy Text Block]

Accounts Receivable and Reserves

 

In accordance with FASB ASC Topic 326, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”, (“ASC 326”), the Company presents financial assets at the net amount expected to be collected, requiring immediate recognition of estimated credit losses expected to occur over the asset’s remaining life. This is in contrast to previous U.S. GAAP, under which credit losses were not recognized until it was probable that a loss had been incurred. The Company performed its expected credit loss calculation based on historical accounts receivable write-offs, including consideration of then-existing economic conditions and expected future conditions. The adoption of this ASU did not have a significant impact on the financial statements. Prior to the implementation of ASU No. 2016-13, the Company calculated its reserve for accounts receivable by considering many factors including historical data, experience, customer types, credit worthiness and economic trends.

 

The carrying amount of accounts receivable is reduced by an allowance for credit losses that reflects the Company’s best estimate of the amounts that will not be collected as of the balance sheet date. This allowance is based on the credit losses expected to arise over the life of the asset and is based on the Current Expected Credit Losses (“CECL”). At December 31, 2024 and 2023, the allowance for credit losses related to accounts receivable amounted to $14,342 and $16,672, respectively.
Revenue [Policy Text Block]

Revenue Recognition

 

The Company records revenue in accordance with ASC Topic 606 “Revenue from Contracts with Customers.” Under this guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company’s principal source of revenue is product sales.

 

The Company’s sales, as reported, are subject to a variety of deductions, some of which are estimated. These deductions are recorded in the same period in which the revenue is recognized. Such deductions, primarily related to the sale of the Company’s pharmaceutical products, include chargebacks from the United States Department of Veterans Affairs (“VA”), rebates in connection with the Company’s current participation in Medicare programs, distribution fees, discounts, and outdated product returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on sales for a reporting period.

 

During 2024 and 2023, the Company participated in various government drug rebate programs related to the sale of Renacidin, its most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (“FSS”), and the Medicare Part D Coverage Gap Discount Program (“CGDP”). These programs require the Company to sell its product at a discounted price. The Company’s sales, as reported, are net of these rebates, some of which are estimated and are recorded in the same period that the revenue is recognized.

 

On January 1, 2025, the Centers for Medicare & Medicaid Services (“CMS”) implemented a new Medicare Part D Manufacturer Discount Program (“Discount Program”), which replaced the prior CGDP. The new Discount Program eliminates the coverage gap benefit phase, introduces pharmaceutical manufacturer discounts in the initial and catastrophic coverage phases, and lowers the cap on enrollee out-of-pocket costs. Under the new Discount Program, additional rebates are expected to be owed by pharmaceutical manufacturers due to the restructuring of the benefit periods and removal of the cap that was in place that limited the drug manufacturer’s liability. The overall financial impact of this new program will vary depending on the products being reimbursed but is expected to increase Medicare Part D rebates for drug manufacturers. On January 31, 2024, the Company was notified by CMS that it qualified as a “specified small manufacturer” and would be entitled to a multi-year phase-in period during which it would pay a lower percentage discount on drugs dispensed to beneficiaries. Based on the “specified small manufacturer” designation, it appears, that based on our current level of sales through the Medicare Part D Program, the Company would have reduced rebate liabilities in years 2025 and 2026, with rebates gradually increasing each year until they reach their full value in 2031. By the end of the phase in period in 2031, these rebate liabilities are expected to significantly exceed the liabilities we have recorded under the CGDP in previous years.

 

As long as a valid purchase order has been received and future collection of the sale amount is reasonably assured, the Company recognizes revenue from sales of its products when those products are shipped, which is when the Company’s performance obligation is satisfied. The Company’s cosmetic products are shipped EXW from the Company’s facility in Hauppauge, NY, and the risk of loss and responsibility for the shipment passes to the customer upon shipment. Sales of the Company’s non-pharmaceutical medical products are deemed final upon shipment, and there is no obligation on the part of the Company to repurchase or allow the return of these goods unless they are defective. Sales of the Company’s pharmaceutical products are final upon shipment unless (a) they are found to be defective; (b) the product is damaged in shipping; (c) the product cannot be sold because it is too close to its expiration date; or (d) the product has expired (but it is not more than one year after the expiration date). This return policy conforms to standard pharmaceutical industry practice. The Company estimates an allowance for outdated material returns based on previous years’ historical returns of its pharmaceutical products.

 

The Company does not make sales on consignment, and the collection of the proceeds of the sale of any of the Company’s products is not contingent upon the customer being able to sell the goods to a third party.

 

Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience under ASC Topic 606-10-32-8. At December 31, 2024 and 2023, the Company had an allowance of $276,732 and $247,847, respectively, for possible outdated material returns, which is included in accrued expenses. There is no asset value associated with these outdated material returns, as these products are destroyed.

 

The timing between recognition of revenue for product sales and the receipt of payment is not significant. The Company’s standard credit terms, which vary depending on the customer, range between 30 and 60 days. The Company recognizes an allowance for credit losses on its accounts receivable in accordance with ASU 2016-13, which is based on the credit losses expected to arise over the life of the asset and is based on Current Expected Credit Loss (“CECL”). Prompt-pay discounts are offered to some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded when they are taken.

 

At December 31, 2023, the Company recorded advance payments from two of its customers in the amount of $15,498, which was recorded as deferred revenue on the balance sheet. The related performance obligations associated with these payments were satisfied in the first quarter of 2024. No such advanced payments existed at December 31, 2024.

 

The Company has distribution agreements with certain distributors of its pharmaceutical products that entitle those distributors to distribution and services-related fees. The Company records distribution fees, and estimates of distribution fees, as offsets to revenue.

 

Disaggregated net sales by product class are as follows:

 

   

Years ended December 31,

  
    2024     2023  

Cosmetic ingredients

   $ 5,438,262     $ 4,132,334  

Pharmaceuticals

     4,715,145       4,950,594  

Medical lubricants

     2,028,564       1,750,632  

Industrial and other

     ---       51,594  

Total Net Sales

   $ 12,181,971     $ 10,885,154  

 

The Company’s cosmetic ingredients are currently marketed worldwide by five distributors, of which the United States (“U.S.”)-based ASI purchases the largest volume. For the years ended December 31, 2024 and 2023, approximately 16% and 21%, respectively, of the Company’s sales were to (a) its foreign-based distributors (which does not include ASI), which marketed and distributed the Company’s cosmetic ingredients to customers outside the U.S, and (b) a few foreign customers for the Company’s medical lubricants, which were sold directly to those customers by the Company.

 

Disaggregated sales by geographic region are as follows:

 

Years ended December 31,

  
   

2024

    

2023

  

United States*

   $ 10,175,926     $ 8,601,205  

Other countries

     2,006,045       2,283,949  

Net Sales

   $ 12,181,971     $ 10,885,154  

 

* Although a significant percentage of ASI’s purchases from the Company are sold to foreign customers, all sales to ASI are considered U.S. sales for financial reporting purposes, since all shipments to ASI are shipped to ASI’s warehouses in the U.S. A certain percentage of those products are subsequently shipped by ASI to its foreign customers. Based on sales information provided to the Company by ASI, 79% of ASI’s sales in 2024 were to customers in foreign countries, compared with 69% in 2023. ASI’s largest foreign market in both 2024 and 2023 was China, which accounted for approximately 43% of ASI’s sales in 2024 and 29% of sales in 2023.
Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

 

For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of three months or less at the time of purchase. The Company deposits cash and cash equivalents with financially strong, FDIC-insured financial institutions, and it believes that any amounts above FDIC insurance limitations are at minimal risk. The amounts held in excess of FDIC limits at any point in time are considered temporary and are primarily due to the timing of maturities of United States Treasury Bills and Certificates of Deposit. Cash and cash equivalents held in these accounts are currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to a maximum of $250,000. At December 31, 2024 and 2023, approximately $234,000 and $311,000 respectively, exceeded the FDIC limit. The Company also invests in certain money market mutual funds that are protected as securities by the Securities Investor Protection Corporation (“SIPC”). At December 31, 2024, cash held in these money market mutual funds of approximately $563,000 exceeded the SIPC limit. At December 31, 2023, cash held in these money market mutual funds was below the SIPC limit.
Stockholders' Equity, Policy [Policy Text Block]

Dividends

 

On July 10, 2024, the Company’s Board of Directors declared a cash dividend of $0.35 per share, which was paid on July 31, 2024, to all holders of record as of July 23, 2024. Dividends totaling $1,607,855 were paid and the balance of $156 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment. On January 30, 2024, the Company’s Board of Directors declared a cash dividend of $0.25 per share, which was paid on February 20, 2024, to all holders of record as of February 12, 2024. Dividends totaling $1,148,468 were paid. The balance of $112 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment. On January 27, 2025, the Company’s Board of Directors declared a cash dividend of $.0.35 per share, which was paid on February 18, 2025, to all stockholders of record as of February 10, 2025.

 

On July 12, 2023, the Company’s Board of Directors declared a cash dividend of $0.10 per share, which was paid on August 2, 2023, to all stockholders of record as of July 26, 2023. The Company did not declare any other dividends in 2023. During 2023, the Company declared total dividends of $459,432, of which $459,387 was paid. The balance of $45 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment. In June of 2023, the Company’s Board of Directors changed the Company’s dividend declaration practice and expects to consider a semi-annual dividend declaration in January and July of each year.
Marketable Securities, Policy [Policy Text Block]

Marketable Securities

 

The Company’s marketable securities include investments in equity mutual funds, United States Treasury Bills (“U.S. Treasury Bills”) and Certificates of Deposit with maturities longer than 3 months. The Company’s marketable equity securities are reported at fair value with the related unrealized and realized gains and losses included in net income. U.S Treasury Bills and Certificates of Deposit are recorded at amortized cost. Realized gains or losses on mutual funds are determined on a specific identification basis. The Company evaluates its investments periodically for possible other-than-temporary impairment by reviewing factors such as the length of time and extent to which fair value had been below cost basis, the financial condition of the issuer and the Company’s ability and intent to hold the investment for a period of time which may be sufficient for anticipated recovery of market value. The Company would record an impairment charge to the extent that the cost of the available-for-sale securities exceeds the estimated fair value of the securities and the decline in value is determined to be other-than-temporary. During 2024 and 2023, the Company did not record an impairment charge regarding its investment in marketable securities because management believes, based on its evaluation of the circumstances, that the decline in fair value below the cost of certain of the Company’s marketable securities is temporary.
Inventory, Policy [Policy Text Block]

Inventories

 

Inventories are valued at the lower of cost and net realizable value. Net realizable value is equal to the selling price less the estimated costs of selling and/or disposing of the product. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out (“FIFO”) method. Inventory costs include material, labor and factory overhead.
Property, Plant and Equipment, Policy [Policy Text Block]

Property, Plant and Equipment

 

Property, plant and equipment are carried at cost, less accumulated depreciation. Major replacements and betterments are capitalized, while routine maintenance and repairs are expensed as incurred. Assets are depreciated under both accelerated and straight-line methods. Depreciation charged as a result of using accelerated methods was not materially different than that which would result from using the straight-line method for all periods presented. Certain factory equipment and fixtures are constructed by the Company using purchased materials and in-house labor. Such assets are capitalized and depreciated on a basis consistent with the Company's purchased fixed assets.

 

Estimated useful lives are as follows: 

 

Factory equipment and fixtures  

5 - 7 years  

Building  

40 years  

Building improvements  

Lesser of useful life or 20 years  
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Long-Lived Assets

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No impairments were necessary at December 31, 2024 and 2023.
Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

 

Management of the Company believes that the fair value of financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses, approximates their carrying value due to their short payment terms and liquid nature.
Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of Credit Risk

 

Accounts receivable potentially expose the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history to determine how much credit to allow or whether credit should be given at all. It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable. As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its accounts receivable credit risk has been reduced.

 

For the year ended December 31, 2024, four of the Company’s pharmaceutical wholesalers and cosmetic ingredient distributors accounted for approximately 80% of the Company’s gross sales during the year and approximately 87% of its outstanding accounts receivable on December 31, 2024. For the year ended December 31, 2023, the same four pharmaceutical wholesalers and cosmetic ingredient distributors accounted for a total of approximately 77% of the Company’s gross sales during the year and 89% of its outstanding accounts receivable on December 31, 2023.

 

Supplier Concentration

 

Most of the principal raw materials used by the Company consist of common industrial organic and inorganic chemicals and are available in ample supply from numerous sources. However, there are some raw materials used by the Company that are not readily available or require longer lead times. The Company has three major raw material vendors that collectively accounted for approximately 83% and 76% of the raw material purchases by the Company in 2024 and 2023, respectively. In addition to the Company’s raw materials concentration, the Company utilizes one contract manufacturer for the production of its pharmaceutical product, Renacidin. Any disruption in this manufacturer’s operations could have a material impact on the Company’s revenue stream.
Income Tax, Policy [Policy Text Block]

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to the temporary differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized.

 

Uncertain tax positions are accounted for utilizing a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As of December 31, 2024 and 2023, the Company did not have any unrecognized income tax benefits. It is the Company’s policy to recognize interest and penalties related to taxes as interest expense as incurred. During the years ended December 31, 2024 and 2023, the Company did not record any tax-related interest or penalties. The Company’s tax returns for 2021 and all subsequent years are subject to examination by the United States Internal Revenue Service (“IRS) and by the State of New York.
Research, Development, and Computer Software, Policy [Policy Text Block]

Research and Development

 

Research and development expenses are expenditures incurred in connection with in-house research on new and existing products. It includes payroll and payroll related expenses, outside laboratory expenditures, lab supplies, equipment repairs and maintenance and equipment depreciation.
Advertising Cost [Policy Text Block]

Advertising Expenses

 

Advertising costs are expensed as incurred. The Company did not incur any advertising costs for the years ended December 31, 2024 or 2023.
Earnings Per Share, Policy [Policy Text Block]

Earnings Per Share Information

 

Basic earnings per share are computed by dividing net income by the weighted average number of common shares outstanding during the year. Diluted earnings per share would include the dilutive effect of outstanding stock options, if any.
New Accounting Pronouncements, Policy [Policy Text Block]

New Accounting Standards

 

On November 4, 2024, the FASB issued ASU 2024-03 “Disaggregation of Income Statement Expenses” (“DISE”). This guidance requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. Subsequently issued ASU 2025-01, clarified the effective date of this standard. This guidance is effective for annual reporting periods beginning after December 15, 2026, and for interim periods, within annual reporting periods beginning after December 15, 2027.

 

In December 2023, the FASB issued ASU 2023-09 “Income Taxes- Improvements to Income Tax Disclosures”. This guidance enhances the transparency and decision usefulness of income tax disclosures. More specifically, the amendments relate to the income tax rate reconciliation and income taxes paid disclosures and require 1) consistent categories and greater disaggregation of information in the rate reconciliation and 2) income taxes paid disaggregated by jurisdiction. This guidance is effective for fiscal years beginning after December 31, 2024.

 

In November 2023, the FASB issued ASU 2023-07, "Improvements to Reportable Segment Disclosures". This amendment requires additional disclosures by public entities, including those with a single reportable segment, to disclose significant segment expenses and other segment items for each reportable segment. The guidance applies to fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. On January 1, 2024, we adopted the new standard and applied the guidance under the new standard to include additional disclosures for our single reportable segment. See notes A and G for additional information.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.25.1
Note A - Nature of Business and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2024
Notes Tables  
Disaggregation of Revenue [Table Text Block]
   

Years ended December 31,

  
    2024     2023  

Cosmetic ingredients

   $ 5,438,262     $ 4,132,334  

Pharmaceuticals

     4,715,145       4,950,594  

Medical lubricants

     2,028,564       1,750,632  

Industrial and other

     ---       51,594  

Total Net Sales

   $ 12,181,971     $ 10,885,154  
Revenue from External Customers by Geographic Areas [Table Text Block]

Years ended December 31,

  
   

2024

    

2023

  

United States*

   $ 10,175,926     $ 8,601,205  

Other countries

     2,006,045       2,283,949  

Net Sales

   $ 12,181,971     $ 10,885,154  
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.25.1
Note B - Cash and Cash Equivalents (Tables)
 12 Months Ended
Dec. 31, 2024
Notes Tables  
Schedule of Cash and Cash Equivalents [Table Text Block]
    December 31,  
    2024     2023  

Demand Deposits

   $ 404,801     $ 340,034  

Certificates of Deposit (original 3-month maturity)

     ---       125,000  

Money market funds

     1,470,854       1,031,361  

U.S. Treasury Bills (original 3-month maturity)

     ---       6,746,727  

Total cash and cash equivalents

   $ 1,875,655     $ 8,243,122  
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.25.1
Note C - Marketable Securities (Tables)
 12 Months Ended
Dec. 31, 2024
Notes Tables  
Gain (Loss) on Securities [Table Text Block]
    Years ended December 31,  
    2024     2023  

Net gains recognized during the year on marketable securities

   $ 26,989    

$

 81,095  

Less: Net losses realized during the year on marketable securities sold during the period

     ---       433,769  

Net unrealized gains recognized during the reporting year on marketable securities still held at the reporting date

   $ 26,989    

$

 514,864  
Marketable Securities [Table Text Block]
    Cost     Fair Value       Unrealized Gain  

Equity Securities:

                        

Equity and other mutual funds

   $ 634,705     $ 663,682     $ 28,977  
                         

Other short-term investments:

                        

Fixed income Certificates of Deposit (original maturities > 3 months)

     570,000       570,000       ---  

U.S. Treasury Bills (original maturities > 3 months)

     6,288,943       6,288,943       ---  
                         

Total other short-term investments

   $ 6,858,943     $ 6,858,943     $ ---  

Total marketable securities

   $ 7,493,648     $ 7,522,625     $ 28,977  
    Cost     Fair Value     Unrealized Gain  

Equity Securities:

                        

Equity and other mutual funds

   $ 574,330     $ 576,318     $ 1,988  
                         

Other short-term investments:

                        

Fixed income Certificates of Deposit (original maturities > 3 months)

     275,000       275,000       ---  

Total marketable securities

   $ 849,330     $ 851,318     $ 1,988  
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.25.1
Note D - Inventories (Tables)
 12 Months Ended
Dec. 31, 2024
Notes Tables  
Schedule of Inventory, Current [Table Text Block]
   

December 31,

  
   

2024

    

2023

  

Raw materials

   $ 448,113     $ 476,501  

Work in process

     58,699       92,089  

Finished products

     945,183       654,916  

Total Inventories

   $ 1,451,995     $ 1,223,506  
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.25.1
Note E - Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2024
Notes Tables  
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
   

Years ended December 31,

  

Current

  

2024

    

2023

  

Federal

   $ 981,244     $ 609,006  

State

     805       788  

Total current provision for income taxes

     982,049       609,794  
                 

Deferred

                

Federal

     (124,467 )     59,614  

Total deferred (benefit) expense from income taxes

     (124,467 )     59,614  
                 

Total provision for income taxes

   $ 857,582     $ 669,408  
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
   

Years ended December 31, .

  
    2024     2023  
    ($)    

Tax rate

     ($)    

Tax rate

  

Income taxes at statutory federal income tax rate

   $ 862,776       21.0

%

   $ 682,664       21.0

%

State taxes, net of federal benefit

     636       ---       623       ---  

Research & development credits

     (9,000

)

     (0.1 )     (14,000

)

     (0.4

)

Other, net

     3,170       ---       121       ---  

Provision for income taxes

   $ 857,582       20.9

%

   $ 669,408       20.6

%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
   

December 31,

  
   

2024

    

2023

  

Deferred tax assets

                

Allowance for credit losses

   $ 3,012     $ 3,501  

Inventories

     6,886       9,870  

Accounts payable

     89,251       28,235  

R&D expenses

     206,069       159,838  

Accrued expenses

     306,381       285,200  

Total deferred tax assets

   $ 611,599     $ 486,644  

Deferred tax liabilities

                

Accounts receivable

     (302,987

)

     (332,537

)

Prepaid expenses

     (58,171

)

     (46,484

)

Depreciation on property, plant and equipment

     (68,959

)

     (56,275

)

Unrealized gain on marketable securities

     (6,085 )     (418 )

Total deferred tax liabilities

     (436,202

)

     (435,714

)

Net deferred tax asset

  $ 175,397     $ 50,930  
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.25.1
Note G - Geographic and Other Information (Tables)
 12 Months Ended
Dec. 31, 2024
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
    Years ended December 31,  
    2024     2023  

Cosmetic Ingredients

   $ 5,817,172     $ 4,283,071  

Pharmaceuticals

     5,602,259       5,894,220  

Medical Lubricants

     2,028,564       1,750,632  

Industrial and other

     ---       51,594  

Gross Sales

     13,447,995       11,979,517  

Less: Discounts and allowances

     (1,266,024

)

     (1,094,363

)

Net Sales

   $ 12,181,971     $ 10,885,154  
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]
   

Years ended December 31, .

  
   

2024

    

2023

  

United States

   $ 10,175,926     $ 8,601,205  

Other countries

     2,006,045       2,283,949  

Net Sales

   $ 12,181,971     $ 10,885,154  
Segment, Reconciliation of Other Items from Segments to Consolidated [Table Text Block]
    Years ended December 31,  
   

2024

    

2023

  

Customer A

   $ 5,387,048     $ 3,464,861  

Customer B

     2,239,705       2,502,846  

Customer C

     1,831,551       1,726,753  

Customer D

     1,331,544       1,490,158  

All other customers

     2,658,147       2,794,899  

Total Gross Sales

   $ 13,447,995     $ 11,979,517  
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.25.1
Note H - Accrued Expenses (Tables)
 12 Months Ended
Dec. 31, 2024
Notes Tables  
Schedule of Accrued Liabilities [Table Text Block]
   

2024

    

2023

  

Bonuses

   $ 290,000     $ 187,002  

Distribution fees

     441,397       407,133  

Payroll and related expenses

     73,915       96,157  

Company 401(k) contribution

     115,000       109,000  

Annual report expenses

     83,238       81,725  

Audit fee

     73,364       71,000  

Reserve for outdated material returns

     276,732       247,847  

Sales rebates

     90,904       132,250  

Other

     23,383       30,930  

Total accrued expenses

   $ 1,467,933     $ 1,363,044  
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.25.1
Note A - Nature of Business and Summary of Significant Accounting Policies (Details Textual)
 3 Months Ended 12 Months Ended
Mar. 31, 2025
$ / shares
Sep. 30, 2024
USD ($)
$ / shares
Mar. 31, 2024
USD ($)
$ / shares
Sep. 30, 2023
USD ($)
$ / shares
Dec. 31, 2024
USD ($)
$ / shares
Dec. 31, 2023
USD ($)
$ / shares
Accounts Receivable, Allowance for Credit Loss         $ 14,342 $ 16,672
Contract with Customer, Liability, Current         0 15,498
Cash, Uninsured Amount         234,000 $ 311,000
Cash, SIPC Uninsured Amount         $ 563,000  
Common Stock, Dividends, Per Share, Cash Paid | $ / shares         $ 0.6 $ 0.1
Dividends payable         $ 268 $ 45
Dividends         268 45
Impairment, Long-Lived Asset, Held-for-Use         $ 0 $ 0
Number of Vendors         3 3
Unrecognized Tax Benefits         $ 0 $ 0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued         0 0
Advertising Expense         $ 0 $ 0
Distributors and Marketing Partners [Member]            
Number of Customers         4 4
Factory Equipment And Fixtures [Member] | Minimum [Member]            
Property, Plant and Equipment, Useful Life (Year)         5 years  
Factory Equipment And Fixtures [Member] | Maximum [Member]            
Property, Plant and Equipment, Useful Life (Year)         7 years  
Building [Member]            
Property, Plant and Equipment, Useful Life (Year)         40 years  
Building Improvements [Member]            
Property, Plant and Equipment, Useful Life (Year)         20 years  
O 2024 Q3 Dividends [Member]            
Common Stock, Dividends, Per Share, Cash Paid | $ / shares   $ 0.35        
Dividends Payable, Date to be Paid   Jul. 31, 2024        
Dividends Payable, Date of Record   Jul. 23, 2024        
Payments of Ordinary Dividends, Common Stock   $ 1,607,855        
Dividends payable   $ 156        
O 2024 Q1 Dividends [Member]            
Common Stock, Dividends, Per Share, Cash Paid | $ / shares     $ 0.25      
Dividends Payable, Date to be Paid     Feb. 20, 2024      
Dividends Payable, Date of Record     Feb. 12, 2024      
Payments of Ordinary Dividends, Common Stock     $ 1,148,468      
Dividends payable     $ 112      
O2025Q1 Dividends [Member] | Forecast [Member]            
Common Stock, Dividends, Per Share, Cash Paid | $ / shares $ 0.35          
Dividends Payable, Date to be Paid Feb. 18, 2025          
Dividends Payable, Date of Record Feb. 10, 2025          
O 2023 Q3 Dividends [Member]            
Common Stock, Dividends, Per Share, Cash Paid | $ / shares       $ 0.1    
Dividends Payable, Date to be Paid   Aug. 02, 2023        
Dividends Payable, Date of Record   Jul. 26, 2023        
Payments of Ordinary Dividends, Common Stock       $ 459,387    
Dividends payable       45    
Dividends       $ 459,432    
Accrued Expenses [Member]            
Allowance for Material Returns         $ 276,732 $ 247,847
Revenue Benchmark [Member] | Product Concentration Risk [Member] | LUBRAJEL and RENACIDIN IRRIGATION [Member]            
Concentration Risk, Percentage         93.00% 92.00%
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Lubrajel [Member]            
Concentration Risk, Percentage         60.00% 54.00%
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Renacidin [Member]            
Concentration Risk, Percentage         33.00% 38.00%
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Personal Care [Member] | Non-US [Member]            
Concentration Risk, Percentage         16.00% 21.00%
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | ASI [Member] | Non-US [Member]            
Concentration Risk, Percentage         79.00% 69.00%
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | ASI [Member] | CHINA            
Concentration Risk, Percentage         43.00% 29.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Distributors and Marketing Partners [Member]            
Concentration Risk, Percentage         80.00% 77.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Distributors and Marketing Partners [Member]            
Concentration Risk, Percentage         87.00% 89.00%
Cost of Goods and Service, Product and Service Benchmark [Member] | Supplier Concentration Risk [Member] | Three Raw Material Vendors [Member]            
Concentration Risk, Percentage         83.00% 76.00%
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.25.1
Note A - Nature of Business and Summary of Significant Accounting Policies - Disaggregated Revenue (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Net Sales $ 12,181,971 $ 10,885,154
Cosmetic Ingredients [Member]    
Net Sales 5,438,262 4,132,334
Pharmaceuticals [Member]    
Net Sales 4,715,145 4,950,594
Medical Lubricants [Member]    
Net Sales $ 2,028,564 1,750,632
Industrial And Other [Member]    
Net Sales   $ 51,594
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Note A - Nature of Business and Summary of Significant Accounting Policies - Revenue by Geographic Region (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Net sales $ 12,181,971 $ 10,885,154
UNITED STATES    
Net sales 10,175,926 8,601,205
Non-US [Member]    
Net sales $ 2,006,045 $ 2,283,949
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.25.1
Note B - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Certificates of Deposit (original 3-month maturity)   $ 125,000
Money market funds $ 1,470,854 1,031,361
U.S. Treasury Bills (original 3-month maturity)   6,746,727
Total cash and cash equivalents 1,875,655 8,243,122
Demand Deposits [Member]    
Demand Deposits $ 404,801 $ 340,034
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.25.1
Note C - Marketable Securities (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Proceeds from Sale and Maturity of Marketable Securities $ 1,815,000 $ 5,505,145
Debt and Equity Securities, Realized Gain (Loss) $ 0 $ (433,769)
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.25.1
Note C - Marketable Securities - Net Gains and Losses on Marketable Securities (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Net gains recognized during the year on marketable securities $ 26,989 $ 81,095
Less: Net losses realized during the year on marketable securities sold during the period 0 (433,769)
Net unrealized gains recognized during the reporting year on marketable securities still held at the reporting date $ 26,989 $ 514,864
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.25.1
Note C - Marketable Securities - Summary of Investments (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Other Short-term Investments, cost $ 6,858,943  
Other Short-term Investments, fair value 6,858,943  
Total marketable securities, cost 7,493,648 $ 849,330
Total marketable securities, fair value 7,522,625 851,318
Total marketable securities, unrealized gain 28,977 1,988
Equity And Other Mutual Funds [Member]    
Equity securities, cost 634,705 574,330
Equity securities, fair value 663,682 576,318
Equity securities, unrealized gain 28,977 1,988
Certificates of Deposit [Member]    
Other Short-term Investments, cost 570,000 275,000
Other Short-term Investments, fair value 570,000 $ 275,000
US Treasury Bill Securities [Member]    
Other Short-term Investments, cost 6,288,943  
Other Short-term Investments, fair value $ 6,288,943  
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.25.1
Note D - Inventories (Details Textual) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Inventory Valuation Reserves $ 32,792 $ 47,000
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.25.1
Note D - Inventories - Summary of Inventories (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Raw materials $ 448,113 $ 476,501
Work in process 58,699 92,089
Finished products 945,183 654,916
Total Inventories $ 1,451,995 $ 1,223,506
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.25.1
Note E - Income Taxes - Provision for Income Taxes (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Federal $ 981,244 $ 609,006
State 805 788
Total current provision for income taxes 982,049 609,794
Federal (124,467) 59,614
Total deferred (benefit) expense from income taxes (124,467) 59,614
Total provision for income taxes $ 857,582 $ 669,408
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.25.1
Note E - Income Taxes - Reconciliation of the Effective Income Tax Rate (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income taxes at statutory federal income tax rate $ 862,776 $ 682,664
Income taxes at statutory federal income tax rate, tax rate 21.00% 21.00%
State taxes, net of federal benefit $ 636 $ 623
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent 0.00%  
Research & development credits $ (9,000) $ (14,000)
Research & development credits, tax rate (0.10%) (0.40%)
Other, net $ 3,170 $ 121
Other, net, tax rate 0.00%  
Total provision for income taxes $ 857,582 $ 669,408
Provision for income taxes, tax rate 20.90% 20.60%
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.25.1
Note E - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Allowance for credit losses $ 3,012 $ 3,501
Inventories 6,886 9,870
Accounts payable 89,251 28,235
R&D expenses 206,069 159,838
Accrued expenses 306,381 285,200
Total deferred tax assets 611,599 486,644
Deferred tax liabilities    
Accounts receivable (302,987) (332,537)
Prepaid expenses (58,171) (46,484)
Depreciation on property, plant and equipment (68,959) (56,275)
Unrealized gain on marketable securities (6,085) (418)
Total deferred tax liabilities (436,202) (435,714)
Net deferred tax asset $ 175,397 $ 50,930
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.25.1
Note F - Benefit Plans (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Defined Contribution Plan, Employer Discretionary Contribution Amount $ 84,000 $ 83,000
Defined Contribution Plan, Employer Discretionary Contribution Amount Per Year Authorized $ 115,000 $ 109,000
DC Plan [Member]    
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay 4.00%  
DC Plan [Member] | Discretionary Contributions Vesting at Two Years [Member]    
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage 20.00%  
Defined Contribution, Discretionary Contribution Plan, Vesting Period (Year) 2 years  
DC Plan [Member] | Discretionary Contributions Vesting Each Additional Year [Member]    
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage 20.00%  
Defined Contribution, Discretionary Contribution Plan, Vesting Period (Year) 6 years  
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.25.1
Note G - Geographic and Other Information (Details Textual)
 12 Months Ended
Dec. 31, 2024
Number of Operating Segments 1
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.25.1
Note G - Geographic and Other Information - Net Sales (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Gross Sales $ 13,447,995 $ 11,979,517
Less: Discounts and allowances (1,266,024) (1,094,363)
Net Sales 12,181,971 10,885,154
Cosmetic Ingredients [Member]    
Gross Sales 5,817,172 4,283,071
Net Sales 5,438,262 4,132,334
Pharmaceuticals [Member]    
Gross Sales 5,602,259 5,894,220
Net Sales 4,715,145 4,950,594
Medical Lubricants [Member]    
Gross Sales 2,028,564 1,750,632
Net Sales $ 2,028,564 1,750,632
Industrial And Other [Member]    
Gross Sales   51,594
Net Sales   $ 51,594
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.25.1
Note G - Geographic and Other Information - Geographic Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Net Sales $ 12,181,971 $ 10,885,154
UNITED STATES    
Net Sales 10,175,926 8,601,205
Non-US [Member]    
Net Sales $ 2,006,045 $ 2,283,949
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.25.1
Note G - Geographic and Other Information - Sales to Major Customers (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Gross Sales $ 13,447,995 $ 11,979,517
Customer A [Member]    
Gross Sales 5,387,048 3,464,861
Customer B [Member]    
Gross Sales 2,239,705 2,502,846
Customer C [Member]    
Gross Sales 1,831,551 1,726,753
Customer D [Member]    
Gross Sales 1,331,544 1,490,158
All Other Customers [Member]    
Gross Sales $ 2,658,147 $ 2,794,899
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.25.1
Note H - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Bonuses $ 290,000 $ 187,002
Distribution fees 441,397 407,133
Payroll and related expenses 73,915 96,157
Company 401(k) contribution 115,000 109,000
Annual report expenses 83,238 81,725
Audit fee 73,364 71,000
Reserve for outdated material returns 276,732 247,847
Sales rebates 90,904 132,250
Other 23,383 30,930
Total accrued expenses $ 1,467,933 $ 1,363,044
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.25.1
Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities (Details Textual)
 12 Months Ended
Dec. 31, 2024
USD ($)
shares
Convertible Common Stock, Shares Issuable upon Conversion | shares 447
Payments for Accrued Dividends on Unconverted Shares | $ $ 447
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.25.1
Note J - Related Party Transactions (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Previous President and CEO [Member] | Consulting Services [Member]    
Related Party Transaction, Amounts of Transaction $ 20,000 $ 100,000
Director [Member] | Accounting and Tax Services [Member]    
Related Party Transaction, Amounts of Transaction $ 23,250 $ 20,000
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.25.1
Note K - Subsequent Events (Details Textual)
Jan. 27, 2025
$ / shares
Subsequent Event [Member]  
Common Stock, Dividends, Per Share, Declared $ 0.35
EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

QW$TB<=;1WX5R.%_$[2?FC*3)>%/Y2-7ZM:^A='%OO>#BL3).W1LO9D8 MY$%)9@'_GF>_2,CH66^Q,O(*;NI9P9_1A=O=67)WAF=Z\UJ:2?G%_.8YS:XP MX5,K#O+G^Y&)&:X+-T8GB&22MY5)QA,G'T8DB6&RX'.>F1C]A!?8],4@F@U" M,)LO"0??$3C7:+3D'Z5AWYMLK_'1H4"S])]6+(60S@W?'[9WMU]O+L)'BZ?M MX=,/O18NV9,Y+DBTWYV.VV#"YY1PX?3*?\*8:^=TX9<9"NHNO(&>+S2Q?'7! M!VR_:9W_#5!+ P04 " .2'5:6@R>>G # U!P &0 'AL+W=O *<[J5YTB6C@M:Z$GGFE M,.2;TEA!,)\V;(-/:+XT#XIVP0&EX#4*S:4 MA>N9]R&Z6J16WRE\Y;C31VNPD:RD?+&;NV+FA9805I@;B\#HM\5KK"H+1#2^ M]YC>P:4U/%[OT3^ZV"F6%=-X+:MOO##ES)MX4.":M95YE+M/V,!H:0[7F0]RB+#B7^ M"TH4P[T4IM1P*PHL?@<(B-*!5[SGM8C/(MY@/H0D\B$.X_0,7G*(,W%XR9DX M-1@)'[E@(N>L@B?##-+],B<#[N#2TW"V5:YTPW*<>=0+&M46O?D_[Z)Q^.\9 MLNF!;'H.?;ZOQ1O<<)U74K<*X;]G?#6PJ&3^\O\IPNI:$B'9.\@,A/1Y&?92.WCN.$/(U_TV&4J2VK M6D)FQL5"@1!["BR7%" 3!0B:=33 *OZ#K:I>?0C+$U+@&O![2SSHYE@P&B>4 MV0VQYCE!V[BL&+7A-AN%'#KN1Y":PAB%?G5G?G1PBKMZZ.7&GSG@N_7]%4 M[E&&\&<%J%:_TDCS\KCPK@M=[OZ4)B[C-J,4%X.^%^SF(HG]RRQV5A?II1^& MH6_/&W2#N'H;GNJ4X&B4U:@V;F#;^%IANJEVD![>A _=*/REWCTH]TQMN-!4 MI369AL/+D0>J&]+=QLC&#<:5-#1FW;*D=PV55:#SM:2AT6^L@\-+.?\)4$L# M!!0 ( Y(=5IV)YT6!@4 +@* 9 >&PO=V]R:W-H965T]!+1P%-=-?IDL#2F/1J/=;G$ MFNN1;+&A?Q92U=S0J[H?ZU8AGSNGNAJ'OI^.:RZ:P>38[5VKR;%*U MK^J:J^[Q%\UM[K>AMO$69BQH;+60#"A8F^7)(!_ '!=\59D;N?X5^W@2BU?*2KM? M6'>V43* 1$8T6Y-8K^%>1G)E?2(%S (5PVI:P19OP)]?'8$+0U&)<]S%D' M$[X#$X3P539FJ>&BF>/\-<"8.&V)A1MB9^%>Q"F6(X@"!J$?QGOPHFV@D<.+ M]@2JP4CX(AK>E()7<&NX02HP\V; '5S\-ISME2/=\A)/!M0,&M4C#B:?/@2I M_WD/V7A+-MZ'/GD1 Z9"EY74*X7P]PR?#)Q5LGSXYRW&>S'?9GSU;79!\E]> MG7_[>@&STS\O;F&V1&B5?!2N\:CO071TC*T-*"5UI#8:Y (,F2YD19TMFOLC M[R_D2@/:"@#2#^L[5%9#[WRE%.79LUK:G\C[@G-4I,%'*/* A7%,J]0O&-TE MGM,%&,+S#!A?"' ^T:VG*3@EZ]>GO >RA]A'R).,)7EH8TP+%ONY2_(V M8/62P%IE,+AX2&D862?W@V5+E?E$C[Q MNOU,VCW2AZ6U70PE:2BH,(>VC'SO (;^*""=AD'\LA%[!]XWRI/J3HQ8D/GN M@" ,W '7_T?(T!\5742]GK21TH:5U2:@4ZGK$:Q;J>B#!W-!NU3%)4&MEX)B M(.Q6":HS*]RV#"T UQK)GS=SH(*XHZHPPB:>K@&N^\K11]ZK+GOIKNG/4-ZI M=:&;#UU<7:Z ;A;M HN8'X3NF?@!B?U("97*'IFR/$^A8'GF>Z=E*5=T7T++ MG_E=14U:L# )(,Q9&"7>C=-DNND>35E)F9\6$%"KY%%N_=6*:&T-(C*(<@N0 M,)HC?FS(G4Q0JH. )45!JSA/61K'K\/<2=,+3^HI%(^.ZC#R0U;DF2V#* I9 M$M&2U,:6BQU&PR2GD@BL59RR.+?U,D6Z,V M:.,@AX.W$K);#\,XHB/\T-&-$I8%EN\5%?;/.:3$!5G"HB*C5>*S(O+AK6_5 M>&>:J%'=NYG)WON4T6ZPV.YNQ[+3;AIY,>]FNJ];W$E#DXY;+FFT1&4-Z/^%I,]V_V(/V ZKD_\ 4$L#!!0 ( Y( M=5I![]Q+R , &<( 9 >&PO=V]R:W-H965TA:;2R#(/*D681-&7L&1 2YQI,799,[\8HU&88Q,'^ MQ2-?%=:]"$>#BJUP@?;W:J[)"@\L&2]1&JXD:,R'P6U\/>Z[_7[#'QPWYF@- MSI.E4FMGW&?#('*"4&!J'0.CQS/>H1".B&1\;SF#PY$.>+S>L\^\[^3+DAF\ M4^)/GMEB&%P%D&'.:F$?U>87;/VY='RI$L;_PJ;9V^L%D-;&JK(%DX*2R^;) MMFT-KS?+TSGAJP"F9<,IER)F!AF46J,'O2 MX8:N?YK.799K4[$4AP'=!H/Z&8/1QW?QE^CFC-C^06S_'/OH$2W77MH^,0;^ M>L(MF4*EZ[]/Z3W/^/#;T[1)]/1A.KM_@OFOMP\+F!"WQ SN*'F:+VM_55P- MP%.!]+:LF-R!J90T2AM@T(_B3^O/KO ]+CW&50[WZ>.[JR2);B9WGL=;\>B2\O^I?1%$$3&:T[OFU\]SYL$-& 45W6R@+*99+4K.O M=X^@1>^".I^IT/":([19H^AUK.K0HTT<&)9CIV!Z2;K=$*@%:W+YO6:"Y]Q=*A+5QL:73DU. M:>I>6KL"OG]XFM.E-]+X;FSS\EC[F[0,1MS3>Y_ )9;BHK=*#!\>ZJSA$?-OT2]\B/. M@$]P,P<.;P]3]+89'B_;FQ'\C>D5)PT"AFK#6&594?)4ME:3#Y M94'_!%"[#?0]5]1D6\,=&PO=V]R:W-H965T!=S M,X#<[APF&'"8X,4XP)Z]Q>)P#VR)W>)8$K64Y+;OU]]71<5VVQ<>[%8@*]=7 M5=3'K;'W6:A4+A[C*,D^'81YGKX_.LK\4,4RZYM4)7BS-C:6.6[MYBA+K9(! M;XJCH]%@,#N*I4X.CC_RLQM[_-$4>:03=6-%5L2QM$^G*C+;3P?#@^K!K=Z$ M.3TX.OZ8RHVZ4_GOZ8W%W5%-)="Q2C)M$F'5^M/!R?#]Z836\X*_:[7-6M>" M-%D9*BLN$N=VV._C40YVM.G(+TF? M.M*C%T@/1^+2)'F8B<])H((N@2/(60L[JH0]';U*\5SY?3$>>F(T&$U>H3>N ME1\SO?$KRFH']^I#LS% M:63\^W_N$_Q5TOL%O[K^\=E%QN?KK[2:^%M(&6B;BNUP9*W-C-4PP)A)4X,W$JDR?A MFR0H?&PBGM+ZH2=2:^@1\NH!>)&2PA["/2G62-_"0FN/PQ, ",C/(CQ"EA(N\<5>+1CH5,$'+#L)-)B/H#@&E((O3598J"K/\"6P"9+>E MF"N5AHBAV4)Q, QU5CY6;N]6DA4SF Q:%\1IG?-"!07(D.(O6)X>@0L)*8)" MD>! W5*0!Q,5,2CI/!2)$1O$7Q[VQ4D4,9E*"MS(?$=#,C;$XZWT1CWZ*F54 M!;=;E4A?!QK>E;:B0Q+F'!&PC8XT:RR^R2)-9;%1GK@"8/\)P.YW]HO"FLAL MV$^E0)Z +3I&7AO;D6_U!+L+5)Q,!XJB*K=8VMYC^PC2>L.;7Q:CX?Q#)F[? MR#C]<(YH2V$[SJ[$Y,(D\'49@9E((&AMFU61"P23$;$)])I"VWE\#1]E,(O. M."@;C]8FVQBH!&NI1X@0T"(V.A ('L6KTLB[RM6R5B3[XI)T!B5:M2_TN\:" M<5KDD!;05/M%)"V4)/]\1SK(GRJJ8W0+!+2'5.J09P8:(>_^10*3JF7RL)8; M16E%/O<+:\$:%(O,\8Q;0L;R)Y2*42@>1"+B'YX$YC':],=9Z) MM @P0:-; @P2S5>K*V).P%(AL&R!PH_IS#D;""*4893<%TDW(S4;N[03\1* MA3):5W8KR;-XG#[P!'5"OD(C0RNT98.A16*SED0-B*HUKBE>G[#^$$U0Y"+. MM!DB026+6:2$%"5![CF4LPHR#\FY(M';^F*QW,#H609!X/100AZ*I9IT[0.* M?QB.MX>P'KDM)P7)1CG^2"[::K8)5#S$XDSMM5V6R_6ZCY:$JS_P&O08:W,:A*ISSU4 9Q/V MS;Y4$C<$3OIN(55!K7593T;8<5S->(#V,G:F. MC2YA&K)&*,3"*M(9I3;!TR$$K_.@L$W-:4)1^Q9P)*#UBAT7ZW:VIHK4D+ M<*CY&QM0*)&+18[I"98$DNO,U?FZ(]E785X$5!0WJET\$5! 7^&/91CN ABID^8?$ M)_[[9 -LH)E0KL"7C@/.*1J A!])';LT!Y/2#VU$=D*\("'H^%$1J+U-DL,H M&"#EIRMM?%>,"./APLQ$[)U&09@7(:^CI[I,O@H0KH8'MMB(;6C@,KB-L.?+ MLSKF/7=XWD:*)BAVJ8D,W6'TU.Y&R[K4R.UAD8^\IX3.4IW#Y [)G=%V.XDL=&@P]7 MYR=\-?SPK@F84B'8 #@9T63T5Z&9:MP91-S$4'8@!7+/TH DHW=7,(V$/(% M+[%QN%P.RLJV9UJ$"2CY7X.0)X=C"*0FP79ZZN6A;2: MU9L8)UO0@/DH-BZ%1NJ^<<^-K8QOQH.&I[ M.W]BN(9;41K03&.@#"CC=WS3%]__53.;1VGK&<4$@PF]'(Y%)J MSY&'PY7_.>J=3!OT2-:A$5"@%2G/CS!>#IL=XW:3JXR&YSZG/H";QR8DN2[M M:PG0$L$WJAN6SZI^HW/KD*=U#I27\WG2.8IR>U\YPGJ&*J=P. :OC;@KCZ(T MN[@:D*LN5@0;%G6%N?Y?APK&6#7RO M,<>M6L=999GY/=&D"!_30NXSFN)2/6K?X%[1%(*6& ,5I&:.=Y@_P^J) MDW1M:#!C5[CIEH\]$Q1-=D[3:#;/56]Y_)" T#' MB+P^,JXAHH:W\I];VSHO(//08>3_Z\EJO8LACIA^[ZU\U[L"!-S1PMZ?2EHZ M!"+J[1&^QX=30!\\^G FXU'O8NFG#1MS>'AH9@. MO>ERTOMJ#;"0U1##L3>9S+WEZZ-: MZU/:BT85?39KC\W:\9XC/9Q/O>5HAIL%S ;I!M.>^U#'"O"G%EAJ )DG4UR1 MT9>3Y7\GKO^N8S'$VR7/?%7>_H=8<$*W ( B8+R80Y0%KF'_V<1;S(;-DE.2 M<+STY@.2=8HP6$QFS>LSN'H!ZM/ID)P^FL'Q+0;G>#BFUQ.*BG3( MX0*A29.1-YLNO.%DCJLY7+A8+GL_#"9'T=;WUW:,_-J*$K'OV]U1ZXLKF&SX MNW+FW. ^OM9/ZT_7)^Z+;;/^E!9#58:2N\;607\^/1#6?4MV-QCJ^?OM MRN30B"]#+L^T ._7!G!5WA"#^H/^\;\!4$L#!!0 ( Y(=5H)24\(-@, M (H& 9 >&PO=V]R:W-H965T,#DH_F1VBA>>Z:LPXW%F[OXUC4^RP%N9&[;&AFXW2M;"TU=O8[#6* MTAO55#![G=67<0 M3T9[L<45VD_[I:9=?$(I98V-D:H!C9MQ.$UO9YG3]PI_2SR8,QE<)&NEGMSF MSW(<)HX05EA8AR!H^8ISK"H'1#3^.V*&)Y?.\%Q^17_G8Z=8UL+@7%6?96EW MXW 00HD;T5;V01W>XS&>GL,K5&7\%PZ=;L9"*%IC57TT)@:U;+I5/!_?X M?H=I4>@62U@\4[X-FE%L"=XIQ<41:M9!L1] I0P^J,;N#"R:$LMO 6+B=2+' M7LG-V%7$.RQN@*<1L(1E5_#X*5CN\?B58 U8!>]D(YI"B@I65EBD(K,7 ^[@ MLLMPKE]NS5X4. ZI(0SJKQA.?ODI[2=_7"&;GS%33.MN?@0V3*$D2 MDM)!3A(+*#"KY;KU?;I!TLJR-.+#'+(DCU+.@Z5XT:JJO!.-%>7LC$[.HV': M@V$_2GMY,%?U7C0O9)K^^O2;8_.&G:8][SI-AFX-IDW34A%HW"MMWP '/&)\ M (,TREDOF+:EM(Z6<\3[&>2I-W[H7@YH,@*-N]*3HCF!6GI,V^K& ,O[4K$1%'C2NA:M%>HIADD'*6<1Z2=#EG)&; 0=.=SP)'I4E./%]#NCU MHJR?DPKW,N_S*,DRN%1Y\=E\J%%O_10T]#1M8[M1<3H]#=II-U_>U+LI_4'H MK:2P*MR0:7*3]T+0W>3K-E;M_;19*TNSRXL[^EF@=@ITOU'4A,>-]>B^X)CS\SC9UY-;Z?TJ\D0+>QS(4T_R*PM[L/0)!GF MS-RH B5)-DKGS-)6;T-3:&2I-\I%V&FUOH8YXS(8]/S90@]ZJK2"2UQH,&6> M,WT8H5"[?M .C@=/?)M9=Q .>@7;XA+M<['0M L;E)3G* U7$C1N^L&P?3_J M.GVO\,)Q9\Z^P7FR5NK5;:*T'[0<(1286(? :'G#,0KA@(C&WS5FT%SI#,^_ MC^@S[SOYLF8&QTK\XJG-^L&W %+HH3QO["K=5L!)*6Q M*J^-B4'.9;6R?1V'_V/0J0TZGG=UD6EKM0#MM0G,?WE5O3>2X=$E9 M6DU23G9V$"N+$,$U+,NB$$CAMDS A)M$*%-J-* V,&8F@QGE#R)9U8$/J$PA M5O(Z<=)(OJ&Q7&[]\8Q+)A.W&[JH<\O1]$)+?-VM85)S&U7<.A]P:W?@44F; M&9C*%-/? 4)RM/&V<_1VU+F(.,'D!F[;5]!I=;H7\&Z;Z-UZO-L+T3-@U=%A M"MW2,NO#^*[#%5SW?3C7@/>F8 GV ^HP@_H-@\'G3^VOK>\7R'8;LMU+Z(,F MBUXMC(1*7O]\C__E&^+Y:EH5T_-B\3!]G,:KX0-,HN7X8;Y\?IHN M83Z#\7#Y$V8/\U\0Q;/YT^-P%.QW MXU7T$JTB AKZPJ1\8KY&W>3T"FR&,%9YP>0!,I8" UEZ%5(O9:*H3K7%%'Z4 M3*><21C3F.,)Q<%DS(7 9LS2*"E%"K6V2S K"JWVG$H?Q0&ZW;NC.L$^2TZ( MUT?$*VH&*K-$Y3EU"75P\@I\ TP(I^SX:73CTK5'ID2*VE0"9?!$JX8_$29# MKL_D'I>8_>OV2G #JU,A9_H=;38F[UK<\X44U!TB.[K%@OOW),O=XA."#5FCN$(WK"_BKU-RDW$]D M\QM)X.1LJ341HP"S)-&E@TMI>J0H4Z(A/>99Z'VF,O:&()6% [U@:T0)N$\R M)K<4,J5I0!N^EO->LX9G,SI'O?4OD43*= \HVBN55OW 7-7X#!/U!+ P04 M" .2'5:WXK!(E@# ""!P &0 'AL+W=OA>:4A.FWJG(PSB*/H0%"AF,A_YLH<=#5=E<2%IH,%51H#Y.*5?[ M4= +7@^68I=9=Q".AR7N:$7VCW*A>1>V**DH2!JA)&C:CH))[W8ZX$]! M>W.R!I?)1JEGM_F:$9Y[H"8QK<&,VA#.L?3]2OZO<^= M<]F@H9G*_Q*IS4;!30 I;;'*[5+M?Z,FGVN'EZC<^%_8U[;7'#&IC%5%X\S[ M0LCZ'P^-#B<.-]$;#G'C$'O>=2#/S,Y(5U15E;S M5\%^=ORH+,'O\ LL*4=+*2Q0VR.L-4J#7C@S#"T'# ]* MVLS G4PI_1$@9(8MS?B5YC2^B#BGI O]7@?B*!Y#:4+$AW=8'4*9NT>]XVYDJ2I1' MOK4I08E'KS&H+5S%42>*(F]^U8OJ#.8\X+%5I7MJP[$14C9++)-E M+4Z%YZ>*.?$Q250E:YG8TN*A+4(7ON*>,TN(Q1%D M+798"5<%R>S0OAV\.&PO=V]R:W-H965T MFPQ.-'2>!#"2>(1"FI<-'"="'3A\4 M^Q)K(DM&DF/X]SW)P:33D!=9)]WN[479&]5*KTR.:.&U$-*,@]S:\C0,39IC MP4Q'E2CI9J%TP2R%>AF:4B/+/*@081Q%QV'!N R2D3^[U\E(559PB?<:3%44 M3+]-4*AZ''2#]X,'OLRM.PB34,%2L.5!(V+<7#>/9WT M7;Y/>.98FZT]N$[F2JU<\#T;!Y$3A )3ZQ@8?=9X@4(X(I+QLN$,VI(.N+U_ M9[_RO5,O-7J)O<'E5,*V-5 ML0%37'#9?-GKYG?8 @RC3P#Q!A![W4TAK_*269:,M*I!NVQB3."[= MH\RLIEM..)O<*HOP [["K)H;?*E06IBN:36CT!*_RPK3#=>DX8H_X>K&<*.D MS0U,98;9OP0A"6O5Q>_J)O%>QDM,.]#K'D$Q'X_8BO%B9"I:L_N]3NY=NM]O;N<4KO/WN:S*8_GZ:WCS!]IG4&=Q*NF:S( MJ!"?^ <8'('-$2Y443+Y=G@PC+LG9P8FBND,U (NN2:K*6W(%:E@&C-@D#*3 M0\;7/$/IL[Y$G=X 2J3!D%/.$=0Y3W.HF8&2<4J1<(5S[0MWATUA]V),"" W MI*M'@ DV$ !D !X;"]W;W)K&ULU5U;<]M&EG[WKT!I/#/V%"CSHIOCQ%6R9&>T%2?^ZU/M[Z]J^K/ MS4KK-OFR+LKFNX-5VVZ^>?6JR59ZK9K#:J-+/%E4]5JU^%HO7S6;6JNZJ.Z^.Y@6J MI1]>O?UVHY;Z1K>_;*YK?'OE9\G-6I>-JZ*&@FP/&;G?3 KTD#X\]N]@^, M/)"9JT9?5,7?3-ZNOCLX.TARO5!=T7ZJ[OZJ+4+'-%]6%0W_/[F3=T]G!TG6 M-6VUMH,!P=J4\J_Z8@D1#3@;/S!@:@=,&6Y9B*&\5*UZ^VU=W24UO8W9Z .C MRJ,!G"F)*S=MC:<&X]JW-V99FH7)5-DFYUE6=65KRF5R714F,[I)7KA/+[]] MU6(]&O4JLW._D[FG#\P]F28?J[)=-;/3#?$,;_.)\W;0UI^:\AC&6^H^'Y2(6^:38JT]\= M0$<:7=_J@[=_^L/D9/QF#[1''MJC?;._O=%+Z$.;?-*;JB:@4X%ZF_S#_ONS M_M(F[XHJ^SP(_..FORI%V4EI?E[IY*):;U2Y36 ):M6"0J9MDGG78'C3)!U8 M6R=5J>USHF4C,Z7)W$)F(0<-HH76NJU-UJ18,2NZG! I86/QK5IK07FM5=/5H-O"D2)13:-! M)./H)+,2;'-58&80C4VU JI5BV5Z(,MH2T^0)P6L%1:^,^V*)WE7J3I/?EHD MEZ:&5:QJP-THTT+>JZ(@&\ENRU"7+1IXLZFJ]B\Z+6K==71(J M\LM+C!.RTMQW*PW@:IJWUJ:\U4T+WE0+$I>J#O3&\XI?W*B:'BT8)S@D59I_ M,4M3P034(5= +I&%8 *$JXSU8!$!$M'H@G2 MK2L #73F7;[$=+>8N&O(*7:8!$O#BUG1\:+GV @UTF6'M=T/PATB3E$U=NG( MC[C7F)*-%C@8*P594:U:?-#OM*I@="3 (:&!EA!_D!XF2I3+L5]57)]ZQC1;$E M/ZTW1)#8?6&VS&R(_U;Z?@&_\F-]$> V(X-+E;;TAYK!ZHQ0(VA9?V$J36!!^O;FT!#2V, MFIM"5,AI@>6\M8? GK"*;,B]<;(2"8;3F4%2TC@KO_S9RV3>,?T#N/0-3L=4 M^2$(&ZL%P.D*,A? L!8+UZX@I8$BA\D-&1[W/8>KT^O&VD^1?3)C=VS"P=<$ M=@QBM$@5,JTN64\";E/0F?6 M0="SJG/F"&O8A_.;=\GYS47R<[4Q63*;GJ2)U91!2)LD0H8B93_NY3?)1_'M MCMS]-T'6X0E3MK^9JNLM2:-H#RN/PZ<.^+"*YET&ML_)G^V3,-%0Y#N4##4/ M.RGN^CJFBC^WDVTPR$7.KZ_^,%9/>AZFR"M MT.LYEG*I!<^.#[/T:[H+HA;*P3S ):&@/'\^.4IG1U.>_/GD)#TYG;+J$[!( M38OM/@T[]1IVNE?T/UEC]T@]>MQD4*-J24'/3DH 1*%#C;>PYKY:!8TZ&9\X MA7+SLBV]@+&G?*N1 1><]%+<8WD$3Y:S&(#=R\[PW&E8DLE-T/T+5$8L"1!L MXDQYR;Q5IFS8H=1(KB%""%[6AH1F654Y1WAD$TRF.>!E11*]NZ\S%(T@%:C% M-,;B.M>6Z63[Z5&V4O!?+"_B*^ZMULM[O!INQ(^3$^/D@B".4 7P4/E6(KWA M&?A12GKIW'#* 5C3S?_)#AJ"FMQ"OS1B"\R>DQ%A/XX CX)Y_"9Y&XWR+HT7 M Q[A=7XN$B!8^Q!/W"C])!.)DQW@E_6;,0@@ )R3*;:Q9LG,A3O MYR%@JC%CJUV\5MI"DT^W=J',K'FB=0PQF5_'X(\P*!E1$X O:[4&X ->GD(D MMB\I6Q#O])U,6)\_P"@(@N2Z40QG*>F(7,T+LU26KV7.\D/)5)I\+JN[0B-I MX%7_B?1!WLW"ZJHH CP \)UR==*DY+4ZY6K"O*S=91&,PEQ]IC:R3!^(IU8?.\Q[+\5";_H;K^ M2:TW;^Q7 Y-@;70@Y4?/%9*'@B,[ A3(W=UCST>LNZ#4NH8+>I ]NP_B:A:1 M!$0L%(5W!#7(#GB)HT)[6O;>S+HP:P26K7;NRDK)$E(R1_I(23MDN-%D&%MF ML+YG/-&10-%@NY^F'\<.<>&(MR3+P',)>85Q" MNQ6>,@6A?E&Y,K*A$&\BBE5@B<9O2;ISS04K KVTLB+N#SC0K[4VZWE74\@# M?T)J$M,+QJI&LG+?QC@"DY[<0Z'IZ9<+F_NFF:B"=,$LC+ #.B3$ 55_0WHM M#_"2)7I<82Q M7JE;[5-'ZQ?CT@JH1C1LV&8ZMXMDF.,:)Q68/.^X&F4%B,BK%:C+]*>J5$%K M4QBG) 0T=;+H6&@+216FX]D$]-LRC)I"&M$K9EX2F&=?37L>I%\-VC$"4342 M$"(:UU87XT%WVI'".IG.6Q^RLPP [2!0.,$$0:X(G:6*.@LM\("KV"!*9WAI MCAHSDMKI,J0#1,!%1ZQW6;.MJ_BXP^8;[+]4 ^LV!]!47ZO)@\8,]/XMI%Q2 M<&=YH*)H\-R-1&62??C?.!-8&M)Q5I)&40,OD\/NPV%H/8E)"..C$-@E54YVO4HK'1%'\=< M(SC(V8@7_04\_#4'*V45D]39;E+?/@2R,1+)F=0CK.N2G14774F6V94%;*=JP,S]!65<+[!>S(6G9LQF;GE!N](6*]R/LS MDH;R>UCZ!3O$5KC1(MSG@%B5O)_)ADPM6FL3=N9^:8M;E@,;J;;8LCU+6M/2 M;E.=[Y+5E#GD#VYS0U6/W6BZ5V;?J3P]6.<-[J)OL2QG$P#:5C6O[D8X8S', M\CY(>:4M@6@?P!J;4LHAR[(GV@,V#G.2_6UZ-H^*FN7V04%TDF<9$^T'L 3V ME%BB'*ZVN02&GHLJ<&" X(G8 -5"I'6.93U9);QQ-.%]*J!8BH&O7:8:7"[Y MP,%<9'^!(UI/]!'L0Z1.<9%C7,0B\F2(+8CKXI)Z-;319#R:34=GCZI<.@ZN M5-X7)V#T?'IZDI[.;#UR>G2:GN&_7D$R9?+X/80]^PS>E=CD-[>U0-ZR<)LN M+%7>^$D=5Z(!?*X04='!FR(=OV!XC5'0;8R2048#Q0"[LE-]6BXGAGDS#8;L3:+" :X<. M[-F8 3H9P^YL=S0S"@B^L@- 7INH-+23,%2U_052-(&PS2+>_F_5[O?5[1^H MVB.^76_:$47P(4=5O'NXT';7DBL,CJK-&VK@ ,M!WRCWZX!R337BUALC/X)L M@:MF1<6WWM=^F<+%4=M@2@;5='8_K./Q*K]E'EAI<[7*N\J9ZP";M4)AC^CY MY#@]>GWFV'6GFFC>AGUQ7>NP&SK46.(: *0V-AS\-0\HJX?YCE3LU6'R8]639W+.O=*G6M;:;N7R6I9;X:6J_IHODX3*IHHV'NX- MARCTUZ1^!EL!&CEB4 WVON[1YL= J99WFN-2Z] []&#!F]LLFK4NE,;!+5,UQ,5*A&!$^1_R*E;[YY]G?.V31UVO7D[1F[!1*Z9Q+S43J93=/9[.C9=8^:#9Z<0L(F1\?X]/IXG!Z_/GKV MT0; 13>OV1@B:4S'T[/T^.0HF:2G>.UD-GUV)1&/JQM)"\MH-$J.)SS-S]S+ M1%TN$IX^3R;3='(V25^?3NC+.#T[P]+'1_M3C1@KHHY-FY%,R78WR6M5%_F= MR371DM$VLWX45P!+L&#P[K2;)J0^O!&MH3Q! M04/N'+#1 )?5[2ZUOB>%W@BR*:JX>8,ZWHJMV'TR 6'>^3:>=E<%O?HM-954 MN-B)9VPHGJ*"SU@%>S+U%Q'NR>EQ^GIZ@B]GZT\]/5"#=Y?\"0W^$I;;[9 MF]:5$N0G#_P=G@'=)NJ#HD7/O>/HXSU4'>GFC?ZM$\/A5@'[:6&;9MY#/:H" M"GK]/M/JUN1AK\D14^9,D]/7?]QE@9M$S()3XY[S]S X$4GQ$1/7SBN?8%J9 M87;8F]S9)C>#J#6].X=E[ELB#B,ND/(HIU(V@"2/2)6(GITZFGT%$YY6T(T? MS/8U/ISYQH>S_:U%JEGQ OSA_6\=HMM"LS%X6CO?[UR&;?Q #UHDTC'WG5I0 M.)5D-)>.YB*Q7YGE"D0M#'[/$VF,C2(AJE+49LEE&="?>KAL"(N(B=H]J?&> M6C2I1&.WRA"1L-@[%=])\Z&%#4>9#L=[V*[3-2/*E"SP3(\=(P6NP1@IVR,LN_*N)2%* M'&QNR;UTK6N@P[=^T/!SS8U@V^2=*0I)+"]@B-@(V]#P4JA^F%P\2'6'E 3: M/H7KQSB.^-:;N7UF.SWUF5EZ7E0U(\Z@TA^@[/;V/T4!\5>$JR='D>XSQ:V^,7^\_ M2Q+UK_^9K62[?:H=WK_"I2&G2GC01F1'4?)X8!?2.R(Y^U!%9Q_H!$+!_E() MX7([)0O\^'!V3,$"0@"\$V?5&^H0J.RBT=9G)59;D)8"$R6(MD.2WR8>2=X; MP.>#'&1*GD\0_9VF9\?'XO%Y'7]*P*;IDNB?<"^8VOJB9T1N.@M#Y1<(P??( MMG,#1W&QTFL.D1F91O:]*,S?ZE:VJUS'&D#*9 M_C_@R?2TUPGS;_+D\.LZ$DA\YE<6IO3(\S!GA)?'AT'+IP,5M']#K";C_1B< M=TN$W4E8]1'@BZZ?I#;X[L58F)68;*&231#.]7(O>CYJ#^UO.P5#CY.< @M# M":>CX]?IT6P:%3/XI]G9J4?LOOPBL?P_*KY7Q/A2VY+AX_GN%Q]XW'";I&L[ @ "K?&+'/MT[&X*_O M^QA.;X3PY:GN]?>L,5A_&SY+X@I(<=Y"<3F' KU )-T?,\=UMYUG/F+=$U=+ MRA+%Z-3 P3L3$.*9S9.&]W BQ"S8\5F9.C[GA&Q:F=IN9OD&8%<[[DJ 77"# MNC0KV"]+[DV71KFFT?W-L_BX*'!_0BK1WY.@,'A-U15:D?KL#I-/?0#L.3[9 M).J%B#N;E53R2FQO4Y;P(5M9GD1_KAJS4R%WQT3ER' L";)O2O:CV.[L,9(Q M'!%W1B$3BPXOS;?V6"^?GE.BZ^[8)Y=>=;FDDYH+F]VQ,KK6*UL,W/ M=B?9@>TJKEMN?>@6U'#F7RY#RS.Q^5;7VW"H2Q#K,T(:OYR/*F-Z2F>\RVH= MI5;^2'0XDZINE2E(&T8 8L2[^)$^2*8B+ B-O!&EW>[__>-F9$ A7]*^7<@6 M>B1UMJES0"X>TR#N'.X^Y*G46[/GZL@KMPY MQ2<[GL?-ZS)R]YEL$9/$G]>7QDT^+FK/4Y/-%.O*^%M-^''@5VZ#I2Y4?P) M%QSN5;\B+:@&-/(\;1K9A.W5$YQ3D4]6UH9AS]>$G[QIEZD-/RJU%Q/EG MUUJ1)M#M2NR9F-7MHTY^3J9!8*9[&7M=TZ4.7 "5J+*@.V->Z(0[5UK M^"*.O0 DX>G&/]7^*=?:5%T;$3^B86I+JQFTN1-'G]-!&]H:A[H?)A_5/[FY MB/O"PW'DN6Z)FV&;4BX>((?,$@ 1K<%.,@5TK0X,,D?I$CEL^!")ZW?EEF1N M/NEV7%;8'QK*]?W :\N[&T-O-/=UHJNKAFQ\1%Q@1^_C%"Q=C)W M;5%T*IJD7:0YGM .=[W?7KJH=LK'IZUW*<7LV73+>B>>EO><@IH,02=.$$F8 MZ\WW-WD<!U?SY;[_H%7.:^H\:Z\Y'O,4D M&N-:O +A(X;:"T0"(SB$X@!#\HJ&_>WND;$_-]'B %J'RSW>>X,$"!9=D13F M5M_O!OBP%_]GQ\DH.97=Z&?O.E.0\WMV--[YA5QE#2/ LOKL!TB[V%N_\H+; M4:=V7++/3(0K>29[[]!Y>Q4=5.?3,["N T< K?7 MIW!4:)MB;?A'?LWU[M@?)/H,%R](%,6U89($OA;$-.X2&CE#;G<031,%*WO@ MH$U@:6PGO\O%E05)W^YYG' [C%4S'@Z7M'"!>U"=:!^&QPI!71]\1%Y_Z-8= M_=U!)FJ.PK?0U#& D >I'\7>CUV=#I[')!7_KSETWTT*>U'*X.IUO S[$W'/ MMI.5&J3V:56X.FJR_W*G#[3*KPZ9P>L'GJQ-__:*=%#.A<\[/>_]/<+[[.AO M,7H,K$VUT=B#^YCI4!]D]*.M@\F.Y6X7:]H/T%H^V>(9*Q"&C4)#M44(A.\@ MY4Y0>Y\)[^R65)O8>Y'-)-QD,]E_VRYHJ>1\H--T4Y&[DW@ Y.3._?Y!ARR>DL-MVV<:MGK=V_9&HV:G#]*^3V60 M0JP1%=]V^R?3*,9P/\:'\*DD81DFG=D,G8_#^3*P-1DOU]];V5,9&.@NM+*/ MP'Y[7&T)WU%R088T^ZIU5Y;=:W\7YDA?HO2^=[K?!L,M!*X#7D[5-=RZ0@>5 MA< ;19F#='H:$6H>WJ:;ZM2PC&A+0.E9D7.J/I:B]J\%?.1&=1 ML6)-\;9I'SQ58)N[=YMI!!EI6+51DP.DS'>1].>[@"BP-,V*+/\M5X?Y:%B_ MCI/N,6H/M6-' A\?)^/S>OU.PH<:":EMOZOE?WS.W.!A7UD_1H6=<.=$K>ZB M6)=CA)W(V!I8R;K7:RYY^^9.N8LMLT&R^Y;9G8)0Y_>5)!8Q.DX-T>7C\"QG M):QY36=8[/UZA\E?7>=VR^<'I UMK1\!KV\#D!J0RJF-(ZS/^9D_-^5E^>;)(?.S&73_A+RU^8\+WFK7#> M,;3E^R/)OG!PZ1K',W$4H^X9\)@S;G/D=N2O873OI#A0R[*".O17C= MJ5JRX\<1Q4>DXFWH=HG6CI*[-'OG)E@%;-NB9%31%2KL+ <)-7 $WJ8!9)OH MQIF6#DF+/&NYIHU.L3T"!R*I35L8, ]W_]H="W-\,X.M+]DJ&N$MEW'PM5"# MY*O#J61.1D+A-)QKH:0J=RZA.ZVO8BTH^2\6TM[Q([(D#6\& M$,77T6UA3C_T3HMLD/MXGMW1S*\8*'N>C3QI7T+D=[*_PE4^6,4^FS>2'G>L MS!77\=\^LQCNKII\[;ZI!F)/M\Y;%H]:3W((\>]*ZW[-T:ZLIQ0Q<#^>)1[>:M2K[803:J;/(2SF%>1:J$6(1N MSW!Q"7]V>XPA.W%]]5R=DMM.8^BXT"O^EG>-0X7(5Q=)J'8JC^&M7HUS']=# MX^YD?TOM>7Y+&YEL(;EF_EB./G[:]XY7\8^2:3]<2QWHV]B';^B-F^QO77NO MZA+K-\DUB?/J]\CR4Q?H7>K\3C4(R[1[R;>_V H,ZQG;8&YQZ%__Z^*K.[[N MG"AF]S$0M,W=;@S'A;:W(X[OHSLWN1DBN30%KS4 BQ2%XZN4 MY-RP I]@>XT-'S#>)Z#3T&\QW=\+\2/4LW?7:E56='#P=Y5-GK;6C3U'RFV. M/U(MEJA\%+?6\<65O!N=VW.;TZ/1>.8OKXR.LUAO:>/"&^]2O'I%W^7,%'52^I=Z+0"PP= M'YX>'R!CX[\ (%_::L.W[L^K%GDF?Z2M-%W3"WB^J*K6?:$%_-]A>/O?4$L# M!!0 ( Y(=5I6@?EI/0, #<' 9 >&PO=V]R:W-H965T+8)5< MK7-G[PU^%W@TK\;@(MDI]>@F'\M%$#M"V&!A'0*GWQ->8],X(*+Q^809#$-O5?'#WB*QQ,L5&/\%XXGVSB MHC-6M2=G8M *V?_Y\RD/7^/ 3@[,\^X/\BQON.7+N59'T,Z:T-S A^J]B9R0 M3I2MU;0KR,\N[Y1%6,$%W'';:02UAW5GR,@8X+*$;2^66]^*2HJ]*+BTL"H* MU4DK9 4;U8A"H($?'_BN0?-N'EDBYN"CXD1BW9-@_T,B87"KI*T-O)(2TB0$%K/L#%XZI"GU>.F9-!GH WPKOMX[>]O;%=:5 M.? "%P%5CD']A,'RA^^29NDT9&-&XRQ,4A:F:3;:U)PJK,".''AC:&>2Y&&2Y32:Y7&8 MS[+1+8'0)C3=3OM+:("%,9N&^3B#))R0V3AEHX^RI*K1@BS=_56V)FH7%Q>0 M)Q[F05G:NJ-VM^4D)M%(6)A,DW V2=PD#J=3.CK/X(PT^2!-?E::%R'V6K7P M_MFBEG3XM2]KI SNOL"OJ"K-#S5E:D5=U7RE:&?/_0;11EZT3U)8VMU:3M?] MISX=R20/9VQ,DVDXCI.0Q?GH-Y]5WP*T*WT2(AZ',>G%0C9-PUDV&WUKBJ-7 MS8R25/F6;?K#^KXVK ZOPJIOAO^:]T_*+=>5D 8:W)-K?#FAK.F^3?<3JPZ^ M->Z4)47\L*:7#;4SH/V]HKH_3=P!PUNY_ =02P,$% @ #DAU6O?%/+J_ M @ ZP4 !D !X;"]W;W)K&ULA53?;]HP$'[G MKSAEU;1*@?P&U %2H9VVATY5H=O#M >37,#"B:GME/+?[YP$QB3*'B!G^[[O MOCO[;K23:J/7B ;>"E'JL;,V9GOC>3I=8\%T3VZQI)-)/1 MEJUPCN9Y^ZAHY1U9,EY@J;DL06$^=FZ#FVEL_6N''QQW^L0&F\E2RHU=?,O& MCF\%H<#46 9&GU>-E_VUM;A!##TWP&$ M+2"L=3>!:I5WS+#)2,D=*.M-;-:H4ZW1)(Z7]E+F1M$I)YR9?)<&80I=F#&] M!E9FC7'_4O%7)K T&CXMV%*@OAYYA@):F)>VY-.&/'R'/ CA099FK>&^S##[ ME\ CI4>YX4'N-+S(>(=I#Z+ A= /XPM\T3']J.:++J2OH4GP7'X-.CZ/M@US MH[%C@FX&I MD.GF][D\+D8ZGP>5&HLE*EONCBVWK7G4N:.A0#KN<"LUI_A7$/NQ._0#LJ+8 M=_TH[LQ0&9[SE-GBDOK6&3Y)Q5>\9 *B;F$?!KUD4REN]M?0[78A"!/7]_T. M/1K'24R63XJB?M!Y[LU[L*!1I"NUARD70O\W1-\= MQ/0+!YV%-.25'@I;&WA2V"N*-!PD;C])R!ZZ81RY01C"N9OU3AJP0+6JQXR& M5%:E:7KQN'N<9+=- _]U;\;@ U.D7X/ G*!^;Y XH)K1TBR,W-;MO)2&AD-M MKFD:H[(.=)Y+>M/MP@8XSO?)'U!+ P04 " .2'5:CJG6Y;@# "L"0 M&0 'AL+W=OR-99,#<0&*_JS%+)DFJ9RY:F-1)9; MH[+P M]/O)+QRIE/[=J5G$]%K0M>X94$59?Q8:X0+Z M\(G)>]3LKD"XQJR67'-4<'9C5M3YU-/DS)AXV0YXT0 '+P / _@D*KU6\+[* M,7\.X!'+EFJPI[H(.A'?83: <.A"X =1!U[8AAY:O+ C= 5-@*?B:ZRCT]:F M629JPS*<.=0-"N4#.O/7/PT3_TT'MZCE%G6ASS]0.\'91Z'4.5#M'NW('Y8P MW."CAD4ALOL_3W'O1#_-_7=D4@&:S0)*-99W*$VZ>R;=)N=A[S,=$BMBIJ@= M,[&J^%^DFQ.S:@5ZC?!$$(9N>:@E=6#^"H+$':?CWBM(AZX_CGL?4:D)&-2" M(D4#RXI_!ZI$\4Q[@Y*+'/K]/D1AZ(Z2L65=5RUT5P 2-T)J,_N.5\V+ M9( MOIG^AV7.J*..8HV'D9LF$7141=Q61=Q9%:=[],DFCJL_?^6\WUTQ&5R7Z)53D(2HN$LM8U*V!95[FI@"2,W)$?&RD)W20- M3*92=SP:]7ZU^FI-:>QKE"7PZ@&5I@M $_ E?R2WO,I$2><54JJ7/&.F@<62 MRG4C%-=P)B1?\8K\T7&]3\_KE7X#(93V,#J'>.2[ON^W(U5*[W9P/8 ;"D[5 M\@D6M+?JA[ 2-TB)?!0>20;O1FBR$QT!F02X:=R8/)G*G# %+LG4'XRH M\V3S-F@F6FSL?7PG--WN5ES3&PO=V]R:W-H965T-A6-GMD/AW\]V M0E:DTI?XVK[GW',<7\^W0CZJ&E'#<\.X6GBUUNUI$*BRQH:H8]$B-SMK(1NB MS51N M5*))4#-2R(PW :-(1RKYB[M1M9S$6G&>5X(T%U34/DRQ*9V"Z\R'M= MN*6;6MN%H)BW9(-WJ'^V-]+,@I&EH@UR104'B>N%=Q:=+E.;[Q)^4=RJG1BL MDY40CW9R52V\T I"AJ6V#,0,3WB.C%DB(^/OP.F-)2UP-WYEOW3>C9<547@N MV .M=+WP9AY4N"8=T[=B^QT'/YGE*P53[@O;/C<+/2@[I44S@(V"AO)^),_# M.>P 9N\!X@$0.]U](:?R@FA2S*78@K39ALT&SJI#&W&4VY]RIZ79I0:GBQ]" M(US %[CB3\BUD!05?+HG*X;J\SS0IH1-#,J!;MG3Q>_013%<"ZYK!=]XA=5; M@L!H&P7&KP*7\4'&"RR/(8E\B,,X/<"7C(83QY<<,*R@-[C/7X].]Z-MBYRJ MEI2X\$P/*)1/Z!4?/T33\.L!;>FH+3W$7MR9EJLZAB#6X_]X\>&\D]+$\-NI MAGM\UK!DHGS\L\_ P1+[#9@SQF:%TI[SQ)ZS_2236[(U5TVCI(0I.((TG?E1 ME-CH9.IG831Y,!T'E$,K18E*03;SIWD.>>R'LWQR23DU-[.RVU57:@5YFOG1 M+(%IEOIY-)W<"TW8FZMW!)&?9I&?YYF+XS@QE::P[W2#G6O?H-RXYE90BH[K MO@/&U?']..O;YG]Z__A<$[FA7 '#M8&&QR>9![)OZ'ZB1>N::"6T:4D7UN8- M1&D3S/Y:F'LU3&R!\54M_@%02P,$% @ #DAU6M4Y;B_,! +@L !D M !X;"]W;W)K&ULC5;K;]LV$/^NO^+@M84-,+:> ME-0F!O(J6F#M@B3=, S[0,OG6(@DJB2=Q_[Z'2GYDMR* M.[Q!\Z.]4K2;;%#F98V-+F4#"A_MYNO\ M9.!;0EAA82R"H,<#GF-562"B\;/''&Q,6L7=]1K]L_.=?)D)C>>R^J.W\2BU?(2KM_>.QDTW@ Q4H;6??*Q* NF^XIGOHX["AD M_BL*8:\0.MZ=(!#Q HLQ1 &#T _C WC1QN/(X44'/-;0.;C/OTX[WJ]M[\A' MW8H"3P9T"32J!QQ,/_P2.09X%+(QC6G$_9]0<.@R4G9O&56&>A3YK%W@0LDI?G&UC (8Q;S%$:0 MY(P'<8\][P5A.%N'"/N@+92L7UIY#>0 L7>0)2E+LM#ZR',6^QDUMN3]L^+4TP]@E&%R"A^]&GB6A+(G= MC?=U-S;"@*9TKXQ4S[#H$[6-7J=. >0A2U,.83#VO?,3AZ.@(>!C9IW=-92M4L80/HFX_414\T#>GK6V5%50-)=VD MH2U(WQO!T!\'E/%A$&\/8F_D_6:6J#J+$0M2WQD(PL 9N'I+283^..\\ZBN# M#KCW_D!]\$U]\#?7Q_HNN+HXU1K).=',X==2S*@V3$FBS+YH"7< M9:GOG1:%7-D^V(IGYU&6LS )(,Q8&"7>M4OWQ?J*:PHX9S[/(:#[G$69U5*,,Q['+]VLMO'>\E04G_+!41U& M?LCR++45%D4A2R):4B%A*\H=1L,DHVH+K%3,69S94KQ BGC17W/Z44-J49EG M!FTEJ*9MNO'GJNPJ?,@SEB>Y14@X"].$$'XT-*=5Y3_$]8[F,PM"D]<]&D=- M(_7@KE*&%+ LL?7[G>[,_V-(@0O2A$5Y M2JO$9WGD[^V5DYT9ID9UYR8U#2ZBW3BS.=T,@Z?=#+05[R;);T+=E8V&"A>D MZH]3ZGZJF\ZZC9&MFXAFTM!\Y99+&FA160%ZOY T(_0;:V S(D__!5!+ P04 M " .2'5:>D0+0Q($ "%"0 &0 'AL+W=OBG.?F%GKL;HS97@Z'NMA@P_6% MW**@G954#3>T5.NAWBKD96O4U,/ \Y)APROA3D;MMWLU&7: VRRMN^&2DY!Z4U29O5FA+;:TI MN4K8H2R,HMV*[,SDBS0(US" :Y1KQ;>;J@ N2OC9;%#!C>C&;OOWZ9$O:]3G MHZ&AN-9Z6!QBS+H8P3_$\ .XD\)L-'P6)99_=S"DA/NL@]>L9\%)CU=87$#H M,PB\(#KA+^R[$+;^PA-=T- 5^%Y]G77TOK7ES:7>\@+'+A%#HWI&=_+]=W[B M_7 BMZC/+3KE?;(@'I:[&D&N8(%K(H2!!]Q*92JQ/IX0@^6W7N/WMAAXQ!<# MLUH63W^\5]?)R._7]1MRI0'M(('&@,V2<$*C<.PH[#Q"9RYU@X: ="/6"LN* M\M%P!C'+_)3Y:4!RQ((L9%[J._<;3OD7N",#7FO22KR !7%N]7/2"SSGCIS0 M)MSNEHH$ZRY@7I"Q.(G 9VGLL20,G!M1$F%419H6PK*%\& P@-AG<1XYUTIJ M#0M.0P8_9%&4LCR/P?=9GN8L]E/G%K6^A*M*%W)GHU@WO*:#BXN"C#[Y+$@2 MBAPYYW;A47YA$CKGSAZQ$'\8"P_X MC&*'L%*R@<\O!I6@PN?MD8&JR_U6BO7@EHZ]$J9:H]$M1MZH3@93.LKU!^%R M,KE_!Q>X: 'CM(#Y*BI#^PO#3==!CV 2LSQ(:)$1(*CO7NQT9U([&E5ABP&/ MIA'%)%DXY5'^?P>1](-(3@^BHQFC*112%%5==85P;@ZX&(V$N MA99U57);[\>:?C*1_\#1KN6O.(%IR\PP2ZF1&*_JQS[EHQ!0H0\"G!%'T.['5FN1CG--LZ<:5T?"%KTB U8 M$F?,CU*24J)6EN?.HS0$TF/FGAUS]^R(O>_.=7AT-5*0=?L T!V(NENR_]J_ M,:;=U?JFWCU0[KA:5T)#C2LR]2Y2HH/J+OUN8>2VO6B7TE!%K;BA=Q(JJT#[ M*TG7S&%A _0OK\E?4$L#!!0 ( Y(=5J_#.Q3!P, #8& 9 >&PO M=V]R:W-H965T??=]).^T.&KS9 ^( M#IX;U=IE?'"NNTY36QVP$?9*=]C2SDZ;1CB:FGUJ.X.B#D&-2EF63=-&R#9> M+<+:G5DM=.^4;/'.@.V;1IB7#2I]7,9Y_+IP+_<'YQ?2U:(3>WQ ]T=W9VB6 MCBBU;+"U4K=@<+>,U_GUIO#^P>%/B4?[Q@:O9*OUDY_\5B_CS!-"A97S"(*& MKWB#2GD@HO'O"3,>4_K M_8K^J]!.VG9"HLW6OTE:W=8QK,8:MR)7KE[??R( M)ST3CU=I9<,7CH/OA#)6O76Z.073O)'M,(KGTSF\"9AEWPE@IP 6> ^) LM; MX<1J8?01C/6&W81 M\1:K*^!Y BQCQ04\/JKF 8]?4&UA$'A.WQ!=G(_V=7)M.U'A,J9"L&B^8KSZ MZ8=\FOUR@5LQJ.[J7B'HW7@IGZ382B6=)-9_!]KPB,\.-DI73_^< M4W QQWD%_FPC^O!HH]O>/X$?@10%T,J#75@135-!H9,%UO6@NLG"8E9\"*,ID59?0@Z'W0[E;XYT)' M,<\*R#E+V"2+?G<'-, HS8P#ISV>18_:$9PXW=K(D4XO*:8EN?!@\RE/LJ* M(3C+^*U7]02P,$% @ #DAU M6M7LR9U*#0 IY !D !X;"]W;W)K&ULQ9W_ M<]HX&L;_%0VW<[,[DQ;\%=)+,D-BR_C5]*#;)T\9_F78B)ER5ZF25J<=B9E.7O7[1:C MB9Q&Q=ML)E/UEXID_=HM9+J/QHM(TZ=J]GM^=1G':.3M9'+O.STZR M>9G$J;S.63&?3J/\Z[E,LN?3CM5Y/7 3/T[*ZD#W[&06/K"HL2O\7RN5C[G55OY3[+OE0O+L>GG5[5(IG( M45DA(O7C25[()*E(JAV_U]#.ZIQ5Q?7?7^EB\>;5F[F/"GF1)?^(Q^7DM#/H ML+%\B.9)>9,]OY?U&_(JWBA+BL7_[+DNV^NPT;PHLVE=6;5@&J?+G]%+_4&L M5;"]'17LNH*]4<%Q=E1PZ@K.H17F8W2XE6AV_C1_3^"$>16G)AJ-1-D_+.'UDUUD2CV)9 ML)\#649Q4K#/\J6<1\DO)]U2M; Z3W=4M^9\V1I[1VL<]C%+RTG!>#J6XX;Z M@JYOV02@JSZ:U>=COWX^YS9)_!CE;YEC'3&[9WOL)]9EQ23*9='0M@N:="MG MBM1;D%QV=QNPGW_ZA28&A[?M0"(_O(W.841!$P,Y:MO&\'#B_C8:07=6%X6S M.(6[XQ2UN@MV(TJ0. MYKE,RZ9@D^RVP4;" B2,(V%B"?/7PMC;"/1V"WU0!!I7*E%'8=Q6/V)ST2.2?/U58D2%B MA'$D3"QA@_7,_M;?4$A3&:OY\A^L C\@ [\*-9M%7ZL16U,\243;>")A 1+& MD3 QV+KH;7^P$<_M,J[7',[C53B/#PMG4QC)JFW#B(0%2!A'PL3Q=M^\%<;M M,KO":/6TO] C WDYG45Q/E5#9S6IGLP?VF[IVL[SQ MZJ49K6.*I 50&H?21$U;OSR=S9A21Z-*>TZ=M+0.H 0:E<2A-U#3*%B&+F#+0[I=% MVU_#\9/,R[BH['S^,I/ICLX8:G1!:0&4QJ$T4=/(BYLJ8D956UT6[74%<5'F M\?V\5/WPXLK]&.5?Y/([FR@O4ZD._^NCK'KL?S>&&VJ!06D!E,:A- &EA2B: M*2)MJEFTJZ9'=*^N>'._#[73H+0 2N-0FJAIQI1K,S501%;-S=A0Y0<1OU3? >NLP/YD'^,TGLZG=** VF106@"E<2A-0&DA MBF9*2MMO%NV_7>?93 TBOAZQZZ1:(5!U."MY'3$UOW^8)^Q#_"#9S_^44=Z\ M.@!JT$%I 93&H32Q)S8>^ZH^\<;OVE'M,%6C73Z+MOE:)*+H97\B@AJ#4%H MI7$H34!I(8IFKM?1AJ--&XZ01$2?HZV2H+0 2N-0FM@3F_[N1(1JAZD:[5S: MM'-Y/H^3<34UHO(+S6BM"JAS":5Q*$U :2&*9BI%^Z$V[8=B\@O4)X72 BB- M0VEB3VS<'I%@0 TQ9:.M5INV6E<)YG(ZR[,G6:F%]E]H8&N-0$U4*(U#:0)* M"U$T4S;:FK5I:Q:3;:#&+9060&D<2A-[8F-3V0;4$%,VVONU:>_WTW*]]=\= MO02*SC50KQ=*"Z T#J4)*"U$T4S1:*_7WK."$KIVCCY9:TDM:?WU+TC>.I[I ME0;0*O M\V1YG\@B%38F%J@W#*4)*"U$T4RU:&_8/G1MIJF6[*&ZPR;+F\4"]8+WM' A M%MNAQ *U?Z$T :6%*)HI%FT)V[0EK"2RG!LI=7S*U92INOUPK3-:[Z4:=0,U M@6N:>;]1KS_PMKH>J+\+I0DH+431S%OSM+_KT![B00N]:49;$3C;2R4M;V-- M>P ])8?2!)06HFBF +15Z]!6[>O>4T!I(8IF2F7MYF_:J?VVN0T-;2T) M[#W?]!L6\EX-?GN[![\A>#Q,%RD.@U)A;HXEHHC4-I M DH+433S,5G:?'4/-5];S';V,)=BZ1%BH0%MQ0*E<2A-0&DABF:*11NU[@%& MK7/X(A0:UW;H J4%4!J'T@24%J)HIFBT4>O^+XU:^F2M)04U:J$T7M-V/5.I M5@K4IT713*5HG];]$3XM#6VMB#T/$IT_OF6L5[ME3J,*H"MIH30!I84HFBF7 MM4=\_@"CEF:V5@O=PN4B%)\2"[(Y'$H34%J(HIEBT4:M^V.-6AK?6C=0HQ9* MX^ZV[>MZQ\Z@O]GU0'U:%,V4A_9I78!/2S-::P#JTT)IW&UX1(&W&7^H38NB MF?'7-JU[X/+7QKA#'5@H+8#2>$W;N/9=Q]Z,/=1;1=',V&MOU:6]U?JQ5Z\/ M2MHSI84N8H72 BB-0VD"2@M1-%,QVF)U:3?4W#G@HQITYG&4J%%G.<_3YA0" M7<,*I050&H?2A+N]6M?N^_W-A!0VE7/[ [??_& =3_NC'NUEWL@GFW%R&P\^7GZ[(A$.WKZURH+0 2N-0FH#20A3-5*$V7CW:>-T6V,(^ MJXY%CXUC51K86C90ZQ5*XU":J&G'ANMVO/E8UN92._8L\;15ZM%6*2+9S._S MZ#\RH7,*U$2%T@(HC4-I DH+4313;-IM]6@K\QMR"M1IA=("*(U#::*FF=EB M

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end XML 63 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 64 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 66 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 85 252 1 false 51 0 false 6 false false R1.htm 000 - Document - Document And Entity Information Sheet http://u-g.com/20241231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Statements of Income Sheet http://u-g.com/20241231/role/statement-statements-of-income Statements of Income Statements 2 false false R3.htm 002 - Statement - Balance Sheets Sheet http://u-g.com/20241231/role/statement-balance-sheets Balance Sheets Statements 3 false false R4.htm 003 - Statement - Balance Sheets (Parentheticals) Sheet http://u-g.com/20241231/role/statement-balance-sheets-parentheticals Balance Sheets (Parentheticals) Statements 4 false false R5.htm 004 - Statement - Statements of Stockholders' Equity Sheet http://u-g.com/20241231/role/statement-statements-of-stockholders-equity Statements of Stockholders' Equity Statements 5 false false R6.htm 005 - Statement - Statements of Stockholders' Equity (Parentheticals) Sheet http://u-g.com/20241231/role/statement-statements-of-stockholders-equity-parentheticals Statements of Stockholders' Equity (Parentheticals) Statements 6 false false R7.htm 006 - Statement - Statements of Cash Flows Sheet http://u-g.com/20241231/role/statement-statements-of-cash-flows Statements of Cash Flows Statements 7 false false R8.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure Sheet http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure Cybersecurity Risk Management and Strategy Disclosure Notes 9 false false R10.htm 995550 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies Sheet http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies- Note A - Nature of Business and Summary of Significant Accounting Policies Notes 10 false false R11.htm 995551 - Disclosure - Note B - Cash and Cash Equivalents Sheet http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents Note B - Cash and Cash Equivalents Notes 11 false false R12.htm 995552 - Disclosure - Note C - Marketable Securities Sheet http://u-g.com/20241231/role/statement-note-c-marketable-securities Note C - Marketable Securities Notes 12 false false R13.htm 995553 - Disclosure - Note D - Inventories Sheet http://u-g.com/20241231/role/statement-note-d-inventories Note D - Inventories Notes 13 false false R14.htm 995554 - Disclosure - Note E - Income Taxes Sheet http://u-g.com/20241231/role/statement-note-e-income-taxes Note E - Income Taxes Notes 14 false false R15.htm 995555 - Disclosure - Note F - Benefit Plans Sheet http://u-g.com/20241231/role/statement-note-f-benefit-plans Note F - Benefit Plans Notes 15 false false R16.htm 995556 - Disclosure - Note G - Geographic and Other Information Sheet http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information Note G - Geographic and Other Information Notes 16 false false R17.htm 995557 - Disclosure - Note H - Accrued Expenses Sheet http://u-g.com/20241231/role/statement-note-h-accrued-expenses Note H - Accrued Expenses Notes 17 false false R18.htm 995558 - Disclosure - Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities Sheet http://u-g.com/20241231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities Notes 18 false false R19.htm 995559 - Disclosure - Note J - Related Party Transactions Sheet http://u-g.com/20241231/role/statement-note-j-related-party-transactions Note J - Related Party Transactions Notes 19 false false R20.htm 995560 - Disclosure - Note K - Subsequent Events Sheet http://u-g.com/20241231/role/statement-note-k-subsequent-events Note K - Subsequent Events Notes 20 false false R21.htm 995561 - Disclosure - Significant Accounting Policies (Policies) Sheet http://u-g.com/20241231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies- 21 false false R22.htm 995562 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies (Tables) Sheet http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables Note A - Nature of Business and Summary of Significant Accounting Policies (Tables) Tables http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies- 22 false false R23.htm 995563 - Disclosure - Note B - Cash and Cash Equivalents (Tables) Sheet http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-tables Note B - Cash and Cash Equivalents (Tables) Tables http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents 23 false false R24.htm 995564 - Disclosure - Note C - Marketable Securities (Tables) Sheet http://u-g.com/20241231/role/statement-note-c-marketable-securities-tables Note C - Marketable Securities (Tables) Tables http://u-g.com/20241231/role/statement-note-c-marketable-securities 24 false false R25.htm 995565 - Disclosure - Note D - Inventories (Tables) Sheet http://u-g.com/20241231/role/statement-note-d-inventories-tables Note D - Inventories (Tables) Tables http://u-g.com/20241231/role/statement-note-d-inventories 25 false false R26.htm 995566 - Disclosure - Note E - Income Taxes (Tables) Sheet http://u-g.com/20241231/role/statement-note-e-income-taxes-tables Note E - Income Taxes (Tables) Tables http://u-g.com/20241231/role/statement-note-e-income-taxes 26 false false R27.htm 995567 - Disclosure - Note G - Geographic and Other Information (Tables) Sheet http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-tables Note G - Geographic and Other Information (Tables) Tables http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information 27 false false R28.htm 995568 - Disclosure - Note H - Accrued Expenses (Tables) Sheet http://u-g.com/20241231/role/statement-note-h-accrued-expenses-tables Note H - Accrued Expenses (Tables) Tables http://u-g.com/20241231/role/statement-note-h-accrued-expenses 28 false false R29.htm 995569 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies (Details Textual) Sheet http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual Note A - Nature of Business and Summary of Significant Accounting Policies (Details Textual) Details http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables 29 false false R30.htm 995570 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies - Disaggregated Revenue (Details) Sheet http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details Note A - Nature of Business and Summary of Significant Accounting Policies - Disaggregated Revenue (Details) Details 30 false false R31.htm 995571 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies - Revenue by Geographic Region (Details) Sheet http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details Note A - Nature of Business and Summary of Significant Accounting Policies - Revenue by Geographic Region (Details) Details 31 false false R32.htm 995572 - Disclosure - Note B - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) Sheet http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details Note B - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) Details 32 false false R33.htm 995573 - Disclosure - Note C - Marketable Securities (Details Textual) Sheet http://u-g.com/20241231/role/statement-note-c-marketable-securities-details-textual Note C - Marketable Securities (Details Textual) Details http://u-g.com/20241231/role/statement-note-c-marketable-securities-tables 33 false false R34.htm 995574 - Disclosure - Note C - Marketable Securities - Net Gains and Losses on Marketable Securities (Details) Sheet http://u-g.com/20241231/role/statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details Note C - Marketable Securities - Net Gains and Losses on Marketable Securities (Details) Details 34 false false R35.htm 995575 - Disclosure - Note C - Marketable Securities - Summary of Investments (Details) Sheet http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details Note C - Marketable Securities - Summary of Investments (Details) Details 35 false false R36.htm 995576 - Disclosure - Note D - Inventories (Details Textual) Sheet http://u-g.com/20241231/role/statement-note-d-inventories-details-textual Note D - Inventories (Details Textual) Details http://u-g.com/20241231/role/statement-note-d-inventories-tables 36 false false R37.htm 995577 - Disclosure - Note D - Inventories - Summary of Inventories (Details) Sheet http://u-g.com/20241231/role/statement-note-d-inventories-summary-of-inventories-details Note D - Inventories - Summary of Inventories (Details) Details 37 false false R38.htm 995578 - Disclosure - Note E - Income Taxes - Provision for Income Taxes (Details) Sheet http://u-g.com/20241231/role/statement-note-e-income-taxes-provision-for-income-taxes-details Note E - Income Taxes - Provision for Income Taxes (Details) Details 38 false false R39.htm 995579 - Disclosure - Note E - Income Taxes - Reconciliation of the Effective Income Tax Rate (Details) Sheet http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details Note E - Income Taxes - Reconciliation of the Effective Income Tax Rate (Details) Details 39 false false R40.htm 995580 - Disclosure - Note E - Income Taxes - Deferred Tax Assets and Liabilities (Details) Sheet http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details Note E - Income Taxes - Deferred Tax Assets and Liabilities (Details) Details 40 false false R41.htm 995581 - Disclosure - Note F - Benefit Plans (Details Textual) Sheet http://u-g.com/20241231/role/statement-note-f-benefit-plans-details-textual Note F - Benefit Plans (Details Textual) Details http://u-g.com/20241231/role/statement-note-f-benefit-plans 41 false false R42.htm 995582 - Disclosure - Note G - Geographic and Other Information (Details Textual) Sheet http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-details-textual Note G - Geographic and Other Information (Details Textual) Details http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-tables 42 false false R43.htm 995583 - Disclosure - Note G - Geographic and Other Information - Net Sales (Details) Sheet http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-net-sales-details Note G - Geographic and Other Information - Net Sales (Details) Details 43 false false R44.htm 995584 - Disclosure - Note G - Geographic and Other Information - Geographic Information (Details) Sheet http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-geographic-information-details Note G - Geographic and Other Information - Geographic Information (Details) Details 44 false false R45.htm 995585 - Disclosure - Note G - Geographic and Other Information - Sales to Major Customers (Details) Sheet http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details Note G - Geographic and Other Information - Sales to Major Customers (Details) Details 45 false false R46.htm 995586 - Disclosure - Note H - Accrued Expenses - Summary of Accrued Expenses (Details) Sheet http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details Note H - Accrued Expenses - Summary of Accrued Expenses (Details) Details 46 false false R47.htm 995587 - Disclosure - Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities (Details Textual) Sheet http://u-g.com/20241231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities-details-textual Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities (Details Textual) Details http://u-g.com/20241231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities 47 false false R48.htm 995588 - Disclosure - Note J - Related Party Transactions (Details Textual) Sheet http://u-g.com/20241231/role/statement-note-j-related-party-transactions-details-textual Note J - Related Party Transactions (Details Textual) Details http://u-g.com/20241231/role/statement-note-j-related-party-transactions 48 false false R49.htm 995589 - Disclosure - Note K - Subsequent Events (Details Textual) Sheet http://u-g.com/20241231/role/statement-note-k-subsequent-events-details-textual Note K - Subsequent Events (Details Textual) Details http://u-g.com/20241231/role/statement-note-k-subsequent-events 49 false false All Reports Book All Reports ug-20241231.xsd ug-20241231_cal.xml ug-20241231_def.xml ug-20241231_lab.xml ug-20241231_pre.xml ug20241231_10k.htm signature.jpg http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/cyd/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 69 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ug20241231_10k.htm": { "nsprefix": "ug", "nsuri": "http://u-g.com/20241231", "dts": { "schema": { "local": [ "ug-20241231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "ug-20241231_cal.xml" ] }, "definitionLink": { "local": [ "ug-20241231_def.xml" ] }, "labelLink": { "local": [ "ug-20241231_lab.xml" ] }, "presentationLink": { "local": [ "ug-20241231_pre.xml" ] }, "inline": { "local": [ "ug20241231_10k.htm" ] } }, "keyStandard": 229, "keyCustom": 23, "axisStandard": 17, "axisCustom": 0, "memberStandard": 22, "memberCustom": 29, "hidden": { "total": 36, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 15, "http://xbrl.sec.gov/ecd/2024": 4, "http://xbrl.sec.gov/cyd/2024": 6, "http://u-g.com/20241231": 6 }, "contextCount": 85, "entityCount": 1, "segmentCount": 51, "elementCount": 395, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 388, "http://xbrl.sec.gov/dei/2024": 37, "http://xbrl.sec.gov/cyd/2024": 15, "http://xbrl.sec.gov/ecd/2024": 5 }, "report": { "R1": { "role": "http://u-g.com/20241231/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R2": { "role": "http://u-g.com/20241231/role/statement-statements-of-income", "longName": "001 - Statement - Statements of Income", "shortName": "Statements of Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "unique": true } }, "R3": { "role": "http://u-g.com/20241231/role/statement-balance-sheets", "longName": "002 - Statement - Balance Sheets", "shortName": "Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "unique": true } }, "R4": { "role": "http://u-g.com/20241231/role/statement-balance-sheets-parentheticals", "longName": "003 - Statement - Balance Sheets (Parentheticals)", "shortName": "Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R5": { "role": "http://u-g.com/20241231/role/statement-statements-of-stockholders-equity", "longName": "004 - Statement - Statements of Stockholders' Equity", "shortName": "Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R6": { "role": "http://u-g.com/20241231/role/statement-statements-of-stockholders-equity-parentheticals", "longName": "005 - Statement - Statements of Stockholders' Equity (Parentheticals)", "shortName": "Statements of Stockholders' Equity (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true }, "uniqueAnchor": null }, "R7": { "role": "http://u-g.com/20241231/role/statement-statements-of-cash-flows", "longName": "006 - Statement - Statements of Cash Flows", "shortName": "Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "unique": true } }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R9": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R10": { "role": "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "longName": "995550 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies", "shortName": "Note A - Nature of Business and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R11": { "role": "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents", "longName": "995551 - Disclosure - Note B - Cash and Cash Equivalents", "shortName": "Note B - Cash and Cash Equivalents", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R12": { "role": "http://u-g.com/20241231/role/statement-note-c-marketable-securities", "longName": "995552 - Disclosure - Note C - Marketable Securities", "shortName": "Note C - Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R13": { "role": "http://u-g.com/20241231/role/statement-note-d-inventories", "longName": "995553 - Disclosure - Note D - Inventories", "shortName": "Note D - Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R14": { "role": "http://u-g.com/20241231/role/statement-note-e-income-taxes", "longName": "995554 - Disclosure - Note E - Income Taxes", "shortName": "Note E - Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R15": { "role": "http://u-g.com/20241231/role/statement-note-f-benefit-plans", "longName": "995555 - Disclosure - Note F - Benefit Plans", "shortName": "Note F - Benefit Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R16": { "role": "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "longName": "995556 - Disclosure - Note G - Geographic and Other Information", "shortName": "Note G - Geographic and Other Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R17": { "role": "http://u-g.com/20241231/role/statement-note-h-accrued-expenses", "longName": "995557 - Disclosure - Note H - Accrued Expenses", "shortName": "Note H - Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R18": { "role": "http://u-g.com/20241231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities", "longName": "995558 - Disclosure - Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities", "shortName": "Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R19": { "role": "http://u-g.com/20241231/role/statement-note-j-related-party-transactions", "longName": "995559 - Disclosure - Note J - Related Party Transactions", "shortName": "Note J - Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R20": { "role": "http://u-g.com/20241231/role/statement-note-k-subsequent-events", "longName": "995560 - Disclosure - Note K - Subsequent Events", "shortName": "Note K - Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R21": { "role": "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies", "longName": "995561 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R22": { "role": "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables", "longName": "995562 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies (Tables)", "shortName": "Note A - Nature of Business and Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R23": { "role": "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-tables", "longName": "995563 - Disclosure - Note B - Cash and Cash Equivalents (Tables)", "shortName": "Note B - Cash and Cash Equivalents (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R24": { "role": "http://u-g.com/20241231/role/statement-note-c-marketable-securities-tables", "longName": "995564 - Disclosure - Note C - Marketable Securities (Tables)", "shortName": "Note C - Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:GainLossOnInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:GainLossOnInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R25": { "role": "http://u-g.com/20241231/role/statement-note-d-inventories-tables", "longName": "995565 - Disclosure - Note D - Inventories (Tables)", "shortName": "Note D - Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R26": { "role": "http://u-g.com/20241231/role/statement-note-e-income-taxes-tables", "longName": "995566 - Disclosure - Note E - Income Taxes (Tables)", "shortName": "Note E - Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R27": { "role": "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-tables", "longName": "995567 - Disclosure - Note G - Geographic and Other Information (Tables)", "shortName": "Note G - Geographic and Other Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R28": { "role": "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-tables", "longName": "995568 - Disclosure - Note H - Accrued Expenses (Tables)", "shortName": "Note H - Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R29": { "role": "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "longName": "995569 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note A - Nature of Business and Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:CreditLossFinancialInstrumentPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:CreditLossFinancialInstrumentPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R30": { "role": "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "longName": "995570 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies - Disaggregated Revenue (Details)", "shortName": "Note A - Nature of Business and Summary of Significant Accounting Policies - Disaggregated Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true }, "uniqueAnchor": null }, "R31": { "role": "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "longName": "995571 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies - Revenue by Geographic Region (Details)", "shortName": "Note A - Nature of Business and Summary of Significant Accounting Policies - Revenue by Geographic Region (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true }, "uniqueAnchor": null }, "R32": { "role": "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details", "longName": "995572 - Disclosure - Note B - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)", "shortName": "Note B - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:CertificatesOfDepositAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:CertificatesOfDepositAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R33": { "role": "http://u-g.com/20241231/role/statement-note-c-marketable-securities-details-textual", "longName": "995573 - Disclosure - Note C - Marketable Securities (Details Textual)", "shortName": "Note C - Marketable Securities (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://u-g.com/20241231/role/statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details", "longName": "995574 - Disclosure - Note C - Marketable Securities - Net Gains and Losses on Marketable Securities (Details)", "shortName": "Note C - Marketable Securities - Net Gains and Losses on Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:DebtAndEquitySecuritiesGainLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:GainLossOnInvestmentsTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:DebtAndEquitySecuritiesGainLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:GainLossOnInvestmentsTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R35": { "role": "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details", "longName": "995575 - Disclosure - Note C - Marketable Securities - Summary of Investments (Details)", "shortName": "Note C - Marketable Securities - Summary of Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "ug:OtherShorttermInvestmentsAtCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31", "name": "ug:OtherShorttermInvestmentsAtCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R36": { "role": "http://u-g.com/20241231/role/statement-note-d-inventories-details-textual", "longName": "995576 - Disclosure - Note D - Inventories (Details Textual)", "shortName": "Note D - Inventories (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:InventoryValuationReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:InventoryValuationReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R37": { "role": "http://u-g.com/20241231/role/statement-note-d-inventories-summary-of-inventories-details", "longName": "995577 - Disclosure - Note D - Inventories - Summary of Inventories (Details)", "shortName": "Note D - Inventories - Summary of Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R38": { "role": "http://u-g.com/20241231/role/statement-note-e-income-taxes-provision-for-income-taxes-details", "longName": "995578 - Disclosure - Note E - Income Taxes - Provision for Income Taxes (Details)", "shortName": "Note E - Income Taxes - Provision for Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R39": { "role": "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details", "longName": "995579 - Disclosure - Note E - Income Taxes - Reconciliation of the Effective Income Tax Rate (Details)", "shortName": "Note E - Income Taxes - Reconciliation of the Effective Income Tax Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R40": { "role": "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details", "longName": "995580 - Disclosure - Note E - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "shortName": "Note E - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R41": { "role": "http://u-g.com/20241231/role/statement-note-f-benefit-plans-details-textual", "longName": "995581 - Disclosure - Note F - Benefit Plans (Details Textual)", "shortName": "Note F - Benefit Plans (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R42": { "role": "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-details-textual", "longName": "995582 - Disclosure - Note G - Geographic and Other Information (Details Textual)", "shortName": "Note G - Geographic and Other Information (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": null, "uniqueAnchor": null }, "R43": { "role": "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-net-sales-details", "longName": "995583 - Disclosure - Note G - Geographic and Other Information - Net Sales (Details)", "shortName": "Note G - Geographic and Other Information - Net Sales (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "ug:RevenueFromContractWithCustomerIncludingAssessedTaxGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "ug:SalesReturnsAndAllowances", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "unique": true } }, "R44": { "role": "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-geographic-information-details", "longName": "995584 - Disclosure - Note G - Geographic and Other Information - Geographic Information (Details)", "shortName": "Note G - Geographic and Other Information - Geographic Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true }, "uniqueAnchor": null }, "R45": { "role": "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details", "longName": "995585 - Disclosure - Note G - Geographic and Other Information - Sales to Major Customers (Details)", "shortName": "Note G - Geographic and Other Information - Sales to Major Customers (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "ug:RevenueFromContractWithCustomerIncludingAssessedTaxGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31_MajorCustomersAxis-CustomerAMember", "name": "ug:RevenueFromContractWithCustomerIncludingAssessedTaxGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "unique": true } }, "R46": { "role": "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details", "longName": "995586 - Disclosure - Note H - Accrued Expenses - Summary of Accrued Expenses (Details)", "shortName": "Note H - Accrued Expenses - Summary of Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:AccruedBonusesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:AccruedBonusesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R47": { "role": "http://u-g.com/20241231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities-details-textual", "longName": "995587 - Disclosure - Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities (Details Textual)", "shortName": "Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "ug:ConvertibleCommonStockSharesIssuableUponConversion", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31", "name": "ug:ConvertibleCommonStockSharesIssuableUponConversion", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R48": { "role": "http://u-g.com/20241231/role/statement-note-j-related-party-transactions-details-textual", "longName": "995588 - Disclosure - Note J - Related Party Transactions (Details Textual)", "shortName": "Note J - Related Party Transactions (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "d_2024-01-01_2024-12-31_RelatedPartyTransactionAxis-ConsultingServicesMember_RelatedPartyTransactionsByRelatedPartyAxis-PreviousPresidentAndCeoMember", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31_RelatedPartyTransactionAxis-ConsultingServicesMember_RelatedPartyTransactionsByRelatedPartyAxis-PreviousPresidentAndCeoMember", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } }, "R49": { "role": "http://u-g.com/20241231/role/statement-note-k-subsequent-events-details-textual", "longName": "995589 - Disclosure - Note K - Subsequent Events (Details Textual)", "shortName": "Note K - Subsequent Events (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "d_2025-01-27_2025-01-27_SubsequentEventTypeAxis-SubsequentEventMember", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-27_2025-01-27_SubsequentEventTypeAxis-SubsequentEventMember", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ug20241231_10k.htm", "first": true, "unique": true } } }, "tag": { "ug_ASIMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "ASIMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "ASI [Member]", "documentation": "Refers to information regarding the entity ASI, which is located in Canada." } } }, "auth_ref": [] }, "ug_AccountingAndTaxServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "AccountingAndTaxServicesMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-j-related-party-transactions", "http://u-g.com/20241231/role/statement-note-j-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Accounting and Tax Services [Member]", "documentation": "Represents accounting and tax services." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "presentation": [ "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r40", "r653" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r591" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivable, net of allowance for credit losses of $14,342 in 2024 and $16,672 in 2023", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r754" ] }, "ug_AccruedAnnualReportExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://u-g.com/20241231", "localname": "AccruedAnnualReportExpensesCurrent", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "ug_AccruedAnnualReportExpensesCurrent", "terseLabel": "Annual report expenses", "documentation": "The carrying value of accrued annual report expenses classified as current liabilities." } } }, "auth_ref": [] }, "us-gaap_AccruedBonusesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedBonusesCurrent", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccruedBonusesCurrent", "terseLabel": "Bonuses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r42" ] }, "ug_AccruedDistributionFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://u-g.com/20241231", "localname": "AccruedDistributionFeesCurrent", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "ug_AccruedDistributionFeesCurrent", "terseLabel": "Distribution fees", "documentation": "Accrued distribution fees" } } }, "auth_ref": [] }, "ug_AccruedExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "AccruedExpensesMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Accrued Expenses [Member]", "documentation": "Related to accrued expenses." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets", "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "Accrued expenses", "totalLabel": "Total accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r42" ] }, "us-gaap_AccruedMarketingCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedMarketingCostsCurrent", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccruedMarketingCostsCurrent", "terseLabel": "Sales rebates", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccruedProfessionalFeesCurrent", "terseLabel": "Audit fee", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r42" ] }, "ug_AccruedReserveForOutdatedMaterial": { "xbrltype": "monetaryItemType", "nsuri": "http://u-g.com/20241231", "localname": "AccruedReserveForOutdatedMaterial", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "ug_AccruedReserveForOutdatedMaterial", "terseLabel": "Reserve for outdated material returns", "documentation": "Carrying value on reserves for outdated material." } } }, "auth_ref": [] }, "us-gaap_AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedSalariesCurrent", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccruedSalariesCurrent", "terseLabel": "Payroll and related expenses", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r42", "r611" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Less accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r31", "r122", "r479" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Advertising Cost [Policy Text Block]", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r104" ] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AdvertisingExpense", "terseLabel": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": [ "r320", "r640" ] }, "ug_AllOtherCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "AllOtherCustomersMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details" ], "lang": { "en-us": { "role": { "label": "All Other Customers [Member]" } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable", "terseLabel": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r125", "r200", "r239", "r243", "r245", "r861" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent", "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r125", "r200", "r239" ] }, "ug_AllowanceForMaterialReturns": { "xbrltype": "monetaryItemType", "nsuri": "http://u-g.com/20241231", "localname": "AllowanceForMaterialReturns", "crdr": "credit", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "ug_AllowanceForMaterialReturns", "terseLabel": "Allowance for Material Returns", "documentation": "The amount of allowance for material returns." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "TOTAL ASSETS", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r89", "r100", "r123", "r140", "r165", "r171", "r187", "r190", "r233", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r361", "r363", "r380", "r470", "r540", "r625", "r626", "r653", "r681", "r767", "r768", "r849" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r117", "r128", "r140", "r233", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r361", "r363", "r380", "r653", "r767", "r768", "r849" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_AuditorFirmId", "terseLabel": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r685", "r686", "r698" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_AuditorLocation", "terseLabel": "Auditor Location" } } }, "auth_ref": [ "r685", "r686", "r698" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_AuditorName", "terseLabel": "Auditor Name" } } }, "auth_ref": [ "r685", "r686", "r698" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r268", "r863", "r864" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r32", "r33", "r268", "r863", "r864" ] }, "us-gaap_BuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingImprovementsMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Building Improvements [Member]", "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r84" ] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r84" ] }, "us-gaap_BuildingsAndImprovementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingsAndImprovementsGross", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Building and improvements", "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [ "r84" ] }, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CN", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "CHINA" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details": { "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details" ], "lang": { "en-us": { "role": { "label": "Demand Deposits", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r102", "r473", "r512", "r535", "r653", "r681", "r731" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 }, "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets", "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "totalLabel": "Total cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r12", "r120", "r607" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents", "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r120" ] }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsDisclosureTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents Disclosure [Text Block]", "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify." } } }, "auth_ref": [ "r120", "r473" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r13" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "Cash and cash equivalents, beginning of year", "periodEndLabel": "Cash and cash equivalents, end of year", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r12", "r74", "r139" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net (decrease) increase in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r74" ] }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowSupplementalDisclosuresTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities" ], "lang": { "en-us": { "role": { "label": "Cash Flow, Supplemental Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r70" ] }, "ug_CashSIPCUninsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://u-g.com/20241231", "localname": "CashSIPCUninsuredAmount", "crdr": "debit", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "ug_CashSIPCUninsuredAmount", "terseLabel": "Cash, SIPC Uninsured Amount", "documentation": "The amount of cash as of the balance sheet date that is not insured by the Securities Investor Protection Corporation." } } }, "auth_ref": [] }, "us-gaap_CashUninsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashUninsuredAmount", "crdr": "debit", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashUninsuredAmount", "terseLabel": "Cash, Uninsured Amount", "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "us-gaap_CertificatesOfDepositAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CertificatesOfDepositAtCarryingValue", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details": { "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details" ], "lang": { "en-us": { "role": { "label": "Certificates of Deposit (original 3-month maturity)", "documentation": "A savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate. A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit). Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties. Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [ "r731" ] }, "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CertificatesOfDepositMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-c-marketable-securities", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "lang": { "en-us": { "role": { "label": "Certificates of Deposit [Member]", "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }, "auth_ref": [ "r8", "r675", "r676", "r677", "r678" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_CityAreaCode", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r46", "r92", "r472", "r526" ] }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareCashPaid", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20241231/role/statement-statements-of-stockholders-equity-parentheticals" ], "lang": { "en-us": { "role": { "label": "Dividends declared per share (in dollars per share)", "terseLabel": "Common Stock, Dividends, Per Share, Cash Paid", "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r87" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://u-g.com/20241231/role/statement-note-k-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_CommonStockDividendsPerShareDeclared", "terseLabel": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r87" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r671", "r672", "r673", "r675", "r676", "r677", "r678", "r743", "r744", "r746", "r840", "r893", "r895" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r50" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r50", "r527" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r50" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r50", "r527", "r546", "r895", "r896" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $.10 par value; 10,000,000 shares authorized; 4,594,319 shares issued and outstanding at December 31, 2024 and 2023", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r50", "r474", "r653" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r18", "r20", "r34", "r35", "r198", "r591" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r18", "r20", "r34", "r35", "r198", "r503", "r591" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r18", "r20", "r34", "r35", "r198", "r591", "r722" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r38", "r107" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r18", "r20", "r34", "r35", "r198" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r18", "r20", "r34", "r35", "r198", "r591" ] }, "ug_ConsultingServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "ConsultingServicesMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-j-related-party-transactions", "http://u-g.com/20241231/role/statement-note-j-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Consulting Services [Member]", "documentation": "Represents consulting services." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Deferred revenue", "terseLabel": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r285", "r286", "r289" ] }, "ug_ConvertibleCommonStockSharesIssuableUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://u-g.com/20241231", "localname": "ConvertibleCommonStockSharesIssuableUponConversion", "presentation": [ "http://u-g.com/20241231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "ug_ConvertibleCommonStockSharesIssuableUponConversion", "terseLabel": "Convertible Common Stock, Shares Issuable upon Conversion", "documentation": "Number of shares issuable upon the conversion of convertible common stock." } } }, "auth_ref": [] }, "ug_CosmeticIngredientsMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "CosmeticIngredientsMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-net-sales-details" ], "lang": { "en-us": { "role": { "label": "Cosmetic Ingredients [Member]", "documentation": "Represents information related to cosmetic ingredients." } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-income": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-income" ], "lang": { "en-us": { "role": { "label": "Cost of sales", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r60", "r61", "r435" ] }, "us-gaap_CostOfGoodsProductLineMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsProductLineMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Cost of Goods and Service, Product and Service Benchmark [Member]", "documentation": "Cost of product sold and service rendered from specified product or service, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r721" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-income": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-income" ], "lang": { "en-us": { "role": { "label": "us-gaap_CostsAndExpenses", "totalLabel": "Total costs and expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r69" ] }, "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditLossFinancialInstrumentPolicyTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Credit Loss, Financial Instrument [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status." } } }, "auth_ref": [ "r236", "r237", "r238", "r240", "r241", "r246", "r248", "r249", "r250", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r261" ] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-provision-for-income-taxes-details": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-provision-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_CurrentFederalTaxExpenseBenefit", "terseLabel": "Federal", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r723", "r741", "r839" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-provision-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-provision-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_CurrentIncomeTaxExpenseBenefit", "totalLabel": "Total current provision for income taxes", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r345", "r741" ] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-provision-for-income-taxes-details": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-provision-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_CurrentStateAndLocalTaxExpenseBenefit", "terseLabel": "State", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r723", "r741", "r839" ] }, "ug_CustomerAMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "CustomerAMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details" ], "lang": { "en-us": { "role": { "label": "Customer A [Member]", "documentation": "Represents customer A." } } }, "auth_ref": [] }, "ug_CustomerBMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "CustomerBMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details" ], "lang": { "en-us": { "role": { "label": "Customer B [Member]", "documentation": "Represents a second customer." } } }, "auth_ref": [] }, "ug_CustomerCMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "CustomerCMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details" ], "lang": { "en-us": { "role": { "label": "Customer C [Member]", "documentation": "Represents a third customer." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r79", "r198" ] }, "ug_CustomerDMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "CustomerDMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details" ], "lang": { "en-us": { "role": { "label": "Customer D [Member]", "documentation": "Represents a fourth customer." } } }, "auth_ref": [] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r693", "r710" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r693", "r710" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r695", "r712" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r695", "r712" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r697", "r714" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r695", "r712" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r688", "r705" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r689", "r706" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r689", "r706" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r687", "r704" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r687", "r704" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r687", "r704" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r690", "r707" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r692", "r709" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r692", "r709" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r693", "r710" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r696", "r713" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r694", "r711" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r691", "r708" ] }, "ug_DCPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "DCPlanMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-f-benefit-plans", "http://u-g.com/20241231/role/statement-note-f-benefit-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "DC Plan [Member]", "documentation": "Represents DC plan." } } }, "auth_ref": [] }, "us-gaap_DebtAndEquitySecuritiesGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtAndEquitySecuritiesGainLoss", "crdr": "credit", "presentation": [ "http://u-g.com/20241231/role/statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details" ], "lang": { "en-us": { "role": { "label": "Net gains recognized during the year on marketable securities", "documentation": "Amount of unrealized and realized gain (loss) on investment in debt and equity securities." } } }, "auth_ref": [ "r65", "r68" ] }, "us-gaap_DebtAndEquitySecuritiesRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtAndEquitySecuritiesRealizedGainLoss", "crdr": "credit", "presentation": [ "http://u-g.com/20241231/role/statement-note-c-marketable-securities-details-textual", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Less: Net losses realized during the year on marketable securities sold during the period", "label": "us-gaap_DebtAndEquitySecuritiesRealizedGainLoss", "terseLabel": "Debt and Equity Securities, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on investment in debt and equity securities." } } }, "auth_ref": [ "r554", "r555", "r583", "r584", "r585", "r736", "r737" ] }, "us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtAndEquitySecuritiesUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://u-g.com/20241231/role/statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details" ], "lang": { "en-us": { "role": { "label": "Net unrealized gains recognized during the reporting year on marketable securities still held at the reporting date", "documentation": "Amount of unrealized gain (loss) on investment in debt and equity securities." } } }, "auth_ref": [ "r560", "r561", "r586", "r587", "r588", "r736", "r737" ] }, "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNICost": { "xbrltype": "monetaryItemType", "nsuri": "http://u-g.com/20241231", "localname": "DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNICost", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "lang": { "en-us": { "role": { "label": "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNICost", "totalLabel": "Total marketable securities, cost", "documentation": "Cost of investment in debt securities classified as held to maturity and equity securities." } } }, "auth_ref": [] }, "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://u-g.com/20241231", "localname": "DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIFairValue", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "lang": { "en-us": { "role": { "label": "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIFairValue", "totalLabel": "Total marketable securities, fair value", "documentation": "Fair value of investment in debt securities classified as held to maturity and equity securities." } } }, "auth_ref": [] }, "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://u-g.com/20241231", "localname": "DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "lang": { "en-us": { "role": { "label": "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIUnrealizedGainLoss", "totalLabel": "Total marketable securities, unrealized gain", "documentation": "Amount of accumulated unrealized gain (loss) in debt securities classified as held to maturity and equity securities." } } }, "auth_ref": [] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-provision-for-income-taxes-details": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-provision-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredFederalIncomeTaxExpenseBenefit", "terseLabel": "Federal", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r741", "r838", "r839" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Deferred income taxes, net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r326", "r327" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-provision-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 }, "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-provision-for-income-taxes-details", "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredIncomeTaxExpenseBenefit", "terseLabel": "Deferred income taxes", "totalLabel": "Total deferred (benefit) expense from income taxes", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r4", "r112", "r741" ] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredIncomeTaxLiabilities", "negatedTotalLabel": "Total deferred tax liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r47", "r48", "r90", "r339" ] }, "ug_DeferredTaxAssetsAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://u-g.com/20241231", "localname": "DeferredTaxAssetsAccountsPayable", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "ug_DeferredTaxAssetsAccountsPayable", "terseLabel": "Accounts payable", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accounts payable." } } }, "auth_ref": [] }, "ug_DeferredTaxAssetsCapitalizedResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://u-g.com/20241231", "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "R&D expenses", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsInventory", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsInventory", "terseLabel": "Inventories", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory." } } }, "auth_ref": [ "r836" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "totalLabel": "Net deferred tax asset", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r835" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsNet", "totalLabel": "Total deferred tax assets", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r835" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "terseLabel": "Accrued expenses", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities." } } }, "auth_ref": [ "r836" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "terseLabel": "Allowance for credit losses", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r836" ] }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesAbstract", "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities" } } }, "auth_ref": [] }, "ug_DeferredTaxLiabilitiesAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://u-g.com/20241231", "localname": "DeferredTaxLiabilitiesAccountsReceivable", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "ug_DeferredTaxLiabilitiesAccountsReceivable", "negatedLabel": "Accounts receivable", "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from accounts receivable." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses", "negatedLabel": "Prepaid expenses", "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses." } } }, "auth_ref": [ "r836" ] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment", "negatedLabel": "Depreciation on property, plant and equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r836" ] }, "us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities", "negatedLabel": "Unrealized gain on marketable securities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on trading securities." } } }, "auth_ref": [ "r836" ] }, "ug_DefinedContributionDiscretionaryContributionPlanVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://u-g.com/20241231", "localname": "DefinedContributionDiscretionaryContributionPlanVestingPeriod", "presentation": [ "http://u-g.com/20241231/role/statement-note-f-benefit-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "ug_DefinedContributionDiscretionaryContributionPlanVestingPeriod", "terseLabel": "Defined Contribution, Discretionary Contribution Plan, Vesting Period (Year)", "documentation": "Represents the vesting period of discretionary contributions made under the defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": [ "http://u-g.com/20241231/role/statement-note-f-benefit-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount", "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan." } } }, "auth_ref": [] }, "ug_DefinedContributionPlanEmployerDiscretionaryContributionAmountPerYearAuthorized": { "xbrltype": "monetaryItemType", "nsuri": "http://u-g.com/20241231", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmountPerYearAuthorized", "crdr": "debit", "presentation": [ "http://u-g.com/20241231/role/statement-note-f-benefit-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "ug_DefinedContributionPlanEmployerDiscretionaryContributionAmountPerYearAuthorized", "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount Per Year Authorized", "documentation": "Defined Contribution Plan, Employer Discretionary Contribution Amount Per Year, Authorized." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": [ "http://u-g.com/20241231/role/statement-note-f-benefit-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "presentation": [ "http://u-g.com/20241231/role/statement-note-f-benefit-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "terseLabel": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage", "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year." } } }, "auth_ref": [] }, "us-gaap_DemandDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DemandDepositsMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents", "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details" ], "lang": { "en-us": { "role": { "label": "Demand Deposits [Member]", "documentation": "Accounts that may or may not bear interest and that depositor is entitled to withdraw at anytime without prior notice. Checking and negotiable order of withdrawal (NOW) accounts are the most common forms of demand deposits." } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r4", "r165", "r174", "r190", "r625", "r626" ] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-j-related-party-transactions", "http://u-g.com/20241231/role/statement-note-j-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "auth_ref": [ "r753", "r894" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r770" ] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents", "http://u-g.com/20241231/role/statement-note-c-marketable-securities", "http://u-g.com/20241231/role/statement-note-d-inventories", "http://u-g.com/20241231/role/statement-note-e-income-taxes", "http://u-g.com/20241231/role/statement-note-f-benefit-plans", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-h-accrued-expenses", "http://u-g.com/20241231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities", "http://u-g.com/20241231/role/statement-note-j-related-party-transactions", "http://u-g.com/20241231/role/statement-note-k-subsequent-events" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "ug_DiscretionaryContributionsVestingAtTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "DiscretionaryContributionsVestingAtTwoYearsMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-f-benefit-plans", "http://u-g.com/20241231/role/statement-note-f-benefit-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Discretionary Contributions Vesting at Two Years [Member]", "documentation": "Represents discretionary contributions vesting after two years of employment." } } }, "auth_ref": [] }, "ug_DiscretionaryContributionsVestingEachAdditionalYearMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "DiscretionaryContributionsVestingEachAdditionalYearMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-f-benefit-plans", "http://u-g.com/20241231/role/statement-note-f-benefit-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Discretionary Contributions Vesting Each Additional Year [Member]", "documentation": "Represents discretionary contributions vesting each additional year of employment." } } }, "auth_ref": [] }, "ug_DistributorsAndMarketingPartnersMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "DistributorsAndMarketingPartnersMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Distributors and Marketing Partners [Member]", "documentation": "Represents distributors and marketing partners of the company." } } }, "auth_ref": [] }, "us-gaap_DividendPayableDateToBePaidDayMonthAndYear": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendPayableDateToBePaidDayMonthAndYear", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DividendPayableDateToBePaidDayMonthAndYear", "terseLabel": "Dividends Payable, Date to be Paid", "documentation": "Date the declared dividend will be paid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r15" ] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Dividends", "crdr": "debit", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20241231/role/statement-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_Dividends", "negatedLabel": "Dividends declared", "terseLabel": "Dividends", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": [ "r2", "r87" ] }, "us-gaap_DividendsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsAxis", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Dividends [Axis]", "documentation": "Information by distribution of earnings to shareholder. Includes, but is not limited to, distribution paid and declared." } } }, "auth_ref": [] }, "ug_DividendsDeclared": { "xbrltype": "monetaryItemType", "nsuri": "http://u-g.com/20241231", "localname": "DividendsDeclared", "crdr": "credit", "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "ug_DividendsDeclared", "negatedLabel": "Dividends declared", "documentation": "The value of dividends declared." } } }, "auth_ref": [] }, "us-gaap_DividendsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsDomain", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Dividends [Domain]", "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock." } } }, "auth_ref": [] }, "us-gaap_DividendsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableCurrent", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Dividends payable", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r42" ] }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_DividendsPayableCurrentAndNoncurrent", "terseLabel": "Dividends payable", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding." } } }, "auth_ref": [ "r42", "r45", "r91", "r679", "r860" ] }, "us-gaap_DividendsPayableDateOfRecordDayMonthAndYear": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableDateOfRecordDayMonthAndYear", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DividendsPayableDateOfRecordDayMonthAndYear", "terseLabel": "Dividends Payable, Date of Record", "documentation": "Date the holder must own the stock to be entitled to the dividend, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_DocumentAnnualReport", "terseLabel": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r685", "r686", "r698" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_DocumentFinStmtErrorCorrectionFlag", "terseLabel": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r685", "r686", "r698", "r700" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_DocumentPeriodEndDate", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_DocumentTransitionReport", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r699" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_DocumentType", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-income" ], "lang": { "en-us": { "role": { "label": "Earnings per common share (basic and diluted) (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r135", "r147", "r148", "r149", "r150", "r151", "r152", "r157", "r158", "r160", "r161", "r162", "r164", "r357", "r360", "r373", "r374", "r466", "r485", "r617" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r16", "r17", "r163" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "totalLabel": "Provision for income taxes, tax rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r329", "r642" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "terseLabel": "Income taxes at statutory federal income tax rate, tax rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r141", "r329", "r348", "r642" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments", "terseLabel": "Other, net, tax rate", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r642", "r742", "r832", "r833" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "terseLabel": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r331", "r642", "r742", "r832" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "negatedTerseLabel": "Research & development credits, tax rate", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r642", "r742", "r832", "r834" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressAddressLine1", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressCityOrTown", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressPostalZipCode", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressStateOrProvince", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r683" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityCommonStockSharesOutstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityCurrentReportingStatus", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets", "http://u-g.com/20241231/role/statement-balance-sheets-parentheticals", "http://u-g.com/20241231/role/statement-document-and-entity-information", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables", "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents", "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details", "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-tables", "http://u-g.com/20241231/role/statement-note-c-marketable-securities", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-details-textual", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-tables", "http://u-g.com/20241231/role/statement-note-d-inventories", "http://u-g.com/20241231/role/statement-note-d-inventories-details-textual", "http://u-g.com/20241231/role/statement-note-d-inventories-summary-of-inventories-details", "http://u-g.com/20241231/role/statement-note-d-inventories-tables", "http://u-g.com/20241231/role/statement-note-e-income-taxes", "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details", "http://u-g.com/20241231/role/statement-note-e-income-taxes-provision-for-income-taxes-details", "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details", "http://u-g.com/20241231/role/statement-note-e-income-taxes-tables", "http://u-g.com/20241231/role/statement-note-f-benefit-plans", "http://u-g.com/20241231/role/statement-note-f-benefit-plans-details-textual", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-details-textual", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-geographic-information-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-net-sales-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-tables", "http://u-g.com/20241231/role/statement-note-h-accrued-expenses", "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details", "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-tables", "http://u-g.com/20241231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities", "http://u-g.com/20241231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities-details-textual", "http://u-g.com/20241231/role/statement-note-j-related-party-transactions", "http://u-g.com/20241231/role/statement-note-j-related-party-transactions-details-textual", "http://u-g.com/20241231/role/statement-note-k-subsequent-events", "http://u-g.com/20241231/role/statement-note-k-subsequent-events-details-textual", "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies", "http://u-g.com/20241231/role/statement-statements-of-cash-flows", "http://u-g.com/20241231/role/statement-statements-of-income" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r683" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityFileNumber", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r683" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityInteractiveDataCurrent", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r715" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityPublicFloat", "terseLabel": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityRegistrantName", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r683" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityShellCompany", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r683" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r683" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r683" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityVoluntaryFilers", "terseLabel": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityWellKnownSeasonedIssuer", "terseLabel": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r716" ] }, "ug_EquityAndOtherMutualFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "EquityAndOtherMutualFundsMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-c-marketable-securities", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "lang": { "en-us": { "role": { "label": "Equity And Other Mutual Funds [Member]", "documentation": "Equity And Other Mutual Funds Member" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r115", "r132", "r133", "r134", "r142", "r143", "r144", "r146", "r151", "r153", "r155", "r166", "r234", "r235", "r267", "r284", "r346", "r347", "r354", "r355", "r356", "r358", "r359", "r360", "r365", "r366", "r367", "r368", "r369", "r370", "r372", "r381", "r382", "r383", "r384", "r385", "r386", "r388", "r389", "r391", "r483", "r497", "r498", "r499", "r511", "r568" ] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details": { "parentTag": "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIFairValue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "lang": { "en-us": { "role": { "label": "Equity securities, fair value", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r124", "r379", "r609" ] }, "us-gaap_EquitySecuritiesFvNiCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiCost", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details": { "parentTag": "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNICost", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "lang": { "en-us": { "role": { "label": "Equity securities, cost", "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r469" ] }, "ug_EquitySecuritiesFvniAccumulatedUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://u-g.com/20241231", "localname": "EquitySecuritiesFvniAccumulatedUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details": { "parentTag": "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIUnrealizedGainLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "lang": { "en-us": { "role": { "label": "ug_EquitySecuritiesFvniAccumulatedUnrealizedGainLoss", "negatedLabel": "Equity securities, unrealized gain", "documentation": "Accumulated amount of unrealized gain (loss) on equity securities." } } }, "auth_ref": [] }, "ug_FactoryEquipmentAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "FactoryEquipmentAndFixturesMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Factory Equipment And Fixtures [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r7" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://u-g.com/20241231/role/statement-note-c-marketable-securities", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r241", "r242", "r246", "r247", "r252", "r260", "r261", "r262", "r282", "r283", "r371", "r376", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r484", "r632", "r643", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r654", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r756", "r757", "r758", "r759", "r841", "r842", "r843", "r844", "r845", "r846" ] }, "us-gaap_FixturesAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FixturesAndEquipmentGross", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Factory equipment and fixtures", "documentation": "Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines." } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_GainLossOnDispositionOfAssets1", "negatedLabel": "Gain on sale of asset", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r739" ] }, "us-gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnInvestments", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-income": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-income" ], "lang": { "en-us": { "role": { "label": "Net gain on marketable securities", "documentation": "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": [ "r65", "r68", "r717" ] }, "us-gaap_GainLossOnInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnInvestmentsTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-c-marketable-securities-tables" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Securities [Table Text Block]", "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security." } } }, "auth_ref": [ "r736", "r737" ] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeographicConcentrationRiskMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Geographic Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": [ "r19", "r591" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_IcfrAuditorAttestationFlag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r685", "r686", "r698" ] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse", "terseLabel": "Impairment, Long-Lived Asset, Held-for-Use", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r4", "r30", "r85", "r644" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r86" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-income": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-income" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Income before provision for income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r59", "r94", "r99", "r467", "r481", "r619", "r625", "r747", "r749", "r750", "r751", "r752" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r141", "r322", "r329", "r332", "r333", "r334", "r337", "r341", "r349", "r351", "r352", "r353", "r507", "r642" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-income": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 }, "http://u-g.com/20241231/role/statement-note-e-income-taxes-provision-for-income-taxes-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-provision-for-income-taxes-details", "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details", "http://u-g.com/20241231/role/statement-statements-of-income" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxExpenseBenefit", "terseLabel": "Provision for income taxes", "totalLabel": "Total provision for income taxes", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r101", "r113", "r154", "r155", "r165", "r175", "r190", "r328", "r329", "r350", "r487", "r642" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r131", "r324", "r325", "r337", "r338", "r340", "r344", "r505" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "terseLabel": "Income taxes at statutory federal income tax rate", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r329", "r642" ] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxReconciliationOtherAdjustments", "terseLabel": "Other, net", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r642", "r832", "r833" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes", "terseLabel": "State taxes, net of federal benefit", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r331", "r642", "r832" ] }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationTaxCreditsResearch", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxReconciliationTaxCreditsResearch", "negatedTerseLabel": "Research & development credits", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r642", "r832", "r834" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Taxes paid", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r14", "r138", "r342", "r343" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities", "terseLabel": "Accrued expenses", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability", "terseLabel": "Deferred revenue", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r433", "r738" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "(Increase) decrease in operating assets:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract", "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in operating liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInPrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidTaxes", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidTaxes", "negatedLabel": "Prepaid income taxes", "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods." } } }, "auth_ref": [ "r3" ] }, "ug_IndustrialAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "IndustrialAndOtherMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-net-sales-details" ], "lang": { "en-us": { "role": { "label": "Industrial And Other [Member]" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "auth_ref": [ "r701" ] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-d-inventories" ], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r263" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-d-inventories-summary-of-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-d-inventories-summary-of-inventories-details" ], "lang": { "en-us": { "role": { "label": "Finished products", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r83", "r612" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://u-g.com/20241231/role/statement-note-d-inventories-summary-of-inventories-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets", "http://u-g.com/20241231/role/statement-note-d-inventories-summary-of-inventories-details" ], "lang": { "en-us": { "role": { "label": "Inventories, net", "totalLabel": "Total Inventories", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r127", "r608", "r653" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r103", "r119", "r126", "r263", "r264", "r266", "r434", "r615" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-d-inventories-summary-of-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-d-inventories-summary-of-inventories-details" ], "lang": { "en-us": { "role": { "label": "Raw materials", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r83", "r614" ] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryValuationReserves", "crdr": "credit", "presentation": [ "http://u-g.com/20241231/role/statement-note-d-inventories-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_InventoryValuationReserves", "terseLabel": "Inventory Valuation Reserves", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": [ "r83", "r734" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-d-inventories-summary-of-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-d-inventories-summary-of-inventories-details" ], "lang": { "en-us": { "role": { "label": "Work in process", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r83", "r613" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_InventoryWriteDown", "terseLabel": "Allowance for obsolete inventory", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r265" ] }, "us-gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNet", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-income": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-income" ], "lang": { "en-us": { "role": { "label": "Investment income", "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r63", "r64", "r67" ] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-c-marketable-securities" ], "lang": { "en-us": { "role": { "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r96", "r114", "r201", "r202", "r377", "r378", "r858" ] }, "ug_LUBRAJELAndRENACIDINIRRIGATIONMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "LUBRAJELAndRENACIDINIRRIGATIONMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "LUBRAJEL and RENACIDIN IRRIGATION [Member]", "documentation": "Refers to the products LUBREJEL and RENACIDIN IRRIGATION." } } }, "auth_ref": [] }, "us-gaap_Land": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Land", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Land", "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale." } } }, "auth_ref": [ "r732" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets", "http://u-g.com/20241231/role/statement-balance-sheets-parentheticals", "http://u-g.com/20241231/role/statement-document-and-entity-information", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables", "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents", "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details", "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-tables", "http://u-g.com/20241231/role/statement-note-c-marketable-securities", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-details-textual", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-tables", "http://u-g.com/20241231/role/statement-note-d-inventories", "http://u-g.com/20241231/role/statement-note-d-inventories-details-textual", "http://u-g.com/20241231/role/statement-note-d-inventories-summary-of-inventories-details", "http://u-g.com/20241231/role/statement-note-d-inventories-tables", "http://u-g.com/20241231/role/statement-note-e-income-taxes", "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details", "http://u-g.com/20241231/role/statement-note-e-income-taxes-provision-for-income-taxes-details", "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details", "http://u-g.com/20241231/role/statement-note-e-income-taxes-tables", "http://u-g.com/20241231/role/statement-note-f-benefit-plans", "http://u-g.com/20241231/role/statement-note-f-benefit-plans-details-textual", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-details-textual", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-geographic-information-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-net-sales-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-tables", "http://u-g.com/20241231/role/statement-note-h-accrued-expenses", "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details", "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-tables", "http://u-g.com/20241231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities", "http://u-g.com/20241231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities-details-textual", "http://u-g.com/20241231/role/statement-note-j-related-party-transactions", "http://u-g.com/20241231/role/statement-note-j-related-party-transactions-details-textual", "http://u-g.com/20241231/role/statement-note-k-subsequent-events", "http://u-g.com/20241231/role/statement-note-k-subsequent-events-details-textual", "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies", "http://u-g.com/20241231/role/statement-statements-of-cash-flows", "http://u-g.com/20241231/role/statement-statements-of-income" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r10", "r41", "r42", "r43", "r44", "r45", "r46", "r49", "r140", "r233", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r362", "r363", "r364", "r380", "r525", "r618", "r681", "r767", "r849", "r850" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r54", "r93", "r476", "r653", "r740", "r760", "r847" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r43", "r118", "r140", "r233", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r362", "r363", "r364", "r380", "r653", "r767", "r849", "r850" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_LocalPhoneNumber", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ug_LubrajelMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "LubrajelMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Lubrajel [Member]" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r198", "r637", "r664", "r668", "r770", "r862", "r865", "r866", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892" ] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_MarketableSecuritiesCurrent", "terseLabel": "Marketable securities", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r733" ] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesPolicy", "presentation": [ "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Marketable Securities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [ "r37" ] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-c-marketable-securities-tables" ], "lang": { "en-us": { "role": { "label": "Marketable Securities [Table Text Block]", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r269", "r270", "r271", "r272", "r310", "r319", "r375", "r432", "r495", "r496", "r502", "r517", "r518", "r575", "r577", "r579", "r580", "r582", "r601", "r602", "r631", "r634", "r639", "r646", "r647", "r651", "r652", "r665", "r769", "r851", "r852", "r853", "r854", "r855", "r856" ] }, "ug_MedicalLubricantsMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "MedicalLubricantsMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-net-sales-details" ], "lang": { "en-us": { "role": { "label": "Medical Lubricants [Member]", "documentation": "Represents medical lubricants." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r269", "r270", "r271", "r272", "r310", "r319", "r375", "r432", "r495", "r496", "r502", "r517", "r518", "r575", "r577", "r579", "r580", "r582", "r601", "r602", "r631", "r634", "r639", "r646", "r647", "r651", "r665", "r769", "r851", "r852", "r853", "r854", "r855", "r856" ] }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsAtCarryingValue", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details": { "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details" ], "lang": { "en-us": { "role": { "label": "Money market funds", "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r702" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": [ "r198", "r637", "r664", "r668", "r770", "r862", "r865", "r866", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash used in financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r137" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash (used in) provided by investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r137" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r74", "r75", "r76" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 }, "http://u-g.com/20241231/role/statement-statements-of-income": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows", "http://u-g.com/20241231/role/statement-statements-of-income", "http://u-g.com/20241231/role/statement-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Net income", "totalLabel": "Net income", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r62", "r76", "r95", "r116", "r129", "r130", "r134", "r140", "r145", "r147", "r148", "r149", "r150", "r151", "r154", "r155", "r159", "r233", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r357", "r360", "r374", "r380", "r482", "r548", "r566", "r567", "r680", "r767" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r702" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r702" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonUsMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-geographic-information-details" ], "lang": { "en-us": { "role": { "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r897", "r898", "r899", "r900" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash items:" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-income": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-income" ], "lang": { "en-us": { "role": { "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other income", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r66" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-income" ], "lang": { "en-us": { "role": { "label": "Other income:" } } }, "auth_ref": [] }, "ug_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "ug_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "ug_NumberOfCustomers": { "xbrltype": "integerItemType", "nsuri": "http://u-g.com/20241231", "localname": "NumberOfCustomers", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "ug_NumberOfCustomers", "terseLabel": "Number of Customers", "documentation": "The number of customers affecting an entity's concentration risk." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r626", "r748" ] }, "ug_NumberOfVendors": { "xbrltype": "integerItemType", "nsuri": "http://u-g.com/20241231", "localname": "NumberOfVendors", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "ug_NumberOfVendors", "terseLabel": "Number of Vendors", "documentation": "The number of vendors affecting an entity's concentration risk." } } }, "auth_ref": [] }, "ug_O2023Q3DividendsMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "O2023Q3DividendsMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "O 2023 Q3 Dividends [Member]", "documentation": "Represents the ordinary dividends for Q3 of 2023." } } }, "auth_ref": [] }, "ug_O2024Q1DividendsMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "O2024Q1DividendsMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "O 2024 Q1 Dividends [Member]", "documentation": "Represents the ordinary dividends for Q1 of 2024." } } }, "auth_ref": [] }, "ug_O2024Q3DividendsMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "O2024Q3DividendsMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "O 2024 Q3 Dividends [Member]", "documentation": "Represents the ordinary dividends for Q3 of 2024." } } }, "auth_ref": [] }, "ug_O2025Q1DividendsMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "O2025Q1DividendsMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "O2025Q1 Dividends [Member]", "documentation": "Represents 2025 Q1 dividends." } } }, "auth_ref": [] }, "us-gaap_OperatingCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingCostsAndExpenses", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-income": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-income" ], "lang": { "en-us": { "role": { "label": "Operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense." } } }, "auth_ref": [] }, "us-gaap_OperatingCostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingCostsAndExpensesAbstract", "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-income" ], "lang": { "en-us": { "role": { "label": "Costs and expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-income": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-income" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Income from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r99", "r619", "r747", "r749", "r750", "r751", "r752" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": [ "r39", "r77", "r78", "r88" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherAccruedLiabilitiesCurrent", "terseLabel": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r42" ] }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-h-accrued-expenses" ], "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for other liabilities." } } }, "auth_ref": [ "r42", "r45", "r763" ] }, "ug_OtherShorttermInvestmentsAtCost": { "xbrltype": "monetaryItemType", "nsuri": "http://u-g.com/20241231", "localname": "OtherShorttermInvestmentsAtCost", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details": { "parentTag": "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNICost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "lang": { "en-us": { "role": { "label": "Other Short-term Investments, cost", "documentation": "Represents the amount of other short-term investments at cost." } } }, "auth_ref": [] }, "ug_OtherShorttermInvestmentsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://u-g.com/20241231", "localname": "OtherShorttermInvestmentsFairValue", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details": { "parentTag": "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIFairValue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "lang": { "en-us": { "role": { "label": "Other Short-term Investments, fair value", "documentation": "Represents the fair value of other short-term investments." } } }, "auth_ref": [] }, "ug_PaymentsForAccruedDividendsOnUnconvertedShares": { "xbrltype": "monetaryItemType", "nsuri": "http://u-g.com/20241231", "localname": "PaymentsForAccruedDividendsOnUnconvertedShares", "crdr": "credit", "presentation": [ "http://u-g.com/20241231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities-details-textual" ], "lang": { "en-us": { "role": { "label": "ug_PaymentsForAccruedDividendsOnUnconvertedShares", "terseLabel": "Payments for Accrued Dividends on Unconverted Shares", "documentation": "The amount of cash outflow for payments for accrued dividends on unconverted shares." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfDividends", "negatedLabel": "Dividends paid", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": [ "r73" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfDividendsCommonStock", "terseLabel": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r73" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireMarketableSecurities", "negatedLabel": "Purchases of marketable securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r755" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Acquisitions of property, plant and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r72" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-f-benefit-plans" ], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r290", "r294", "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r638" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "terseLabel": "Company 401(k) contribution", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current." } } }, "auth_ref": [ "r42", "r291", "r292", "r293", "r638" ] }, "ug_PersonalCareMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "PersonalCareMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Personal Care [Member]", "documentation": "The products for personal care." } } }, "auth_ref": [] }, "ug_PharmaceuticalsMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "PharmaceuticalsMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-net-sales-details" ], "lang": { "en-us": { "role": { "label": "Pharmaceuticals [Member]" } } }, "auth_ref": [] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyTextBlockAbstract", "presentation": [ "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r735" ] }, "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidTaxes", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Prepaid income taxes", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r610", "r633", "r761" ] }, "ug_PreviousPresidentAndCeoMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "PreviousPresidentAndCeoMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-j-related-party-transactions", "http://u-g.com/20241231/role/statement-note-j-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Previous President and CEO [Member]", "documentation": "Represents previous President and CEO." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-c-marketable-securities-details-textual", "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sales of marketable securities", "terseLabel": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of asset", "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r71" ] }, "us-gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductConcentrationRiskMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth_ref": [ "r80" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-net-sales-details" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r194", "r435", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r605", "r635", "r663", "r665", "r666", "r669", "r670", "r765", "r766", "r770", "r862", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-net-sales-details" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r194", "r435", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r605", "r635", "r663", "r665", "r666", "r669", "r670", "r765", "r766", "r770", "r862", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Property, plant, and equipment:" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r5", "r390" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_PropertyPlantAndEquipmentGross", "totalLabel": "Total property, plant and equipment", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r84", "r121", "r480" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_PropertyPlantAndEquipmentNet", "totalLabel": "Total property, plant, and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r390", "r468", "r480", "r653" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r5", "r108", "r111", "r478" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r84", "r390" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProvisionForDoubtfulAccounts", "terseLabel": "Allowance for credit losses", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r136", "r244" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r269", "r270", "r271", "r272", "r294", "r310", "r316", "r317", "r318", "r319", "r375", "r407", "r416", "r432", "r495", "r496", "r502", "r517", "r518", "r575", "r577", "r579", "r580", "r582", "r601", "r602", "r631", "r634", "r639", "r646", "r647", "r651", "r652", "r665", "r673", "r764", "r769", "r843", "r852", "r853", "r854", "r855", "r856" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r269", "r270", "r271", "r272", "r294", "r310", "r316", "r317", "r318", "r319", "r375", "r407", "r416", "r432", "r495", "r496", "r502", "r517", "r518", "r575", "r577", "r579", "r580", "r582", "r601", "r602", "r631", "r634", "r639", "r646", "r647", "r651", "r652", "r665", "r673", "r764", "r769", "r843", "r852", "r853", "r854", "r855", "r856" ] }, "us-gaap_RealizedInvestmentGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealizedInvestmentGainsLosses", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_RealizedInvestmentGainsLosses", "negatedLabel": "Net gain on marketable securities", "documentation": "Amount of realized gain (loss) on investment." } } }, "auth_ref": [ "r486" ] }, "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-tables" ], "lang": { "en-us": { "role": { "label": "Segment, Reconciliation of Other Items from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of reconciliation of other items from reportable segments to their consolidated amount. Excludes reconciliation of revenue, profit (loss), and assets." } } }, "auth_ref": [ "r27", "r28" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://u-g.com/20241231/role/statement-note-j-related-party-transactions", "http://u-g.com/20241231/role/statement-note-j-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r199", "r298", "r395", "r396", "r471", "r477", "r520", "r521", "r522", "r523", "r524", "r545", "r547", "r574" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://u-g.com/20241231/role/statement-note-j-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_RelatedPartyTransactionAmountsOfTransaction", "terseLabel": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r36", "r395" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://u-g.com/20241231/role/statement-note-j-related-party-transactions", "http://u-g.com/20241231/role/statement-note-j-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r395", "r396", "r848" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://u-g.com/20241231/role/statement-note-j-related-party-transactions", "http://u-g.com/20241231/role/statement-note-j-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://u-g.com/20241231/role/statement-note-j-related-party-transactions", "http://u-g.com/20241231/role/statement-note-j-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r199", "r298", "r395", "r396", "r471", "r477", "r520", "r521", "r522", "r523", "r524", "r545", "r547", "r574", "r848" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-j-related-party-transactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r392", "r393", "r394", "r396", "r397", "r508", "r509", "r510", "r551", "r552", "r553", "r572", "r573" ] }, "ug_RenacidinMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "RenacidinMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Renacidin [Member]", "documentation": "Represents the product line, Renacidin." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-income": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-income" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r321", "r603", "r625", "r857" ] }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Research, Development, and Computer Software, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination." } } }, "auth_ref": [ "r762", "r831", "r901" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents", "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r120" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Retained earnings", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r51", "r87", "r475", "r500", "r501", "r506", "r528", "r653" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r115", "r142", "r143", "r144", "r146", "r151", "r153", "r155", "r234", "r235", "r267", "r346", "r347", "r354", "r355", "r356", "r358", "r359", "r360", "r365", "r367", "r368", "r370", "r372", "r388", "r389", "r497", "r499", "r511", "r895" ] }, "us-gaap_RetirementPlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanNameAxis", "presentation": [ "http://u-g.com/20241231/role/statement-note-f-benefit-plans", "http://u-g.com/20241231/role/statement-note-f-benefit-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Retirement Plan Name [Axis]", "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r639", "r720", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830" ] }, "us-gaap_RetirementPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanNameDomain", "presentation": [ "http://u-g.com/20241231/role/statement-note-f-benefit-plans", "http://u-g.com/20241231/role/statement-note-f-benefit-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Retirement Plan Name [Domain]", "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r639", "r720", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-statements-of-income": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-geographic-information-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-net-sales-details", "http://u-g.com/20241231/role/statement-statements-of-income" ], "lang": { "en-us": { "role": { "label": "Net Sales", "terseLabel": "Net sales", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r97", "r98", "r165", "r172", "r173", "r186", "r190", "r194", "r196", "r198", "r287", "r288", "r435" ] }, "ug_RevenueFromContractWithCustomerIncludingAssessedTaxGross": { "xbrltype": "monetaryItemType", "nsuri": "http://u-g.com/20241231", "localname": "RevenueFromContractWithCustomerIncludingAssessedTaxGross", "crdr": "credit", "presentation": [ "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-net-sales-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details" ], "lang": { "en-us": { "role": { "label": "Gross Sales", "documentation": "Gross Amount before sales allowance and return, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r81" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r549", "r604", "r616" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r702" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r702" ] }, "ug_SalesReturnsAndAllowances": { "xbrltype": "monetaryItemType", "nsuri": "http://u-g.com/20241231", "localname": "SalesReturnsAndAllowances", "crdr": "debit", "presentation": [ "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-net-sales-details" ], "lang": { "en-us": { "role": { "label": "ug_SalesReturnsAndAllowances", "negatedLabel": "Less: Discounts and allowances", "documentation": "Total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions) and price reductions (allowance, price protection agreements) given by the entity. Returns and allowances are a deduction from gross revenue in arriving at net revenue." } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r198", "r721" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]" } } }, "auth_ref": [ "r315", "r745" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20241231/role/statement-note-f-benefit-plans", "http://u-g.com/20241231/role/statement-note-f-benefit-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r156", "r315", "r718", "r745" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r837" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r835" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-e-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r330", "r642", "r832" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-d-inventories-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r11", "r55", "r56", "r57" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r29", "r58" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r24", "r25", "r26" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r682" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r684" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-geographic-information-details" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [ "r196", "r197", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r514", "r515", "r516", "r576", "r578", "r581", "r589", "r590", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r606", "r636", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r667", "r673", "r770", "r862", "r865", "r866", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892" ] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r100", "r165", "r167", "r168", "r169", "r170", "r171", "r176", "r177", "r178", "r188", "r189", "r190", "r191", "r192", "r194", "r195", "r198", "r620", "r623", "r624", "r625", "r627", "r629", "r630" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r193", "r196", "r621", "r622", "r628" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharesOutstanding", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r50", "r52", "r53", "r115", "r132", "r133", "r134", "r142", "r143", "r144", "r146", "r151", "r153", "r155", "r166", "r234", "r235", "r267", "r284", "r346", "r347", "r354", "r355", "r356", "r358", "r359", "r360", "r365", "r366", "r367", "r368", "r369", "r370", "r372", "r381", "r382", "r383", "r384", "r385", "r386", "r388", "r389", "r391", "r483", "r497", "r498", "r499", "r511", "r568" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-geographic-information-details" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r196", "r197", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r514", "r515", "r516", "r576", "r578", "r581", "r589", "r590", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r606", "r636", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r667", "r673", "r770", "r862", "r865", "r866", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets", "http://u-g.com/20241231/role/statement-balance-sheets-parentheticals", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables", "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents", "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details", "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-tables", "http://u-g.com/20241231/role/statement-note-c-marketable-securities", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-details-textual", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-tables", "http://u-g.com/20241231/role/statement-note-d-inventories", "http://u-g.com/20241231/role/statement-note-d-inventories-details-textual", "http://u-g.com/20241231/role/statement-note-d-inventories-summary-of-inventories-details", "http://u-g.com/20241231/role/statement-note-d-inventories-tables", "http://u-g.com/20241231/role/statement-note-e-income-taxes", "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details", "http://u-g.com/20241231/role/statement-note-e-income-taxes-provision-for-income-taxes-details", "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details", "http://u-g.com/20241231/role/statement-note-e-income-taxes-tables", "http://u-g.com/20241231/role/statement-note-f-benefit-plans", "http://u-g.com/20241231/role/statement-note-f-benefit-plans-details-textual", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-details-textual", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-geographic-information-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-net-sales-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-tables", "http://u-g.com/20241231/role/statement-note-h-accrued-expenses", "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details", "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-tables", "http://u-g.com/20241231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities", "http://u-g.com/20241231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities-details-textual", "http://u-g.com/20241231/role/statement-note-j-related-party-transactions", "http://u-g.com/20241231/role/statement-note-j-related-party-transactions-details-textual", "http://u-g.com/20241231/role/statement-note-k-subsequent-events", "http://u-g.com/20241231/role/statement-note-k-subsequent-events-details-textual", "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies", "http://u-g.com/20241231/role/statement-statements-of-cash-flows", "http://u-g.com/20241231/role/statement-statements-of-income", "http://u-g.com/20241231/role/statement-statements-of-stockholders-equity", "http://u-g.com/20241231/role/statement-statements-of-stockholders-equity-parentheticals" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r142", "r143", "r144", "r166", "r389", "r435", "r504", "r513", "r519", "r520", "r521", "r522", "r523", "r524", "r527", "r530", "r531", "r532", "r533", "r534", "r536", "r537", "r538", "r539", "r541", "r542", "r543", "r544", "r545", "r547", "r549", "r550", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r568", "r674" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20241231/role/statement-note-f-benefit-plans", "http://u-g.com/20241231/role/statement-note-f-benefit-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r156", "r315", "r718", "r719", "r745" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets", "http://u-g.com/20241231/role/statement-balance-sheets-parentheticals", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables", "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents", "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details", "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-tables", "http://u-g.com/20241231/role/statement-note-c-marketable-securities", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-details-textual", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-tables", "http://u-g.com/20241231/role/statement-note-d-inventories", "http://u-g.com/20241231/role/statement-note-d-inventories-details-textual", "http://u-g.com/20241231/role/statement-note-d-inventories-summary-of-inventories-details", "http://u-g.com/20241231/role/statement-note-d-inventories-tables", "http://u-g.com/20241231/role/statement-note-e-income-taxes", "http://u-g.com/20241231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details", "http://u-g.com/20241231/role/statement-note-e-income-taxes-provision-for-income-taxes-details", "http://u-g.com/20241231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details", "http://u-g.com/20241231/role/statement-note-e-income-taxes-tables", "http://u-g.com/20241231/role/statement-note-f-benefit-plans", "http://u-g.com/20241231/role/statement-note-f-benefit-plans-details-textual", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-details-textual", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-geographic-information-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-net-sales-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-tables", "http://u-g.com/20241231/role/statement-note-h-accrued-expenses", "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details", "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-tables", "http://u-g.com/20241231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities", "http://u-g.com/20241231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities-details-textual", "http://u-g.com/20241231/role/statement-note-j-related-party-transactions", "http://u-g.com/20241231/role/statement-note-j-related-party-transactions-details-textual", "http://u-g.com/20241231/role/statement-note-k-subsequent-events", "http://u-g.com/20241231/role/statement-note-k-subsequent-events-details-textual", "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies", "http://u-g.com/20241231/role/statement-statements-of-cash-flows", "http://u-g.com/20241231/role/statement-statements-of-income", "http://u-g.com/20241231/role/statement-statements-of-stockholders-equity", "http://u-g.com/20241231/role/statement-statements-of-stockholders-equity-parentheticals" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r142", "r143", "r144", "r166", "r199", "r389", "r435", "r504", "r513", "r519", "r520", "r521", "r522", "r523", "r524", "r527", "r530", "r531", "r532", "r533", "r534", "r536", "r537", "r538", "r539", "r541", "r542", "r543", "r544", "r545", "r547", "r549", "r550", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r568", "r674" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://u-g.com/20241231/role/statement-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets", "http://u-g.com/20241231/role/statement-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r50", "r52", "r53", "r82", "r529", "r546", "r569", "r570", "r653", "r681", "r740", "r760", "r847", "r895" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://u-g.com/20241231/role/statement-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityPolicyTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income." } } }, "auth_ref": [ "r6", "r571" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-k-subsequent-events", "http://u-g.com/20241231/role/statement-note-k-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r387", "r399" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://u-g.com/20241231/role/statement-note-k-subsequent-events", "http://u-g.com/20241231/role/statement-note-k-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r387", "r399" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://u-g.com/20241231/role/statement-note-k-subsequent-events", "http://u-g.com/20241231/role/statement-note-k-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r387", "r399" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-k-subsequent-events" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r398", "r400" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information" } } }, "auth_ref": [] }, "us-gaap_SupplierConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierConcentrationRiskMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Supplier Concentration Risk [Member]", "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services." } } }, "auth_ref": [ "r79" ] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables", "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-tables", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-tables", "http://u-g.com/20241231/role/statement-note-d-inventories-tables", "http://u-g.com/20241231/role/statement-note-e-income-taxes-tables", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-tables", "http://u-g.com/20241231/role/statement-note-h-accrued-expenses-tables" ], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "ug_ThreeRawMaterialVendorsMember": { "xbrltype": "domainItemType", "nsuri": "http://u-g.com/20241231", "localname": "ThreeRawMaterialVendorsMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Three Raw Material Vendors [Member]", "documentation": "Represents the three raw material vendors." } } }, "auth_ref": [] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r703" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://u-g.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://u-g.com/20241231/role/statement-note-c-marketable-securities", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r282", "r283", "r371", "r376", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r484", "r643", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r654", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r756", "r757", "r758", "r759", "r841", "r842", "r843", "r844", "r845", "r846" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20241231/role/statement-note-g-geographic-and-other-information-geographic-information-details" ], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_USGovernmentSecuritiesAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentSecuritiesAtCarryingValue", "crdr": "debit", "calculation": { "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details": { "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://u-g.com/20241231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details" ], "lang": { "en-us": { "role": { "label": "U.S. Treasury Bills (original 3-month maturity)", "documentation": "Debt (bills, notes or bonds) that are issued by the government of the United States which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "us-gaap_USTreasuryBillSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasuryBillSecuritiesMember", "presentation": [ "http://u-g.com/20241231/role/statement-note-c-marketable-securities", "http://u-g.com/20241231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "lang": { "en-us": { "role": { "label": "US Treasury Bill Securities [Member]", "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government." } } }, "auth_ref": [ "r859" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefits", "terseLabel": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r323", "r336", "r641" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://u-g.com/20241231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r335", "r641" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://u-g.com/20241231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r21", "r22", "r23", "r105", "r106", "r109", "r110" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://u-g.com/20241231/role/statement-statements-of-income" ], "lang": { "en-us": { "role": { "label": "Weighted average shares (basic and diluted) (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r157", "r162" ] }, "ug_statement-statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "statement-statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "lang": { "en-us": { "role": { "label": "Note A - Nature of Business and Summary of Significant Accounting Policies - Disaggregated Revenue (Details)" } } }, "auth_ref": [] }, "ug_statement-statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "statement-statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "lang": { "en-us": { "role": { "label": "Note A - Nature of Business and Summary of Significant Accounting Policies - Revenue by Geographic Region (Details)" } } }, "auth_ref": [] }, "ug_statement-statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "statement-statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables", "lang": { "en-us": { "role": { "label": "Note A - Nature of Business and Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "ug_statement-statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "statement-statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details", "lang": { "en-us": { "role": { "label": "Note B - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)" } } }, "auth_ref": [] }, "ug_statement-statement-note-b-cash-and-cash-equivalents-tables": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "statement-statement-note-b-cash-and-cash-equivalents-tables", "lang": { "en-us": { "role": { "label": "Note B - Cash and Cash Equivalents" } } }, "auth_ref": [] }, "ug_statement-statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "statement-statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details", "lang": { "en-us": { "role": { "label": "Note C - Marketable Securities - Net Gains and Losses on Marketable Securities (Details)" } } }, "auth_ref": [] }, "ug_statement-statement-note-c-marketable-securities-summary-of-investments-details": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "statement-statement-note-c-marketable-securities-summary-of-investments-details", "lang": { "en-us": { "role": { "label": "Note C - Marketable Securities - Summary of Investments (Details)" } } }, "auth_ref": [] }, "ug_statement-statement-note-c-marketable-securities-tables": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "statement-statement-note-c-marketable-securities-tables", "lang": { "en-us": { "role": { "label": "Note C - Marketable Securities" } } }, "auth_ref": [] }, "ug_statement-statement-note-d-inventories-summary-of-inventories-details": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "statement-statement-note-d-inventories-summary-of-inventories-details", "lang": { "en-us": { "role": { "label": "Note D - Inventories - Summary of Inventories (Details)" } } }, "auth_ref": [] }, "ug_statement-statement-note-d-inventories-tables": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "statement-statement-note-d-inventories-tables", "lang": { "en-us": { "role": { "label": "Note D - Inventories" } } }, "auth_ref": [] }, "ug_statement-statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "statement-statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details", "lang": { "en-us": { "role": { "label": "Note E - Income Taxes - Deferred Tax Assets and Liabilities (Details)" } } }, "auth_ref": [] }, "ug_statement-statement-note-e-income-taxes-provision-for-income-taxes-details": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "statement-statement-note-e-income-taxes-provision-for-income-taxes-details", "lang": { "en-us": { "role": { "label": "Note E - Income Taxes - Provision for Income Taxes (Details)" } } }, "auth_ref": [] }, "ug_statement-statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "statement-statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details", "lang": { "en-us": { "role": { "label": "Note E - Income Taxes - Reconciliation of the Effective Income Tax Rate (Details)" } } }, "auth_ref": [] }, "ug_statement-statement-note-e-income-taxes-tables": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "statement-statement-note-e-income-taxes-tables", "lang": { "en-us": { "role": { "label": "Note E - Income Taxes" } } }, "auth_ref": [] }, "ug_statement-statement-note-g-geographic-and-other-information-geographic-information-details": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "statement-statement-note-g-geographic-and-other-information-geographic-information-details", "lang": { "en-us": { "role": { "label": "Note G - Geographic and Other Information - Geographic Information (Details)" } } }, "auth_ref": [] }, "ug_statement-statement-note-g-geographic-and-other-information-net-sales-details": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "statement-statement-note-g-geographic-and-other-information-net-sales-details", "lang": { "en-us": { "role": { "label": "Note G - Geographic and Other Information - Net Sales (Details)" } } }, "auth_ref": [] }, "ug_statement-statement-note-g-geographic-and-other-information-sales-to-major-customers-details": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "statement-statement-note-g-geographic-and-other-information-sales-to-major-customers-details", "lang": { "en-us": { "role": { "label": "Note G - Geographic and Other Information - Sales to Major Customers (Details)" } } }, "auth_ref": [] }, "ug_statement-statement-note-g-geographic-and-other-information-tables": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "statement-statement-note-g-geographic-and-other-information-tables", "lang": { "en-us": { "role": { "label": "Note G - Geographic and Other Information" } } }, "auth_ref": [] }, "ug_statement-statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "statement-statement-note-h-accrued-expenses-summary-of-accrued-expenses-details", "lang": { "en-us": { "role": { "label": "Note H - Accrued Expenses - Summary of Accrued Expenses (Details)" } } }, "auth_ref": [] }, "ug_statement-statement-note-h-accrued-expenses-tables": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "statement-statement-note-h-accrued-expenses-tables", "lang": { "en-us": { "role": { "label": "Note H - Accrued Expenses" } } }, "auth_ref": [] }, "ug_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://u-g.com/20241231", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/230/tableOfContent" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-4A" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-5A" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479366/326-20-35-8A" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-5" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-17" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-21" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3C" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.M.2.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483530/326-20-S99-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479175/326-30-30-1B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "13A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-13A" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-7A" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3C" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3D" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column C)(Footnote 6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column D)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column D)(Footnote 6)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478790/946-405-45-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r717": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r718": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r719": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-40/tableOfContent" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405/tableOfContent" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/730/tableOfContent" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" } } } ZIP 70 0001171843-25-001611-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-25-001611-xbrl.zip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

HOO\^U\[-;W]":[(-6QO M"'=J/ %*$,Q-.\"[<^"]*?X## *NBG8YLS>Y)=-F@(%FWYP8=(GP/K"1$3

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ug20241231_10k_htm.xml IDEA: XBRL DOCUMENT 0000101295 2024-01-01 2024-12-31 0000101295 us-gaap:SubsequentEventMember 2025-01-27 2025-01-27 0000101295 ug:AccountingAndTaxServicesMember srt:DirectorMember 2023-01-01 2023-12-31 0000101295 ug:AccountingAndTaxServicesMember srt:DirectorMember 2024-01-01 2024-12-31 0000101295 ug:ConsultingServicesMember ug:PreviousPresidentAndCeoMember 2023-01-01 2023-12-31 0000101295 ug:ConsultingServicesMember ug:PreviousPresidentAndCeoMember 2024-01-01 2024-12-31 0000101295 2024-12-31 0000101295 2023-12-31 0000101295 2023-01-01 2023-12-31 0000101295 ug:AllOtherCustomersMember 2023-01-01 2023-12-31 0000101295 ug:AllOtherCustomersMember 2024-01-01 2024-12-31 0000101295 ug:CustomerDMember 2023-01-01 2023-12-31 0000101295 ug:CustomerDMember 2024-01-01 2024-12-31 0000101295 ug:CustomerCMember 2023-01-01 2023-12-31 0000101295 ug:CustomerCMember 2024-01-01 2024-12-31 0000101295 ug:CustomerBMember 2023-01-01 2023-12-31 0000101295 ug:CustomerBMember 2024-01-01 2024-12-31 0000101295 ug:CustomerAMember 2023-01-01 2023-12-31 0000101295 ug:CustomerAMember 2024-01-01 2024-12-31 0000101295 us-gaap:NonUsMember 2023-01-01 2023-12-31 0000101295 us-gaap:NonUsMember 2024-01-01 2024-12-31 0000101295 country:US 2023-01-01 2023-12-31 0000101295 country:US 2024-01-01 2024-12-31 0000101295 ug:IndustrialAndOtherMember 2023-01-01 2023-12-31 0000101295 ug:MedicalLubricantsMember 2023-01-01 2023-12-31 0000101295 ug:MedicalLubricantsMember 2024-01-01 2024-12-31 0000101295 ug:PharmaceuticalsMember 2023-01-01 2023-12-31 0000101295 ug:PharmaceuticalsMember 2024-01-01 2024-12-31 0000101295 ug:CosmeticIngredientsMember 2023-01-01 2023-12-31 0000101295 ug:CosmeticIngredientsMember 2024-01-01 2024-12-31 0000101295 ug:DiscretionaryContributionsVestingEachAdditionalYearMember ug:DCPlanMember 2024-01-01 2024-12-31 0000101295 ug:DiscretionaryContributionsVestingAtTwoYearsMember ug:DCPlanMember 2024-01-01 2024-12-31 0000101295 ug:DCPlanMember 2024-01-01 2024-12-31 0000101295 us-gaap:CertificatesOfDepositMember 2023-12-31 0000101295 ug:EquityAndOtherMutualFundsMember 2023-12-31 0000101295 us-gaap:USTreasuryBillSecuritiesMember 2024-12-31 0000101295 us-gaap:CertificatesOfDepositMember 2024-12-31 0000101295 ug:EquityAndOtherMutualFundsMember 2024-12-31 0000101295 us-gaap:DemandDepositsMember 2023-12-31 0000101295 us-gaap:DemandDepositsMember 2024-12-31 0000101295 ug:ThreeRawMaterialVendorsMember us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember 2023-01-01 2023-12-31 0000101295 ug:ThreeRawMaterialVendorsMember us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember 2024-01-01 2024-12-31 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000101295 ug:DistributorsAndMarketingPartnersMember 2023-01-01 2023-12-31 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000101295 ug:DistributorsAndMarketingPartnersMember 2024-01-01 2024-12-31 0000101295 us-gaap:BuildingImprovementsMember 2024-12-31 0000101295 us-gaap:BuildingMember 2024-12-31 0000101295 srt:MaximumMember ug:FactoryEquipmentAndFixturesMember 2024-12-31 0000101295 srt:MinimumMember ug:FactoryEquipmentAndFixturesMember 2024-12-31 0000101295 ug:O2023Q3DividendsMember 2023-09-30 0000101295 ug:O2023Q3DividendsMember 2023-07-01 2023-09-30 0000101295 ug:O2023Q3DividendsMember 2024-07-01 2024-09-30 0000101295 srt:ScenarioForecastMember ug:O2025Q1DividendsMember 2025-01-01 2025-03-31 0000101295 ug:O2024Q1DividendsMember 2024-03-31 0000101295 ug:O2024Q1DividendsMember 2024-01-01 2024-03-31 0000101295 ug:O2024Q3DividendsMember 2024-09-30 0000101295 ug:O2024Q3DividendsMember 2024-07-01 2024-09-30 0000101295 ug:ASIMember country:CN us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000101295 ug:ASIMember country:CN us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-12-31 0000101295 ug:ASIMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000101295 ug:ASIMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-12-31 0000101295 ug:PersonalCareMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000101295 ug:PersonalCareMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-12-31 0000101295 ug:AccruedExpensesMember 2023-12-31 0000101295 ug:AccruedExpensesMember 2024-12-31 0000101295 ug:RenacidinMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-12-31 0000101295 ug:RenacidinMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-12-31 0000101295 ug:LubrajelMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-12-31 0000101295 ug:LubrajelMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-12-31 0000101295 ug:LUBRAJELAndRENACIDINIRRIGATIONMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-12-31 0000101295 ug:LUBRAJELAndRENACIDINIRRIGATIONMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-12-31 0000101295 2022-12-31 0000101295 us-gaap:RetainedEarningsMember 2024-12-31 0000101295 us-gaap:CommonStockMember 2024-12-31 0000101295 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0000101295 us-gaap:RetainedEarningsMember 2023-12-31 0000101295 us-gaap:CommonStockMember 2023-12-31 0000101295 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000101295 us-gaap:RetainedEarningsMember 2022-12-31 0000101295 us-gaap:CommonStockMember 2022-12-31 0000101295 2025-03-01 0000101295 2024-06-30 thunderdome:item iso4217:USD shares iso4217:USD shares pure utr:Y FY 2024 --12-31 false 0000101295 1 P6Y P2Y 0 0 0 0 0 0 0 0 0 3 3 4 4 0 0 0 0.1 0.1 false false false false true true false true true true 10-K true 2024-12-31 false 1-10526 UNITED-GUARDIAN, INC DE 11-1719724 230 Marcus Blvd. Hauppauge NY 11788 631 273-0900 Common Stock, $0.10 par value UG NASDAQ No No Yes Yes true false Non-accelerated Filer false false false 41073211 4594319 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 1C.</b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Cybersecurity.<a href="#" id="i1c" title="i1c"></a> </b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We continue to augment the capabilities of our people, processes, and technologies to address our cybersecurity risks. Our cybersecurity risks, and the controls designed to mitigate those risks, are integrated into our overall risk management governance and are reviewed yearly by our Board of Directors.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We take steps to protect our data and <span style="-sec-ix-hidden:c36">third-party data</span> we receive through the implementation of technological and organizational measures designed to reduce the risk from cybersecurity threats, including data theft or destruction.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We have undertaken a program of annual enterprise-wide cybersecurity risk assessments and have implemented policies, procedures, and programs designed to help manage the risks to which we are exposed in our business. As part of our risk management process, we have implemented a risk-based approach to identify and assess the cybersecurity threats that could affect our business and information systems, as well as the systems of third parties on whom we rely, such as any cloud hosting partners. Our cybersecurity program is designed to assess, identify, and manage material risks and vulnerabilities to our security posture, including prioritizing and remediating cybersecurity risks.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Our program includes, among other things:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">• Incorporation of cybersecurity in our overall enterprise risk management processes, including periodic risk assessments and tools used to track and monitor risks.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">• Regular reviews of cybersecurity risks and mitigation efforts.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">• Use of software and hardware tools and services to help safeguard our systems, information, and data.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">• Assessments designed to help identify cybersecurity risks to our critical systems, information, products, services, and our broader enterprise IT environment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">• An employee information security training program to educate employees on various cybersecurity risks and mitigation strategies.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">• Policies and processes governing our third-party security risks.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risk Management and Strategy</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We have implemented a set of comprehensive cybersecurity and data protection policies and procedures. Risks from cybersecurity threats are regularly evaluated as a part of our broader risk management activities and as a fundamental component of our internal control system. Our employees receive ongoing cybersecurity awareness training, including specific topics related to social engineering and email fraud. We utilize an outsourced information technology firm and consultants with significant expertise in cybersecurity. We invest in advanced technologies for continuous cybersecurity monitoring across our information technology environment which are designed to prevent, detect, and minimize cybersecurity attacks, as well as alert management of such attacks.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Our Information Technology General Controls are firmly established based on the National Institute of Standards and Technology (“NIST”) cybersecurity framework and cover areas such as risk management, data backup, and disaster recovery. We have utilized an outsourced information technology consultant to reduce and monitor security threats and vulnerabilities.  As part of our gap analysis, identified vulnerabilities have been, and will continue to be, promptly addressed with our senior business leadership and our Board of Directors. </p> We continue to augment the capabilities of our people, processes, and technologies to address our cybersecurity risks. Our cybersecurity risks, and the controls designed to mitigate those risks, are integrated into our overall risk management governance and are reviewed yearly by our Board of Directors. We have undertaken a program of annual enterprise-wide cybersecurity risk assessments and have implemented policies, procedures, and programs designed to help manage the risks to which we are exposed in our business. As part of our risk management process, we have implemented a risk-based approach to identify and assess the cybersecurity threats that could affect our business and information systems, as well as the systems of third parties on whom we rely, such as any cloud hosting partners. Our cybersecurity program is designed to assess, identify, and manage material risks and vulnerabilities to our security posture, including prioritizing and remediating cybersecurity risks. Our Board of Directors is responsible for overseeing our cybersecurity risk management and strategy. Our President regularly meets with and provides periodic briefings to our Board of Directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like. Our Board of Directors is responsible for overseeing our cybersecurity risk management and strategy. Our President regularly meets with and provides periodic briefings to our Board of Directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like. Our Board of Directors is responsible for overseeing our cybersecurity risk management and strategy. Our President regularly meets with and provides periodic briefings to our Board of Directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like. Our Board of Directors is responsible for overseeing our cybersecurity risk management and strategy. Our President regularly meets with and provides periodic briefings to our Board of Directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like. Our Board of Directors is responsible for overseeing our cybersecurity risk management and strategy. Our President regularly meets with and provides periodic briefings to our Board of Directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like. Our Board of Directors is responsible for overseeing our cybersecurity risk management and strategy. Our President regularly meets with and provides periodic briefings to our Board of Directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like. <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 9B.</b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Other Information.<a href="#" id="i9b" title="i9b"></a></b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="-sec-ix-hidden:c53"><span style="-sec-ix-hidden:c54"><span style="-sec-ix-hidden:c55"><span style="-sec-ix-hidden:c56">None.</span></span></span></span></p> 606 GRASSI & CO., CPAs, P.C. Jericho, New York 12181971 10885154 5721584 5479566 2356819 2078564 456779 463992 8535182 8022122 3646789 2863032 434679 306651 26989 81095 461668 387746 4108457 3250778 857582 669408 3250875 2581370 0.71 0.56 4594319 4594319 1875655 8243122 7522625 851318 14342 16672 1428455 1566839 1451995 1223506 207804 191708 179017 176220 12665551 12252713 175397 50930 69000 69000 4743238 4669936 3336352 2976577 8148590 7715513 7192203 7096318 956387 619195 13797335 12922838 425003 134449 1467933 1363044 15498 21533 21265 1914469 1534256 1914469 1534256 10000000 10000000 4594319 4594319 4594319 4594319 459432 459432 11423434 10929150 11882866 11388582 13797335 12922838 4594319 459432 8807212 9266644 2581370 2581370 0.1 45 45 0.1 459387 459387 4594319 459432 10929150 11388582 3250875 3250875 0.6 268 268 0.6 2756323 2756323 4594319 459432 11423434 11882866 3250875 2581370 95885 105682 10000 26989 81095 -2330 -3391 -14208 -17000 -124467 59614 -140714 135872 214281 -465506 16096 -10138 2797 -9008 290554 104034 104889 40988 -15498 15498 3466251 3144480 433077 165716 10000 8459318 621852 1815000 5505145 -7077395 4727577 2756323 459387 -2756323 -459387 -6367467 7412670 8243122 830452 1875655 8243122 1050795 600000 268 45 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE A - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT </b><b>ACCOUNTING POLICIES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Nature of Business</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">United-Guardian, Inc. (“Registrant” or “Company”) is a Delaware corporation that, through its Guardian Laboratories division, manufactures, markets and develops specialty cosmetic ingredients, pharmaceutical products, medical lubricants and sexual wellness ingredients. Prior to July 1, 2023, the Company manufactured and reported sales of a line of specialty industrial products; however, this product line was discontinued after the second quarter of 2023 due to low sales volume with no growth prospects. The Company also conducts research and product development, primarily related to the development of new and unique cosmetic ingredients. The Company’s research and development department also modifies, refines, and expands the uses for existing products, with the goal of further developing the market for the Company's products. Two major product lines, Lubrajel and Renacidin<sup style="vertical-align:top;line-height:120%;"> </sup>Irrigation Solution (“Renacidin”) together accounted for approximately 93% and 92% of the Company’s sales for the years ended December 31, 2024 and December 31, 2023, respectively. Lubrajel accounted for approximately 60% and 54% of the Company’s sales for the years ended December 31, 2024 and December 31, 2023, respectively, and Renacidin accounted for approximately 33% and 38% of the Company’s sales for the years ended December 31, 2024 and December 31, 2023, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Segment Information</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company operates its business under one operating segment, which is also its reportable segment. The Company's chief operating decision maker (“CODM”), who is the President, reviews financial information presented at the consolidated level and decides how to allocate resources based on financial metrics, including net income. The measure of segment assets is reported on the balance sheet as total consolidated assets. The CODM, along with the Board Of Directors, use such financial metrics, including net income, to evaluate income generated from segment assets (return on assets) in deciding whether to reinvest profits or allocate to other parts of the organization, such as working capital needs, mandatory and discretionary capital expenditures or other growth opportunities that may arise that are in the Company’s best interest and the best interest of the stockholders.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Net income, other financial metrics and sales forecasts are used to monitor budget versus actual results. The reported segment revenue, segment profit or loss and significant segment expenses are the same as the consolidated results disclosed on the consolidated statements of income.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Impact of Global Supply Chain Instability, Inflation and Tariffs</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The continued supply chain instability, primarily caused by military tensions in the Middle East, continues to impact vessels’ access to the Red Sea and Suez Canal. Shipping experts say this crisis may last into the first half of 2025. The Company continues to work with its suppliers regarding lead times and is closely monitoring this situation. Although the Company has not yet experienced any delays in receiving raw materials or an increase in shipping costs, the Company is aware that the situation is fluid and could impact it at any time. If that occurs, the Company may experience longer lead times and increased shipping costs for some of its raw materials, which may impact future gross margins. As a result of this global supply chain instability, there continues to be uncertainty regarding the potential impact on the Company’s operations or financial results and its unable to provide an accurate estimate or projection as to what the future impact will be.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Trump administration has communicated its intention to impose tariffs on many products imported from China, Canada and Mexico. Some of those tariffs went into effect on March 4, 2025. Since that time the Trump administration has increased some of those tariffs and postponed others. It has threatened to levy tariffs on additional countries, including those of the European Union. Many of the countries on which those tariffs have been levied have imposed their own retaliatory tariffs or threated to impose tariffs on goods they import from the U.S. The tariff situation remains fluid and is subject to modification at any time. At this time, it is difficult for the Company to determine the impact of these tariffs on its business. The Company will continue to monitor this situation closely.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">While the Company obtains most of its raw materials and lab supplies from domestic sources, it has three suppliers that obtain their raw materials from China. These materials are not purchased by the Company in large quantities, and it has adequate stock on hand to cover the next six months. In addition, the Company has one direct raw material supplier in China; however, the raw materials purchased from this supplier are not in large quantities and the effect of this tariff would not materially impact the pricing of its products.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Many of the Company’s products are used in the formulation of finished products that are manufactured in China and then imported back into the United States (“U.S.”) for sale. There is the possibility that the tariffs levied on these finished products could result in an increase in their price, which could potentially impact demand for these products in the U.S.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Due to the continued uncertainty of this, any other tariffs that may be imposed, there continues to be uncertainty regarding the future impact of any additional tariffs on the Company’s operations or financial results.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Use of Estimates</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In preparing financial statements in conformity with a Generally Accepted Accounting Principles in the United States of America (“US GAAP”), management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the allowance for credit losses, reserve for inventory obsolescence, accrued distribution fees, outdated material returns, possible impairment of marketable securities and the allocation of overhead.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Accounts Receivable and Reserves</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In accordance with FASB ASC Topic 326, “<i>Financial Instruments </i>–<i> Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>”<i>,</i> (“ASC 326”), the Company presents financial assets at the net amount expected to be collected, requiring immediate recognition of estimated credit losses expected to occur over the asset’s remaining life. This is in contrast to previous U.S. GAAP, under which credit losses were not recognized until it was probable that a loss had been incurred. The Company performed its expected credit loss calculation based on historical accounts receivable write-offs, including consideration of then-existing economic conditions and expected future conditions. The adoption of this ASU did not have a significant impact on the financial statements. Prior to the implementation of ASU No. 2016-13, the Company calculated its reserve for accounts receivable by considering many factors including historical data, experience, customer types, credit worthiness and economic trends.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The carrying amount of accounts receivable is reduced by an allowance for credit losses that reflects the Company’s best estimate of the amounts that will not be collected as of the balance sheet date. This allowance is based on the credit losses expected to arise over the life of the asset and is based on the Current Expected Credit Losses (“CECL”). At December 31, 2024 and 2023, the allowance for credit losses related to accounts receivable amounted to $14,342 and $16,672, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Revenue Recognition</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company records revenue in accordance with ASC Topic 606 “Revenue from Contracts with Customers.” Under this guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company’s principal source of revenue is product sales.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s sales, as reported, are subject to a variety of deductions, some of which are estimated. These deductions are recorded in the same period in which the revenue is recognized. Such deductions, primarily related to the sale of the Company’s pharmaceutical products, include chargebacks from the United States Department of Veterans Affairs (“VA”), rebates in connection with the Company’s current participation in Medicare programs, distribution fees, discounts, and outdated product returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on sales for a reporting period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">During 2024 and 2023, the Company participated in various government drug rebate programs related to the sale of Renacidin, its most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (“FSS”), and the Medicare Part D Coverage Gap Discount Program (“CGDP”). These programs require the Company to sell its product at a discounted price. The Company’s sales, as reported, are net of these rebates, some of which are estimated and are recorded in the same period that the revenue is recognized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On January 1, 2025, the Centers for Medicare &amp; Medicaid Services (“CMS”) implemented a new Medicare Part D Manufacturer Discount Program (“Discount Program”), which replaced the prior CGDP. The new Discount Program eliminates the coverage gap benefit phase, introduces pharmaceutical manufacturer discounts in the initial and catastrophic coverage phases, and lowers the cap on enrollee out-of-pocket costs. Under the new Discount Program, additional rebates are expected to be owed by pharmaceutical manufacturers due to the restructuring of the benefit periods and removal of the cap that was in place that limited the drug manufacturer’s liability. The overall financial impact of this new program will vary depending on the products being reimbursed but is expected to increase Medicare Part D rebates for drug manufacturers. On January 31, 2024, the Company was notified by CMS that it qualified as a “specified small manufacturer” and would be entitled to a multi-year phase-in period during which it would pay a lower percentage discount on drugs dispensed to beneficiaries. Based on the “specified small manufacturer” designation, it appears, that based on our current level of sales through the Medicare Part D Program, the Company would have reduced rebate liabilities in years 2025 and 2026, with rebates gradually increasing each year until they reach their full value in 2031. By the end of the phase in period in 2031, these rebate liabilities are expected to significantly exceed the liabilities we have recorded under the CGDP in previous years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As long as a valid purchase order has been received and future collection of the sale amount is reasonably assured, the Company recognizes revenue from sales of its products when those products are shipped, which is when the Company’s performance obligation is satisfied. The Company’s cosmetic products are shipped EXW from the Company’s facility in Hauppauge, NY, and the risk of loss and responsibility for the shipment passes to the customer upon shipment. Sales of the Company’s non-pharmaceutical medical products are deemed final upon shipment, and there is no obligation on the part of the Company to repurchase or allow the return of these goods unless they are defective. Sales of the Company’s pharmaceutical products are final upon shipment unless (a) they are found to be defective; (b) the product is damaged in shipping; (c) the product cannot be sold because it is too close to its expiration date; or (d) the product has expired (but it is not more than one year after the expiration date). This return policy conforms to standard pharmaceutical industry practice. The Company estimates an allowance for outdated material returns based on previous years’ historical returns of its pharmaceutical products.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company does not make sales on consignment, and the collection of the proceeds of the sale of any of the Company’s products is not contingent upon the customer being able to sell the goods to a third party.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience under ASC Topic 606-10-32-8. At December 31, 2024 and 2023, the Company had an allowance of $276,732 and $247,847, respectively, for possible outdated material returns, which is included in accrued expenses. There is no asset value associated with these outdated material returns, as these products are destroyed.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The timing between recognition of revenue for product sales and the receipt of payment is not significant. The Company’s standard credit terms, which vary depending on the customer, range between 30 and 60 days. The Company recognizes an allowance for credit losses on its accounts receivable in accordance with ASU 2016-13, which is based on the credit losses expected to arise over the life of the asset and is based on Current Expected Credit Loss (“CECL”). Prompt-pay discounts are offered to some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded when they are taken.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">At December 31, 2023, the Company recorded advance payments from two of its customers in the amount of $15,498, which was recorded as deferred revenue on the balance sheet. The related performance obligations associated with these payments were satisfied in the first quarter of 2024. <span style="-sec-ix-hidden:c283">No</span> such advanced payments existed at December 31, 2024.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has distribution agreements with certain distributors of its pharmaceutical products that entitle those distributors to distribution and services-related fees. The Company records distribution fees, and estimates of distribution fees, as offsets to revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Disaggregated net sales by product class are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Years ended December 31,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2024</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0pt; text-align: center;">2023</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cosmetic ingredients</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,438,262</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,132,334</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Pharmaceuticals</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,715,145</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,950,594</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Medical lubricants</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,028,564</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,750,632</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Industrial and other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">51,594</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total Net Sales</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">12,181,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">10,885,154</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s cosmetic ingredients are currently marketed worldwide by five distributors, of which the United States (“U.S.”)-based ASI purchases the largest volume. For the years ended December 31, 2024 and 2023, approximately 16% and 21%, respectively, of the Company’s sales were to (a) its foreign-based distributors (which does not include ASI), which marketed and distributed the Company’s cosmetic ingredients to customers outside the U.S, and (b) a few foreign customers for the Company’s medical lubricants, which were sold directly to those customers by the Company.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Disaggregated sales by geographic region are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 15%; width: 70%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td colspan="8" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Years ended December 31,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">United States*</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,175,926</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,601,205</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other countries</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,006,045</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,283,949</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net Sales</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">12,181,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">10,885,154</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 28pt;text-indent:-28pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">* Although a significant percentage of ASI’s purchases from the Company are sold to foreign customers, all sales to ASI are considered U.S. sales for financial reporting purposes, since all shipments to ASI are shipped to ASI’s warehouses in the U.S. A certain percentage of those products are subsequently shipped by ASI to its foreign customers. Based on sales information provided to the Company by ASI, 79% of ASI’s sales in 2024 were to customers in foreign countries, compared with 69% in 2023. ASI’s largest foreign market in both 2024 and 2023 was China, which accounted for approximately 43% of ASI’s sales in 2024 and 29% of sales in 2023.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Cash and Cash Equivalents</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of three months or less at the time of purchase. The Company deposits cash and cash equivalents with financially strong, FDIC-insured financial institutions, and it believes that any amounts above FDIC insurance limitations are at minimal risk. The amounts held in excess of FDIC limits at any point in time are considered temporary and are primarily due to the timing of maturities of United States Treasury Bills and Certificates of Deposit. Cash and cash equivalents held in these accounts are currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to a maximum of $250,000. At December 31, 2024 and 2023, approximately $234,000 and $311,000 respectively, exceeded the FDIC limit. The Company also invests in certain money market mutual funds that are protected as securities by the Securities Investor Protection Corporation (“SIPC”). At December 31, 2024, cash held in these money market mutual funds of approximately $563,000 exceeded the SIPC limit. At December 31, 2023, cash held in these money market mutual funds was below the SIPC limit.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Dividends</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On July 10, 2024, the Company’s Board of Directors declared a cash dividend of $0.35 per share, which was paid on July 31, 2024, to all holders of record as of July 23, 2024. Dividends totaling $1,607,855 were paid and the balance of $156 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment. On January 30, 2024, the Company’s Board of Directors declared a cash dividend of $0.25 per share, which was paid on February 20, 2024, to all holders of record as of February 12, 2024. Dividends totaling $1,148,468 were paid. The balance of $112 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment. On January 27, 2025, the Company’s Board of Directors declared a cash dividend of $.0.35 per share, which was paid on February 18, 2025, to all stockholders of record as of February 10, 2025.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On July 12, 2023, the Company’s Board of Directors declared a cash dividend of $0.10 per share, which was paid on August 2, 2023, to all stockholders of record as of July 26, 2023. The Company did not declare any other dividends in 2023. During 2023, the Company declared total dividends of $459,432, of which $459,387 was paid. The balance of $45 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment. In June of 2023, the Company’s Board of Directors changed the Company’s dividend declaration practice and expects to consider a semi-annual dividend declaration in January and July of each year.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Marketable Securities </span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s marketable securities include investments in equity mutual funds, United States Treasury Bills (“U.S. Treasury Bills”) and Certificates of Deposit with maturities longer than 3 months. The Company’s marketable equity securities are reported at fair value with the related unrealized and realized gains and losses included in net income. U.S Treasury Bills and Certificates of Deposit are recorded at amortized cost. Realized gains or losses on mutual funds are determined on a specific identification basis. The Company evaluates its investments periodically for possible other-than-temporary impairment by reviewing factors such as the length of time and extent to which fair value had been below cost basis, the financial condition of the issuer and the Company’s ability and intent to hold the investment for a period of time which may be sufficient for anticipated recovery of market value. The Company would record an impairment charge to the extent that the cost of the available-for-sale securities exceeds the estimated fair value of the securities and the decline in value is determined to be other-than-temporary. During 2024 and 2023, the Company did not record an impairment charge regarding its investment in marketable securities because management believes, based on its evaluation of the circumstances, that the decline in fair value below the cost of certain of the Company’s marketable securities is temporary.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Inventories</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Inventories are valued at the lower of cost and net realizable value. Net realizable value is equal to the selling price less the estimated costs of selling and/or disposing of the product. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out (“FIFO”) method. Inventory costs include material, labor and factory overhead.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Property, Plant and Equipment</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Property, plant and equipment are carried at cost, less accumulated depreciation. Major replacements and betterments are capitalized, while routine maintenance and repairs are expensed as incurred. Assets are depreciated under both accelerated and straight-line methods. Depreciation charged as a result of using accelerated methods was not materially different than that which would result from using the straight-line method for all periods presented. Certain factory equipment and fixtures are constructed by the Company using purchased materials and in-house labor. Such assets are capitalized and depreciated on a basis consistent with the Company's purchased fixed assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Estimated useful lives are as follows: </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 60%; margin-left: 20%; margin-right: 20%;"> <tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Factory equipment and fixtures  </p> </td> <td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">5 - 7 years  </p> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Building  </p> </td> <td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">40 years  </p> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Building improvements  </p> </td> <td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lesser of useful life or 20 years  </p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Impairment of Long-Lived Assets</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. <span style="-sec-ix-hidden:c332"><span style="-sec-ix-hidden:c333">No</span></span> impairments were necessary at December 31, 2024 and 2023.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Fair Value of Financial Instruments</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Management of the Company believes that the fair value of financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses, approximates their carrying value due to their short payment terms and liquid nature.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Concentration of Credit Risk</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Accounts receivable potentially expose the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history to determine how much credit to allow or whether credit should be given at all. It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable. As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its accounts receivable credit risk has been reduced.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the year ended December 31, 2024, <span style="-sec-ix-hidden:c334">four</span> of the Company’s pharmaceutical wholesalers and cosmetic ingredient distributors accounted for approximately 80% of the Company’s gross sales during the year and approximately 87% of its outstanding accounts receivable on December 31, 2024. For the year ended December 31, 2023, the same <span style="-sec-ix-hidden:c337">four</span> pharmaceutical wholesalers and cosmetic ingredient distributors accounted for a total of approximately 77% of the Company’s gross sales during the year and 89% of its outstanding accounts receivable on December 31, 2023.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Supplier Concentration </span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Most of the principal raw materials used by the Company consist of common industrial organic and inorganic chemicals and are available in ample supply from numerous sources. However, there are some raw materials used by the Company that are not readily available or require longer lead times. The Company has <span style="-sec-ix-hidden:c340"><span style="-sec-ix-hidden:c341">three</span></span> major raw material vendors that collectively accounted for approximately 83% and 76% of the raw material purchases by the Company in 2024 and 2023, respectively. In addition to the Company’s raw materials concentration, the Company utilizes one contract manufacturer for the production of its pharmaceutical product, Renacidin. Any disruption in this manufacturer’s operations could have a material impact on the Company’s revenue stream.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Income Taxes</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to the temporary differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Uncertain tax positions are accounted for utilizing a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As of December 31, 2024 and 2023, the Company did <span style="-sec-ix-hidden:c344"><span style="-sec-ix-hidden:c345">not</span></span> have any unrecognized income tax benefits. It is the Company’s policy to recognize interest and penalties related to taxes as interest expense as incurred. During the years ended December 31, 2024 and 2023, the Company did <span style="-sec-ix-hidden:c346"><span style="-sec-ix-hidden:c347">not</span></span> record any tax-related interest or penalties. The Company’s tax returns for 2021 and all subsequent years are subject to examination by the United States Internal Revenue Service (“IRS) and by the State of New York.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Research and Development </span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Research and development expenses are expenditures incurred in connection with in-house research on new and existing products. It includes payroll and payroll related expenses, outside laboratory expenditures, lab supplies, equipment repairs and maintenance and equipment depreciation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Advertising Expenses</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Advertising costs are expensed as incurred. The Company did <span style="-sec-ix-hidden:c348"><span style="-sec-ix-hidden:c349">not</span></span> incur any advertising costs for the years ended December 31, 2024 or 2023.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Earnings Per Share Information</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Basic earnings per share are computed by dividing net income by the weighted average number of common shares outstanding during the year. Diluted earnings per share would include the dilutive effect of outstanding stock options, if any.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">New Accounting Standards</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On November 4, 2024, the FASB issued ASU 2024-03 “<i>Disaggregation of Income Statement Expenses</i>”<i> </i>(“DISE”). This guidance requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. Subsequently issued ASU 2025-01, clarified the effective date of this standard. This guidance is effective for annual reporting periods beginning after December 15, 2026, and for interim periods, within annual reporting periods beginning after December 15, 2027.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In December 2023, the FASB issued ASU 2023-09 “<i>Income Taxes- Improvements to Income Tax Disclosures</i>”. This guidance enhances the transparency and decision usefulness of income tax disclosures. More specifically, the amendments relate to the income tax rate reconciliation and income taxes paid disclosures and require 1) consistent categories and greater disaggregation of information in the rate reconciliation and 2) income taxes paid disaggregated by jurisdiction. This guidance is effective for fiscal years beginning after December 31, 2024.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In November 2023, the FASB issued ASU 2023-07, <i>"Improvements to Reportable Segment Disclosures"</i>. This amendment requires additional disclosures by public entities, including those with a single reportable segment, to disclose significant segment expenses and other segment items for each reportable segment. The guidance applies to fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. On January 1, 2024, we adopted the new standard and applied the guidance under the new standard to include additional disclosures for our single reportable segment. See notes A and G for additional information.</p> 0.93 0.92 0.60 0.54 0.33 0.38 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Segment Information</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company operates its business under one operating segment, which is also its reportable segment. The Company's chief operating decision maker (“CODM”), who is the President, reviews financial information presented at the consolidated level and decides how to allocate resources based on financial metrics, including net income. The measure of segment assets is reported on the balance sheet as total consolidated assets. The CODM, along with the Board Of Directors, use such financial metrics, including net income, to evaluate income generated from segment assets (return on assets) in deciding whether to reinvest profits or allocate to other parts of the organization, such as working capital needs, mandatory and discretionary capital expenditures or other growth opportunities that may arise that are in the Company’s best interest and the best interest of the stockholders.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Net income, other financial metrics and sales forecasts are used to monitor budget versus actual results. The reported segment revenue, segment profit or loss and significant segment expenses are the same as the consolidated results disclosed on the consolidated statements of income.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Use of Estimates</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In preparing financial statements in conformity with a Generally Accepted Accounting Principles in the United States of America (“US GAAP”), management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the allowance for credit losses, reserve for inventory obsolescence, accrued distribution fees, outdated material returns, possible impairment of marketable securities and the allocation of overhead.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Accounts Receivable and Reserves</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In accordance with FASB ASC Topic 326, “<i>Financial Instruments </i>–<i> Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>”<i>,</i> (“ASC 326”), the Company presents financial assets at the net amount expected to be collected, requiring immediate recognition of estimated credit losses expected to occur over the asset’s remaining life. This is in contrast to previous U.S. GAAP, under which credit losses were not recognized until it was probable that a loss had been incurred. The Company performed its expected credit loss calculation based on historical accounts receivable write-offs, including consideration of then-existing economic conditions and expected future conditions. The adoption of this ASU did not have a significant impact on the financial statements. Prior to the implementation of ASU No. 2016-13, the Company calculated its reserve for accounts receivable by considering many factors including historical data, experience, customer types, credit worthiness and economic trends.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The carrying amount of accounts receivable is reduced by an allowance for credit losses that reflects the Company’s best estimate of the amounts that will not be collected as of the balance sheet date. This allowance is based on the credit losses expected to arise over the life of the asset and is based on the Current Expected Credit Losses (“CECL”). At December 31, 2024 and 2023, the allowance for credit losses related to accounts receivable amounted to $14,342 and $16,672, respectively.</p> 14342 16672 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Revenue Recognition</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company records revenue in accordance with ASC Topic 606 “Revenue from Contracts with Customers.” Under this guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company’s principal source of revenue is product sales.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s sales, as reported, are subject to a variety of deductions, some of which are estimated. These deductions are recorded in the same period in which the revenue is recognized. Such deductions, primarily related to the sale of the Company’s pharmaceutical products, include chargebacks from the United States Department of Veterans Affairs (“VA”), rebates in connection with the Company’s current participation in Medicare programs, distribution fees, discounts, and outdated product returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on sales for a reporting period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">During 2024 and 2023, the Company participated in various government drug rebate programs related to the sale of Renacidin, its most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (“FSS”), and the Medicare Part D Coverage Gap Discount Program (“CGDP”). These programs require the Company to sell its product at a discounted price. The Company’s sales, as reported, are net of these rebates, some of which are estimated and are recorded in the same period that the revenue is recognized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On January 1, 2025, the Centers for Medicare &amp; Medicaid Services (“CMS”) implemented a new Medicare Part D Manufacturer Discount Program (“Discount Program”), which replaced the prior CGDP. The new Discount Program eliminates the coverage gap benefit phase, introduces pharmaceutical manufacturer discounts in the initial and catastrophic coverage phases, and lowers the cap on enrollee out-of-pocket costs. Under the new Discount Program, additional rebates are expected to be owed by pharmaceutical manufacturers due to the restructuring of the benefit periods and removal of the cap that was in place that limited the drug manufacturer’s liability. The overall financial impact of this new program will vary depending on the products being reimbursed but is expected to increase Medicare Part D rebates for drug manufacturers. On January 31, 2024, the Company was notified by CMS that it qualified as a “specified small manufacturer” and would be entitled to a multi-year phase-in period during which it would pay a lower percentage discount on drugs dispensed to beneficiaries. Based on the “specified small manufacturer” designation, it appears, that based on our current level of sales through the Medicare Part D Program, the Company would have reduced rebate liabilities in years 2025 and 2026, with rebates gradually increasing each year until they reach their full value in 2031. By the end of the phase in period in 2031, these rebate liabilities are expected to significantly exceed the liabilities we have recorded under the CGDP in previous years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As long as a valid purchase order has been received and future collection of the sale amount is reasonably assured, the Company recognizes revenue from sales of its products when those products are shipped, which is when the Company’s performance obligation is satisfied. The Company’s cosmetic products are shipped EXW from the Company’s facility in Hauppauge, NY, and the risk of loss and responsibility for the shipment passes to the customer upon shipment. Sales of the Company’s non-pharmaceutical medical products are deemed final upon shipment, and there is no obligation on the part of the Company to repurchase or allow the return of these goods unless they are defective. Sales of the Company’s pharmaceutical products are final upon shipment unless (a) they are found to be defective; (b) the product is damaged in shipping; (c) the product cannot be sold because it is too close to its expiration date; or (d) the product has expired (but it is not more than one year after the expiration date). This return policy conforms to standard pharmaceutical industry practice. The Company estimates an allowance for outdated material returns based on previous years’ historical returns of its pharmaceutical products.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company does not make sales on consignment, and the collection of the proceeds of the sale of any of the Company’s products is not contingent upon the customer being able to sell the goods to a third party.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience under ASC Topic 606-10-32-8. At December 31, 2024 and 2023, the Company had an allowance of $276,732 and $247,847, respectively, for possible outdated material returns, which is included in accrued expenses. There is no asset value associated with these outdated material returns, as these products are destroyed.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The timing between recognition of revenue for product sales and the receipt of payment is not significant. The Company’s standard credit terms, which vary depending on the customer, range between 30 and 60 days. The Company recognizes an allowance for credit losses on its accounts receivable in accordance with ASU 2016-13, which is based on the credit losses expected to arise over the life of the asset and is based on Current Expected Credit Loss (“CECL”). Prompt-pay discounts are offered to some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded when they are taken.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">At December 31, 2023, the Company recorded advance payments from two of its customers in the amount of $15,498, which was recorded as deferred revenue on the balance sheet. The related performance obligations associated with these payments were satisfied in the first quarter of 2024. <span style="-sec-ix-hidden:c283">No</span> such advanced payments existed at December 31, 2024.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has distribution agreements with certain distributors of its pharmaceutical products that entitle those distributors to distribution and services-related fees. The Company records distribution fees, and estimates of distribution fees, as offsets to revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Disaggregated net sales by product class are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Years ended December 31,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2024</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0pt; text-align: center;">2023</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cosmetic ingredients</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,438,262</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,132,334</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Pharmaceuticals</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,715,145</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,950,594</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Medical lubricants</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,028,564</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,750,632</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Industrial and other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">51,594</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total Net Sales</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">12,181,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">10,885,154</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s cosmetic ingredients are currently marketed worldwide by five distributors, of which the United States (“U.S.”)-based ASI purchases the largest volume. For the years ended December 31, 2024 and 2023, approximately 16% and 21%, respectively, of the Company’s sales were to (a) its foreign-based distributors (which does not include ASI), which marketed and distributed the Company’s cosmetic ingredients to customers outside the U.S, and (b) a few foreign customers for the Company’s medical lubricants, which were sold directly to those customers by the Company.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Disaggregated sales by geographic region are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 15%; width: 70%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td colspan="8" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Years ended December 31,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">United States*</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,175,926</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,601,205</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other countries</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,006,045</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,283,949</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net Sales</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">12,181,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">10,885,154</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 28pt;text-indent:-28pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">* Although a significant percentage of ASI’s purchases from the Company are sold to foreign customers, all sales to ASI are considered U.S. sales for financial reporting purposes, since all shipments to ASI are shipped to ASI’s warehouses in the U.S. A certain percentage of those products are subsequently shipped by ASI to its foreign customers. Based on sales information provided to the Company by ASI, 79% of ASI’s sales in 2024 were to customers in foreign countries, compared with 69% in 2023. ASI’s largest foreign market in both 2024 and 2023 was China, which accounted for approximately 43% of ASI’s sales in 2024 and 29% of sales in 2023.</p> 276732 247847 15498 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Years ended December 31,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2024</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0pt; text-align: center;">2023</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cosmetic ingredients</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,438,262</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,132,334</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Pharmaceuticals</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,715,145</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,950,594</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Medical lubricants</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,028,564</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,750,632</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Industrial and other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">51,594</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total Net Sales</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">12,181,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">10,885,154</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> 5438262 4132334 4715145 4950594 2028564 1750632 51594 12181971 10885154 0.16 0.21 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 15%; width: 70%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td colspan="8" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Years ended December 31,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">United States*</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,175,926</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,601,205</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other countries</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,006,045</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,283,949</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net Sales</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">12,181,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">10,885,154</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> 10175926 8601205 2006045 2283949 12181971 10885154 0.79 0.69 0.43 0.29 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Cash and Cash Equivalents</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of three months or less at the time of purchase. The Company deposits cash and cash equivalents with financially strong, FDIC-insured financial institutions, and it believes that any amounts above FDIC insurance limitations are at minimal risk. The amounts held in excess of FDIC limits at any point in time are considered temporary and are primarily due to the timing of maturities of United States Treasury Bills and Certificates of Deposit. Cash and cash equivalents held in these accounts are currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to a maximum of $250,000. At December 31, 2024 and 2023, approximately $234,000 and $311,000 respectively, exceeded the FDIC limit. The Company also invests in certain money market mutual funds that are protected as securities by the Securities Investor Protection Corporation (“SIPC”). At December 31, 2024, cash held in these money market mutual funds of approximately $563,000 exceeded the SIPC limit. At December 31, 2023, cash held in these money market mutual funds was below the SIPC limit.</p> 234000 311000 563000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Dividends</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On July 10, 2024, the Company’s Board of Directors declared a cash dividend of $0.35 per share, which was paid on July 31, 2024, to all holders of record as of July 23, 2024. Dividends totaling $1,607,855 were paid and the balance of $156 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment. On January 30, 2024, the Company’s Board of Directors declared a cash dividend of $0.25 per share, which was paid on February 20, 2024, to all holders of record as of February 12, 2024. Dividends totaling $1,148,468 were paid. The balance of $112 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment. On January 27, 2025, the Company’s Board of Directors declared a cash dividend of $.0.35 per share, which was paid on February 18, 2025, to all stockholders of record as of February 10, 2025.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On July 12, 2023, the Company’s Board of Directors declared a cash dividend of $0.10 per share, which was paid on August 2, 2023, to all stockholders of record as of July 26, 2023. The Company did not declare any other dividends in 2023. During 2023, the Company declared total dividends of $459,432, of which $459,387 was paid. The balance of $45 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment. In June of 2023, the Company’s Board of Directors changed the Company’s dividend declaration practice and expects to consider a semi-annual dividend declaration in January and July of each year.</p> 0.35 2024-07-31 2024-07-23 1607855 156 0.25 2024-02-20 2024-02-12 1148468 112 0.35 2025-02-18 2025-02-10 0.1 2023-08-02 2023-07-26 459432 459387 45 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Marketable Securities </span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s marketable securities include investments in equity mutual funds, United States Treasury Bills (“U.S. Treasury Bills”) and Certificates of Deposit with maturities longer than 3 months. The Company’s marketable equity securities are reported at fair value with the related unrealized and realized gains and losses included in net income. U.S Treasury Bills and Certificates of Deposit are recorded at amortized cost. Realized gains or losses on mutual funds are determined on a specific identification basis. The Company evaluates its investments periodically for possible other-than-temporary impairment by reviewing factors such as the length of time and extent to which fair value had been below cost basis, the financial condition of the issuer and the Company’s ability and intent to hold the investment for a period of time which may be sufficient for anticipated recovery of market value. The Company would record an impairment charge to the extent that the cost of the available-for-sale securities exceeds the estimated fair value of the securities and the decline in value is determined to be other-than-temporary. During 2024 and 2023, the Company did not record an impairment charge regarding its investment in marketable securities because management believes, based on its evaluation of the circumstances, that the decline in fair value below the cost of certain of the Company’s marketable securities is temporary.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Inventories</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Inventories are valued at the lower of cost and net realizable value. Net realizable value is equal to the selling price less the estimated costs of selling and/or disposing of the product. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out (“FIFO”) method. Inventory costs include material, labor and factory overhead.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Property, Plant and Equipment</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Property, plant and equipment are carried at cost, less accumulated depreciation. Major replacements and betterments are capitalized, while routine maintenance and repairs are expensed as incurred. Assets are depreciated under both accelerated and straight-line methods. Depreciation charged as a result of using accelerated methods was not materially different than that which would result from using the straight-line method for all periods presented. Certain factory equipment and fixtures are constructed by the Company using purchased materials and in-house labor. Such assets are capitalized and depreciated on a basis consistent with the Company's purchased fixed assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Estimated useful lives are as follows: </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 60%; margin-left: 20%; margin-right: 20%;"> <tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Factory equipment and fixtures  </p> </td> <td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">5 - 7 years  </p> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Building  </p> </td> <td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">40 years  </p> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Building improvements  </p> </td> <td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lesser of useful life or 20 years  </p> </td> </tr> </tbody></table> P5Y P7Y P40Y P20Y <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Impairment of Long-Lived Assets</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. <span style="-sec-ix-hidden:c332"><span style="-sec-ix-hidden:c333">No</span></span> impairments were necessary at December 31, 2024 and 2023.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Fair Value of Financial Instruments</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Management of the Company believes that the fair value of financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses, approximates their carrying value due to their short payment terms and liquid nature.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Concentration of Credit Risk</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Accounts receivable potentially expose the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history to determine how much credit to allow or whether credit should be given at all. It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable. As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its accounts receivable credit risk has been reduced.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the year ended December 31, 2024, <span style="-sec-ix-hidden:c334">four</span> of the Company’s pharmaceutical wholesalers and cosmetic ingredient distributors accounted for approximately 80% of the Company’s gross sales during the year and approximately 87% of its outstanding accounts receivable on December 31, 2024. For the year ended December 31, 2023, the same <span style="-sec-ix-hidden:c337">four</span> pharmaceutical wholesalers and cosmetic ingredient distributors accounted for a total of approximately 77% of the Company’s gross sales during the year and 89% of its outstanding accounts receivable on December 31, 2023.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Supplier Concentration </span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Most of the principal raw materials used by the Company consist of common industrial organic and inorganic chemicals and are available in ample supply from numerous sources. However, there are some raw materials used by the Company that are not readily available or require longer lead times. The Company has <span style="-sec-ix-hidden:c340"><span style="-sec-ix-hidden:c341">three</span></span> major raw material vendors that collectively accounted for approximately 83% and 76% of the raw material purchases by the Company in 2024 and 2023, respectively. In addition to the Company’s raw materials concentration, the Company utilizes one contract manufacturer for the production of its pharmaceutical product, Renacidin. Any disruption in this manufacturer’s operations could have a material impact on the Company’s revenue stream.</p> 0.80 0.87 0.77 0.89 0.83 0.76 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Income Taxes</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to the temporary differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Uncertain tax positions are accounted for utilizing a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As of December 31, 2024 and 2023, the Company did <span style="-sec-ix-hidden:c344"><span style="-sec-ix-hidden:c345">not</span></span> have any unrecognized income tax benefits. It is the Company’s policy to recognize interest and penalties related to taxes as interest expense as incurred. During the years ended December 31, 2024 and 2023, the Company did <span style="-sec-ix-hidden:c346"><span style="-sec-ix-hidden:c347">not</span></span> record any tax-related interest or penalties. The Company’s tax returns for 2021 and all subsequent years are subject to examination by the United States Internal Revenue Service (“IRS) and by the State of New York.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Research and Development </span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Research and development expenses are expenditures incurred in connection with in-house research on new and existing products. It includes payroll and payroll related expenses, outside laboratory expenditures, lab supplies, equipment repairs and maintenance and equipment depreciation.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Advertising Expenses</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Advertising costs are expensed as incurred. The Company did <span style="-sec-ix-hidden:c348"><span style="-sec-ix-hidden:c349">not</span></span> incur any advertising costs for the years ended December 31, 2024 or 2023.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Earnings Per Share Information</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Basic earnings per share are computed by dividing net income by the weighted average number of common shares outstanding during the year. Diluted earnings per share would include the dilutive effect of outstanding stock options, if any.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">New Accounting Standards</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On November 4, 2024, the FASB issued ASU 2024-03 “<i>Disaggregation of Income Statement Expenses</i>”<i> </i>(“DISE”). This guidance requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. Subsequently issued ASU 2025-01, clarified the effective date of this standard. This guidance is effective for annual reporting periods beginning after December 15, 2026, and for interim periods, within annual reporting periods beginning after December 15, 2027.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In December 2023, the FASB issued ASU 2023-09 “<i>Income Taxes- Improvements to Income Tax Disclosures</i>”. This guidance enhances the transparency and decision usefulness of income tax disclosures. More specifically, the amendments relate to the income tax rate reconciliation and income taxes paid disclosures and require 1) consistent categories and greater disaggregation of information in the rate reconciliation and 2) income taxes paid disaggregated by jurisdiction. This guidance is effective for fiscal years beginning after December 31, 2024.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In November 2023, the FASB issued ASU 2023-07, <i>"Improvements to Reportable Segment Disclosures"</i>. This amendment requires additional disclosures by public entities, including those with a single reportable segment, to disclose significant segment expenses and other segment items for each reportable segment. The guidance applies to fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. On January 1, 2024, we adopted the new standard and applied the guidance under the new standard to include additional disclosures for our single reportable segment. See notes A and G for additional information.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE B </b>–<b> CASH AND CASH EQUIVALENTS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Cash and cash equivalents include currency on hand, demand deposits with banks or financial institutions, and short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. The following table summarizes the Company’s cash and cash equivalents:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 27pt;text-indent:-27pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 252pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">December 31,</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">2024</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">2023</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Demand Deposits</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">404,801</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">340,034</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Certificates of Deposit (original 3-month maturity)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">125,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,470,854</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,031,361</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. Treasury Bills (original 3-month maturity)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">6,746,727</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total cash and cash equivalents</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,875,655</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">8,243,122</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">  </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">December 31,</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">2024</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">2023</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Demand Deposits</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">404,801</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">340,034</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Certificates of Deposit (original 3-month maturity)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">125,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,470,854</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,031,361</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. Treasury Bills (original 3-month maturity)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">6,746,727</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total cash and cash equivalents</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,875,655</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">8,243,122</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> </tbody></table> 404801 340034 125000 1470854 1031361 6746727 1875655 8243122 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE C - MARKETABLE SECURITIES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Marketable securities include investments in equity mutual funds, which are reported at their fair values, and U.S. Treasury Bills and Certificates of Deposit with original maturities greater than 3 months, which are recorded at amortized cost.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The disaggregated net gains and losses on the marketable securities recognized in the income statement for the years ended December 31, 2024 and 2023 are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">Years ended December 31,</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">2024</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">2023</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net gains recognized during the year on marketable securities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">26,989</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">81,095</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Net losses realized during the year on marketable securities sold during the period</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">433,769</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><b>Net unrealized gains recognized during the reporting year on marketable securities still held at the reporting date</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">26,989</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">514,864</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The fair values of the Company’s marketable securities are determined in accordance with US GAAP, with fair value being defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes the three-tier value hierarchy, as prescribed by US GAAP, which prioritizes the inputs used in measuring fair value as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;">•    Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;">•    Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;">•    Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s marketable equity securities, which are considered available-for-sale securities, are re-measured to fair value on a recurring basis and are valued using Level 1 inputs using quoted prices (unadjusted) for identical assets in active markets. The following tables summarize the Company’s investments:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">December 31, 2024</span></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 27pt;text-indent:90pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><b><b>Cost</b></b></td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><b><b>Fair Value</b></b></td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><b>Unrealized Gain</b></td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Equity Securities:</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Equity and other mutual funds</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">634,705</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">663,682</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28,977</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Other short-term investments:</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fixed income Certificates of Deposit (original maturities &gt; 3 months)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">570,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">570,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">U.S. Treasury Bills (original maturities &gt; 3 months)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,288,943</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,288,943</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total other short-term investments</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,858,943</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,858,943</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total marketable securities</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">7,493,648</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">7,522,625</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">28,977</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">December 31, 2023</span></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 432pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><b><b>Cost</b></b></td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><b><b>Fair Value</b></b></td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><b><b>Unrealized Gain</b></b></td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Equity Securities:</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Equity and other mutual funds</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">574,330</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">576,318</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,988</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Other short-term investments:</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fixed income Certificates of Deposit (original maturities &gt; 3 months)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">275,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">275,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>Total marketable securities</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">849,330</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">851,318</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">1,988</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Investment income is recognized when earned and consists principally of dividend income from equity mutual funds and interest income on United States Treasury Bills, Certificates of Deposit and money market funds. Realized gains and losses on sales of investments are determined on a specific identification basis.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Proceeds from the sale and redemption of marketable securities amounted to $1,815,000 for the year ended December 31, 2024 and there were <span style="-sec-ix-hidden:c449">no</span> realized gains or losses. Proceeds from the sale and redemption of marketable securities for the year ended December 31, 2023, amounted to $5,505,145, which included realized losses of $433,769.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">Years ended December 31,</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">2024</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">2023</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net gains recognized during the year on marketable securities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">26,989</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">81,095</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Net losses realized during the year on marketable securities sold during the period</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">433,769</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><b>Net unrealized gains recognized during the reporting year on marketable securities still held at the reporting date</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">26,989</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">514,864</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> 26989 81095 -433769 26989 514864 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><b><b>Cost</b></b></td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><b><b>Fair Value</b></b></td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><b>Unrealized Gain</b></td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Equity Securities:</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Equity and other mutual funds</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">634,705</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">663,682</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28,977</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Other short-term investments:</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fixed income Certificates of Deposit (original maturities &gt; 3 months)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">570,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">570,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">U.S. Treasury Bills (original maturities &gt; 3 months)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,288,943</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,288,943</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total other short-term investments</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,858,943</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,858,943</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total marketable securities</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">7,493,648</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">7,522,625</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">28,977</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><b><b>Cost</b></b></td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><b><b>Fair Value</b></b></td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><b><b>Unrealized Gain</b></b></td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Equity Securities:</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Equity and other mutual funds</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">574,330</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">576,318</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,988</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Other short-term investments:</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fixed income Certificates of Deposit (original maturities &gt; 3 months)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">275,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">275,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>Total marketable securities</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">849,330</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">851,318</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">1,988</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> 634705 663682 -28977 570000 570000 6288943 6288943 6858943 6858943 7493648 7522625 28977 574330 576318 -1988 275000 275000 849330 851318 1988 1815000 5505145 -433769 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE D </b>–<b> INVENTORIES</b> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Inventories consist of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">December 31,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Raw materials</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">448,113</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">476,501</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Work in process</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">58,699</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">92,089</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished products</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">945,183</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">654,916</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><b>Total Inventories</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">1,451,995</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">1,223,506</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Inventories are valued at the lower of cost and net realizable value. Net realizable value is equal to the selling price less the estimated costs of selling and/or disposing of the product. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out method. Finished product inventories on December 31, 2024 and December 31, 2023 are net of a reserve of $32,792 and $47,000, respectively.</p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">December 31,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Raw materials</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">448,113</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">476,501</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Work in process</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">58,699</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">92,089</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished products</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">945,183</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">654,916</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><b>Total Inventories</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">1,451,995</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">1,223,506</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> 448113 476501 58699 92089 945183 654916 1451995 1223506 32792 47000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE E </b>–<b> INCOME TAXES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The provision for income taxes consists of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Years ended December 31,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Federal</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">981,244</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">609,006</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">State</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">805</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">788</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total current provision for income taxes</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">982,049</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">609,794</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Federal</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(124,467</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">59,614</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred (benefit) expense from income taxes</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(124,467</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">59,614</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"><b>Total provision for income taxes</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">857,582</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">669,408</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The following is a reconciliation of the Company’s effective income tax rate to the Federal statutory rate:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Years ended December 31, .</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2024</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0pt; text-align: center;">2023</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">($)</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Tax rate</p> </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">($)</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Tax rate</p> </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 36%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Income taxes at statutory federal income tax rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">862,776</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">21.0</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">682,664</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State taxes, net of federal benefit</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">636</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="-sec-ix-hidden:c598">---</span></td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">623</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research &amp; development credits</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(9,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.1</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(14,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other, net</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,170</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px solid rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="-sec-ix-hidden:c606">---</span></td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">121</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><b>Provision for income taxes</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">857,582</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px solid rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">20.9</td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">669,408</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20.6</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The tax effects of temporary differences which comprise the deferred tax assets and liabilities are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">December 31,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Allowance for credit losses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,012</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,501</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Inventories</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,886</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,870</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts payable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">89,251</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,235</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">R&amp;D expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">206,069</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">159,838</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">306,381</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">285,200</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total deferred tax assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">611,599</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">486,644</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax liabilities</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts receivable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(302,987</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(332,537</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(58,171</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(46,484</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Depreciation on property, plant and equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(68,959</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(56,275</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Unrealized gain on marketable securities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,085</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(418</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total deferred tax liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(436,202</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(435,714</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"><b>Net deferred tax asset </b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">175,397</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">50,930</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">  </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Years ended December 31,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Federal</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">981,244</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">609,006</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">State</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">805</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">788</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total current provision for income taxes</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">982,049</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">609,794</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Federal</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(124,467</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">59,614</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred (benefit) expense from income taxes</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(124,467</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">59,614</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"><b>Total provision for income taxes</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">857,582</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">669,408</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> 981244 609006 805 788 982049 609794 -124467 59614 -124467 59614 857582 669408 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Years ended December 31, .</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2024</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0pt; text-align: center;">2023</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">($)</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Tax rate</p> </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">($)</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Tax rate</p> </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 36%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Income taxes at statutory federal income tax rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">862,776</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">21.0</td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">682,664</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State taxes, net of federal benefit</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">636</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="-sec-ix-hidden:c598">---</span></td> <td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">623</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research &amp; development credits</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(9,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.1</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(14,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other, net</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,170</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px solid rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="-sec-ix-hidden:c606">---</span></td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">121</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><b>Provision for income taxes</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">857,582</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px solid rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">20.9</td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">669,408</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20.6</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> </tr> </tbody></table> 862776 0.21 682664 0.21 636 623 9000 0.001 14000 0.004 3170 121 857582 0.209 669408 0.206 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">December 31,</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Allowance for credit losses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,012</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,501</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Inventories</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,886</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,870</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts payable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">89,251</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,235</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">R&amp;D expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">206,069</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">159,838</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">306,381</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">285,200</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total deferred tax assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">611,599</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">486,644</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax liabilities</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts receivable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(302,987</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(332,537</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(58,171</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(46,484</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Depreciation on property, plant and equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(68,959</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(56,275</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Unrealized gain on marketable securities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,085</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(418</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total deferred tax liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(436,202</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(435,714</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"><b>Net deferred tax asset </b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">175,397</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">50,930</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> 3012 3501 6886 9870 89251 28235 206069 159838 306381 285200 611599 486644 302987 332537 58171 46484 68959 56275 6085 418 436202 435714 175397 50930 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE F - BENEFIT PLANS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Defined Contribution Plan</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company sponsors a 401(k) defined contribution plan (“DC Plan”) that provides for a dollar-for-dollar employer matching contribution of the first 4% of each employee's pay. Employees become fully vested in employer matching contributions immediately. Company 401(k) matching contributions were approximately $84,000 and $83,000 for the years ended December 31, 2024 and 2023, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company also makes discretionary contributions to each employee's account based on a “pay-to-pay” safe-harbor formula that qualifies the 401(k) Plan under current IRS regulations. For the years ended December 31, 2024 and 2023, the Company’s Board of Directors authorized discretionary contributions in the amount of $115,000 and $109,000, respectively, to be allocated among all eligible employees. Employees become vested in the discretionary contributions as follows: 20% after <span style="-sec-ix-hidden:c649">two</span> years of employment, and 20% for each year of employment thereafter until the employee becomes fully vested after <span style="-sec-ix-hidden:c651">six</span> years of employment. The discretionary contribution for 2024 was paid in February 2025 and is included in accrued expenses.</p> 0.04 84000 83000 115000 109000 0.20 0.20 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE G - GEOGRAPHIC AND OTHER INFORMATION </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Through its Guardian Laboratories division, the Company conducts research, product development, manufacturing, and marketing of cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness ingredients. Prior to July 1, 2023, the Company manufactured and reported sales of a line of specialty industrial products, however this produce line was discontinued after the second quarter of 2023 due to low sales volume with no growth. All the products that the Company markets, with the exception of Renacidin, are produced at its facility in Hauppauge, New York. Renacidin, a urological product, is manufactured for the Company by an outside contract manufacturer. The Company’s R&amp;D department not only develops new products but also modifies and refines existing products, with the goal of expanding the potential markets for the Company’s products. Many of the cosmetic ingredients manufactured by the Company, particularly its Lubrajel line of water-based moisturizing and lubricating gels, are currently used by many of the major multinational personal care products companies.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company operates in <span style="-sec-ix-hidden:c654">one</span> business segment. The Company’s products are separated into five distinct product categories: cosmetic ingredients, pharmaceuticals, medical lubricants, sexual wellness ingredients and industrial products. The Company discontinued its industrial line of products after the second quarter of 2023 due to a low volume of sales and no growth. Each product category is marketed differently.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The cosmetic ingredients are marketed through a global network of distributors. These distributors purchase products outright from the Company and provide the main marketing and sales functions for these products on behalf of the Company. They in turn receive their compensation for those efforts by re-selling those products at a markup to their customers. This enables the Company to aggressively have its products marketed without the high cost of maintaining its own in-house marketing and sales staff. In 2024 we hired a marketing director to work alongside our distributors and provide marketing materials, training and aid in customer visits. We believe this strategy will allow us to better serve our mutual customers and build stronger relationships with our distributors. The Company currently has one written distribution agreements with the companies that market its cosmetic ingredients. The marketing contract with ASI terminated on December 31, 2023, and the Company is currently in negotiations with ASI to establish a new marketing agreement. The Company is hopeful that it will have a new marketing agreement in place with ASI by mid-2025. The Company’s relationship with ASI continues to be strong, and during this period of renegotiation the Company continues to fill ASI’s orders on a timely basis. All sales of the Company’s cosmetic ingredients are final other than product later determined to be defective, and the Company does not make any sales on consignment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">No prior regulatory approval is needed by the Company to sell any products other than its pharmaceutical products. The end users of its products may or may not need regulatory approvals, depending on the intended claims and uses of those products.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The pharmaceutical products include a urological product and a topical biocide that are sold to end users primarily through distribution agreements with major drug wholesalers. For these products, the Company does the marketing, and the drug wholesalers supply the product to the end users, such as hospitals and pharmacies. The Company’s marketing effort for Renacidin, its most important drug product, currently includes a Renacidin website which provides product information to patients and healthcare providers as well as a focus group study that was conducted in 2024. There is currently no active marketing effort for Clorpactin. Both of these products were originally developed in the 1950s. Clorpactin pre-dated the need for a formal New Drug Application (“NDA”), and the current sterile liquid form of Renacidin is marketed under an NDA that was approved by the FDA in 1990.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The medical lubricants are not pharmaceutical products. They consist primarily of water-based lubricating gels, which are marketed by the Company directly to manufacturers that incorporate them into urologic catheters and other medical devices and products that they sell. These products are distinguished from pharmaceutical products in that, unlike the pharmaceutical products, the Company is not required to obtain regulatory approval prior to marketing them. Regulatory approvals are the responsibility of the companies that market the finished products in which the Company’s products are used, which are typically classified as medical devices. However, the Company is responsible for manufacturing these products in accordance with current Good Manufacturing Practices, and its manufacturing facility is subject to regular FDA oversight.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The industrial products were marketed by the Company directly to manufacturers, and generally did not require that the Company obtain regulatory approval. However, the manufacturers of the finished products may have to obtain such regulatory approvals before marketing these products. The Company discontinued this product line on July 1, 2023.         </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The sexual wellness ingredients are marketed by Brenntag Specialties, a global market leader in chemicals and ingredient distribution. The Company entered into a marketing and distribution agreement with Brenntag in October of 2023 in the United States, Canada, Mexico, Central America and South America.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following tables present the significant concentrations of the Company’s sales. Although a significant percentage of Customer A’s purchases from the Company are sold to foreign customers, in table “(b)” below all sales to Customer A are included in the “United States” sales numbers because all shipments to Customer A are delivered to Customer A's warehouses in the U.S.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In addition, there are four customers for the Company’s medical lubricants that take delivery of their shipments in the U.S. but potentially ship some of that product to manufacturing facilities outside the U.S. Since the Company makes those shipments to U.S. locations, sales to those customers are also included in the “United States” sales number in the table below.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>(a)</b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Net Sales</span></b>                                                                      </p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 15%; width: 70%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">Years ended December 31,</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2024</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">2023</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cosmetic Ingredients</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,817,172</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,283,071</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Pharmaceuticals</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,602,259</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,894,220</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Medical Lubricants</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,028,564</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,750,632</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Industrial and other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">51,594</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gross Sales</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,447,995</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,979,517</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Discounts and allowances</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,266,024</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,094,363</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>Net Sales</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">12,181,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">10,885,154</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>(b)</b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Geographic Information </span></b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 15%; width: 70%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Years ended December 31, .</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">United States</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,175,926</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,601,205</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other countries</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,006,045</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,283,949</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net Sales</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">12,181,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">10,885,154</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>(c)</b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Gross Sales to Major Customers</span></b></p> </td> </tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 15%; width: 70%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Years ended December 31,</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer A</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,387,048</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,464,861</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer B</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,239,705</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,502,846</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer C</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,831,551</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,726,753</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer D</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,331,544</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,490,158</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">All other customers</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,658,147</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,794,899</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total Gross Sales</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">13,447,995</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">11,979,517</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">  </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 15%; width: 70%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">Years ended December 31,</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2024</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">2023</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cosmetic Ingredients</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,817,172</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,283,071</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Pharmaceuticals</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,602,259</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,894,220</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Medical Lubricants</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,028,564</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,750,632</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Industrial and other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">---</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">51,594</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gross Sales</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,447,995</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,979,517</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Discounts and allowances</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,266,024</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,094,363</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>Net Sales</b></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">12,181,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">10,885,154</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> 5817172 4283071 5602259 5894220 2028564 1750632 51594 13447995 11979517 1266024 1094363 12181971 10885154 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 15%; width: 70%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Years ended December 31, .</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">United States</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,175,926</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,601,205</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other countries</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,006,045</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,283,949</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net Sales</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">12,181,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">10,885,154</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> 10175926 8601205 2006045 2283949 12181971 10885154 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 15%; width: 70%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Years ended December 31,</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer A</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,387,048</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,464,861</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer B</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,239,705</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,502,846</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer C</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,831,551</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,726,753</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer D</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,331,544</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,490,158</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">All other customers</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,658,147</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,794,899</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total Gross Sales</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">13,447,995</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">11,979,517</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> 5387048 3464861 2239705 2502846 1831551 1726753 1331544 1490158 2658147 2794899 13447995 11979517 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE H - ACCRUED EXPENSES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Accrued expenses on December 31, 2024 and 2023 consist of:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 15%; width: 70%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Bonuses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">290,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">187,002</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Distribution fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">441,397</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">407,133</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Payroll and related expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">73,915</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96,157</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Company 401(k) contribution</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">115,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">109,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Annual report expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">83,238</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">81,725</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Audit fee</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">73,364</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">71,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Reserve for outdated material returns</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">276,732</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">247,847</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Sales rebates</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">90,904</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">132,250</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23,383</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30,930</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total accrued expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">1,467,933</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">1,363,044</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 15%; width: 70%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2023</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Bonuses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">290,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">187,002</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Distribution fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">441,397</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">407,133</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Payroll and related expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">73,915</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96,157</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Company 401(k) contribution</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">115,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">109,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Annual report expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">83,238</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">81,725</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Audit fee</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">73,364</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">71,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Reserve for outdated material returns</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">276,732</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">247,847</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Sales rebates</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">90,904</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">132,250</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23,383</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30,930</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total accrued expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">1,467,933</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">1,363,044</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td> </tr> </tbody></table> 290000 187002 441397 407133 73915 96157 115000 109000 83238 81725 73364 71000 276732 247847 90904 132250 23383 30930 1467933 1363044 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE I - SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION AND </b><b>NON-CASH INVESTING AND FINANCING ACTIVITIES<a href="#" id="notes2" title="notes2"></a></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of December 31, 2024, the Company had a number of unconverted Guardian Chemical shares that would convert to approximately 447 shares of United-Guardian, Inc. common stock if all of the remaining holders of those Guardian shares converted their Guardian stock to United-Guardian stock. The Company’s transfer agent continues to try to locate the holders of those shares in anticipation of escheating them to the appropriate state jurisdictions. The Company is currently accruing dividends on the 447 shares that have not yet been exchanged or designated for escheatment as of December 31, 2024, and the Company will continue to do so as dividends are declared.</p> 447 447 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE J - RELATED PARTY TRANSACTIONS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">During the years ended December 31, 2024 and 2023, the Company made payments of $20,000 and $100,000 respectively, to Ken Globus, the Company’s former President, for consulting services subsequent to his departure from the Company. The Company’s consulting agreement with Ken Globus expired on May 31, 2024. Ken Globus is a director of the Company and currently serves as Chairman of the Board of Directors.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">During the years ended December 31, 2024 and 2023, the Company paid PKF O’Connor Davies $23,250 and $20,000, respectively, for accounting and tax services. Lawrence Maietta, a partner at PKF O’Connor Davies, is a director of the Company.</p> 20000 100000 23250 20000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE K </b>–<b> SUBSEQUENT EVENTS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On January 27, 2025, the Company’s Board of Directors declared a cash dividend of $0.35 per share, which was paid on February 18, 2025 to all stockholders of record as of February 10, 2025.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0.35

,!$W@7*8!<]G0)HH-:-QY2'@-E^9H>)S>?"P[))+9 MJ%3#593C:(0&2!MO,J*Q)&(Q6D#(&C"?>6X(%IQ.*%?:!8W/8>AM"O>]X?[$ M,]$]0FF,2;%)\?OIZ1"HE)E$&UFE#Q:E#))'7BR0]5&<1N M(ED2(@1<#"\B M*%GV//;NJ/=^_$H\CD"99J*$ECZ1A5;D6$%NFUX\=O/+@-*4GZD<#)XXM-*R M$"@8@2(GWE*VTQUBM\4F3(0I7($K@F,-&*_HL\>#R*>TFB@4.5=ID,7Y GD\ MEC"F0L#\6^R(YIOJK12W9[H7+<)<3\PW V0##A$'E:A(DKZ@(G%![\(5B[F( M8SSF/$J@547)392? 7B,#MO0X6=D:./(">U][!S#26P?,8YS>XMCKFBWP\03 M)L:4JCMAJW@A^E20/B5)([;@H5+!%T5#!?T@W@/V^113.Y+N-!2%SW@1/OU0 MC+BVJ2LR[#SMGTMKM@Y5"6.5&*EULHBU2-#'O"!^3PJ#\4%VEM1J4J%:I$R$ M6D R0.I*+9WKUQ+%X9E6)*0X40,EPLM>/9HQ#-&/C/%$AR=+^O0E#_H-(X!" M?"@#[(Y5KP+LIMP/R[LC$66.1%I.8LG@I7I&_&E3"K[ZJ.'=LT3MBG4Q,ASC\L6,CDD& M$?=-9%+9*-^?'D@T;HLKZ=Y4SX%4WP+,.X3? J13KH'&5>=%3]9._]^??&-4 M&Q"/7G$SDUS^E2C@-+<+MH^Q*#EUAD_]XG>*+#)Z_IA;KQ2TDGE5TAD433PW MO@CL]C189@K@LUNWL!K5(G'I9)^3S1)UO5Q#!ZQQCP^>USL+10 MX40=Y^ZA MR'6H>@:IGB]+"2AW++?;.^,]\FSA^A&%FI,O,XG[=W@?5JR M4VC&&!NW7/F7Q2!PG3ES7>B),AJ2]"%)?ELXRV0#C>R)"./G$\+FG37S0+I? MZA*\PT42U,0TVH1A%JTGS2X!ZTQJ!O=_Q-C,)_Z*P:MY\(HB^&GZ*@0T&P*J M550(:%=#0,51$6 M< GA@)*B$+OU^-Q@=1ZN9R96!84YW1R/3H31-NO5O;KM?U.,H\;D2!=?YI. M^QLZZ&<0_O(!"^]9X@!'=3.U,3YZ%+-[Q$C0W< '"<5,("/N/")"DC(-([[( M\Y]4P\@X%R:U%O=>2V['VK/,FM1IB?L!]Z5S'",JZ2R>@G +)3.EPR5%U]#P M04HL)G644'7[CI="\JDT8R3N)$T8FP3XHM'=OG:,_15"[2NEMNU8S)Z;AP4J MJ\]'&0A[%,5&P$N>>52..TI#:8/FW*!"FC$KU5]O8#CT^&"$,S"E/HZ]?>*5 M[91&3+*+'XS(.4RO 2\?<*^E\$ ,X_PRRIJ/(Q7Q\XZ%O^=4/B5SZMJ[X]/C MK^^WCPZ*3UX8[@"76X]*^3DLDJ2UF*5)]4%(!0N7B,\%/ :%L\C#\8"T MHD+YJB=9E$+,1Z[IDL\Y4%&)[]]S%P!403A6&K-?@[1RR>D"BI*06T'P1K)'[FEW) M"$5OU4S_2AXP2+,%I#/LSN9,TSW;>-4/C^W:=]A*@[ML79HWRU%#G*0H2\31 MM7JN49G(FQ$[<.S_1+9%C1^22(5LLJ.CUP!C$X#1KF@Z@HYHS)]UIO2M02WF M]%B-=N/TB\R:,8:EO+S9;66;1_A)!^%4/1R/4P4CT+R\>Q3=O/2&$TI21(2" MO@!C>>F.*AL6E%=*XB*MU>60V8!RLU!QQZ@+G M,7F'%5&.G&J2(1[.M[03W)&:#F L\S96DOTDHR^=CC7T_&P^5N*@1.*84/!, M\"YIH:5P2,3FI8])'#YB1UQW51QCD^BI PDC;!M8N-$@'$9.<<;?=ZU6J8*=PF*(.Z M'(%VM!.TVQ,U,B8C$2.CID06^4_K/"7C,;+PW$)2P)#[+]6&CE.:\,F_5%MZ MJUW3*0S!W>;.%,M/O?$DW)\8TU0J@T$UDD.:MXY>&,RUB<5-JK]#*D5@IO@[ M=0<*""E)4KEVF3^S"3LBRB-\_N3BV#[4X&WB7U)#FGW$I1D^>]JX4:9_/ M::\O%7\C-1_!C@$6FP%ZNM %59"0!W^%HA[(#E?,DAT9Y7Z ME,=9N0DALLQS2269GFYR?+E,K$AT]U2P-8BHO9V0?T*IGU)"1&JGI =S+117 M=)' @\B"JX5Z2Y<,(KIQ0L,KW;RQHVO,ILI9P1D,T3&9XNFR_RS<"&(#7_T# M9:>:'N:+8:9EY#C4-$0F#MM^(D@X8#B0==(#DY8>0IM)"R9J'R,*L=*59ZDW M3AR2PM"D<':N)DJ67.6.[7DL'#].3BI6ISG3BUOTQ$UYR%H#%K _]J@/'WHZ M!H%',(KWHNJFWC1H5E5!LUT-FI&<+AR_LYU3'LDI38D;9? RKV2$>.%XIUE, MDZ.RA%K"DU>2#HGH,YR ''L@DX>& ?ZJJ=]M5V7B=.Z8R;51YI Z' ,8E.%)^N@572I_G[(R,5#U.9G1+^C%P=[/Z M:_(T84V3O 2IG(KXZ&#UGNMRWR2FJ4T.J6?QZ,"D4USP:&92#I#5UJ_Z[/LF MEQ#+##21X TWI#<9>S!E][&M- [LPV-YQ.=)=^TRT.1;V 3])W#]4<*L)X39 MT*OUFEZO9^FRJ3?J';W6JLTAR\6I$3X',DG9#*G8@?1LQ35#QTA#H-W!AHFV MN#*(BGH0IYG%2UBI B;LL<<.FIS\LAOB;CB4*9 $GGVX@QB'Q)]^QQ/2/ M1")%7RWV6JZ(/W2E#.= M-)BA2E)>-HX8#K<#AM.T8/+;I>N [CPG&F<\;1B0Q(14XQ;(!QYXE[1'I>YR M<:PR::B>"AWP03R9L"O%+7EZ*9GK,H9C9UY!8^Z=[7N\PC+;BUB,DY%)R2#U M*0V9N2.>M4TB((4 (I9&#"GTJ5<.3[O[<]SI.): M6/)(I1+C@L S;>[MH@3QM":%,G5N$7]#1T#.,Y_/KW@THC)Y]D=Q[O*>_45T0]_",^4=O.="^I%9Y MV2N'WBWCODPV5Z%HQFIF4^]T&WJM5LFIF:U*3:\UNXF:F=M@LOXCRS12RU1K M;;W2ZF:6:<#B;=!Q8R.3X\1M=JGDY;)K=7X5#V^WVF# 5C./;E<:>K?6B?>_ MPW1XPZN,J5,H5]ICG3U6)P%,R8DFAKW0*[ET*O#JQ^VP:+Z-**[+#F(3U@"I M).1\CP/?-.+F8ZFI K(\,YD1,N223#CBA?&=04\NFGT>BS1Y M-PKITT?;R''F<(:TJB,R0X.(ER51$HQ<#3N+89D@G_<7I"L#^8"+7<>_BY@5 M/I'(^RC#FN//*6@APUT\-SGT3AAR"K&-S"5IO@.K#"@[ZYY/*\/9*.S M@/^4LX!S_G^^K>?^?]V@6J_J[L(#5T_"#I%0F*%(\+\%XH4_))968^8TV!J("0BK88B4 > MM%"XLWCC(YR_9D2N.:)\J;2#BZ:UB<3>R"5WJ=@E[]083[[$+&Z#%Z=[OO 0 MDN-L1)WST3LF_':R$5AZX JV?\;'YE\#GBSF1@LG(L\H3ED%1?-T^&@ZD903 MQ=4YZ5% >'[<)5!\+U1VOL\.K83J"2& M4"J"%N>JIOJ34D=KCCWD'I>3C+BG2;0!][BOWP]Y.0B1\=;!FA"+NZ8 I["M ME^=J*@=D3\!D$L,D46Z:]7FV=+/R:]9^3FM'M^D'%MJ=Z*\4,P'$R!8:(HS7 M/C,?A+ZKUPKV"T.PZ<5 QMGA,U:^13$591;V3.PM!T1S M!-2X 9B&$\FI4&&$8X7YY."9J+O8+!^.R!N*8:@N'DHM8)@*SJ<'#V_OX$%* MDQ.Y<K.E=ZK=.>87 MHB(&<#%<''(%2[IXP_3P)WC5]_%=0<)+>+%JK-2FMHRU?%91 V9\[LB6G2%Y MG/M>^Q8_Y(22-CS_DU9[GV=@$V.*W2YE_2S^'KOLY.*\YU]]YEX,!,%-=EP0 M=N1AA1KF98L5^2C3HH;1P(3OX5?>JQ-#RF)Z>9PHSGF7-WMXI/_&VQA[%FCA M/&Z\M1HG);\R]VLYZ5 M!A!VNYTB[ +<3>60Q15TGR>S=,YIE-7. MX/%Y>HH0O?DC4JF1(&Z]TM);N1!QH][06^W')-)3F91Q39#8"ZV5F[:&G2DI M4.J/"V>*4?A^SARR>>IO+H$YDW )0HTY(E&*3P]#SX+G4LX895'&59=<"YS: M<#VSI/Z7?Z?9M4^2B*Y02D>&,Y0VIFB-*5.=F/7(/"5LEPZBW?9TT7N "ZWT M+',Q(8Y44ON!)#EM*ST?C9]I)\$EG:I>Z3833\:?SY<-,K>U M0-8LQ9-QB(.HA*;F2AA!D>,K4^H%J*MC.PQ9_,A9,TW/Y-#*M&G99BDW]#!Y M']Y>B-JKX]9I #R>*U<9*+M;%MV*B92@2[,@H$G/?CIQ&M^.UQ=C_C-HTF-L M-Y8T$\HUTDDU]4GEA O5YL[#L@$9H:#>E3R!/KF+']2VNH"N, >:,D71]R7T MZAOC88>L1*%&I< @M*V0P)"HVERI;K6Z>J/2R2C5G69;;W8RY4GYHIQYNC2M M)!)L:4$><6-#T2T[M1DB97I8K7+03?S$? ; 02OQG6[@L>41\ZMLR\754V-B MAS19G8^PVQFA]J?G4S<64P @CXW5BMZN=O1&LXWE-#/=#'A9*US3!)$$"%IP M34%.R'UNT92?LAB-J259W)L,K9<[L$&H;TRQG$MWTHB'WJ>>392OZHT:HG93RS@KTJ6RE0: W/Y!)MS&V18/!+6Z^TVWH=[+[A0H;HK %)"\5%Z'0H!8LAPC3T M&JS5;+<764N&TJFWTRR&Y-"# O_Q.)FA\.3NDR5NTREQQ.7?'0"/34J#:BOU/#Y'DS>C98FI<@'XGOQ(3A8NCKR&092W' 4 M)(4SHCC.>E2]2;\0]RWPYEM6W@X.J'WM+=4IIWWC&>]N&KRI9GWIAEAI<;8^ MKVMYR%&8Z07D6 .=MZ771;'5+XUF5Z]WLO02S"/.U 3:;/_%F5A)ZIAD5U; M+9E48B,EBV#$W*XL>0RB('ER*Y([V'852GGAK2!RPJ%R4$U_N\$VX#+B-:/! M(-7EC1><'!8-<08@Y>%Z\-<$W5*\)T:<,R"R9$53<$^.[7S KJP!)E AQG#; M' F8,\2X=W12Y$X^+AIWA2UVX[$II$B)7-A,DFVRM;BO,]<1>%H7L<)$78@5 M-UFZ[V6\<5AX3-EE^"CJ#O"#Q;@4]SS7$P9?R&]%F7N1EU&$KSV"("9@I=I' M3$4'_5@B"&DRX'$UP:QDY_XHL"F#6W8G"$+/_#'R'&M71G$6) R ,(HFMS0B M063)#"+;H3[- 0AM]X>#5#X%23C61<+;3'.67["#5:5223>&E_E <[3V.))( M@^^)7@;4E9-W68@+395IG+2L8V$*S.) MX-/(%\H.F"[P/FO'B36FI9T\9;+JF7Y%F4G+OH>J%750Q:GRO"4 #K*;-Q01 MWNQ?V/>$NK.80D7+X5BMWB[%F;SE!!^7NK7L"^-XGX\<"7'TN\&[S29S#_A< M )^EV[HZ]@_&^]3P*XS8^X0U%:+?/CE]9P,7)B GAY](*5EEOK\^'-?.EY5=/]-H_L-%=W?\>C^O98:.77E>ZZ'W=O'O+IP M_4&0=5;0@ME^X8'.(4KS)^.&21H,Z%0[;&]GD\J%28^&PEH)QG0RFH! M%Y_/8WF>CTT_4/'!NB:;*F7CSCEOR1:YOLZI^_>]RIZ&5#-!5A.Z&*^U__1:AG MAY0*3 KV_U$C,O[W"5B>CA>0+#8&7A2*!!_MV@Y^''PV--OZ?<]N&WL:C0$4 MOX\ *7_?^QD>_\$XU(H 3]]/&WXR0_[ Z'4UJMRW'V3-/SD!@RFYOAA:JP\ MDCNBD2C#C8<"X)Q.[&S)?'$/N1ED%T7% 4K$ 3H;PP"2D4']1$@A(^B#2>;0 MWY@"=6*$1DSQG83@.SEZ5^2>"EN[+GL0XAK]?@#(4,R\FJ _ZVR_JHBV1$3; MW1BB/4ZL<"JRLH/\2%^ALU,G%QP2E.B9>$-"](F(CZF[FU!W=T.I>YU]U\#8 M551=)JK>'&7\&#[T/1%/OL+*&@MU[X0R4YIV-Z]I;PIMOBPW,XVIU0XM^G[2]P]/, *>$'6IS#N/S!WPVA_;@ M<&>2E"\I.2))X8\+3+&O:&;&,+J.KWS;Q<\<[?2!F1$9DY<8:*1Y55;J^T02 MB>]UZN8CAZ59HF$JSAC5$]^Q& LOB/?F"5RLY43-]HI/X1,6PYZ$< M"WP=.2S@4*_6C?UJ\QWCW86K38O_Q;\4"YX^B'F^/3/,1;CX=4F8ZU($) TQ MG8X<]FSN9#J1 !)'EI]^%7+ZN;&IGDNO-3 M*J: M(L&?E?!B.;BZF-^FV8K,?RGN4Y*B?Q+ \"J&F*%.S,ZP?3G1.1;*DXA 1GVT M9X,2!]IWX7K$A"!@J*(6B=?,S1/TK\(&\S(0VQ\53=JD'(^\_/>*#F/>P=,8 M$CFW51OZQIC1O!5[EC")X&N?\.-;'H$Y2RZ'(^39LD+[2.H7^XBW'J5.7/JW MAFO_-\FYQHLQB=2Z-Z;\+CXO08[I/K[L7^*@\;HTD,6!S&F**:TCL>4HW4SMK7V&P5.T7/=*.;YFN4Q[OP7:< T[3[$)IY2 M$^-"9"A:MMQB>K)/NA80NIF.*PYM8&L)RUCX\ ZTONQC2O._,(R_#\]ECB@G M0$TO0Z^I,>VT.Q&_ $7P+Y$KF'X%,:7OZ;VGU<<^3U?CQ]FH-&)%0"IWAC\P M@!WL7SXX;$ILFU*4*K4#K8>=XG@FBLZC+%F8(T!$,38?:CSGM3QW!H@J*^5M MLU*:*BME5[-2BJP!\WVF<[5TRSQ+,4^YU#=1+R]-N^Q4@N#S= 5AM1D&^X\Q=^O-VMG;5Y$UHR%H!#7VUQW:8U7%/ M\SIZGKB"$A'16^6 %!HNPFCDXQZ?]/-1_?K"I!6DE3 Y.\=)3BMMP)%E]']%UJUH_2;,6;*:[;'(#I!FN#1!Q".RMC!/$$=S=SSA^!$7-")P &SQ MN"JD6WOD>63TRL3D.YX3)^=6P3LFM2P,7\1%HQ\,GHB[[,;4H)O:!,O* *R? MRJF C$8_NM3LQ^%;/]V_@YB/',W_L42C0;,+E+#"- M"3)E/V*H-*I0\%.AX*.-"05?TC#)\R0PD02!!ZD@\& 7@\":_$^(U(R&LA\P M<]]^V!_9%N#P1[-9?^J"QE,7-)^ZH!6G?0A5IO#'!.VS#%>8PSE4VD@9>,7Q MQO"*5-+"=>SG._-\!@MJ_XA\.[#L=(G8%15I81=C7EL.7\3,Q4PQ%U,Q%R3L M$..R#F!O&9K&K,3.GXNHP9^&LQ8JP1,(H_OBU_ MK%8VB#_&K4-GK!O1NT765FE?T/I TR/)AZU6$IZ(O^\*3WQQ>4N5[[W,$T*$N)^&%BY+Z,VWQB?&(*!UE3O!MD5@-*0XN!U__18 M)@Y5:Z+K6=P>(&ZO,:\?B\KG+1/CJ6X,XTFX#68E,C?(6G+5:HJQ5!5C48Q% M,99U,I;:QC 6T5Q_JEW>NX":(WN"2'5W:"JNG>-%*ZZ8C$KD744B;TLE\FY((N]+V/!S D[_E/&F MA U/YG+A]B%I?7/$+*PD3A2$9DI!:)9? M0>#HNB".KHSDGRO$YN/_ZLX[AX-%A"7W73^H_;I*5,MB^,J@_'1\G_IC%%(B M"#_,3/I]K[:W"$2ZK8/.MH DG>K._W_BF9'HO4_J)(XI,7S1+MZ6M5\':.$5YA<]!]>"33 M4-'GZ-(Y*%*#8.K@CXC:%W,(,)BO.\)>?9>5>/0C\E M^-Y0\"G)ATM?QTW*DHRN$$L49<.O*][P*YV68?OCG;$0)<64B%%GM[2M@%=< M&??*2;)ZXL993(5^= 4*U2L<&M9X;N!BDL_&9>6^2F*$2A&L*V,0#DN M%N,%U#I0YJLY:$3%[R!-8G-.2:7\\3]78ZK3V>\[)]_N>C=?+\^[8OT0.S+9]#X\CA+,/U1+EDP:0VU15#-%PM:_"#>S M5I)[%'Q< 6<'69$S MU<@5;J5SMZ13F_=-Q";>L/J C0QG*+OWT\GR"T1[R,B%N^B!1A2./)I'LPEU M2,6'M@3K2J=QSF1HSDGJ;=*U!9*\Z++O%^Q>Z=GZ!G;=F MA*U\2,%SYTOHQVXZ D \@] _!!^T$\]U#>V?]JWMP.FQF'R7V*R6_9%[\M,O M= (FXD<\$!^F]J@D?0M@JCJ)9&WCBQ1''GG-'L\Z_@09,'+? 8LE\RS61'7;B8VQPTE[]\BRYEL\,[5]>E!JENEGZ M9O85%-67!1N/1S8;%LPJ?">FCM+D\D>&&NJYJ8>I$@6IKG[2;G#V8.1C4*_/ M3)]AC?L&(L%V\J.=U&.5FTF!8Q.\;ELK=Y;0@KX:][PA[MF!]LVP61@::65H MLV3)UAZL;$ZOSJ0\9U)>$;^U(%_<,BID:XIVE'ZB]!-U[ H$H M\K5O!]J)SP*7^4I'+]VQ*AV]?&>B=/02Z^@S3$T%,3?E2-7IE.UT=H>W*85= M@4/9+QMFOV"BPKW6.]"./-/T7*;LE](=J[)?RG?!S]L9;J4[ER5Z5*^,U&F M2^E-ER+>I@BH7*>I3J3L)[*]K$PIZ HY-A&H*R5 MTIVJLE;*=R;EM5:VLS[VN:;*+%M3M*.4DTU03DI1;[WE#:L4('8)[3=+(?^# MN=H7QQM$P<8UF4EO737'6S_V'8\,&SYW9>_[(\_P+?Q#6A3JG$IQ3@L9$Z6: M;+6!:ZC1++6.&LVR(:-9'F,Y2S&9%T^.._U_?S\_.K_1SB].3O_?VT^">]%D M,;&E/$7D-L01C% ZS0:,*/0^9;@ ??+D=+&WP2#RA2 MN)LA30%"]>D;\V^9C[]]=^V06?M?(E"LX(&Z=NZ:!]H[7/Q?GO_C/1Q9.!*# MAD)OWN4GS#'N#9^]QYF7?/@EW2>&(_%6?31Z,!0[H&_D'_)V'%O49Y.0C0>P MNVI%!Y4"P*6]@U4\?X)TC0.3IIK/AHQW.X$]232LOQN\GQV2]%MN[B:N<09 M@\?O_P%\Q^=SE^P SDJ;,L/7&' -2SMC S_"7=>ZM(W.3+_L^CYW2<\C1V?]#I^E95@HA M:U6^Y(9@PF=#3#\=A>'DXX;U)8F!TQYR9ESN?=%9;RLQP$&W:^T*G/._&XUJI5M9Y*BKE8/JW_ZV M:R2Q%*B^L3&@K6M%8ZZ7X&C@$/[&'L#O C8QA%@P;GU&XQ??:P,6WN,DQ<1M M1X23EAIL.,1IQW=,N_#NA%Y!R%M;D%;@!&M>JN&9Q8IN53$_1&<@G(9YP)UQ)%'*15F_L%%&A/E*I M53FV-!:BJ0;:#+M%4\^'TC-<3<>>1?;,:3BR32Z32+'C0X-IT#T@_8(DT5B= M37O"3"%MB#"J7>$&6SE]Q.<#&D"[6VDLJ"QU05GB6UD" 9=;\]S%45F^=N,; MI&E<>8YM3M.;*">?J%7+9.=GMM:/!@!3&ZY@>1OG(VAA[F-3.4L$X1E\JBYD M %=C'"[EX2SW5HF?!C7P26HD>A^E/GQ6KY#@[AO^P'!9L'_YX+"I'((.W+90 M:=N0@U_,\U$]J&W4P2_T5KM]\/6%#GZSCGVA=_J'9\,IFT\>?K?2VKK#?Y&9 MUJRUT.O1:E3JG19!^K#;+IMV_3;OS34IT% =@^8X =I<@\(,KTJ1H%/?!U7 MBP(P2GOWAH_Z*6H)S T(W[C/93$=&4'\?+,Q5I:?5)1K]0VR(.& #LXO^G]# MMV,I,>[<13M)^W]'UU\U4+]# T_SQ#,C-(\V!\;]X[^7'<:^EAWRVCR@'QN.&3ETP[=TI*):6)3*D;!Y_L5-'9HG#$$E7IA/AQ7!A M$B2ISLM *56*]2OX_?]&,+0T]* C^ [6G>+]&N_X-^V;X0("$1*8\ 1$(@WL M%%.:1QZ84(8/-@Z_:#NA\#=.#N\$Y\+LV:,H #() F')H57Y%8 0 ;#> X4, M\='$T.Q &T:^:P68TCEO!%Y(-B 9<)%TBU6Z]G\GI@8Q;&7],[ MFO-\K=HI>/#I@SG"N*G!XO, !?V2NF_O1JR"Q.-BLOH4%!? 6 MVMGY1>_B^+SW5>O?]&Y.OYU>W/1?CYZ*MO+N3,1^T9<5<&?6V^X@[SEK$$,2 M+K0W+K98HL+B195RS^53LR48J][2H%V=7",J5 6FR!MD4\9-0A01RWM*AHX MM@F"V01>2LK)F>V/T7&LO;LZ[ET>:>+4;V#75SC/JU_ M([WL5ZKP+_^U6MNO5_YIM_;YG-KM[AZU*Z_.' MS),/9TR$9Z!!M7U0WUPT2 LF(K8"S! B*/1,(<0+4.7P;/^I^-76T>O2W4Q6 MCC+E:>RPQ3SRS'8-U[0-A]=B47[:BJ8Y;#D/*7UG3,4:M@#F:V0-S^U7EJA; M@6<_I68EW$:6_8W9,W,D=HS?/**S(+Q!5ZDK744Q),60"AC2(*@^69)I.)2& MTA\Q%@:*%2W)BA#2P(H:"$!Q%F@_QP3T-O]75*<,CHTE MCI0*S)ZG ?>!(_X8>0[6//^FG?XGLL.I$D++ZL,,94EKUV2)4H<5BUJ(.9G# MYS&G8R,8:6>.=Z_TXF59$H <6%);L23%DA1+*F!)KA>RIXWT"[P*5?J@;3Z7;$UZ=7E]S\^AL(3DS.RF2>A7:(+Y'Y3 A3$-!2A*Z1C;TN2&7^]][A MC44E M1<4Z\N!1)-L]N/W)M)&!3>L0%QEO'6F8)N]6A"F< Q$8## P^$C#;+P1&P[4 M*I]$KR/ZJ_KIO6B(-S\Q6H^;5OK8*X%9224*W6E3>@2PTA1MB-X&&B-7,7^" MB7Z:(?IIXA9@24N#V45(@=?>@.<^1W17P%Q6,+(,ZE0F7VH8HU.0RA3C M;W@ ,-"\R-<\CH*Z:#\V>X"V>"E\C54W0?X1 M$R^PYS2%7ABV0>0(@.*/">-E/[P]&WXT#W[PBRN!"/LU/2HTP@H:WAL]R?>= M^'!6]L0!N-XR%Q9PL..B:3+JXRMJ_3@"<:JD[?0H8==0'"W/T8Z,P.9G(7B; MXE\SHI2JMPI)#3MW"L2?>%A QZN^L@04]T@9QR6'!]HED'+N+IO\+NP!Z105QW ,-&#!NU- F/'L^14U#VQ^+"CW*KX\G"HA$ M>\D#4@GWEW? &U'5%MVRWV6([;WV3G S2L=/V9_014L!-!?<;8%%NDN9/ M:POFA%^G>1#R,-B";Y&@B'?Y_:!_H V9A6P Z^MD!1^U_I9^FF$E>S /;MB(3D2'&OGDG1VVG M 7UBZ'.0:C,6)8N#E?>B*2#GU&O45CD8GG+R_1XV=8$75( FD.[!-[ M'/FP$7R%%-[RVM TUJ,NI"-@X75@+7@GYMX"7Z OQ5NA2!5O)62IC;:2"UNA M8F7/T:@&/GD#7U;K'FB](*Z]C8]!QW7R]">@!4M%F4[@I \MN)RN#0"J5&@K MY+DHL\6G"%[&VR/GV5G>PS.>\-F$9_(HZ#T)5,%+7TX+(',GE%=5F M=G*9(E31!D'@(%>V/)-9D<]# D!+"% 2>';P(YA+(O(TBPCL"?+1T\2=WP+R M "XT+2X@$,]H*P=:'\\X=7'\.NP!(.H2JB('!S@$(8I)&[;"[FR+&IV!.# ( M>3@_&:.PXV+ L@/3\0+QS+FOQ24ZAZ3A!%YJ_3O#B41[-F'YS*JR42#*RK'[ M-_4#!"C"1NTQ:;!CPV+8F2W1(*@>_1Y=2_ SMP32"&K\DW3_D4>.A#2$ 7-L M=B<8;<*^ :(((X!%FJL.8JTQ99(HRLHKU\>H3F#;.^Z&^6:$0"S*0S"SDQA. M'.?&'$XDKY+?;9(C0]_C,M\4#0>!5=B>E0C+N8)=:! ^JBGC<>321"3J59'3 M23-?"SV4/][,^-'H@>^J[X6U3QR2$W> 3TTS#KI4O YGE^*YQ2H(//Q=#;MM MW'G.G="F2"^VR=H%O=1Q0&D@GB;:3MBH5(C^)0Y[ .!:MPEQ6PR6!2[(Q*ZI M/3H'!HA'LQ#\JVY3L=YXSYN-!FRVLI,!\9N5#@:LU ^:<7\EC!A\ML>@7SGA M[WLH/(P0,.[@K\DMO()OYC_[<"BB#"_M0)79Q>LT35U%%?<%?"!JN%N5O<,O MU[U^_UP6G%\>Z%1QKF/)^4&^N'LEC;HDF.;FQI0)XM)1&S ?N8YP3N95O#0Q88F=/SF^8A7H\]7CC9DE"E7W#O^!CQMY.NT6QS<6XLW; MO6?!6&@5RGZK4'9-A;)+%,I.H>=CC8M6GS"VP SEP6'2KXA'NH\OOYV*$#95 M\XK0-?V>"UD_82^\;F9 "@7<7CY/>,\Z$7LLFI MC*_X,+\'T+R$Q16G*";B?74/GI_W^ZIK ,O!<4:_[[56W]MI1EBL,=.VF(S_ ME;3\R@1$'TN*?:WC*$BP5NB\-#K7GM8,7@7%!1?=YT<%ETT>M,!S;$OS;P?O M*KJ&_[Y?9ZZSA$$VV1G5YK? ^H7AHQ!HXQ"H7F($4MQ5K:'6V,TUUD#[!58] MLJ=:I:%KM3I.GF\VW[\>AY"^@';E<0_CJY>W7;!0"PR'!8^)!FDUOE$=Y2LL M]P(Q_GEP^ OW",S?:>W7PG*U,NR>^TK/:&8#-I$GMVIC;S'_;.3:_(KO_1/I MK8V"_5O#F'R\9G?,C=B9[XV//=[/_T\['!U' >R(^><4CK?=VQXE,3#KQG@ MC0U(FI&'@O>U_WW/?@@_NM%XW_)H]K -.+JGB5\"O/*P6M.KG:K>;5>EYU>^ MS:-GLDKL60S:1?;TFV*Y(JIU$E6S@*CJ"5'5RT54%;W3:>K59F/CB:I$VD.S M28K#:VL/VZH'JC74&LJ^V,!6#5F;XM@+1%(5>\#93BSXN Y_O5I#K;&I:Y2( M8[V93K,NCA7_UXVY%^:U[H!79)'EWMP*FV=>M5?@L\"SO1Q^\3PKZ+E6G_EW MMLF"ON=8RUE13;U=J^K-SOJ,J!US.6P4QG96X!!8/<8VVEV]V6J5%V-+)/NV M7EO/R;Y+WD# O8TU=R4 2\-.NBL0@/$!DXT&'.54G/-RW*2FUYLMO5/MEI>; ME "#=A1AVY45R+^5(VREW0'Q5V*%K43B;]=,OVL6,*KNH#ID=L<<;X(U?=LM M!%>0\;>A(;MV=25Q<(XTP)M.$I01;&HY+M4 H=INKT^HJG"WHI,,G=16$MI> M/9VTZGJW6]MX.BF1R-\=B[?:X:KKX/#&"ZGA33YJ%=>!*=$/4)(;VZJDG79] M15[EEYLF8);4FWJUL_GL3-'(=M%(4;;H,G[L5=!(I5;3J[7-IY$2B?S=L?)K M;2GR^71FWMPHZ9JK!/[V,[.B+-VEO>@ZX*OS)$K5=:>JNYO@INI9F75]IA#XI;'(P!J M7_6"\W6$R7F:[I=_N MYA5TBC($GRM+OP#FH&OATDV8U;)^AI;>5;XX11YE(8^B]+3G2O 5DD>GJE>Z MS8TGCQ))^MVQ:_/9-E[*,Z>IN-O6!Q0Z12F$SQ7U%Y[K96,*+TP?K.JM5F?C M&9HBE>TBE:**_1632KW3UMN-]16-;J'L?S,K?SNC$VH-M8:*>FV)=3"3 MF#=@()L8'X9)@Z!Q]*6P%D+C81=R\\NLX,S37%;15S9)%I)=,&TW BWF,D[3 M/"+DX-?=(#*K72T1O-=GF# M%PKSUXWYJVC^6CK,K^NU9D5OM]=G(BN%OA1*D5I#K;&I:Y2(0VR]0@]+7SVB MLF^SNK[#8IJ&Q^Z*M$PGUWLO;J+6FD8^:>3%#?=G_1&-:G8 23YM MR)R;HGT7LK%5I+X#RKR\:A;=$IWV^E*1E@'I5HMV11NKR+9? 6W40/&MZO5V M98-IHT1"70UT4FNH-4JW1HDXQ-:K_;#TJ>&[MGL;:!/F@Y0;CT'J!2/#9]J[ M@1'8)N^7:SM1R*SWR@J8$6^_;(6*TUVF6N>*^7W$E+RJ(U%*?G^$>+2$RG-^ M<;9W6#E8XVQ890LH"I$4LDS!SAM12+-$$U^415!*K4JMH=;8U#5*Q"%VP2+X MDZ$,9I9F )2-6\;-@6#W[(%21BOGJ2?/KL$K5$SDV??XT5]$XP'S+X=T;7 9 MA4$(QP^:RXL4EH;>[#;TNIHL5:;E2H/(SZZ04XC\=!#])_@Y\*PI;@P;L!S" M!Y9]=_C33\5"YK?<=G[[E"Q-*V<$B9 C0HQDMS&9N\9C+[Z4Z,K@K\DP/1HV MTF=,N_!"6"/TM#/;-5S3-ARM'QHAHX8)C^WQ+>"@UEC;&D "FND8 1#TU9>C M/_;RI%JI_%IDXHI/B$721Z"O99]U=G,=/ZP *[74 KE[1\-]W[N?_=!DCJ-= M?;GX_NW1!Q>3C:2X'/0 '&?[=<$)LC]^^CR*E>VKWI?3_:/KT]X?^[VSF]/K MCYKAW!O30-KZ2(TNR[S4)VW$.'1JDX=/FE"A?Z[0/T7:M?AJ[T,>DG\_*88D M'L?2<+RY//YJNS\2;"B 0 P(_)&Y;AX_FT'.!=EW ??"MUN$'O('N@ UI)81 M2).AC\^#PZ/>U][%\:G6__OIZ4W_LT&">1" S WM$'= OX]\%+X_PQT?C,,X M12B_S[FH^"CSSQHD:P%#,#'<#-Z![/=XJU0@U (E\94L-+AO[H\'D+M%]!VK_" MH#5@4)'ED%4WT--28@S:O9" -'7:H):M-3QP'/D^-J\'[9&%@9J\H=90:Y1; M,UQ[NL/:JYIX+_)C(QA1^-+$7]A_(OO.<&(/\-:&,8N"!.7*R9H7"LJ55MJ+ M3^V% ^ZY%OXX38ZY%QX;OC^UW=M_&DZT9+?$*A8GZ:UFB0J42AA-5.@+Z-LI M0-_%!NJ^'OIV]%JCOM8INZKNM[P2\MON3>C8J-R([K(",3G8?GRNPI!;CH^T M]6:MIK=J2@R6:+FRX&FU4EE6]*T<43O-JEZOJBYWRB"<%7<]TP08A('F,Y.! MF@58IVLN"S5OJ!F.X]T;KLD0US339Y8=\H-SO"" S<$UO\S!_NJR;+HG%SWS M_!,O&H3#R)&;O([W^")ZJ#;T>F-6^]-L5\-=DGT\[[UJRU+U6[Q72V^UY[[7 MH[YL)1S>5CC4ER:/&92Y8.'+L$9OU+#_KU)C2K1<>3"UL33#>P5,;;9:>J=> M_ESC,F@RNV:XX_PW-_1\&Q\*&HP2=^5A(LUEQ9T\U.G2DWE!O('YTUWC8#\E MWDJ,F:UEQ=LJ,+-6J^O-2HDJUTLLSG;-,+_RV<2P+8WQ=J@!6:5\K*2923]1 M: MK80N:LV:WJ[6-YXN2B36E>*OUE!KE&Z-$G&(K5?\J3'1D(%HRCKR=R!E2ZDT MU:73GB7.Q%-BN8ZS?.Y-NZG7N\K%KRBD9!2R=+KUJBFD6=&[=>7V5]J_6D.M MLB4IZ%G MXD,L92:VN7JF4:!9]"?%C9]&QJ!9D(4M^>]&Q M1,)JZU7MG+ Z USP_&FB:9/>/02NJBEK9:+-B[RBR M'1S_1-+.'D]\[RXU\7!K)=X.U\K4BFIE%I*?$E>0,YVG4.4%S*FNU^LMO=Y< M7ZMA%6A6])&ECZ)TZX4$]RO01TWOMEMZL[WYB1@EDO&[8]KFBT](F.BHU<;';W9+;$/3:'LVE&V*(MQP6KL MU:-L6V]7FWISC84:FR0;50Z66D.M4;HU2L0AMEY[QLP%%@2:89K1.'*,D%D@ M428^"!4#Y<9VZ\B[;/D7Y98OVG1>HLI)"E/@=X?A+Z#*],8>T.M_Z?.Y:LZR M&DZU6]-KEM&N^&LEI4JWM=990%OH;]N=F%JM_:B_+9?+ M+4HZM]WKIHK6:DMG7LYE;TN7K76;P-\ZFQ]/4#2R932R=#KHZFFD5>V"2KV^ M@1A;J .\F==@._T_:@VUQI;[%7?'2JBW8BOA\J;W5>OU^ZH@ MZ2POPMGB P?0A$/IE]+K.D7[+M9REDY>Y]TJEFSF4M?;W;9>KY=HQM<"(-QJ MA5_10FWI#/D7T4)-[]9J>J=,91O/I@4AMG^"GP//FN+.<7[H(7Q@V7>'/_U4 M+-]^R^WWMT_)WFAK&1DF1)B08%D:F1%&P&VJIF.$8 0N?IR],=> M7CY4*K\6,7;Q"0EA^@C,C^RSSFZNXX<5;$-++9"[=S3<][W[V0]-YCC:U9>+ M[]\>?7 QG"2(<\#% MG]AI NV1\_?1[%MN-5[\OI_M'U:>^/_=[9S>GU1\UP M[HUI("4<@M]EF9?ZI(T8ATYM\O!)$Q;ASQ7ZI\A8%%_M?7QU]M]T>"#040>%SH:C-2=T$%H0 W\55>2B'+KQY3!NBA1[VOO8OC4ZW_ M]U.T70W2Z09!;4\+[1"W0[^/?-3@?H8[/AB'L8&[GDVO'VK!Q' S" J*J>=3 M&/LCZ+M 'XZ-U+%W^/6\=W3^]?SF_+2O]2Y.M#Z@X1]_O_QZX+*^])06><)7_(!? M-(&N46OJE376_.Q:AN[FHNO2(U-6B:ZP#;W1Z)8774LD^+:^Q'96\/D1LS3V M,&%NH+JMEHEY%!7R+2KK\%"_)K;8R_B'WFBU]6Y=";P2+5<>-"VJL%I4QJT6 M3>NMNEYI-,J+IB42=+MFX<63/7UVQ]QHRRV\DG*0_?W]TM!B"4Y@^P]\CL@H M2L5?2&0C8-1OIQ+ZS+>9: MN^(=W-W>*?6BNHC%AD!+'%F%PZ96U9MKM+94GP!%%AFR:!3UK5]L\O.*R:+6 M4JT!E!&XA"3/M^,V9_,5M!TH ][Y7B>-HA$#BTUB7)F;JEMMZ(W6^N(Q2KXK MVBBDC:)^]XN-A5P9;33K#;W67-_ K"T4\KMCKN>%?$JX*]F^ _QKZ>2@%/]2 M0ET1Q581Q=(I2"L@"B7--]=DW\X<:[6&6F/+<_??3-\_]L9C.Z26/]1=&\6, M[=XRUR2%>[L.^!5-IF*YO73V7^I8>JYUG#Z4M!Q_".R/KNW\OA?Z$<,V$3D9 MK2JWRK3&(XBR=(?S#464$K%:I8RI-=0:I5NC@$.L6U?JAY[Y8^0Y8(X&__MS MIU9M?Z)I).'TXW9Z7DJ9!U&"PK72'8(Z\]W-Y-R=_(]N;+%ZV @.F+&N_9)I M"[-FK^CN'1Y4*W$[./JA30Q?NS.]V[ M7&R.YV*[/ ^":.5HO=ATQ+?88$-O=AMZO5H4,WSV!P+G-9NV1.XX+SEDS0BU M=$L[#4^%+GJJHY-22MZT,J;Y(F>.0,Y_HO!9LK-%LZLWZK7REL&4 %EV%C>7 M'A.W([A9(L5^=W*^N&)_S4+#=K&/A>&[(/"VO(_%#M>B-)<>XR1QY%2@2&;< M]= V[6635JMZHU8'UK2^Q@,J^4M1299*EA[P]&I44M&[M:Y>;189\&5"AXV2 M\[OCP,OG=@>I@ KF;(J@"GPOXBHJXWO[DUM;BWE2"]A<.AYW2OBRM/#O=&IZ MI[7Y2:Z*.+:,.!;SX+\N<=0[';W969_1OH4R?W=L^UH[EODTK?FQV4PY'4 . M:MIZ'4 -LVTM%K][O,*EYUHKXWIJY+.BDO)1R6+QX[>C$C4,.M[OK@Z#WL A MB6J-W5M##2 ^VV^J <2/#R#&'YGK2C23.'^@"U!#:AF!-!GZ -VH?].[.?UV M>G'3UR[/BL?D\M'$ 8LG$^.OSQI,O/J=KP-:_V*&'VC,M9CU5!J6&O5;K+P] M/>IWFPI8:(V"";QS>?DKY;>D\Z6WK4@H"^,WF?I9J$'+@.NNP/>M<;@4Y6=J M>//&84XY9_06P2 [B96GIC_F]2XI'.&&?-O2:) MJ^G?SS^78G5A74$Y6'J1W-H=1IB2$O<:$88RM4J,+4I14VNH-=0::@VUAEIC M[;)QS0EO,DS4K/VZ7K7I\^#PR' ,UV2Z]@_#C0Q_JO%@07W[$]H66*Y;EHK8 M5E&U=HWGU/P[3H'@63+'WGCBN=1K[\$.]E,EL=\H'O14\X&5-6YXK.U 20II MUX]BK_V^OVP$>A<5?+\(*L\N!V45%Q(MA=KX^\BW1NZ-W*FV] M5E4(KA#\"00OJO^MO67M3U>OM5IZJ[&^HOA-JNE1C835&FH-M89:0ZVQ06N4 M2(*^657L=IZD6D.MH=90:Z@U=E:";GTO*5CZ@H6:[9K>F*DHVMO[JO;W]TOC M_%G_ :CS5N>]7>==[(MNY_JS6+SS1*4*_Z::4+Q"W 6X_3DQ^Z]>L.0,XYK> M[%3U>GM]72L59I<7L^L+8;9"TE+IN_S%$(&TLHA%?,?VK<6+P9>>VQ$8RN8"?+ M)@%7:&QA?H;8A/E\CMA[Y1U3WA)UWNJ\U7FO#N+OYLB,]KK<8[%463;9ODSN MAOFJ0FZ)9W=.4\*P1,3268''3>']!E@M\SM^+3S/YLVMFJ?WO$Z7T H@JO!)X9/"IRW&ISE> MF<[;9_C=)EZ<$R';EV\94N^TR^/2>?H4E*M3$>4"1/FBY$1%7\JENC5FMUI# MK:'64&NH-;9OC1))T%UPJ:9[T^9'V:GNM*6J3NHTYD]\5MUI5:[<_/?=B!:' MG>:KH+?J3JLP>]V87=16_/720%>%WM6*WJUU]6JSQ&6H"L/+@>%%G<47RMU< M&;)6]7JGHS<[)6;')3)ME'-0K:'64&NH-=0:&[1&B22HZO"NUE!KJ#74&FJ- M#5JC1!+TS6S0-8;75']:U9&A+ >@SEN=]W:==[$SNELI2)1M)(FRC3+WIZWK MM69%[[1+U9.@;*BVLYA=70BS%9*62L]5GB*UAEI#K:'64&MLT!HEDJ"[X"E: MJC]MMZA0]RF%<#W-+5H[W-RBG#:&\I:H\U;GO;WG/:>.O-MV/L=O91TT:WJ[ MV=+KV%ZI+$Z=4O705&2YN63YH@1%16'*K;I%IK=:0ZVAUE!KJ#6V;XT22=!= M<*L^UJ6VL?U=:O/*8QV41\N+!@[;(".B8--SC(A:03.YQ0QZU>?V>0>PU?ZP M90!2JFZ+RU-0_54H:)=:Z2KBV5GB*6JS_GI)L2ML@-JHU8&(&HJ(%!&MG8B* MFKDOE"N[0GKH=&IZI]7:8'H09N9/\'/@65/=F:[8 /:AJ/%?#@H MP1Y+ RRU$;41M9$7;038JF8Z1@!"Y.K+T1][>?E0J?Q:Q-C%)R20Z:.]P]RS MSFZNXX<5;$-++9"[=S3<][W[V0]-YCC:U9>+[]\>?7 QG"2(\['%O<.S_9:0 M+MD?/WT>Q;[.J]Z7T_VCZ]/>'_N]LYO3ZX^:X=P;TT!*. 2_RS(O]4D;,0Z= MVN3ADR8\F#]7Z)\BYZ;X:N]#'I)_/RF&)!['TG"\N3S^:KL_$FPH@$ ,"/R1 MN6X> L\(X@5UA@)TQ;=;A&B6"!:GEA%(D]$%/@\.^S>]F]-OIQWR3#ON M]?^NG7V]_+/_V>#ZWG!/"^T0MX*_CGS4[7Z&.S\8A[%W]I5T%=J\[5JP\8_= M6=TE==1NY#AX^J1""40EI1(18&)8Z/Z+_PXFAAG_S>\?VNX-WEK,$QXGLV>H MD>D7 C1X(,\[A1JX"OAV$8?MB\8#:X&#=7_?:SW-,M^\>NX5HBA%+Y>-K/R+ M&7Z@,4 W*Q-9>2R@LD5!M2U&\=K>RI'L&5E-&)JLZ!K^^_ZML?YIE8^'#5\? MPQ>&CT*64B-+O<3(LGNI"%+';X/>M=:T!"RHTH:.=Q]H0]\;:]Z$^48(:J.& MGL8[.[19\'$=DE2MH=;8U#5*Q,^V?@!X_!^WG'=E6L%SYVQ6:R7I %VK=%4' MZ+D@VZU8\J:@;+6H5*^>H.Q"8V)7@+(UO=FIZO5VB:<9ETCT;7U6<4[T]:R_ MHB"DB#)&FGT&*&O:#M/<6";BY_B7B5K_Q/>P5,W2!E.E]JLUU!I*[=] WE?M MT#Y.V 08GFV0U,9^-<;8 ]#_ES[8;E-@D>7*HTHMT^Y[IAEEZK#A=X?A+SW7 MZJ7.?#D-J]O4.QUE$91HN?)@;GT%1L#K86ZUTM1;G1*5'Y18.NZ.92"DXQ?# M=C7 Y #P2O.&FA$$+%12<0V\176PW[$#G]-FIEK4POZYT@3)&KU)E^Z)'4R\ MP,8%+H<]I.Z@NJP"R'XRG( ;,C'SR%BEI M4B+FLHJ._]<,WN._S#IW[QAW*R*["9#?L*6G .C=3HG*RU.\I03XL[OH6M0] M^+FR\!70M5/5*]U2.0/** IWSICJ.8YWCXU<$)4TTV>6'6H.X9D2@B7B*IT5 M",$KC)$%\- SSS_QHD$XC)R>:0(1A,LQ%2T L/R^MX_!W'J]5'KV?/K*+:'Z MHVXT713EWSQ7VKXB7=3U>K=:)KHHH]#=.?LS*W2]0> Y+&2:#=J>&WK^5'&8 M\G"8VF*=S1_G,.?R9/_T[9"=>/?+Q442OE)MZ+5*J:;0*>.S#,A:U._[N>)P M]LOJ,?>PV=5;U1*U!"QQ8LO.F84G MS/29$3#M'4A$^NV]AD'*))V=8N$JE5VMH=;8S%3VW5'R:VWNZA)^5*S@8?8= MYEDH%;\\>E)1XM;SG5M<6$GQ=>[*0[^.S_S%[JZ*WBZSVE0"I-I^')YGIA8E M"#W?Z?5*2'Q8K3?U3KM4N>QE='_MCK8O)*-TLZITPW)QDV6FOS_-35*GO62Z M(89\.N6,)9< @;8?7^>@:U%BT,N%WTO1-5'=&JVFWJR4J.F_L@[+(P.O?#8Q M;$MCW+,:4+&S%XZ8KYF1[P,*"I^7DI EDI"KZ'DTRW($+DBONW"V]USK$O&! MEP$MJ8&W]$JW5!Q(2<[U2\[Z*OH@O2$:I[PA%;U:+U7R3VDEZLY9E5*BJIR* M<@K/>E&&ULJ$YPT>][+MV-I=E4=1CN7*(R.+,H!6)B.7Q]9$%G;U2KGR8$LK M"G?'N!3I%!+OM'<6*TRG<&QC8#NJ/:!:0ZVQP3D5.Z?CQSD5$V.J$BK*I3 U M7C6AXHH?^)(:?K>B-YLJB:)$RY4';U?1P>F5\+8*FFNE3&/42RP+=T?)3V2A M'[$D@J1D87EXRBH:-Q7R%#SQKXGQMCQ;Z92K@5/I<&EG47<539Q>#W4;%;W; M45XO91P6",2XJM9G=\R-E'%8IN#/*KHXS;*58W@D+O2G'8Z.HP#HBOF2QTQ? M&FMNZHUNJ5B-B@N50#ZNHNW26R!R"?&WM*)R=VS'>HOC]H Z 2\T/^KSA\'A M=HO2A<<= ]CDQ@:/$M*;LZO%7Z&0JS56T>H), K'$%\)?#J:?@^PA<"EQ*E> MC%++3GILM%IZK;F^2H#%@+QK]JTBG\8JFD^]/OE4&PV]T5E?.ZI5D4^)-(._PL/ON=:I//HE8YCUNEYIEZKB9#[=Y990,R,V MFCR*%_<()-"7D>R]-_EE%4\"\?=)SK6]& MB*@SO1RNCE,"GZPVUVJQJ!0Z13X9\FFNHAGA&Y$/]O-MZM5&<^/)IT1*P^[X M!0J2[]]% 8V!?)])PR_*GU%I^-N41SS'TFJNHD?BG$3B:";*$^\69. MB.U,.U1KJ#54.NMF6QP%*?E#VS5<4Z7DJS74&MO PW8MU')BHPKN6MCZU;:4 M(V3CO<'S/""K:",K8\V7PQAMEAX-T6SI]5I] ST<*CE#D=_SR6\5W7!71GZ4 M\M0I4:5,&8FO1$K)UAM6CX5R1"2GT-)2P9NM9IJK:/<[Q]=\)K%I95$;I=,H MG6:WR',5+8W?C#R5SK-9.H\*-ZDUU!JE6Z-$'&+KK2)8&JV@S+!!,8 0["$R MCK!C"OV";5/N0#RZ:K)]F4I\FJOHSXX*$OYWFISQ-0M"WS9#9N$7/=?*?I"Z M\@K>P;-F.V.;3F2!?G7Z8(X,]Y9=&R$['0Z9N5QWB43/ A.HU=8;K1)I6JK# M>QGJS9NKZ/"^ :1P"-A?K>FMMBI?+Y6>O^ZDD2)1K6L#!M>YZ-7TAMJ4&?YV M2^^=\)<4\[]6KB#'?ANF%[.W$SN8>('A? $:G, =\#=NQW8C9HEFV)Z[=!5] MK5'7J[7UU0JK^C=%;EERJQ:06VU+R*U>T1MK+,S?PNSV77 F/**&,/AT-Q20 M)_E,';#9\B+L,C!P %E@A[^4FC$6;'@.2ZP5L,37]T"\"4NLZIUV4V\U2UPS M5W!.6ZU[[#*EU96N7R[$*JWBH>*<:@VU1NG6*!&'V 73Y//@L!]-)@[#!&?# MT2P06(X71#[UBC9ET9UFNUQ0@;AY*O=SL[#OR88!:BEU2&^X5(GXW]9'B.+_ M:FW:QXWQP':B'F^7+<2B@J#G)H: O>>-&:'+%6#+!5MV-(A>:5;T=ID;#BGG MR>Z0QBH&$ZR*-%J5DDTBV&1?AYKJJ]90:Y1NC1)QB*W7]9_T=8"0V2=_AQVR M,;824EX.M90ZI*WW>:_(\E6Q"U2C3R27D[=I;:QQ$,/*_!T_P<^!9TUQYPB= M0_C LN\.?_JI6/C]EMOO;\^NII?;F,Q=XS'(+&5,9'#V^.*X0 @UTS'" "QKKX<_;&7QYU*Y=>B0Q>?$-G2 M1Z"W9)]U=G,=/ZP "EIJ@=R]H^&^[]W/?F@RQ]&NOEQ\__;H@XN/29YP#GH MCK/]ML"\[(^?/H]BI?.J]^5T_^CZM/?'?N_LYO3ZHV8X]\8TD-B/I^^RS$M] MTD:,0Z?BD"57RYPK]4Z1EBJ_V/N0A^?>38DCB<2P-QYO+XZ^V^R/!A@(( M/$Z0V@PF+L@\"D@#7V41 LV?W@*HGUI&8$B&&+"3U>7-:1\ HIV=7_0NCL][ M7[7^3>_F]-OIQ4W_LT%RP$5R!7X?VB'N2?XY\I'W_PR/^6 >Q)[>>#J/J"+/00S$\2U:0*5XM2#*WB>:;/@ M!K9UY'CFCSVA(K1!>#.0XQ,D4#]B2'*OT@]&(*O6T_:UB][-]^M3[?),._K> M/[\X[?>UWL6)UO_^[5OO^E_X>?_\R\7YV?EQ[^(F95D/#GO'QY??+V[.+[YH M5Y=?SX_/3_MS4?<-A>_+:/NO* CMX70&7I^#B>%FN"=H4AY/L/T(ZALP;\=& MUKUW>(&3L\C'=Q0%\%D $P%R+1P9H0[_!]%WBS[40)/+:5^- 5[E^4!C&O $.X ;=& B;C0$ M+1?.)M#%C,F RF0L=L<<;Q)HP80A,8=36"H8LQ#8!]"KSRR;5\],1@9 Q&01 M>8YPY!2.0,>GP27XB1,-?*)V_N" /43PZ3T(2D2#],,.M"O?AA<'S>T?D3/5 MJKJ&]@"^$M,$&-);MNB!/@, &R369F&AFB'OR6;A].(,',\M470(KQ[>$T? M%P"HBL_YS?=&0,YI3V2.:\80Y!OM) DAW7_ [#%CV 9W*5F10QWCIEZ?"=W MG@/\%I2(< 0JC 8:R3W\!JO@KO!M;U*O!>:'AWR9=J8A0S5\DUU<7>IJ\BE#EB-#P%CZC\1*SS#S$80S:KM3[DMI!]J ML0F\./U*FQY[%K!SQ!\0V$C:.MW"'N!Q5D![BG!B.9A@\*'-9Y E:$+@P8MN M/3@;V/$P\N%/7ZZ)5^/7'#GI*2ET^"T^-GR->]B-\1=X<:,*UH\?IU^Q3./THG=\?G)^<7Y]??ZE=W-^><'O3)GU M5T#",R4@^?6NF(\?&+>L&MOS^[6%#?K:WF%WMBGEKX0(7R@#0\'\49C/ M%LC\BK0=%C :SBPE76,59H EF4 F)\RD_6MU+@D:=&SY3^O(>(BEVL PI@="W'7,4$H>>1UF*-P!5T.1$U&VLC(CTK*9>AI,7Z%Y?E MK.-77==AUY\II1;K/ZO *\$[&_!Z,X'T9N;MR[T\?7:+BOTUF532+3/E_\^[ M9KJ-;K/:J;2ZW7JEA?V0W\I-\PRW@W@?,+93I5,[Y7=(VY@>53_#DN@:& @_ M# <8WZSG,O$+KY,&TRO@$ 0[;62#,8C.!S3Z;#)2$4LPOB2OREB28)J9(YL- MM>1A2)+H> K[0?0B[29CB]/ODES"1?R*@(!<-@R4< M>#( ;<087@<[P52XS);YW0*> !X0R(X'"\?6\I%G^)9V.=1.;!\XC>?#_L#, MUH((3FG!O>L( W9G.!'"@'^FW3*7L,3B,_YRK_/.9V'DN_@J_!/LR\K!BL^^ M'W%3%Y[K,SYQ'&WQ(:(+*@X2WO"]1Q>B*R&0C-A+^9AU_B8 G7O/_X'/!N9B M(YQ?P%2?*S-Z_ %'0#Q_QPO$TDD,(KZ,D 4=5;@/.C@0C42> M>7XBUI?)JPEE9ZX*XO '8H+@%EQ.?\@(ZNU"B.>*Z',@+).(Y8OC#3!4C_G! M4^UX9 #MG;L QH'MV.$47>9#A_-[/,,;V-5PN&MQA!N.9L(I'7!8F00K.PVK MQ#]L&D14@ZDVQN^0/X: Z-@$17*W;[9E@10_!3+4XZ=3!H7-3P<8><"<0+ _ M- =1YVMX>I\9="C]B/U7.S9R M6\?@+),_:FC[\.?(<(;"K=[,>LDS>T/!P 4BBA<"A0U\ LCS%J,>L+###. F M="JX.5P9Z16 (O@+=R[#YP$("4*M ZWGA",*H*2C#B/@ ZX7@C7 &85O@Q5% M 8@I2#_'F!(L@9,Q^PX?ZAOW&MK'&'#@HL_--# /)&Q,+T O>'HMU+'N.1,2 MVDR\._QNZ$0VCWR 3>Y8\HCLD",HRBUX"+[U@78^Y _Q3#/R@WP@99IZ%0W5 M"V#5>9")/5NY'9-Y%*"^@+P-E<'T"TMM$9<0VQM&% $V1L$(G8-#+R'L2S. M3KFXA/>[Y6Q@/FJC2&%95!B Y("7 &T44&F:P@!\X8D'^!Z2RBAX3;%,]^+F M0'A@B:(" M'&)#][;CP#OLA': Y'SC1^.)9EACVZ6P)T$(20QDY!@T,I,$*,(:E2F7!S>) M&7FHFW'&KY$= 8@L T#TO1]KKLPBD_OUO-X@' JCHX?'&[L^T&?8H#^FP,1)YF@\B^HP$2&M<< M+=+L.-6EF6$OY P&_P)HA7@C7 L7(_O)!1;Q418#?C;&:#!^8<>*"OR5?9&T M/9T56$39DE6E%=NLU)%RZ2TY .B@[ $QAAVJ3,7#L_V.RE1\)%.1;!:)+SGL M>=,4Q@2'\ULJWD;^J%^<:BS%G)86;K*PY\^1[; ,'_$&(?&KL<== C/*$O$P MQQA(#3;@7- "H1%@IH;P3!''DJ*!I=1=KN#1*H(A9Q^?"$-B30%++PTZ"*JU M$UAB9 @S(:.+ N,'0##,=@$F%MHRO4-LQK#8?\A[1%X.C42?2^S>].Y$OHP+ M< )6]X"\+QRAC$LD6%8EQ2<"!0%71I]6YCWB%\8MT=MDTG=8[J63%Q(BQ4XL MA/BM"UXN=N5('4 HI4(,W9/&C??*I9Q8PR55$\QY,<\ SSE.3=D%Q2ZM5^15 MZUA%BWT\PO)$%VXDC'K,_4$E:L2LY(;8$9?)^Y(X((_+370_9*F)0R;VV;"M,$( M:M;^XX2*Z,*DL<3OB(V5!+$LAKY.J: $+*7PNK&RM L8=L)5J##C DG;?8): M=5+ZN.M1GECLWQW$ZNOS+'$ .\>(9^1,.6^ M]J77NTH"@?#"QBUM@4?1_A/9OH@.&#\21PN7V:#6@AW.B8O+#"[ PW2(P!CC M_GB.,(]GD>YE<]=26OSG>G 2A[A-Q<%F[N,K6>3X&0I?9@$H><(R!2ADEBP/ M.EB1+[F,+Z/OVH2&=H'EFHE["$F!IBO&5KA^@Z9U#)$#K8_!,_FWQ?MI" 3G_/": ?P5HQ.4R&.KP(X1(<;Y%I]-IUKO=ZO]O[TV;VT:2 MA.'/[_R*"LWT;/L)4$WPINU5!'6YM6U+6DGNV?FT 9%%$6,0X."0S/WU;V96 M%2X"%$7Q $ETM&V)!ZHJ*^^S6]/U=JVU*]Q5,@6/W9%SG.Y8))<1CAT@M\5D M.G= M$>\]+)W?\IZ]V?LP9D -M5K+4W5?GPV3Z(:U@A!/ 9H?T)ZA8Z?80*= MV%>B7_9K^* /']DWD9J@*"WY2:"HS.>KQ]?H\1K^&O)IW"D\.N+3<0M.)F+$ M\S04Q_2E,>A+-DR\KR^=@X^HAED6_:Y)7H\@[3[:IN$#$VQ*\ M*_%0BGJPT ZEC<3J&]"/2%$B$+<%E><4!?C;N.,81M M#J2>*D6970GK-K#TQ1D+GB?47B^48[0KJ2)';XNS& -G$CT1P-R[_PZB0]C2 MY%,V$D'Y9*0F2Y3&BH6D=U8VE5++X K7SC&K5?5614]5$2F 2:#&!5X6K!ZG M(6 0"A1V0&/4<;T8[&( !_EG:+'PFL;ZP!Z<,:+B=()"4E[?"XCZD4C$(C@J M^/HN=C/]O.4G,2[?&Z:E]73KNN1,\^L/ 4HI&I&4D52&H)(AJ&X9@MKE$-3[S4)9B'$7Z;K9MJ!>T[O- M5J-=;77T;GN-N?>KM07E\5CL? =F_L7U>K01W($7^H/,6=,PL@I;U98R"A44 M16"/;!54<.@+9U++]%1\@WTG8T5D5@4F/5N+EO3BELH+!E*,2%-5H4NRAQPJ MS@;[96RBXB%R-S!T(LI\R(@@C4PH<+/*5]*R2!E_0G$0D1TN9]'+B =ZMF96 MRZY9GPBO(]H)%#3%'<>.JJK"*?'X8%3KS/(F#758Y1?5*, 6RZ$Q&"[,141E M@ HWF7):F,DD;%_\5FB'J^!R]'%Z7R!Y%/"CI&KAU\275,X1ST9)Z*S?^F->D0KE$ >/<)XZRT(LE(25%2Y._)-<:P\0RW M*[6K"*@I!^JJH1=6H;UTPF9<%"""\-O$G.H2D@K(SJ,E>QZ0H4KX@Q4:&OMA M.R\6'SP)M]Z_@H$L&*'+ESY[XBSRVD(CTA8].]S@26)CB$-Y]!/6:FKD&J&\%1%=1\=, M-B4IG J?'0\US)#*)4Y%#$NZ V.FD,_!9EI+CY&)A^(U[HB+<. M>&(9?9%,BY@%^T6D%>B%R\X\F5OFV+2)20N]2A+"$Q#"([;(-?F MMHO.,HY"J.(,*Q,P78 "J'3@.%1)L\^GQ3,JE 0EVDBJC+ H>0'G',Q339D$ MC6!X ]^0&5JB8D_"BPA*Q6?'SK/H1:2.)'R!E-3-Z+K$*W@1OKPZ8K'QQ4.> MH.+$4W&G!$'@,+%*UI@D! I&H$@>)?R/SXC= TZUC+AU6^**S )ZY%1QPLWQ M8^!2#E] $?,XO,+XJ1E_*1YB4/B^B,@9;0-%U T)X !4 M_QT *=,;F"JH[!=JRD6O>F,$1!IH:+7@/8AD.[AI3(CR+>EJ9./ \LT*EN4+ M)*S@G0A^*(/HLE39ET^88%6G0%+\H.PD$"(]PA-/3O5\%(V7&(:8 ?>#Z?'' M[#3N;GW#008/@@$+EH H$H!F0 = G^ M(K1%"?PNO2K2VH8!(:TE;-I:M:X#_$1>*4?%5- 571Z++D]^5$L(R62218H) MQ )&%M8R];FDQ?B77K@"A92C0Q0*B4*$0GN4MC]I(8;G8)W4E#)S7)EME_!]D)82 MN3]$N;GJX1=/GQ7F@_ $)#))J28-'QTV)Y"?S+ 11"57"N1+4.U(_"3AU2< MK=&%'?.R5F87__./R%Y,?Q5X@<@?!1S[W0!EUPB>0"A?_S/2:EW3^X''#2N3 MT3>/CA*9>:JJ4G ]4<8=$8Y9247"/D=!9]!92.+#P^@6U1 MH2ER&+&EH0A 2\DXHN>06*.Z7%F&Y#N.* $B62VB_*;TE*$13_U ?QTD MGX@42I^#I7\EF>^+V_#!:!/EHS:ETQ.OCOI7II[]0>8^R!N8D,-9)?P1IGD^ M]EIP!VFPRIZ:F/6!L:64391(T$M%$G,SQ"*)F&3*JO(X%F)7WU#,(OO*M\[- M5]+W/K/^9#96D2I&B5_&P.$2-3!W4K)96SAEG^P$46=P=X F"EUE_O-K M*?\2)6,YE$1["?8E5%A55DL&.+XO"P11ZP/-&!$0F$I9)+?%"*5>+4.4NQRB MW*;*25V.I100!J=BX=3L /B2+?115WF (R,(K9),!]C\P$%L/:$^R(+>06:6 M7*P;@C 2$N$WP/U*O5;I+)0X$U6T#9+2#TZ4DT32J>9GP_SOJ<@SNLLH',OQ+.?6J*B!6D@8ZMDC_$G8U_.ST M37JV"B=Y<]<3?8S2!M0 ?6+.]$!\Q:@/^>@[?0*%PW^1QFT\JSBT16,]Q 4# M"@TVM(8G9-E,C*DJ3D$%)^:-R(D-*#5:YM$A+PHQ(=O'IQ0DP#**B*MMUZNT MH585-/AIJN5 S+1^)4%2=B[(3+3,RD7X'N72ANB[KJS&>1F-.?F,MV"'3_P* MNOLBA[9!%3Q#+BN'*.*BH!J? !!S%,]4%,:^@6)*!3!C\=;$K\FPC?)(3",I M=Q#$EB$DZ[,^( *1,7@F-),$I2+P+XZR[2+P2QT@RA+.DS&U93,R54+-/P#G M53;-5^7!/WO/9#F]J36ZLWUH%3&]&%X,)![Y'+ 8(&1*6>TC50\\$!A/+I=%A'2'DD=%'\):A/F^ M$!%SD-$4Z4]-?!U[WB36I'DM(DA:44B&R2:S$@<3V3)R4JBF(9Y3DO49?&-( M14+D("1L/V0\.#<]X^D)2\\1WI@Z('20QVGD340+E22*@:84"GF_UEL9&:^B>E2X&(@QH^D^P5"R_13^#FRI M'_XNC/RA:3_(''L!M:2_1I]QZM KTI/0J?[RFA?E#0-!$[A0G?RD@=4TH5L, M\]SQ!3WC#7Z#EZ^_9]'K:-5KS?K\]O>H/&CD;_/6;OV2I"92&=>[GTQO1[W576S84N9L M'G715]$]SW6N)TO5+EUGG.4RN5)5\3WT!7I\\&#\7,YMTM0:0':UUFR088MX ML5'$+.E@03IH5Q>;BK63=-#0]'I-J]=GI\(5A@X*)*Z;39+4ZQ;76Q71MPDW MWYY+YT66*PXCTM\AD%/76C FU-:;FMYH%I<)%0 /#Q;ML^95+RI_BXWVW695 M:W9+V5L@4WFKLO>;S)BW@D>7B_$C5J5._ M__T6PBN(=6V-92V\]TJE4BQP'IK$.P@LRY&?K7?(SX@?]>S!#7*C0@G0IKY5 M W95M%8@(;OW=F[X1V3\/="<>ASO3<77>RYK7^4M=4#A@1-0VJ$%&%*X,-D" M&\YA@^V%[.>",#:]IND=7>NV]>*8!@N ?J]5B$,FGLY".D11B*>J=3I-36\6 MR*'T9N*1.L%?X%^1*?T;98-OKJ_Y*]GQA>K_VL]([*)* ME_RIK*<4Q8+>2X MUN %1YP_3MG0?$[6BVA1[\+9=JE9LQ8KHKRO=W\5=AL2;>-H#*?GLV?'"G!4 M\Z5L>S/-R5M.EUP;DXGK_*0J$]A^=DE8-\LWEN$4!GK#M$C1(>7.]'Z<3D^Y MW1\A4$C/)^5'$B@H0T+)S_K:PW0B+(,O'-MT80.]F4_);V='Q+B+392L,[@= M^;E[-?\D>B28&_CA:\?^/NNQNPUIX:B!&>[Q M"UU/SE4T%S.SRJMX^U749K6@7])%ZCDM6V2K!:P&]!UJAH3%9+ T!XXC:3=1 M+_:K(/ZPMXSJ^@H$'O:W#'D)HD/X;=FH;2'>A,.$PP)0)_"QB[A@.,?WHL(, M>S(9; BL5&XV]H747/=PJ?%, "\LQ*1R2(=&[.$<8FLJ*H.Q7"YZ;G)0\M;+ MU38A39)U:6%-VE.(_S@NE>H&-U>7MNHZM)CB=?'3YR[2O+KSTVE$ZCWL<)== MG8;38#95G=:CPPAF%J7!+^"O^WZ%%,XKF;\USIZ:[ MQ>6Y;?+-\>_WQ?&UZNVFUJW->DL*D\-4HGU!T'[!5/H=0/N.UJKJ6JU:X)J1 M DGA0\CPTVGZBR8A_]65_J6$_"K+:VZQ0JX,FNQ)+,D MF2V8];];9%;KU+5NH[OS9%8@W>+0$A;+5,6]S[;J9*42E*F*9:IB23P+$,]B MY0Y%(9XR57$-B1ZAR*QU4ED?%7JE*,DG_X_U+']$DS"-^*R%^$A/9XBI1]$( MJC#',#VB3\SPPQ0?WYG-&=)P:H*:ONE0NB+E1^*LK %-$L"DQMAH\FB4:VQ$ M>>!.'!J1ZYG8CYT>*>?-)1ZK1@F*E\+-O\![<%STL!PS-W/TV*!3<3S3%@1JTD@VY]D<1!/#%3#%,[7L9+]Z M-B\2SA,L7/\VK-6T2]IY%?7)U)E55)?8I)">/O*$:?!CW"EKIH3D'.A M65Z=0F=O%OY"6UD7*NZN?IRX5I4IK>Y.I%?B9T$$C9)YT312XFP$S$FE-LI1 M+]C%'Z=OOIXU7:_N7-;T(I=]=KWY.V[4WTJTN0G4]>K.)5 7]59J.:PT?A-U MD=V[J6*2<@1EJ*NG%4L:0:F7(RAW>03E^W.TSPQOU+,'^,_%OP/S&4@5=.I; M&ER#;B__1#[)1RM-+GW^!Q!U!R<)FPKCPE.F+65=P0418:3KQB?80CN&E: MN.'3XCZ @<8!2FLS.1MI :A1S/,U(W.[(M6#@^)MIKO.O:3QB[/K\X 'E[@ MRC'L @KPBF_Z-$')$_4O)LX5MTP0XW+&$YFX8SF-[M%YYO0L1L^BZ6"6.39] M0TX'PVH-GXU-&\4BC:079U!/&'&+IH(!">.YX:ST-'H&@0&7FSBF37HHP2-E M+\.M@5V,(PYQN_CFQ(7%7$"C^.0]7PQGA 4D\,$FP=^2E84/6'H1P+-.3I<0/V8G>5"71U*S$(+9R F"R$5\&6QSR6'XP"(Y./950C/ M,\>=2$H.*Q\12*KRD043,<=Z;(#"'8QI=%VM6=5 A+PZ4#:IIV=/O*M76_GC M8U^9> >@ 0B+H_;HSI>,V=4;>)ZW#(.M5]M+#^I;U;;KNIZ][631'&(_'\C" MM8@ DN0.SW0D6R'M43EK@'5P55?+QH$? !8-@>,K>B6*<'PQZA*8E\?["O\E M[MU'KUS1\X$-W8JO(#2S$/#^ZC9$P&PDTP1=)&DA?Z\X\7TA7.R\&1>?Z#YQ MQS-WNN!-5NI')\U6/?LJ$Y>'JZC+RQY3^2:HH)4-[-=Y23]\>U;#^W6L>Q]T MJ)%CH31%]<.?9NM7>JU1[S:;W4:K7:LV],:N*%CG)KHRX?H.3*&ZL=E_!4"Y M>E5Q@*SBV%,'YQ2C(*4*6*SU!4A:Y!DT!'4,) #SA[#6JSEC2=HAZE6[E7KU M?\.[("_ #;[SW_7PQ:RT%+#[[T=&EH-@#'1*N!M^7WT6^/CX]QG< RZ$)?@ R7@T5Z=J)X^]:88BSI''CS@W/*\;#G MQO0;:JU@+F%-H2I1U5-GQZGA%5)O\/3@A=E,!(3TM6;:" Z>73\1"-&@\)C^!,V!P#L.-7P)@K,# MV=F(CZG_ #$/,$<,,-*PA\*4HS''R=H:X=!W"K<)"ZBBOJZ!#M@_5M\-;2HY M/!XD\(@;9-<>,V3XAAV@[57? ,_77XT75.OHFS?.; MB_.[2_[H$LK4JNOC^ZL$PUOX?FL)..BU%?#^5[OJ+4L:F^']>J.C-5JS ^PC MWB]LX048?[9]N*KCKY'QZ[/MQW> \=?:A+W-U3#^XYQ+S=+VFQ%Z-W/OMSES MOU&0\+[/;3!Y'!&ME+]<.K!1P_.+(R96;AIL!G#OE2FU-]@1$2_M"&S,E2D) M$GJK8-DFX-X@A6IOL#XBR%6S(7<0W:="ST5->>G6I\76C-4*ZB=)BV'G@HMXQ0XX1S9%2'/OJ')K+R6EZ/\WE GO)87#- MKM;(F$,3:X>:=\2N]YI9^C_DG$LJO[7LF-^*[_>E:O_&46_ M1=7^KU!:VG0+;Q*6X>(9'P\%IZ!NE12.D, $=WB#_\2 J6C9*:/_F*T/9ZX8 MMAW$.$'B&69DJN!3B%O!KK@!I(0\;*DFSOR$/2.X-E2FQ-V.,53JX8M_Q@%O>)3> &5YB?6!.B5@_/FC ?>Z.@0A( M4P;V!CP/%V7(V.3RR-4>#<], I)QA =MSJ3;CS !M''3H8[$P/LP.1\V[ID( M:5*^*G@[E2B-RH3GF2ZEPCU.X6C/)G]!&3 T!!OW LSVE\W5N?T$\,!30M])797(V,@!)%(:4#XB),($1*EH0$K')AT4-E.VO2\ /F]G2T] MC$?30I2AA#5;K3^B(JQ1G"Q$;8*$2+AMU4UZ"AN#XPT!S&;X80![WYP0:N$U M/W-W*K+(*%N##I:\B!0>9G*/CS#H\]GEU2*I)XBCO*YFZ/O&\$F"9CV,:3R-%4*8D:>U0U9?@T M20,QQ.F;;C\8>SZJC81F$M8Q,,3 %J7:J+M0258Y;JW:TAMU'?1EO=K9F9Q^=2SJ>'902G+LY*1!$2,? MJ 1Z8.>@-B ?1WZ.0@LU/:$3$M>6\OLZXU5DXZ"*@CHBY;4'U$3EUR[:I)2G MGQ3 N CIANJ3L.!O#GJW/-051?HY?D764A^#/(%M)25P0!\4.@!WL02;]C[F M_L@9A,664:JL)]Z//4%F]0Y-UT-H:?(G)_"C_/&KRYM0H1>//F8A;N= MIMZL-MJM3JO1U7>%2:AC:HP.2O<8'O7 V$8$BTD("ZY@(2HU#!>8"G$2) =- M%N;T09T,A*4YX!-0=$T"]3'[9OP+: .L5,OH%F[$U88Z#'": -S%KZ+ M&B"<_TQJYXH;Q6X0>93YTP]<*1?09PCD2440R?DZ[)"O3($ M\SMF]\+\#0$?NU QARAV$63#DX4K?)8>&7RART)NX#^\V.*P:0(]/O\@8J\7 MH?@$( \#BUGFL[RSV)R?U_>Z8G@(H^ZU43KKZE\_8XO58J](6PQ?RIV3L^)^ M>U'KH[S^@G+GC=9*VW5ML9'PY5R>DK93\CH '@RXYFAA\1*M_\W5M6)]("3H MP[?@8Y<2[C*CY@XC2?39;UA:&HRS0]^YBWTG5O/5'/(PY-U)1.LJ'N]_' 0N MAHB.3F:R8EAE7O1^O0<659[O/W!WSH';,P>F<9GSL#ZC%VG)A-Y+5:>!::'P M*=G-&MF- O*[2:I>G4-2C6I)4X5 '77=&)MPG6=AJY4$EH+25VRHZ0J[3ZKE M0X[1RW50WE7L)MY/A?H<*JPM3X7;&P&^8G?751B3NW'/R35I6#?#KX[]]!5, MKX%P*N2XOJH=O5OKZ'JWW6K46COC^HJ.C!B-1ZW06:4'Y<"<7W1^B\X?+V[Z,N,V![S%LY>93!H/(Y!)=*.(!5GAA0!D2L:"VX;I3OB B^_@UL541H:8&"FB0!>@T,7'FLA'V4S%D MKTG3BP6"Y^P#&[4&J&U3=( 2N8?H=9 Y9V%8_ D (3Q?TH-$7S]F5T.5%!%Y MA6(-:NB[ J#H]*.,A B\XFT\[I--3J348?RP6P[^)GQH.0<*MY3,$)C-"Y#N M)>4_%%L040I.:1'IA)M$+"5S=3>^#+E*11 !$Q>Y91VS!+4B4ZZ8/RLCFT=Z:'!IZ1_:EP-CPFBYWSP)CVMRC[ M)9F,DNK/-4OQR?9>$GJ:\DC+L&1N#S$M:F %3(K#R\"C8R_*#&71+0Q>=3'\ M*L,5GI:,5,+>8&,A[Q [C)ITF5@U CP'GREX(W?',F=/=%6S,;60[S3USC0: M/0-&;_KXDZ39&A!LK56M-NKUIMYH[@K))@Z&*"4.QO!D!:+5>9;34K.!%>@R M4EO42'M)PKU90F(3!V-"(F@&5(-9_7':%MGN$5PIO: O !MUTU.?'CNV23F: M,:4A^CPFJUI"K\'L=WB#F@=&K>FC0)QZ,>IW[YJ8."KIY;L$+3HT;UOJ$ /#$P4P*YHL@7E.=)9=)Z\ 2?T,-% M/H@11'5P4'B-P3-%:"ET&?4\%P49ZG,R 1(V\.\ \T,<6VBVO61(%?<@[RR6 M'>($/NZ9?!028 1(J9K3Y:F%-0R2O6":EZ&4O7XLI72,0>FPT>0L6$4K8B/= MP%T''JD"/J48;E)1[:Q:8W0AWRF^SS@#RWR-R Z0'C=VT3<4U8+HF7NZ>"90\Y4E"690WW_DB3?ZGBY#R83 ML*)RE2X"6QT%SH!:?< M'&A(SQ>4C>IK09D&J&DTP"(5EQF+9/C881@(IH%P35%&O66I]O=+Z->-5-R3_2_]TGUS$UMS$BB&$@&';GV-EG%FHQ MUI=P8[S3X:,KZE+Q8/S,3M"IMVN=>J?>:C7T:JW5VI78D3@5@V,=8 $K'=W' MHPM=(B$.12U7F+0A@Z$J+4:5;I[S(7L$O MH1I$$WTQCF@6D_1 *6P08BJ[>I3;P;_!9WQR?X=T3"M5)Z(%TODF=F? MZ%!ANC&>1EM[)$Z(;TLV (_#'BKB&[AW$1Z@M?!<+X8KBMH6 TJ8;2/B7\BA M?/DME\+6\30@@[0Z.3:94@?Q%Y660^&[3$"I(KY8.I%,<<)HB&H*>43:\>>DOTTH&=\4_/*#TTVFB$"\ MCE:30%P.',FF0"GU6,J?7);N._.*H=)XU91I'IT $J4,&:%GH#9D)TA)\6PX M@LV')H:0%PE>A\^@-D4NETT))D![%M&RZF*%3%=(!"_ZJ,RJ2=8 GR==6%Y> M,&5YT+5>!5T["W1A$Z I'J6B3A:>!O,)U+FS>X)%"$'CY''WNC"YL;5J.()> MGEO.I?\7 T1NDT97*F<-@DX>KN7G0[4V/2 M\'N(EDC5_W3<'SNM2-YQ#\#6'YW#Z2U'E9WA%0#1N_?.T U'( ]"HJH5?\AE*^'=N6HP&I ME#VLD'?5$7DE]+/B%%$2(?J%S8$L MP3=$66YL=]281#C<3/PM*MD-6RB@?$JU5X@^E6CD4/;K*E!^2:/,+]GE_)+W M2ZG>@"KNT#!#QV%.65*]H3?:'9!%W:JN8T1U-^11['#L0C*[ Q-%<1"(@I'\ M;C?I5O*O**6=5]76;I;:2NN)*=QO&TA#R%6VAJ>YVC:[0;S:[>:#9:[9TI!U2G8W \1N<#:T#X\>'#!T:"IX8'.,(52,+9';*. MC>P!LH&HOSH20]0M69E&+R10D6!ESSH[()J(@JJRL7P\PI]*OL!Y9Q:ME;$7 MT35*=:0C3Q!^&%V$REDV3#RB6/6"]^^],#K]CTJ7QV3PY-SWCZ0F[,*MXG8Q A%.J8KJ( M>2*[1,(7&?ZJ?"/G5_<7T?SW!PS2@\;MBE'$3KN M$Z#!@5X:ZM^N6-8/?>_(6 ;2W4-A24\B8/JPV"0T_(9H&$[#*$3UK!F6/V"H M!.[4)A_L$.RA2''0FW2#+5%"1]77:#"98_5539UZZ6>W#\(??A5+#XL\G1DD M@0-A8B01CSY66+P9!6)6]"X(J! 18[211@ENCT0U/(7-7,,&CH51H*GTM_1! MI01R$'TU;"R5QJ!YY%*.H?LQ^X8A$C4& (N8-%GR/)&LB)'$$=*$O)X0/R-IH!)3:%)/A&]PO9/@T4(5 M%$2]3PX\H><)Y1!#JN1F-,0FT1RS5'<"V7G_2005976@1<5K !TB&=B"_$#, MO8FQ9"I(5&^9("Z\J+QN]NG"_ RQSA"^1FH=L1"^249IO[YYN&"G#!5R"MR!KOAXPLYZ][^SWO6Y M^.'BO[]?_=G[>G']<'_@BOM97IN%D);$%#E0%H"@08\8:* QC&5C80RF"V;! M'@W[!_7B279W,/U 6KS4[1F[*52P0%MC([#0@5G(1@KQ^4!A1C%UC%8IQ8"Z MY/Z2*4 _;.?%CF?QA TC/ ?X@N'*W!TY_&D:UB!/5<-F-L96G:B^8ADO/B'J M(J3&KXA!+\GWPH Q);4(/BS: I. $*PD& /H*5LQ*P"?V]SB8UD\O+W@3K,, M[NQR<&=#4H:I/[5V2KFMT"O;T+&C/35KF83^/A7@OC_B@\#B-\-L9> !>=Z, M'M#-R,,0W%$02]C ?%Y#5YOSF573A]AIF7JZAZL\&>VX>A:UP 6B-[4_SQJK;Z5?8:0.#J) MF]^;/&U&(]T26Y;&EEJ(+8*S5 3LX+N3GZ .6J!?ND^/OU8UAO]_6!U,LY$* M&6D6,#:\N?)>9N^E7L![V0(OR% [\:RU*L9NZAWXJ]G\L#Z.$8X5J?VRW:;2 MY\*2E:-SO7F-MI5^O=)^VOD$NH;E9NVWHY._S5L;>X?'"8F4K?7N)[/6LU'5 MD[6>B;[>V2JI:#E UZMN=Z;*\OO]>9:S*RRFK"Y<2UG%=OH-K5/59PHJMWBY M&\6N$ID71>9:!C+7BX7,]495J]8;Q47F LG,9I/$Y;IEYE;E9-ZL^5\=(",3 M(R+URAB>,PK=K1_V6Y8NLMP6.$ZE4BD,B1;@!O;_PG-$3"-?Q+PB,F*$?C.4 M9-[SSV35-#5 7TZDZ+6F5JW.=M K#+X62*1LR S;JDCYYMA\BJ_]X#X; @3V MW/K:+0;2S#>XYC,0NE;1V^T2+W4UO$-KM*M:IUE@A;0 V+,%9%T??#/H(!=9 M6\M*NS4A:[6N:_56@5T!!1)UAV ]?3^^/V8/+K6CF+)3T[*\P[6]D** MRX7WOD$[;,'@Q8$)L!5CV=91ZBWBL+.L./Q^_P7[/]F8A7?/^\B-3+X:H=C2 MV@WX4YMMBUPLA-@IV;GW9F+XITO;>* ^YKFYDWLN-Y>71L6*BRR\[1SVUEW6 M-,V)K:Q&Y^^TFUJKV=QY]E82S:)$L_4]OD$GT*M+.X371S0=K=:H:WJMMO-$ M4YB!W/'Z_MFEUU$==!75;5S9Y_S1#T<[( 009?QI3)<$3!(5UP^N@3F_8N!O M?C%1HUDSME]-=,8J[%OO[H^+A][IUPMV?W'V_>[JX>JB$,5#*S]WYJQ7=:- M2^HRPPJA>.T.UM+3I;-QX&-M.+GV-=F0-F.,LQD?U"S+A+(<)OAZ7AB:"I!" MAXITI. .54DP]7*M,W*TI#:#/2'%9HPQ%K%C.TULKG,0=;@/U+ M@#YE5U_'P_)4V<5\G(D%LQU]90%UU)EUL39%JA^H:!>+U9HT''3#)5'O8X=? M '1? 6@W=HPQ9C"ULC*BS'4O=F7$/W-HM:R2V%7,*5XV?EDE4G3&W!1KIZ%JUN[UH MPRY%20\AP^@K][R/#.6T]-BHL4,+BVG4Y1*?%IW ]EQZE[E(A8RGE%BVVEGF)^V>Y$WE)V&X$$0P3F:3 MTG>>U1PU37Y%,/LX3G#$+14QBWT3.T*',J@(_@11UU.-;PL['#<=\U',:T@NF3*>X(-.H@@ZEFF/0G@$($G M4$0 "/<3@^-VTG%6+(\2*KND+QJ9T?H43Y^,__T5AY$RG544E.14BVC,N)AX M#U;/TY3H#3DD !*Q +;Y:V ; Z1T/OA ]VTB<:,QIH:%Q[!#3I M+N:AO1?>M07AK1(0DS!','LF[!VLJIP)]3-05E,0Q)JJ_[CS"!+NF;BJ2F&; M)6F-<9-&-PQ,8(4XTX<&YJC?-+&?X!'G%/@F3DP1LX$"G" /_$:Q]&3?=#>@ M400'>/EB-I2N?UJ8Y ([=E'4 3XV:T.-8HIX64P";!*^9;OU"(VHW7JK;+>^ M"^W6M]9H/4\=GJ/[RM3S2 6.YWHK58NF0AH@'N ;%6#.%<](J,V:S RO2$9! M"FR,?Z!6B%IOX)*6)'0Y&E;C"B[%41?$MY3V$&I8^.);%819C2!KXH07C9S( M-!!B.?J[J,&M=I;C3.[Y@D,<5[WQ_%$"W74DIT=5')'+(9V;7FM?G)YWVMV* MWKG4*XWZQ66E5S]K5NK==JM9[71K>JN72EZGK9@VH'W/AR=T.MU&J]? )YPU M*HV+L]/*:;?7J%PV3\_/&\UV[;RCEPGO9=KRCJ;'(J=Y/,'9[X);/&9ZU]J>\?]_!CNIA 7D(LQD?N=H?^](-O- >#AQ?F5#&_4MYP/ M#_^3OE.I9U(>17.DX]T7 M#CT[[# :8[7JO;@!K'F&R$-M<)=9+Y(.GWE\OG: M1,-XR1:!]8;6KI8=M$KJ*B1U98U4V#AU+4E9K;K6ZNQ^FZV2LO:2LN;,&E@Q M93UE$)5M]OK]8!Q8V/YH10F8455)K:-UVV73V]US-FW;2UNN4:Y1KE&NL0?M M%R/\8:2)8#:YZUHU:!2$^MJ MW/.7]_4WV]5B#X,M *H=+&9GS:_:*&9CVN [YEJ4R%VXY0Y\%'N!5*^]=P:D M5*_YLS\/5-,ZX(YH[:Q)3*])M^_W"H,0@:+HU394MY96ZW2T;J.^\T&MDJ;V MA:;T M#4.Y7&DJQ*LBI;Q)89"=MV2)=KE&N4:Y1KE!D)N^R$$#$X,2_=F9.7 M4/8./I0LV_:_^_LGGO M^]_'BDK)*RII#65EM<]=#69MOFZMKW<[N$UZ!%/NR1JUB WOOBOE4=LTMERHO:=^6*B]I7X,#>U_#4G;-79^UO-L-G]&R6G=U;+E!154E19G;V#WO&]][6$ M?_2.,C7*4NT#K:+K9G4@KA>I5+O3Z&XUI:6L.2VI):26K-[":Z"6=ZJ>G::^ MU5R5DF1*D@E)IK89DEE5F?9VDTW67:4=K_'-K3S^C]3>_V.1VN-MEV7'"WCK M+=I%9,LKOZWI,9?WG2>;BM->1MQFW'!M^!F3O@$XGNGY'INX\'ES8EC6%+V[ M _/9A.>&WM^AZXP9%\GB\11Q>HB)I7"PK/HP$,)W0')8XMXG=W%R_(>6ZTO& MAXT=FT^E6B[6.&9WJK;N"?!8!PM-38H%39K@<%3YF M,&\"2 ^K,CR97!^)]M$ $!S/N[E]P8Y;U^ES#K=&U^F/. &/X.GR 1]/"!X MRDRKB!EC,!SQ6GV'_2V;]352+JR!Z%!1U>'_UYM5R Q6M[\&$9Q=@LMD#JNZ-AQ75>9E_$+AWL]LOU]V]S'YSM<%+:3YIU'YU< M5O3VY]]@*=1!XO_\Y?,H=/;=]KY<5$[O+GI_5'J7#Q=W'YEAO1A33RE Z,C" M?BH)L(VX $]M\O,3DRZ\OU;IORSOGGSKZ+O. M>,$T87B"81U<>Y&BQ;=RPE?-ZMM;M6;CG;^J:K[E_,[SCL*WG91U\C49' MT_7MC8 YM(3!W47=.1FT6T+==DMK5O7BHFZ!I.'>9R'"TO]PW!_,M-D$0R/> MGLO 0J84Y_*.[KO%'E[NE7TKKG8%S*/9T5K=V;A.87A' =#G4+%5?WL2Z[JQ MM5O3JIT"8VN!)-W>5Y)2]:AM>B,^0%$W"/K^GLNZ@ZBRR>%%62G";Y.<"EF^ M.,Y@);RHT=3T3CDTM*21HM#(VW."UTTCK69#Z^JMG:>1 LGUO;=@4QTBPC*Z M6.Y$63RWQ[4-33VK6_3;9#VPKF43=AM-7>MVRV&,)244@!+F='9>/R74:G6M M6=V>\"[ ;,7WIMO%\\*Z!:K2B.1R]SV":&:0>T M"&7)JT_"@K\Y+AN8'I;LP LR0U(:^<<,JYYQG5CU34 ?Q$\9H)@93USL?((@CA"%,YE !)PJ5*I'>I\[7:UJ[6YNM9<%CYFW^_2QL M19MOM#,+<32\@0F'7YZY-17U#)MB#REVL)[L;ZR7>S!^YF=_-_6,I-P-3GV] MQH3PB]F$\+.;;Q?LH?<_(B-\[W+!'P1+>S8]I!:LJI*UC;[Q,TH/]_8E/_S, M&4\<&RLG,5=<(N7%SPFW/7[*;3XT+AIC=ULMI%+2E6"5-Z]N"KTU\99^I4MYPK@ZNM3AO( M"4S5*I2I04DJ24NJK4P562BEHRK>[V_-&K5$/V*Y!G@Q*[N<4 MZ7*-)BSCG0PY29K _T\C+-:VB-5KLX@=&%0?^A))N=)9L>A[VW%C9JH$B@@X#B9?LUT>!@A\8%R@I!BJ5X8>]XG!YBD%[A8I!J1&4 M&L&^T$L.N63EQ"ZK$92J0*%5@8TY ?;3G5.N4:ZQYV["O3<6PC^U]B31Q&Q> MIE+9TVQ_.SEUL@HJWFHNK%3OZ33;6K,SV\RER,BPUQE*!TP=W55,@EYM;E*K MJS6JV\M1WH/>9]OH=1;*W5B/G;!Q#K8,PWY;@&E]TS(-->8MFZ9S?[FFR_-03VOEQ[;XC"-7W(Z]/#CLM./;N.T9N87[RH M/W%.>YK"=1K9YDTM",Z504@*PM?[PLR"9L-;+7G%9AHC;1H#,W'NU[]EAN2V MC'('?RW+*2\K5%<>I%4T3SDID:2DW?):2MK=#9VB(,4X]=:6BW&NXKVH#3_F MYQI*SU?*,79HL:M7G._UHK3RZF:5_RX=>4IZ_7)<[CW5\^M>(4W"<[ADO*I5 MT]KM C?^VB^$7V2Y->-X+D8WWHK1MX'+TRB]B%=[442NU!;&Y!H8\/KQ[!B* M5ZYUUM&SB22))2(6B0#0+Z50**A0R"IK6CK@NCVAT.K4M%:K;&A:H.6*@^-O M+D+:?3&QG4C9RL5$@>R^O:]H_B3[I@I33U.#R925)VN<]EN0[Q9?6T7E48[L M3K1Z##^S]/3G>FFN%6BY]9MKZ&A5JU8\WJ^8/RLC8WP\DPY%YRLJ(LMP4,)LY5D LOD'J\]Y4\L#2. MG37<_HC]W1A//@%C>.:6,QECX^&^RP>FO^=E_@6ER.S"_%8UJ_/YBM1C>.%, MW+C"B25[!&=.(MY+V_Y#21OU]1:&S))=/FV\N6GVLBZQ.93R!B]8_>BD>JP7 MB5#VM#/%CK'X572T7C.+UQLECR^)8QO$D14=7TO88X4\OE 1O T22H$LN4,( M=-SX(^Y2B&._.=8*&TUMG+&]K]%4J[J*AJTYN@&A3V^ E;AH_2_I2ZQK>GM[ MBL%^C8 MVY[_8;]X=4DN;]C[!L-->]B!/TEO1_UJK';YX76P";K*P; M*N75N^25OHHA]7O5]G&_Y%5I\;V?1+(R-E84S5NM!"M0JO_",-]\25-AVK'" MHOQGWPH&_.3SP'Q6739OOYS^<92^K.I,;\TXW&4#3G@)VWLFGG7YG#4G@?\7_^ M\GD4>C-N>U\N*J=W%[T_*KW+AXN[C\RP7HRII_ -+76;)T[UB8VX $]M\O,3 MDSZ*OU;IORSWA7SKZ+(R1.;VDC/7<_Q7N_QIH,8Q<4T3/8HY;"?#QQ7,.= MLH$)K[K<[L,V7D9F?P1(,)ZXIL>IC7 X3 P? '?#X?N&/6"6:3R:ENF;V'W% MY? 6$WV,O;DMAE?/)%;51%C-[@'9TZ-C8FU&=,C,_L$MO5[V#RX[*!:WVVKA MV@?'6P:7#8-W'85KQ6D87#A,%[V*UX_A.].SN$26NS^K?VY";Y1KE&KNZ1H&XU][GL*?R/GKH$3#L/J>D#U&,S"P'V-B>ER2_ MN?/>QF>AY3KT4UW)S#DW&OK .QWWFZ%OI]?MN8%A>B"*7CGON M!(_^,+#@/2"=Y?/7JWJ!Q@;N>>AK=Q&]G8'H;QKSO7U$;U8+57Q<6+E[:/F6 M5_8SF):.:^Z[G%UDN>)PG,[*1*NZX.F2:21:IU.@>'@!D>9@<;2[,JGX3ASM M:ITMEB'NDG0[.*M2:DUL8DPQ8EJ*N,*PCUKUS2+N:99SJ N^%?>[9&I_5ZLU M"ZP>%P!M#A9+]3<+N75A::VCU>K-XF)I@<3G#4?Z/#U2#HIX].(_:=R[)4JHMK=IZ<\%.*?D. 7'KJY!\:T)< MO0DV7WU[Q2V[) P/T.9S SXX$&&XPH*BC;.>=Q84U1H;CC\*Q(JE>B\9C &I M6^^4O5A*0BH*(34W'-]<$2'5.DVMML7.M&6[F1U6%O2.J'AR0#W-JEW:<[5A M377[.\?Z5I?#=,V7K=37=:W9W9X57NH#)87,H9#5)3\M32&-3DMK-;;767L/ M!?W>>P72%1&Q,N2R+*)T M9OU0B:% E+AO@Z6K=9 MJ#S;4KH?!EUDYS),$G4PX=_ M<-&1U^/]P'TU4KC[K.P@4A[S&&-6SN,[%(8(H[X 0GDW]H-K8!_G^Q"7ENV_ M4.T4B$$N#/8/)5*K!R-_9'5@3H&3D!#E2S F,*7 M8F1L.(=)OCW/,*\((\8DEZ['T-M-K=XM4%K5 H M7)!@VP#9$])HO#WK<)VD MT:QJW7J!FE&^F3(^%V6Z9VQ\7\;2.,DQ,>IQ!2/^;KGMP67U[,&-/^+NK>/Y M+O=-EV. 2PYC]LY-KV\Y7N#.SOAKZ+,S_C8SRE%H!C^YYDSAB-/F3=Q;,]Q/6:P1E7_]<<'5"L)2OTX ME##QA?WZ][]V:K7JI_,S@AK]IG_ZP/R1X6.2S+,YX#C6TX6'#1S+,MP*_%(1 M/S(^GEC.E+O G?S^R+2?DBO@D%'8U]!T/=!CLYE\/6-V]"Q!_^]=2*ZXS6N@ M[MY/TZNX"OSI26FQ!$%OWLAC_!-GB#Q/G?[\0CX&^9-U\#FG)$5 MOR!$N-$?*<#Q_Z &ML=,[@) _>$XLW4"E_P3-HW?9'_+N:3&0I?TJE">!W_DOLB3'=MPI_$/ M]<98,+!D_]>&5LUH(T+97GEG;;YUF'E1SEK//BO2+E+AE!O $CAPC0&+C^!D M>($$$3R=QESN3<0@=D"E0V.= $P'Z.4'+#J(7U**='QGAHP-4=C"'@T/ SH M9##)6H' *[Y3@7\D=V6>,>25D>&"!D<7'%B&8+C_#F#C0YRGC#X'NTGV-V^<9+]J,SXZ;T]B>/G3J&.T .=0Z-2-L4\< !_P@<:A+WXA#S::KV'CSR]DZR F_\3P-,+S[2DB:PWW\Y4VN]A M*D4Y>+6;>? DR]"0.!X!&2Q0H V47H 6('O@=\:!*DTT4!3=>!F2+Y)Y-'M\ M#MK%YHWG:1>=E6D7_WOOPVGP(_>@$P#+<<1'\D#O_0GG *';\Q]>' 2_MPHM MQ+]B_JR,S %PTX\ M[.[1B?_B2,5;LB)4>&CO"#F-:"3[JIK5K5_5!;#TWF!@TD]3F[>?C]XHY=75_>W'WK/5S= M7+/#,$2'!HWG GIX-M$_E=#+$$T&09\Z1(C^ MRAH:Y/@24'_89ED#==4.AD#V@0N((5BL2'E%DP^HK^]X8_BE#X3RA-,WX4L> M/ KTS['1YP'%]^ %M!_A)V8%CX"D!K:FP$=Y_"=P*C 6+-@_8@-_+L6$"?[,7T1\QVV)/KO/BC8]:S!'=4NQ"*>O*$"&S8'GV5..G/ M/I\H#\@=B*"^.3#A=@U7/0=WZ!-& &S0,XTG9K\;P61B!$]<(Y3\I^/^.$Y\ MGP6N8SE/=$]R0QKRP@20E<&G]O<(9@WL)/ ]<\ %MX6/QK_C"K:<-@C4\($! MGP#L2'#8#NCW-MRUQ$"/V;#1$#; Q*4)Y0R$'2-N' 4DF"4@A0DIHQL-0?;D MP)%05/R$+6"NH "ZX\.JB 02R.G#A7M5CSQFW_#,TO.4A?I)8 %P8H\#LC P MX V&E0N'Q/OY"N1@_(M;(8Z^@&[A5H29-W;@1$!W_X<;QJ-*XJ%3/G$D*[QS M:;;!$P-/K#F.;7)L_ L.!48@?,L0N@>;@-Y /_0CG('-]&F;IA)P>\\X(R3& MXA0 /-F:KR@AC:,3Q^9*"7D,/),8ER=$:#:JAQ!&<'N([X8P0H!%#,&N0>8" MU]/W0Q:,MLT3L>^/RW-8;1Y[%8K.+!],G"#)]1!A8]]0*!N=;D&N:!!?E!P1 M^3)Q2-Q/C#.BNIP&QU1P(Z15\AD,AUQ@_B81%K0MX,"H')Z@,L;ZEN&!HGS[ MY?2/HW2(KEK])2NV)E^AX"B]A%I4XEF7#W='B1"%C*>B)L_=3RRV0.J[HV$% M(#C[8A]P@-U^N?[^;>Z#LW--5(@Q39=')Y<5O2L5T>0_?_D\"O-\;GM?+BJG M=Q>]/RJ]RX>+NX_ QE^,J:>BC)C#@@&7!-A&7("G-OGYB^U' -]F0YC\!X;.Z_@/*"K ,9)UEWCBLXE\<3 MK[%) *HM2-.(2X&J0H3'AJXS3J@RR(%D4$J*3M..*;NDKQ*K&@9V7SB)I,*0 M>+X-)N[(L(9* LO'T_9($0.9;LO&;+20Z9+H!=O2"*U4?^3 0_D0?D;-9PJ? M!UED64)W<>(+@JIGT#:#"7)7^4"X #"S!51,=-IB--Y+G!=9\1, W?/(M\9& M!NP'F7SXZ/ .4),"P-'71P ]O#;RQ2*,?/B#^\*O.B\V'+$"'_9X)NP\WQ@. MC]F5+0UQ?!XI[[%/#Z2+&'=(-VU8COU$"J83N,D+CE]:] 2,.*&0 J(!?51L M#S\I37X%'8:6$$ MA>WH.X@I!MP>N:*\2-<-M3AA2PB8T-UDD9I8-@)GS@Q !)L E,3UB,H6V; M9:OD,E0PD] *0N\<@L\.M2L+B05L+G'3R''I=)@M2F[WV2L>.+ ^6FL8S&*4 M%2"V9..Y/) ='F'8$9<.P!']%/(B!EJJ13V?@9@FVC!\L&,)8@01FY.H(LD M1W0UQ(43&GY*0>=P(\!BA0)"YR"N%N&<@. 8-@*W"N4-F9R^:%33]P@R?V,G* \(#XW"A.&[LG;99L_3B_CT@[_33F M!9.)-8U[IZ1V$>T;--( K#0#V;)' ]ND/!9 0T]")G>-F+10<$CCB7FB$)_' MJ&"88_3F80<=VE[HE(K+%[H'S$8*'P!*Q2.(=>#W(U,8D2+/2!W#M$7P@U@R MD"_\%%K$(VY8_DCY1?![+H4"7XA:<9FA Z(>S=0 $3,83,7%HH]0^E1%U #5 M&SH^/"HA$L'(-8BO9L/A#,R9"7[ /F:G#FH*P[2*2;DU#FBQR-$C=UD4U]2[ MS2K /GH4?)=7!H90I[E@"B+MBD!A$26=(XQ[<.OD8W*B]*WK\YY*W8H01F4+ M>*AI6>@I_7=@TE/'"<=DPF87B0; X."1$=P$3XJXY"6\"5_4N]WJUAG-O+3: MA4LSXC:9XCT95IMD/RS&?[+\YG#YR-GGR8>ID,.>'V,M*>_BK#-1D$O"]DJ) M+:&86R2_XAY>J6L",0+"8>2![)JQ\' I!HE>G!$J&8+2A+13YP,4-OL\5.>3 MSO I"4MEWR6\:<)S]A2 %HDHC29=/LNF!VJ A);Y0YAX.9]-LDU3Z#HN=O!R MA7KD/*+1DRGS)RIJ$5$WP@)=[;-"F,Z :V&2 ][8HW#7AQ[F+%U>9#W:XLCQ MXXD+G.? IO7031R_;7]*@@JNE;PV,"0=(]8 MS"C-O$1 %11<^>C_(89GPL.,'H@@'BJS'?W$A MI\3-N,1*@+6X'IK\6V"<7,C#2G$.P5BQX04=B\#LB:1MW+O22YG<0-U!?36 /ND((>,6:@G M)Y3DY-V2-UN%6(R4(RI;MQ:L*-P;K'O3]YW'6/A"*E??;1,/0FE L.\SPS8& MAL:^\9]FWX'?.7I0P)RG= R#5KQW G0AB%<.A@N)]#DB0^%\G&"N@4@08N@D M $F#*@WJ*GV"FO 1Y3@VR,6 #A!T19(_./Z,29CFA-\_4PZ^7B0"I2?8RW#\ MQHPR9"#PV,B?I]&]4X,OJ0[_^OA!Y=H^FV@()'.> M?I#)@Q['!.>CSU/F-PH*+6*ZXK.Q& R"!U.%EF6_ZO."\1.;WR3CE,L2Q5,B M/5+2!!' ?@I_]R8 5?E[%C--^!2JP!JP(05UX! 5NOF-.'QG,ML60SV[LV"A M>N>U%ABO$6^:=E\%X>?'DU^-#PNVM# "W]G\_MY0?(H=.^X1)6/%ILL9(>7? MF_P[I_'-;&7\QG2P=V:'@_TU""Q^,TSGB5]%CO33J7QS)F.\TY[-&'\S>Y,J MQ="T'^14)P&WI':H-],J)+TB";Y=_>4UG>T-+1269ZZK[G*TQOY%^4Q^K6N MFHH<[S^/6D>K7H]E*/)')__,*6S<\VF9>XPYM=5CSK)=UK)1#OGM.L&S@MZ MF[ZI!<&Y7E: GKXL8&QXN,SV3B MY#],?Z2OP>6G^\7:&#;E:] M^VQ+B-VD@X96PW8TQ1I[65AQO??-;G%L;K(8;K^E>(7^+C?:=+LC?C)XPA4'[ LG>O1^$ TM_DZ'E MKV%HN12_Q>%#"S9 S>1#\F:CBRT4)ZIIU5I':[8*-':C@)AXL(B?U51V40%< M;,37M7:SJK7J!78#%4@$'X+Y>Q6E^X>5-?LMA ]B\E6E4BD6. ]-XAT$EN7( MSZQFRHO*SX@?J9D8A1*@35UK=K>G-JZ*U@HD9/?>SDW-@2?D4\F9^RQG"\G: MM@D3FKN?P;FOIO&)EUK=ON:DV] M0,/]"BPO#\$H_0IH]9%A*W&<$B%J=ZF1&M;][[G8/ C#(6Q%*QF ^]$&66]9;56BV-DFV+PIB*.)VYI+\]H;]V=;'4K\W17[7;T.JM M>DE_.S(=_7",>5FB*J>C2W.^G(>^MT.?V]7%LM'FCU]F'2SR+Y;05A7BJ6J?3U/1F@17_W1FJ7K:E>&=;BL>]:4OQA3M/KC$9 M44%Z?3"%B& MU7.YX5'[@G2/A':U7O9(*"O="],C(<.5OC5'\ML:-K#C>2QV71=2MFY83T. MW*9[174+K8$6LF"0#+2(3A+KQ_H=["A1(E &LM0+C"R'YP8M3)N+1$O$0W.! M%LU)D^N#:2Y6SQ/.J$\8()B;^?V^. X:O=W4NK56<1PTA^:\W!FT7S ;>0?0 MOJ.UJKI6JQ8XZZ] 0O@0$J4H09Y1EA0.?-YST7L(F1DY3&RQ].0Y3.S:L;_/ MKT7<-#>K:=5J2ZLVML?-RLJEDLR29+98XO2.D1EVO.HVMM=LIBQ:VCW=(IWG M%$MRVFL5XY!S--Z5?%TF.)4)3@=,//J[,J?+!*F $YSZ^Y/@%!5WXVBI M;S1L/4^J8[Q\;MNK$ISN.DQE-RR0PW0S)4W4?#5T,W[>?KL"6HK0H M.0;&>W" _9&)@%/'9S*>=+W,>"H31-Z;\;3.^'XY%6;_,*= 4V$*EU)7IA&5 MR/(69"G3B(KD92Q,&E$T@/K0O(Q%\X/DNCD6[ E,AD]4W4"30>1OO6+U<]/J MG;96;72*XP@Y-"?ASN#^@FV!=P;WZUJCU= ZK0)YT LLC \AG2@4P*?[+8 + MF;N0RW<6S-N=PW=."\5W:EJMWM7:14YC+ #^'2RZ+YBONT/HWJS6M$ZCP+GJ M!1*S>Y]9$Q>S9Z68+0[?63#%=@[?.2L4W]&U3EW7FLT"J_<%P+^#1?<%4UUW M"-W;M9;6;A:H66"!Q>Q!6;/GI9@M#M]9<,KZ'+YS7C"^4T]0 MT;VVX##U'4+W1K>JZD/CB^8;&#F:9WR,5UM<6RS@K"WHHXG*^L3#U=X8+F;WSV^TRVK2LB:P+/,J M:P)+9"EK LN:P(+5!)XZ=N =GG.G:.9GGG792*5SF MW"I/ZF;S?L\!U@1DL MZ5#N5K5JM5H$;_72_Y.IM%HZ%J]6R"G: &QYF"1 MM/9FJ;8F)*VV-;U>)N 7R([;JF2[-::N8UGD5':YA2*PS_J[[3A M[@W+P/$C[V(>[;K6U0L4,B\@QAPL@C;>:;:M!$&[+4UO%E@#*Y!P.P2S[$[/'E!.PZT#BC+W39?FOISS MH6GSP2FWX0?_UC)LQ5MB\>9E,V":I3.S6,L5!YM;RPK"K6%SM5ML;"Z0U#P$ MD[!GVX%A@34X<5R_- 8+R&+:RWL\Q>7>T=U>R*M]E\K=J6M $,5E'@5 G(/% MT\[R3L_5XRDV'RFP[Z) 0NX03,->,#!]#.650 BU7&$1MO3='9;6(JI?F6VF^A9+MCL.WGSDB$',"G^9SP4=\ M>"19=7[@VJ4U5R!F\H[\%7G7EXY[(V_ZF[SH);,TVRVM72]PWEL!$.=@\?0= M*2PKQ]-&6^MLL1',+LF\0[#FQ#1/ES\"5I6RK4 \X[UI*]\,]P?W3?OIS/'\ M=^8&5+5NM;3G"K1<<=#TOD5]?JG>WEAI?M%4OJ2%+'TKDTZZ"..BB0]>T)YK(AXN[)[_!/ M=Q+U0S1277[V7+@?<%^WUML3=9)VQ:I8EZXU6FW@7@6J^RK;'1XN6;P]+VA= M9%%OU;5JD>:"[&XCPZ@]'/^)_2;Y"78O5&W7;K^<_G&4AF2UFFZV%@>*[,@& M+V&_M\2S+A_NPH=E-"MBL052WQT-*Z[S,OLB=HMCMU^NOW^;^^!L%4!A0@J2 M )K+2DV7G1N3__SE\RA4OVY[7RXJIW<7O3\JOC*FGD %5"YLG M3O6)C;@ 3VWR\Q.32M5?J_1?EKXEWSKZ+0W*W\^S08GWL30@'V[.OIKVCP@U M,B @_B$L50B30I]LA6T&7Q5GC&V3Z&-+BWGY3Z83"S* M^#>LJ#&G-],2L=5=7V?.S#:<5ZS"[K_?WGZ]^'9Q_=#[RLZO[L^^WMQ_O[NX M9S>7[*QW_SN[_'KS#W9U?7ES]ZWW<'5SS7K7YPI2C^)1UQ7ZY-7UGQ?W#U?7 M7_ C[/+JNG=]1K^=/5S]>?5P=7'_V:"CVH[/O=H1\TT?CZ9^';D(W+_"_GXS M3O:R'6B\.V2])9(6/>8,9SN":@RL7::*W4;&@!D,!!]^!#X>V(".:.&!R?$E M,-P!;(&=C?@8+3[FC0Q +WB X;,7)["P&1Y]FOD.,R83U_EI8O*(-679PKR] M6/K"/:X3"PR?B55,$%6P\;%CW_N W?0I[\KS I1AWR>.+3Z'F5)+B'C 1&S+ M,1LG5L<&\'R''?)!14%&8U=V_QA.A'N">X9-,7,(#-G"#R.<73XV3-NTG]C( ML8 [>^(-Q^,1>.7C(\##%TTW]CX]%R"<6EV\<